"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,DE,A1,DE 2324575 A1,073-725-629-716-935,1974-01-03,1974,DE 2324575 A,1973-05-16,US 25420772 A,1972-05-17,"FILTER, INSBESONDERE FUER IN LUFT, GAS OD.DGL. MEDIEN BEFINDLICHE AEROSOLE",,HANKISON CORP,FOLTZ DONALD RICHARD,,https://lens.org/073-725-629-716-935,Patent Application,no,0,2,12,12,0,B01D46/24;;F02M35/024;;B01D46/24;;F02M35/024,B01D46/24;;F02M35/024,,0,0,,,,EXPIRED
2,US,A1,US 2010/0242371 A1,167-519-662-562-043,2010-09-30,2010,US 72941110 A,2010-03-23,US 72941110 A;;US 16292809 P,2009-03-24,WINDOW SHIELD AND SHIELD MOUNTING BRACKET AND METHOD FOR USE,The purpose of the current invention is to provide a system and method that provides an effective and visually appealing way to board windows and doors.,FOLTZ RICHARD E,FOLTZ RICHARD E,,https://lens.org/167-519-662-562-043,Patent Application,yes,0,0,1,1,0,E06B9/02;;E06B2009/005;;Y10T29/4998;;Y10T29/4998;;E06B9/02;;E06B2009/005,E06B3/30;;B23P17/04;;B65D25/00,49/460;;49/506;;220/737;;29/527.1,0,0,,,,DISCONTINUED
3,AU,A,AU 1973/054912 A,003-644-537-602-742,1974-10-31,1974,AU 1973/054912 A,1973-04-27,US 25420772 A,1972-05-17,AEROSOLCOALESCING FILTER,,HANKISON CORP,FOLTZ DONALD RICHARD,,https://lens.org/003-644-537-602-742,Patent Application,no,0,0,12,12,0,B01D46/24;;F02M35/024;;B01D46/24;;F02M35/024,B01D46/24;;F02M35/024,,0,0,,,,DISCONTINUED
4,US,B1,US 7494376 B1,078-399-959-796-078,2009-02-24,2009,US 4505708 A,2008-03-10,US 4505708 A,2008-03-10,Multiple direction wire cover with positioning latch and position assurance lock,A multi-positional wire cover having a first piece configured to detachably engage a second piece having an opening configured to allow passage of one or more wires. The second piece is moveable about the first piece and removable to a second position once a first position is found. The wire cover has a feature that provides both an audible and tactical indication of an available position. A lock is provided to secure the second piece in place once a desired location is determined.,TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD,TYCO ELECTRONICS CORPORATION (2008-03-03),https://lens.org/078-399-959-796-078,Granted Patent,yes,4,19,1,1,0,H01R13/567;;H01R13/567,H01R13/40,439/596,0,0,,,,INACTIVE
5,CA,A1,CA 2609775 A1,025-773-272-968-202,2006-12-14,2006,CA 2609775 A,2006-06-07,US 14709005 A;;US 2006/0022030 W,2005-06-07,CONNECTOR ASSEMBLY WITH TERMINAL POSITION ASSURANCE DEVICE,"A connector assembly (10) including a housing (14) and a TPA device (16). The housing is configured to receive a first terminal (222) in a first direction, and includes a first slot (68), a second slot (70), and a first latch (86) that is movable between a flexed position wherein the first latch is disengaged from the first terminal and an unflexed position wherein the first latch is engaged with the first terminal to inhibit movement of the first terminal in a second direction that is opposite the first direction. The TPA device is configured to be coupled to the housing for movement between a mated position and a pre-latched position, and includes a first retention block (158) that is received by the first slot, the first retention block inhibiting the first latch from moving from the unflexed position to the flexed position when the TPA device is in the mated position, and a second retention block (162) that is received by the second slot, the second retention block inhibiting movement of the first terminal in the second direction.",TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/025-773-272-968-202,Patent Application,no,0,0,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,0,0,,,,INACTIVE
6,WO,A1,WO 2019/180562 A1,147-479-989-061-372,2019-09-26,2019,IB 2019052122 W,2019-03-15,US 201815933735 A,2018-03-23,CONNECTOR POSITION ASSURANCE MEMBER,"A connector position assurance device 200 having a base portion 202 and a pair of resiliently deformable beams 204, 205. Cam engaging members 250 extend from side walls 256 of the pair of resiliently deformable beams 204, 205. A first lockout projection engagement member 230 is provided proximate the beam front ends 224 of the pair of resiliently deformable beams 204, 205 and extends between the first beam 204 and the second beam 205. A second lockout projection engagement member 240 is spaced from the base front end 210 and spaced from the first lockout projection engagement member 230. The second lockout projection engagement member 240 extends between the first beam 204 and the second beam 205. A lockout projection receiving opening 254 is formed by the first lockout projection engagement member 230, the second lockout projection engagement member 240, and portions of the pair of resiliently deformable beams 204, 205.",TE CONNECTIVITY CORP,FOLTZ KEITH RICHARD;;EVANS NICHOLAS LEE,,https://lens.org/147-479-989-061-372,Patent Application,yes,3,0,9,9,0,H01R13/639;;H01R13/6272;;H01R13/641;;H01R13/6272;;H01R13/639;;H01R13/641;;H01R13/4223;;H01R13/4368;;H01R13/4368;;H01R13/4223;;H01R13/641;;H01R13/6272;;H01R13/639,H01R13/627;;H01R13/639;;H01R13/641,,0,0,,,,PENDING
7,CN,A,CN 101218714 A,055-669-219-378-973,2008-07-09,2008,CN 200680024935 A,2006-06-07,US 2006/0022030 W;;US 14709005 A,2005-06-07,Connector assembly with terminal position assurance device,,TYCO ELECTRONICS CORP,RICHARD FOLTZ KEITH;;SCOTT BUCHTER BRADLEY,,https://lens.org/055-669-219-378-973,Patent Application,no,0,1,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,0,0,,,,ACTIVE
8,CA,A1,CA 2420542 A1,183-419-116-867-888,2003-09-01,2003,CA 2420542 A,2003-02-28,US 8703002 A,2002-03-01,CONTACT GUIDE RETENTION APPARATUS,An electrical connector configured for connection to a substrate includes a housing which carries a plurality of electrical contacts. Each contact has a contact interface interconnectable with a reciprocal contact interface carried by a substrate. A contact guide has a plurality of apertures positioned to align and mate with the contact interfaces of the contacts. The housing includes a single locking mechanism configured to mate with both the contact guide and the substrate for securin g the contact guide and the substrate to the housing.,TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;MARTIN GALEN MONROE,,https://lens.org/183-419-116-867-888,Patent Application,no,0,0,6,6,0,H01R12/724;;H01R12/724;;H01R12/724,H01R12/16;;H01Q13/18;;H01R12/00;;H01R12/14;;H01R12/71;;H01R13/639,,0,0,,,,DISCONTINUED
9,CA,C,CA 2420961 C,136-092-427-219-304,2010-01-05,2010,CA 2420961 A,2003-03-06,US 9334502 A,2002-03-07,MATE ASSIST ASSEMBLY FOR CONNECTING ELECTRICAL CONTACTS,"An electrical connector is provided including first and second housings configured to be matable with one another to join electrical contacts. The first and second housings are movable between initial and final positions, at which th e electrical contacts partially and fully mate, respectively. The electrical connector includes a lever member that engages the first and second housings, moving the first and seco nd housings between the initial and final positions. The lever member includes a cam arm having first, second, and third gear surfaces. The second housing includes first an d second mating posts that are configured to engage the first, second, and third gear surfaces at first, second, and third distances, respectively, from the rotational axis a s the lever member rotates through a range of motions to move the first and second housings between the initial and final positions. The first, second, and third distances are all different.",TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;MARTIN GALEN MONROE,,https://lens.org/136-092-427-219-304,Granted Patent,no,0,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
10,US,A1,US 2001/0030190 A1,179-080-788-898-754,2001-10-18,2001,US 68109901 A,2001-01-04,US 68109901 A;;US 17562000 P,2000-01-11,Confection cup assembly,"
   A confection cup assembly comprising a sleeve that slidably receives a confection cup and a collar having a portion that is slidably received within the open top of a confection cup in a manner such that a portion of the sleeve and collar overlap and retain the cup therebetween. 
",VOGEL RICHARD E.;;FOLTZ TIMOTHY J.,VOGEL RICHARD E;;FOLTZ TIMOTHY J,DART CONTAINER CORPORATION (2001-01-03),https://lens.org/179-080-788-898-754,Patent Application,yes,4,4,1,1,0,B65D25/02;;B65D25/34;;B65D25/34;;B65D25/02,B65D8/06;;B65D25/02;;B65D25/34,220/4.03;;220/592.14,0,0,,,,DISCONTINUED
11,EP,A2,EP 1343225 A2,001-011-279-398-837,2003-09-10,2003,EP 03100577 A,2003-03-07,US 9334502 A,2002-03-07,Mate assist assembly for connecting electrical contacts,"An electrical connector comprises first and second housings (18,22) configured to be matable with one another to join electrical contacts. The first and second housings are movable between initial and final positions, at which the electrical contacts partially and fully mate, respectively. The electrical connector includes a lever member (14) which engages the first and second housings for moving the housings between the initial and final positions. The lever member includes a cam arm (26) having first, second, and third gear surfaces. The second housing includes first and second mating posts (46,50) configured to engage the first, second and third gear surfaces at first, second and third distances, respectively, from the rotational axis (36) as the lever member rotates through a range of motions to move the first and second housings between the initial and final positions. The first, second and third distances are all different.",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/001-011-279-398-837,Patent Application,yes,2,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
12,WO,A1,WO 2006/133244 A1,038-515-464-237-455,2006-12-14,2006,US 2006/0022030 W,2006-06-07,US 14709005 A,2005-06-07,CONNECTOR ASSEMBLY WITH TERMINAL POSITION ASSURANCE DEVICE,"A connector assembly (10) including a housing (14) and a TPA device (16). The housing is configured to receive a first terminal (222) in a first direction, and includes a first slot (68), a second slot (70), and a first latch (86) that is movable between a flexed position wherein the first latch is disengaged from the first terminal and an unflexed position wherein the first latch is engaged with the first terminal to inhibit movement of the first terminal in a second direction that is opposite the first direction. The TPA device is configured to be coupled to the housing for movement between a mated position and a pre-latched position, and includes a first retention block (158) that is received by the first slot, the first retention block inhibiting the first latch from moving from the unflexed position to the flexed position when the TPA device is in the mated position, and a second retention block (162) that is received by the second slot, the second retention block inhibiting movement of the first terminal in the second direction.",TYCO ELECTRONICS CORP;;FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/038-515-464-237-455,Patent Application,yes,5,0,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,0,0,,,,PENDING
13,US,A1,US 2012/0058672 A1,035-377-834-091-755,2012-03-08,2012,US 87497010 A,2010-09-02,US 87497010 A,2010-09-02,ELECTRICAL CONNECTOR HAVING SHAPED DIELECTRIC INSERT FOR CONTROLLING IMPEDANCE,"Electrical connector that includes a connector housing having mating and terminating ends. The connector housing has a housing cavity and a leading edge at the mating end that defines an opening to the housing cavity. A central axis extends through the housing cavity between the mating and terminating ends. The electrical connector also includes a dielectric insert within the housing cavity and an electrical contact that is held by the insert along the central axis. The insert has a recess surface that faces the mating end and extends a radial distance, outward from the electrical contact. The insert includes a dielectric rim that projects from the recess surface toward the mating end. The dielectric rim surrounds: and is radially spaced from at least a portion of the electrical contact. The dielectric rim and the recess surface define an impedance-control space that surrounds at least the portion of the electrical contact.",BLASICK FRANCIS J;;FOLTZ KEITH RICHARD;;TYCO ELECTRONICS CORP,BLASICK FRANCIS J;;FOLTZ KEITH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/035-377-834-091-755,Patent Application,no,8,5,5,5,0,H01R24/44;;H01R24/44,H01R9/05,439/578,0,0,,,,ACTIVE
14,DE,B2,DE 2324575 B2,067-527-048-732-676,1978-11-09,1978,DE 2324575 A,1973-05-16,US 25420772 A,1972-05-17,DE 2324575 B2,,"HANKISON CORP., CANONSBURG, PA. (V.ST.A.)","FOLTZ, DONALD RICHARD, PITTSBURGH, PA. (V.ST.A.)",,https://lens.org/067-527-048-732-676,Patent Application,no,0,3,12,12,0,B01D46/24;;F02M35/024;;B01D46/24;;F02M35/024,B01D46/24;;F02M35/024,,0,0,,,,EXPIRED
15,CN,A,CN 112020801 A,008-495-450-311-227,2020-12-01,2020,CN 201980027337 A,2019-03-15,US 201815933735 A;;IB 2019052122 W,2018-03-23,CONNECTOR POSITION ASSURANCE MEMBER,"A connector position assurance device 200 having a base portion 202 and a pair of resiliently deformable beams 204, 205. Cam engaging members 250 extend from side walls 256 of the pair of resilientlydeformable beams 204, 205. A first lockout projection engagement member 230 is provided proximate the beam front ends 224 of the pair of resiliently deformable beams 204, 205 and extends between the first beam 204 and the second beam 205. A second lockout projection engagement member 240 is spaced from the base front end 210 and spaced from the first lockout projection engagement member 230. The second lockout projection engagement member 240 extends between the first beam 204 and the second beam 205. A lockout projection receiving opening 254 is formed by the first lockout projection engagement member 230, the second lockout projection engagement member 240, and portions of the pair of resiliently deformable beams 204, 205.",TE CONNECTIVITY CORP,FOLTZ KEITH RICHARD;;EVANS NICHOLAS LEE,,https://lens.org/008-495-450-311-227,Patent Application,no,15,0,9,9,0,H01R13/639;;H01R13/6272;;H01R13/641;;H01R13/6272;;H01R13/639;;H01R13/641;;H01R13/4223;;H01R13/4368;;H01R13/4368;;H01R13/4223;;H01R13/641;;H01R13/6272;;H01R13/639,H01R13/627;;H01R13/639;;H01R13/641,,0,0,,,,ACTIVE
16,JP,A,JP 2003272762 A,166-293-747-374-564,2003-09-26,2003,JP 2003061834 A,2003-03-07,US 9334502 A,2002-03-07,ELECTRICAL CONNECTOR,"<P>PROBLEM TO BE SOLVED: To provide an easy-to-manufacture electric connector constituting a mating auxiliary device assembly using a lever for engaging friction-resistant components, generating a strong mating releasing force. <P>SOLUTION: This electric connector is equipped with first and second mating posts 46, 50 mounted in an inner area of a second housing 22. The first mating post 46 is engaged with a first gear face 138 at a first distance D1 from a rotational axis 36, when a lever member 14 rotates along a predetermined range of motions, in order to move first and second housings 18, 22 towards a final position. The second mating post 50 is engaged with a second gear face 142 at a second distance D2 different from the first distance D1 from the rotational axis 36, when the lever member 14 rotates in an opposite direction along a predetermined range of motions, in order to move the first and second housings 18, 22 towards an initial position. <P>COPYRIGHT: (C)2003,JPO",TYCO ELECTRONICS CORP,MARTIN GALEN M;;FOLTZ-KEITH RICHARD,,https://lens.org/166-293-747-374-564,Patent Application,no,0,1,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
17,ES,T3,ES 2346417 T3,005-833-466-081-702,2010-10-15,2010,ES 03100577 T,2003-03-07,US 9334502 A,2002-03-07,DISPOSITIVO DE AYUDA AL ACOPLAMIENTO PARA CONECTAR CONTACTOS ELECTRICOS.,"Un conector eléctrico que incluye: alojamientos primero y segundo (18, 22) que tienen extremos configurados para recibir contactos eléctricos, teniendo los citados alojamientos primero y segundo (18, 22) extremos delanteros configurados para ser acoplables uno con el otro para unir contactos eléctricos correspondientes, siendo amovibles los citados alojamientos primero y segundo (18, 22) entre las posiciones inicial y final, en el cual los contactos eléctricos correspondientes se acoplan parcial y totalmente, respectivamente; un miembro de palanca (14) que se aplica a los citados alojamientos primero y segundo (18, 22) para mover los citados alojamientos primero y segundo (18, 22) entre las citadas posiciones inicial y final cuando el citado miembro de palanca (14) es rotado en un rango de movimientos alrededor de un eje de rotación (36), incluyendo el citado miembro de palanca (14) al menos un brazo de leva (26) que tiene una abertura de retención (118) que se aplica al citado primer alojamiento (18) y una primera superficie de desengranado (134) configurada para aplicarse al citado segundo alojamiento (22), y postes de acoplamiento primero y segundo (46, 50) montados dentro de una región interior del citado segundo alojamiento (22), estando configurado el citado primer poste de acoplamiento (46) para aplicarse a la citada primera superficie de desengranado (134) en una primera distancia (D1) desde el citado eje de rotación (36) cuando el citado miembro de palanca (14) está rotando en el citado rango de movimientos para mover los citados alojamientos primero y segundo (18, 22) a la citada posición inicial, estando caracterizado el conector eléctrico porque el citado miembro de palanca (14) incluye una segunda superficie de desengranado (142) configurada para aplicarse al citado segundo alojamiento (22), estando configurado el citado segundo poste de acoplamiento (50) para aplicarse a la citada segunda superficie de desengranado (142) en una segunda distancia (D2) desde el citado eje de rotación (36) cuando el citado miembro de palanca (14) está rotando en el citado rango de movimientos para mover los citados alojamientos primero y segundo (18, 22) a la citada posición inicial, siendo diferentes las citadas distancias primera y segunda ( D1, D2).",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/005-833-466-081-702,Granted Patent,no,0,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
18,JP,A,JP 2003257524 A,034-739-927-294-067,2003-09-12,2003,JP 2003051182 A,2003-02-27,US 8703002 A,2002-03-01,ELECTRIC CONNECTOR,"<P>PROBLEM TO BE SOLVED: To provide a compact electric connector with a single mechanism of fixing both a contact guide and a board to the electric connector. <P>SOLUTION: The electric connector 100 so structured as to be connected with a board 400 is provided with a housing 200 retaining a plurality of electric contacts 212. Each contact is provided with a contact interface 215 which can be reciprocally connected with a reciprocal contact interface 405 retained by the board. A contact guide 300 is provided with a plurality of openings 305 arranged so as to be aligned and insertion-coupled with the contact interface of the contacts. The housing 200 is provided with a single lock part 230 structured so as to get insertion-coupled with both the contact guide 300 and the board 400 in order to fix the contact guide and the board to the housing. <P>COPYRIGHT: (C)2003,JPO",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ-KEITH RICHARD,,https://lens.org/034-739-927-294-067,Patent Application,no,0,3,6,6,0,H01R12/724;;H01R12/724;;H01R12/724,H01R12/16;;H01Q13/18;;H01R12/00;;H01R12/14;;H01R12/71;;H01R13/639,,0,0,,,,PENDING
19,US,B1,US 10135172 B1,056-442-593-101-632,2018-11-20,2018,US 201815933735 A,2018-03-23,US 201815933735 A,2018-03-23,Connector position assurance member,"A connector position assurance device having a base portion and a pair of resiliently deformable beams. Cam engaging members extend from side walls of the pair of resiliently deformable beams. A first lockout projection engagement member is provided proximate the beam front ends of the pair of resiliently deformable beams and extends between the first beam and the second beam. A second lockout projection engagement member is spaced from the base front end and spaced from the first lockout projection engagement member. The second lockout projection engagement member extends between the first beam and the second beam. A lockout projection receiving opening is formed by the first lockout projection engagement member, the second lockout projection engagement member, and portions of the pair of resiliently deformable beams.",TE CONNECTIVITY CORP,FOLTZ KEITH RICHARD;;EVANS NICHOLAS LEE,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2018-03-22);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/056-442-593-101-632,Granted Patent,yes,18,20,9,9,0,H01R13/639;;H01R13/6272;;H01R13/641;;H01R13/6272;;H01R13/639;;H01R13/641;;H01R13/4223;;H01R13/4368;;H01R13/4368;;H01R13/4223;;H01R13/641;;H01R13/6272;;H01R13/639,H01R13/627;;H01R13/422;;H01R13/436;;H01R13/641,,0,0,,,,ACTIVE
20,BR,A,BR 0300402 A,122-605-654-532-635,2004-08-17,2004,BR 0300402 A,2003-03-07,US 9334502 A,2002-03-07,Conjunto de auxìlio de união para conexão de contatos elétricos,"""CONJUNTO DE AUXìLIO DE UNIãO PARA CONEXãO DE CONTATOS ELéTRICOS"". é fornecido um conector elétrico que inclui primeiro e segundo alojamentos configurados para serem correspondidos entre si para casar contatos elétricos. Os primeiro e segundo alojamentos são móveis entre posições inicial e final, nas quais os contatos elétricos se unem parcial e totalmente, respectivamente. O conector elétrico inclui um elemento de alavanca que engata os primeiro e segundo alojamentos, movendo os primeiro e segundo alojamentos entre as posições inicial e final. O elemento de alavanca inclui um braço de came que tem primeira, segunda e terceira superfícies de engrenagem. O segundo alojamento inclui primeiro e segundo postes correspondentes que são configurados para engatar as primeira, segunda e terceira superficies de engrenagem nas primeira, segunda e terceira distâncias, respectivamente, do eixo rotacional à medida que o elemento de alavanca gira através de uma faixa de movimentos para mover os primeiro e segundo alojamentos entre as posições inicial e final. As primeira, segunda e terceira distâncias são todas diferentes.",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/122-605-654-532-635,Patent Application,no,0,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,DISCONTINUED
21,CN,A,CN 102570132 A,129-337-729-996-351,2012-07-11,2012,CN 201110362241 A,2011-09-02,US 87497010 A,2010-09-02,Electrical connector having shaped dielectric insert for controlling impedance,"A electrical connector that includes a connector housing (100) having mating (104) and terminating ends(106). The connector housing has a housing cavity (105) and a leading edge (108) at the mating end that defines an opening (110) to the housing cavity. A central axis(190) extends through the housing cavity between the mating and terminating ends. The electrical connector (112) also includes a dielectric insert within the housing cavity and an electrical contact (125) that is held by the insert along the central axis. The insert has a recess surface (210) that faces the mating end and extends a radial distance(RD4), outward from the electrical contact. The insert includes a dielectric rim(222) that projects from the recess surface toward the mating end. The dielectric rim surrounds: and is radially spaced from at least a portion of the electrical contact. The dielectric rim and the recess surface define an impedance-control space (134) that surrounds at least the portion of the electrical contact.",TYCO ELECTRONICS CO LTD,BLACK FRANCIS J;;FOLTZ KEITH RICHARD,,https://lens.org/129-337-729-996-351,Patent Application,no,4,2,5,5,0,H01R24/44;;H01R24/44,H01R13/46;;H01R13/02,,0,0,,,,ACTIVE
22,EP,A1,EP 1341265 A1,163-443-247-183-798,2003-09-03,2003,EP 03251197 A,2003-02-27,US 8703002 A,2002-03-01,Contact guide retention apparatus,An electrical connector (100) configured for connection to a substrate (400) includes a housing (200) which carries a plurality of electrical contacts. Each contact has a contact interface (215) interconnectable with a reciprocal contact interface carried by a substrate. A contact guide (300) has a plurality of apertures (305) positioned to align and mate with the contact interfaces (215) of the contacts. The housing (200) includes a single locking mechanism comprising posts (230) configured to mate with both the contact guide and the substrate for securing the contact guide and the substrate to the housing.,TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ-KEITH RICHARD,,https://lens.org/163-443-247-183-798,Patent Application,yes,4,0,6,6,0,H01R12/724;;H01R12/724;;H01R12/724,H01Q13/18;;H01R12/16;;H01R12/00;;H01R12/14;;H01R12/71;;H01R13/639,,0,0,,,,DISCONTINUED
23,DE,D1,DE 60333052 D1,028-825-242-121-335,2010-08-05,2010,DE 60333052 T,2003-03-07,US 9334502 A,2002-03-07,Kupplungshilfe Vorrichtung für elektrische Verbindungskontakte,,TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/028-825-242-121-335,Granted Patent,no,0,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
24,EP,A2,EP 1341263 A2,085-907-341-187-408,2003-09-03,2003,EP 03251198 A,2003-02-27,US 8758002 A,2002-02-28,Electronic module assembly,"An electronic module assembly comprises a pin organizer (30) installed after a header (10) is assembled to a module (50). Opposing forces tension the organizer, header and module assembly so as to provide a relatively fixed anchor for the header (10) upon the module (50), as well as providing orientation for the module and support for a pin array (15).",TYCO ELECTRONICS CORP,KANE VINCENT MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/085-907-341-187-408,Patent Application,yes,0,2,9,9,0,H01R12/724;;H01R12/724;;H01R13/514;;H05K3/306;;H05K3/306,H01R12/16;;H01R12/71;;H01R13/46;;H05K3/30,,0,0,,,,DISCONTINUED
25,CA,A1,CA 2420961 A1,120-392-077-216-245,2003-09-07,2003,CA 2420961 A,2003-03-06,US 9334502 A,2002-03-07,MATE ASSIST ASSEMBLY FOR CONNECTING ELECTRICAL CONTACTS,"An electrical connector is provided including first and second housings configured to be matable with one another to join electrical contacts. The first and second housings are movable between initial and final positions, at which th e electrical contacts partially and fully mate, respectively. The electrical connector includes a lever member that engages the first and second housings, moving the first and seco nd housings between the initial and final positions. The lever member includes a cam arm having first, second, and third gear surfaces. The second housing includes first an d second mating posts that are configured to engage the first, second, and third gear surfaces at first, second, and third distances, respectively, from the rotational axis a s the lever member rotates through a range of motions to move the first and second housings between the initial and final positions. The first, second, and third distances are all different.",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/120-392-077-216-245,Patent Application,no,0,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
26,KR,A,KR 20200131901 A,146-649-671-625-484,2020-11-24,2020,KR 20207030602 A,2019-03-15,US 201815933735 A;;IB 2019052122 W,2018-03-23,커넥터 위치 보증 부재,"커넥터 위치 보증 장치(200)는 베이스부(202) 및 한 쌍의 탄성 변형가능 빔(204, 205)을 갖는다. 캠 맞물림 부재(250)는 한 쌍의 탄성 변형가능 빔(204, 205)의 측벽(256)으로부터 연장된다. 제1 잠금 돌출부 맞물림 부재(230)는, 한 쌍의 탄성 변형가능 빔(204, 205)의 빔 전방 단부(224)에 근접하게 제공되며, 제1 빔(204)과 제2 빔(205) 사이에서 연장된다. 제2 잠금 돌출부 맞물림 부재(240)는, 베이스 전방 단부(210)로부터 이격되며 제1 잠금 돌출부 맞물림 부재(230)로부터 이격된다. 제2 잠금 돌출부 맞물림 부재(240)는 제1 빔(204)과 제2 빔(205) 사이에서 연장된다. 잠금 돌출부 수용 개구(254)는, 제1 잠금 돌출부 맞물림 부재(230), 제2 잠금 돌출부 맞물림 부재(240), 및 한 쌍의 탄성 변형가능 빔(204, 205)의 일부들에 의해 형성된다.",TE CONNECTIVITY CORP,FOLTZ KEITH RICHARD;;EVANS NICHOLAS LEE,,https://lens.org/146-649-671-625-484,Patent Application,no,8,0,9,9,0,H01R13/639;;H01R13/6272;;H01R13/641;;H01R13/6272;;H01R13/639;;H01R13/641;;H01R13/4223;;H01R13/4368;;H01R13/4368;;H01R13/4223;;H01R13/641;;H01R13/6272;;H01R13/639,H01R13/627;;H01R13/422;;H01R13/436;;H01R13/639;;H01R13/641,,0,0,,,,ACTIVE
27,BR,A,BR 0300546 A,136-259-962-425-056,2004-08-10,2004,BR 0300546 A,2003-02-27,US 8703002 A,2002-03-01,Dispositivo de retenção de condutor de contato,"""DISPOSITIVO DE RETENçãO DE CONDUTOR DE CONTATO"". Um conector elétrico, configurado para conexão a um substrato, inclui um alojamento que suporta uma pluralidade de contatos elétricos. Cada contato apresenta uma interface de contato que pode ser interligada com uma interface de contato recíproca, suportada por um substrato. Um condutor de contato apresenta uma pluralidade de aberturas, posicionadas para se alinharem e conjugarem às interfaces de contato dos contatos. O alojamento inclui um único mecanismo de travamento, configurado para se conjugar tanto ao condutor de contato, quanto ao substrato, para segurança do condutor de contato e do substrato ao alojamento.",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/136-259-962-425-056,Patent Application,no,0,0,6,6,0,H01R12/724;;H01R12/724;;H01R12/724,H01R12/16;;H01Q13/18;;H01R12/00;;H01R12/14;;H01R12/71;;H01R13/639,,0,0,,,,DISCONTINUED
28,EP,A3,EP 1343225 A3,130-719-058-604-466,2004-08-25,2004,EP 03100577 A,2003-03-07,US 9334502 A,2002-03-07,Mate assist assembly for connecting electrical contacts,"An electrical connector comprises first and second housings (18,22) configured to be matable with one another to join electrical contacts. The first and second housings are movable between initial and final positions, at which the electrical contacts partially and fully mate, respectively. The electrical connector includes a lever member (14) which engages the first and second housings for moving the housings between the initial and final positions. The lever member includes a cam arm (26) having first, second, and third gear surfaces. The second housing includes first and second mating posts (46,50) configured to engage the first, second and third gear surfaces at first, second and third distances, respectively, from the rotational axis (36) as the lever member rotates through a range of motions to move the first and second housings between the initial and final positions. The first, second and third distances are all different.",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/130-719-058-604-466,Search Report,yes,1,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
29,CA,C,CA 2609775 C,167-258-643-290-027,2010-08-03,2010,CA 2609775 A,2006-06-07,US 14709005 A;;US 2006/0022030 W,2005-06-07,CONNECTOR ASSEMBLY WITH TERMINAL POSITION ASSURANCE DEVICE,"A connector assembly (10) including a housing (14) and a TPA device (16). The housing is configured to receive a first terminal (222) in a first direction, and includes a first slot (68), a second slot (70), and a first latch (86) that is movable between a flexed position wherein the first latch is disengaged from the first terminal and an unflexed position wherein the first latch is engaged with the first terminal to inhibit movement of the first terminal in a second direction that is opposite the first direction. The TPA device is configured to be coupled to the housing for movement between a mated position and a pre-latched position, and includes a first retention block (158) that is received by the first slot, the first retention block inhibiting the first latch from moving from the unflexed position to the flexed position when the TPA device is in the mated position, and a second retention block (162) that is received by the second slot, the second retention block inhibiting movement of the first terminal in the second direction.",TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/167-258-643-290-027,Granted Patent,no,0,0,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,0,0,,,,INACTIVE
30,DE,C3,DE 2324575 C3,168-775-183-942-240,1979-07-12,1979,DE 2324575 A,1973-05-16,US 25420772 A,1972-05-17,DE 2324575 C3,,"HANKISON CORP., CANONSBURG, PA. (V.ST.A.)","FOLTZ, DONALD RICHARD, PITTSBURGH, PA. (V.ST.A.)",,https://lens.org/168-775-183-942-240,Granted Patent,no,0,0,12,12,0,B01D46/24;;F02M35/024;;B01D46/24;;F02M35/024,B01D46/24;;F02M35/024,,0,0,,,,EXPIRED
31,EP,A1,EP 1889332 A1,099-650-325-859-777,2008-02-20,2008,EP 06772370 A,2006-06-07,US 2006/0022030 W;;US 14709005 A,2005-06-07,CONNECTOR ASSEMBLY WITH TERMINAL POSITION ASSURANCE DEVICE,,TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,"TE CONNECTIVITY CORPORATION, BERWYN, US (2018-10-23);;TYCO ELECTRONICS CORPORATION, US (2018-06-26)",https://lens.org/099-650-325-859-777,Patent Application,yes,0,1,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,1,0,,,See references of WO 2006133244A1,ACTIVE
32,EP,A1,EP 3769375 A1,112-323-937-268-178,2021-01-27,2021,EP 19717361 A,2019-03-15,US 201815933735 A;;IB 2019052122 W,2018-03-23,CONNECTOR POSITION ASSURANCE MEMBER,,TE CONNECTIVITY CORP,FOLTZ KEITH RICHARD;;EVANS NICHOLAS LEE,TE CONNECTIVITY SOLUTIONS GMBH (2023-09-27),https://lens.org/112-323-937-268-178,Patent Application,yes,0,0,9,9,0,H01R13/639;;H01R13/6272;;H01R13/641;;H01R13/6272;;H01R13/639;;H01R13/641;;H01R13/4223;;H01R13/4368;;H01R13/4368;;H01R13/4223;;H01R13/641;;H01R13/6272;;H01R13/639,H01R13/627;;H01R13/639;;H01R13/641,,0,0,,,,PENDING
33,US,A1,US 2009/0020309 A1,143-461-308-746-851,2009-01-22,2009,US 77955507 A,2007-07-18,US 77955507 A,2007-07-18,WIRE MANAGEMENT COVER AND SYSTEM,"A wire management cover having a cover body configured to detachably engage a connector and having an opening configured to allow passage of one or more wires. The cover includes a wire management portion hingedly attached to the cover body. The wire management portion has a plurality of channels, each channel configured to receive at least one of the one or more wires. The wire management portion is capable of latching engagement with the cover body. The cover body includes features permitting orientation of the cover in a plurality of directions with respect to the connector.",TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;MARTIN GALEN M,TYCO ELECTRONICS CORPORATION (2007-07-06),https://lens.org/143-461-308-746-851,Patent Application,yes,9,10,2,2,0,H02G3/0487;;H02G3/0608;;H02G3/0608;;H02G3/0487,H02G3/04,174/97;;174/95,0,0,,,,INACTIVE
34,EP,B1,EP 1889332 B1,180-966-144-580-802,2011-08-17,2011,EP 06772370 A,2006-06-07,US 2006/0022030 W;;US 14709005 A,2005-06-07,CONNECTOR ASSEMBLY WITH TERMINAL POSITION ASSURANCE DEVICE,,TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,"TE CONNECTIVITY CORPORATION, BERWYN, US (2018-10-23);;TYCO ELECTRONICS CORPORATION, US (2018-06-26)",https://lens.org/180-966-144-580-802,Granted Patent,yes,5,0,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,0,0,,,,ACTIVE
35,CA,A1,CA 2420165 A1,184-394-883-312-742,2003-08-28,2003,CA 2420165 A,2003-02-26,US 8758002 A,2002-02-28,"ELECTRONIC MODULE ASSEMBLY APPARATUS, METHODS AND ARTICLES OF MANUFACTURE","Apparatus, methods and articles of manufacture for electronic module assemblies are shown, comprising a pin organizer installed after a header is assembled to a module. Opposing forces tension the organizer, header and module assembly, so as to provide a relatively fixed anchor for the header upon the module, as well as providing orientation for the module and support for a pin array.",TYCO ELECTRONICS CORP,KANE VINCENT MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/184-394-883-312-742,Patent Application,no,0,0,9,9,0,H01R12/724;;H01R12/724;;H01R13/514;;H05K3/306;;H05K3/306,H01R12/16;;H01R12/71;;H01R13/46;;H05K3/30,,0,0,,,,DISCONTINUED
36,TW,A,TW 201223025 A,072-009-689-409-538,2012-06-01,2012,TW 100131041 A,2011-08-30,US 87497010 A,2010-09-02,Electrical connector having shaped dielectric insert for controlling impedance,"An electrical connector comprises a connector housing having a mating end and a terminating end. The connector housing has a housing cavity and a leading edge at the mating end that defines an opening to the housing cavity, wherein a central axis extends through the housing cavity between the mating end and the terminating end. A dielectric insert is positioned within the housing cavity, and an electrical contact is held by the insert along the central axis and configured to engage a coupling connector in the housing cavity. The insert has a recess surface that faces the mating end and extends a radial distance (RD4) outward from the electrical contact. The insert includes a dielectric rim that projects from the recess surface toward the mating end. The dielectric rim surrounds and is radially spaced from at least a portion of the electrical contact. The dielectric rim and the recess surface define an impedance-control space that surrounds at least the portion of the electrical contact.",TYCO ELECTRONICS CORP,BLASICK FRANCIS J;;FOLTZ KEITH RICHARD,,https://lens.org/072-009-689-409-538,Patent of Addition,no,0,0,5,5,0,H01R24/44;;H01R24/44,H01R13/6473;;H01R24/44,,0,0,,,,PENDING
37,BR,A,BR 0300482 A,157-382-210-739-234,2004-08-17,2004,BR 0300482 A,2003-02-27,US 8758002 A,2002-02-28,"Aparelho, métodos e artigos de fabricação para montagem de módulo eletrônico","""APARELHO, MéTODOS E ARTIGOS DE FABRICAçãO PARA MONTAGEM DE MóDULO ELETRôNICO"". Aparelho, métodos e artigos de fabricação para montagens de módulo eletrônico são mostrados, compreendendo um organizador de pino instalado depois que uma placa atravessada por terminais isolados é montada em um módulo. Forças opostas tracionam o organizador, placa atravessada por terminais isolados e montagem de módulo, de modo a proporcionar um apoio relativamente fixo para a placa atravessada por terminais isolados sobre o módulo, bem como proporcionar orientação para o módulo e suporte para uma formação de pino.",TYCO ELECTRONICS CORP,KANE VINCENT MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/157-382-210-739-234,Patent Application,no,0,0,9,9,0,H01R12/724;;H01R12/724;;H01R13/514;;H05K3/306;;H05K3/306,H01R12/16;;H01R12/71;;H01R13/46;;H05K3/30,,0,0,,,,DISCONTINUED
38,EP,A3,EP 1341263 A3,192-447-869-106-615,2004-08-25,2004,EP 03251198 A,2003-02-27,US 8758002 A,2002-02-28,Electronic module assembly,"An electronic module assembly comprises a pin organizer (30) installed after a header (10) is assembled to a module (50). Opposing forces tension the organizer, header and module assembly so as to provide a relatively fixed anchor for the header (10) upon the module (50), as well as providing orientation for the module and support for a pin array (15).",TYCO ELECTRONICS CORP,KANE VINCENT MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/192-447-869-106-615,Search Report,yes,5,1,9,9,0,H05K3/306;;H01R12/724;;H01R13/514;;H01R12/724;;H05K3/306,H01R12/71;;H01R12/16;;H01R13/46;;H05K3/30,,0,0,,,,DISCONTINUED
39,EP,B1,EP 1343225 B1,048-333-339-817-501,2010-06-23,2010,EP 03100577 A,2003-03-07,US 9334502 A,2002-03-07,Mate assist assembly for connecting electrical contacts,,TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KEITH RICHARD,,https://lens.org/048-333-339-817-501,Granted Patent,yes,1,0,13,13,0,H01R13/62944;;H01R13/629;;H01R13/62944,H01R13/629,,0,0,,,,EXPIRED
40,CN,B,CN 101218714 B,070-885-809-270-153,2010-05-19,2010,CN 200680024935 A,2006-06-07,US 2006/0022030 W;;US 14709005 A,2005-06-07,Connector assembly with terminal position assurance device,"A connector assembly (10) includes a housing (14) and a TPA device (16). The housing is configured to receive a first terminal (222) in a first direction, and includes a first slot (68), a second slot(70), and a first latch (86) that is movable between a flexed position wherein the first latch is disengaged from the first terminal and an unflexed position wherein the first latch is engaged with the first terminal to inhibit movement of the first terminal in a second direction that is opposite the first direction. The TPA device is configured to be coupled to the housing for movement between amated position and a pre-latched position, and includes a first retention block (158) that is received by the first slot, the first retention block inhibiting the first latch from moving from the unflexed position to the flexed position when the TPA device is in the mated position, and a second retention block (162) that is received by the second slot, the second retention block inhibiting movement of the first terminal in the second direction.",TYCO ELECTRONICS CORP,RICHARD FOLTZ KEITH;;SCOTT BUCHTER BRADLEY,,https://lens.org/070-885-809-270-153,Granted Patent,no,0,0,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,0,0,,,,ACTIVE
41,US,B2,US 7537478 B2,075-796-373-166-239,2009-05-26,2009,US 77955507 A,2007-07-18,US 77955507 A,2007-07-18,Wire management cover and system,"A wire management cover having a cover body configured to detachably engage a connector and having an opening configured to allow passage of one or more wires. The cover includes a wire management portion hingedly attached to the cover body. The wire management portion has a plurality of channels, each channel configured to receive at least one of the one or more wires. The wire management portion is capable of latching engagement with the cover body. The cover body includes features permitting orientation of the cover in a plurality of directions with respect to the connector.",TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;MARTIN GALEN M,TYCO ELECTRONICS CORPORATION (2007-07-06),https://lens.org/075-796-373-166-239,Granted Patent,yes,9,19,2,2,0,H02G3/0487;;H02G3/0608;;H02G3/0608;;H02G3/0487,H01R13/58,439/468;;439/466,0,0,,,,INACTIVE
42,KR,A,KR 20080006014 A,095-572-685-186-266,2008-01-15,2008,KR 20077028442 A,2006-06-07,US 14709005 A,2005-06-07,CONNECTOR ASSEMBLY WITH TERMINAL POSITION ASSURANCE DEVICE,"A connector assembly (10) including a housing (14) and a TPA device (16). The housing is configured to receive a first terminal (222) in a first direction, and includes a first slot (68), a second slot (70), and a first latch (86) that is movable between a flexed position wherein the first latch is disengaged from the first terminal and an unflexed position wherein the first latch is engaged with the first terminal to inhibit movement of the first terminal in a second direction that is opposite the first direction. The TPA device is configured to be coupled to the housing for movement between a mated position and a pre-latched position, and includes a first retention block (158) that is received by the first slot, the first retention block inhibiting the first latch from moving from the unflexed position to the flexed position when the TPA device is in the mated position, and a second retention block (162) that is received by the second slot, the second retention block inhibiting movement of the first terminal in the second direction.",TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/095-572-685-186-266,Patent Application,no,0,2,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436;;H01R13/64,,0,0,,,,INACTIVE
43,US,B2,US 8475204 B2,162-373-881-211-066,2013-07-02,2013,US 87497010 A,2010-09-02,US 87497010 A,2010-09-02,Electrical connector having shaped dielectric insert for controlling impedance,"Electrical connector that includes a connector housing having mating and terminating ends. The connector housing has a housing cavity and a leading edge at the mating end that defines an opening to the housing cavity. A central axis extends through the housing cavity between the mating and terminating ends. The electrical connector also includes a dielectric insert within the housing cavity and an electrical contact that is held by the insert along the central axis. The insert has a recess surface that faces the mating end and extends a radial distance, outward from the electrical contact. The insert includes a dielectric rim that projects from the recess surface toward the mating end. The dielectric rim surrounds: and is radially spaced from at least a portion of the electrical contact. The dielectric rim and the recess surface define an impedance-control space that surrounds at least the portion of the electrical contact.",BLASICK FRANCIS J;;FOLTZ KEITH RICHARD;;TYCO ELECTRONICS CORP,BLASICK FRANCIS J;;FOLTZ KEITH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/162-373-881-211-066,Granted Patent,yes,16,11,5,5,0,H01R24/44;;H01R24/44,H01R9/05,439/578;;439/584,1,0,,,"BNC Specifications to MIL-C-39012 (IEC 169-8); Spectrum Elektrotechnik GmbH, Apr. 1998, 4 pgs.",ACTIVE
44,MX,A,MX 2007015451 A,010-988-738-856-063,2008-02-19,2008,MX 2007015451 A,2006-06-07,US 14709005 A;;US 2006/0022030 W,2005-06-07,CONNECTOR ASSEMBLY WITH TERMINAL POSITION ASSURANCE DEVICE.,"A connector assembly (10) including a housing (14) and a TPA device (16). The housing is configured to receive a first terminal (222) in a first direction, and includes a first slot (68), a second slot (70), and a first latch (86) that is movable between a flexed position wherein the first latch is disengaged from the first terminal and an unflexed position wherein the first latch is engaged with the first terminal to inhibit movement of the first terminal in a second direction that is opposite the first direction. The TPA device is configured to be coupled to the housing for movement between a mated position and a pre-latched position, and includes a first retention block (158) that is received by the first slot, the first retention block inhibiting the first latch from moving from the unflexed position to the flexed position when the TPA device is in the mated position, and a second retention block (162) that is received by the second slot, the second retention block inhibiting movement of the first terminal in the second direction.",TYCO ELECTRONICS CORP,FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/010-988-738-856-063,Patent Application,no,0,0,13,13,0,H01R13/436;;H01R13/4362;;H01R13/4362;;H01R13/424;;H01R13/424;;H01R13/64,H01R13/436,,0,0,,,,ACTIVE
45,JP,A,JP 2003257536 A,108-439-026-477-729,2003-09-12,2003,JP 2003053385 A,2003-02-28,US 8758002 A,2002-02-28,"MODULE ASSEMBLY, ASSEMBLING METHOD AND MANUFACTURING DEVICE","<P>PROBLEM TO BE SOLVED: To provide a pin organizer, compact and easy to operate, for helping to hold the whole pins during assembly of a module. <P>SOLUTION: Shown here are an electronic module assembly consisting of a pin organizer set after a header is fitted into the electronic module, its assembly method, and the manufacturing device. The position and the direction are fixed by an inverse tensile force of an organizer, a header and a module assembly to support a pin alignment, and the header and module are connected with each other. <P>COPYRIGHT: (C)2003,JPO",TYCO ELECTRONICS CORP,KANE VINCENT MICHAEL;;FOLTZ-KEITH RICHARD,,https://lens.org/108-439-026-477-729,Patent Application,no,0,1,9,9,0,H01R12/724;;H01R12/724;;H01R13/514;;H05K3/306;;H05K3/306,H01R12/16;;H01R12/71;;H01R13/46;;H05K3/30,,0,0,,,,EXPIRED
46,US,A,US 2736334 A,138-680-781-080-812,1956-02-28,1956,US 25791251 A,1951-11-23,US 25791251 A,1951-11-23,Twin-arch pipe line span,,RILEY WALTER E;;FOLTZ FRANKLIN J;;RICHARD BENNETT,RILEY WALTER E;;FOLTZ FRANKLIN J;;RICHARD BENNETT,,https://lens.org/138-680-781-080-812,Granted Patent,no,6,6,1,1,0,F16L3/00;;Y10T137/402;;Y10T137/402;;F16L3/00,F16L3/00,,0,0,,,,EXPIRED
47,TW,B,TW I361528 B,109-362-724-535-619,2012-04-01,2012,TW 95107520 A,2006-03-07,US 7559605 A,2005-03-09,Electrical connector and electrical connector assembly having lever assist with latch hold down mechanism,,TYCO ELECTRONICS CORP,BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,,https://lens.org/109-362-724-535-619,Granted Patent,no,0,0,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,,,0,0,,,,INACTIVE
48,US,A1,US 2003/0077688 A1,103-818-279-973-294,2003-04-24,2003,US 19505002 A,2002-07-12,US 19505002 A;;AU 1989/044695 A;;CA 2002902 A;;EP 89312101 A;;JP 30885989 A;;KR 890017394 A;;US 44382095 A;;US 10681693 A;;US 74832791 A;;US 27730588 A,1988-11-29,Rapid read-out biological indicator,"
   A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product. 
",MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,,https://lens.org/103-818-279-973-294,Patent Application,yes,3,7,5,20,0,C12Q1/22;;C12Q1/22;;Y10S435/81;;Y10S435/81,C12Q1/22,435/31;;435/287.1,0,0,,,,DISCONTINUED
49,US,A1,US 2010/0055961 A1,181-056-053-266-23X,2010-03-04,2010,US 20143508 A,2008-08-29,US 20143508 A,2008-08-29,TERMINAL POSITION ASSURANCE MEMBER FOR ELECTRICAL CONNECTOR,"A connector assembly is comprised of a connector housing and a terminal position assurance member (TPA). The connector housing has a latch which abuts with a tine on the TPA. The terminal, when received in the fully inserted position, deflects the tine, and the TPA may move to its fully locked position.",TYCO ELECTRONICS CORP,MARTIN GALEN M;;FOLTZ KEITH RICHARD;;WHITEFOOT JOHN M,TYCO ELECTRONICS CORPORATION (2008-08-20),https://lens.org/181-056-053-266-23X,Patent Application,yes,5,20,3,3,0,H01R13/4365;;H01R13/4365;;H01R13/64;;H01R13/629;;H01R13/639,H01R13/62,439/345,0,0,,,,DISCONTINUED
50,ES,T3,ES 2087087 T3,072-389-814-757-046,1996-07-16,1996,ES 89312101 T,1989-11-22,US 27730588 A,1988-11-29,METODO RAPIDO PARA DETERMINAR LA EFICACIA DE UN CICLO DE ESTERILIZACION E INDICADOR BIOLOGICO DE LECTURA RAPIDA.,"SE PRESENTA UN METODO RAPIDO DE DETERMINACION DE LA EFICACIA DE UN CICLO DE ESTERILIZACION, Y UN INDICADOR ADAPTADO PARA REALIZAR DICHO METODO, QUE COMPRENDE LA EXPOSICION DEL CICLO DE ESTERILIZACION A UNA FUENTE DE UNA ENZIMA ACTIVA QUE TENGA ACTIVIDAD QUE SE CORRELACCIONE CON LA VIABILIDAD DE UN MICROORGANISMO COMUNMENTE USADO PARA SEGUIR LA ESTERILIZACION, E INCUBAR LA FUENTE DE ENZIMA, SIGUIENDO LA FINALIZACION DEL CICLO DE ESTERILIZACION, CON UNA CANTIDAD EFECTIVA DE UN SISTEMA DE SUSTRATO CAPAZ DE REACCIONAR CON CUALQUIER ENZIMA ACTIVA RESIDUAL PARA PRODUCIR ASI UN PRODUCTO DE ENZIMA MODIFICADA DETECTABLE.",MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,,https://lens.org/072-389-814-757-046,Granted Patent,no,0,0,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
51,CN,A,CN 101160696 A,064-139-195-791-242,2008-04-09,2008,CN 200680012722 A,2006-03-06,US 2006/0008345 W;;US 7559605 A,2005-03-09,Electrical connector assembly having lever assist with latch hold down mechanism,,TYCO ELECTRONICS CORP,SCOTT BUCHTER BRADLEY;;RICHARD FOLTZ KEITH;;RAYMOND SHUEY JOHN,,https://lens.org/064-139-195-791-242,Patent Application,no,0,17,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R13/629,,0,0,,,,INACTIVE
52,WO,A1,WO 2006/099007 A1,158-049-888-466-230,2006-09-21,2006,US 2006/0008345 W,2006-03-06,US 7559605 A,2005-03-09,ELECTRICAL CONNECTOR ASSEMBLY HAVING LEVER ASSIST WITH LATCH HOLD DOWN MECHANISM,"A connection system is shown where a mating assist member (6) may be added to assist in the mating between two connectors (4, 8) as is needed depending upon a number of connector terminals loaded and the mating force between them. The mating assist member is locked in place by the interaction of the mating assist member (6) and the corresponding latching structure (76, 170) of the connectors. The mating assist member (6), when moved into the disconnection condition, has a projection (78) which holds the cantilever beam arm (172) of the latch (10) in a position allowing the two connectors to be disconnected, which does not require the user to continue depressing the latch at the same time as rotating the mating assist member.",TYCO ELECTRONICS CORP;;BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,,https://lens.org/158-049-888-466-230,Patent Application,yes,2,2,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R13/629,,0,0,,,,PENDING
53,US,A,US 5252484 A,074-511-311-196-231,1993-10-12,1993,US 74832791 A,1991-08-21,US 74832791 A;;US 27730588 A,1988-11-29,Rapid read-out biological indicator,"A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product.",MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,3M INNOVATIVE PROPERTIES COMPANY (2002-03-28),https://lens.org/074-511-311-196-231,Granted Patent,yes,32,89,5,20,0,C12Q1/22;;C12Q1/22;;Y10S435/81;;Y10S435/81,C12Q1/22,435/288;;422/55;;422/58;;435/296,17,14,003-052-556-881-426;;069-546-987-795-188;;059-097-821-340-163;;128-020-145-716-975;;008-820-833-702-213;;043-783-355-192-907;;066-321-154-144-982;;024-833-774-176-761;;023-532-052-619-713;;063-627-138-008-326;;009-142-964-897-483;;003-290-222-786-254;;101-627-427-868-409;;132-604-543-178-619,10.1002/9780470110355.ch5;;4893470;;pmc238996;;3089149;;10.1128/aem.51.5.969-977.1986;;10.1128/jb.143.1.27-34.1980;;6772628;;pmc294174;;10.1093/oxfordjournals.jbchem.a130278;;4756897;;10.1016/0167-4838(84)90321-2;;13229367;;10.1016/0003-9861(55)90018-7;;pmc169838;;10.1128/aem.31.6.807-812.1976;;7193;;10.1016/0005-2744(76)90092-9;;8145;;10.1016/0167-4838(82)90070-x;;10.1128/br.41.3.711-753.1977;;334155;;pmc414021;;10.1111/j.2042-7158.1982.tb04238.x;;6124601;;10.1016/s0196-6553(80)80029-0;;10297938;;pmc413821;;10.1128/br.37.3.320-342.1973;;4357018;;4145864;;10.1128/jb.114.3.1336-1345.1973;;pmc285397,"Roth, M., Fluorimetric Assay of Enzymes , Methods of Biochemical Analysis, vol. 17, pp. 189 285.;;Fluorescence in Enzymology , Quantitative Assay of Enzymes, pp. 312 348.;;Snyder, A. P. et al., Pattern Recognition Analysis of In Vivo Enzyme Substrate Fluorescence Velocities in Microorganism Detection and Identification , Appl. Environ. Microbiol., vol. 51, No. 5, pp. 969 977 (1986).;;Laurence, D. J. R., Fluorescence Techniques for the Enzymologist , Techniques for Characterization of Proteins, pp. 174 212.;;Warth, A. D., Heat Stability of Bacillus cereus Enzymes within Spores and in Extracts , Journal of Bacteriology, vol. 143, No. 1, pp. 27 34 (1980).;;Yutani, K. et al., Comparison of Thermostable Amylases from B. stearothermophilus Grown at Different Temperatures , J. Biochem., 74, pp. 573 579 (1973).;;Suzuki, Y. et al., Assignment of A p Nitrophenyl D Glucopyranosidase of Bacillus stearothermophilus ATCC 12016 to A Novel Exo 1,4 Glucosidase Active for Oligomaltosaccharides and Glucans , Biochemica et Biophysica Acta., 787, pp. 281 289 (1984).;;Campbell, L. L. Jr., Purification and Properties of an Amylase from Facultactive Thermophilic Bacteria , Amylase Studies, pp. 154 161.;;Suzuki, Y. et al., Production of Extracellular Glucosidase by a Thermophilic Bacillus Species, Applied and Environmental Microbiology , pp. 807 812 (1976).;;Suzuki, Y. et al., Purification and Properties of Extracellular Glucosidase of a Thermophile, Bacillus thermoglucosidius KP 1006 , Biochimica et Biophysical Acta., 445, pp. 386 397 (1976).;;Suzuki, Y. et al., Assignment of A p Nitrophenyl D Glucopyranoside Hydrolyzing Glucosidase of Bacillus stearothermophilus ATCC 12016 to An Exo Oligo 1,6 Glucosidase , Biochemica et Biophysics Acta., 704, pp. 476 483 (1982).;;Warth, A. D., Stabilization of Spore Enzymes to Heat by Reduction in Water Activity , Sporulation and Germination, Proceedings of the Eighth International Spore Conference, Woods Hole, Mass., pp. 249 252 (1980).;;Priest, F. G., Extracellular Enzyme Synthesis in the Genus Bacillus , Bacteriological Reviews, pp. 711 753 (1977).;;Hodges, N. A., A Comparison of Heat Resistance in Commercially Available Bacillus stearothermophilus Spore Preparations Used for Monitoring Steam Sterilization , J. Pharm. Pharmacol., 34, pp. 259 260 (1982).;;Starkey, D. H., The Use of Indicators For Quality Control of Sterilizing Processes in Hospital Practice: A Review , American Journal of Infection Control, vol. 8, No. 3, pp. 79 84 (1980).;;Singleton et al., Proteins from Thermophilic Microorganisms , Bacteriol Rev. 37, 320 42 (1973).;;Wisdom et al., Membranes of Bacillus stoarothermophilus : Factors Affecting Protoplast Stability and Thermostability of Alkaline Phosphatase and Reduced Nicotinamide Adenine Dinucleotide Oxidase , J. Baceriol. 114, 1336 45 (1973).",EXPIRED
54,US,B2,US 8197270 B2,172-407-192-107-453,2012-06-12,2012,US 45679409 A,2009-06-23,US 45679409 A,2009-06-23,Electrical connector having reversible wire dress,"An electrical connector assembly is disclosed having a main housing portion, camming slide mounting in camming slide receiving guides of the main housing portion, a wire guide and a lever. The lever is operably coupled to the camming slides to translate the camming slides upon rotation of the lever. The lever is mounted to the wire guide, and the combination of the wire guide and the lever are reversible to reverse the orientation of the wires in the wire dress.",VASBINDER ANDREW JACOB;;SHUEY JOHN R;;FOLTZ KEITH RICHARD;;TYCO ELECTRONICS CORP,VASBINDER ANDREW JACOB;;SHUEY JOHN R;;FOLTZ KEITH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/172-407-192-107-453,Granted Patent,yes,8,22,2,2,0,H01R13/62977;;H01R13/62977;;H01R13/62922;;H01R13/62922;;H01R13/62944;;H01R13/62944,H01R12/00,439/157,0,0,,,,ACTIVE
55,AU,B2,AU 616069 B2,108-221-908-445-970,1991-10-17,1991,AU 1989/044695 A,1989-11-14,US 27730588 A,1988-11-29,RAPID METHOD FOR DETERMINING EFFICACY OF A STERILIZATION CYCLE AND RAPID READ-OUT BIOLOGICAL INDICATOR,,MINNESOTA MINING & MFG,MATNER RICHARD REYNOLD;;WOODSON LEWIS PAYNE;;FOLTZ WILLIAM EDWARD,,https://lens.org/108-221-908-445-970,Granted Patent,no,2,1,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
56,EP,B1,EP 1856771 B1,086-956-653-282-698,2009-05-13,2009,EP 06737512 A,2006-03-06,US 2006/0008345 W;;US 7559605 A,2005-03-09,ELECTRICAL CONNECTOR ASSEMBLY HAVING LEVER ASSIST WITH LATCH HOLD DOWN MECHANISM,,TYCO ELECTRONICS CORP,BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,,https://lens.org/086-956-653-282-698,Granted Patent,yes,2,0,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R13/629,,0,0,,,,ACTIVE
57,TW,A,TW 200642208 A,135-478-215-070-486,2006-12-01,2006,TW 95107520 A,2006-03-07,US 7559605 A,2005-03-09,Electrical connector and electrical connector assembly having lever assist with latch hold down mechanism,"A connection system is shown where a mating assist member (6) may be added to assist in the mating between two connectors (4, 8) as is needed depending upon a number of connector terminals loaded and the mating force between them. The mating assist member is locked in place by the interaction of the mating assist member (6) and the corresponding latching structure (76, 170) of the connectors. The mating assist member (6), when moved into the disconnection condition, has a projection (78) which holds the cantilever beam arm (172) of the latch (10) in a position allowing the two connectors to be disconnected, which does not require the user to continue depressing the latch at the same time as rotating the mating assist member.",TYCO ELECTRONICS CORP,BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,,https://lens.org/135-478-215-070-486,Patent of Addition,no,0,1,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R3/00,,0,0,,,,INACTIVE
58,CN,B,CN 101160696 B,146-131-238-146-865,2010-07-07,2010,CN 200680012722 A,2006-03-06,US 2006/0008345 W;;US 7559605 A,2005-03-09,Electrical connector assembly having lever assist with latch hold down mechanism,"A connection system is shown where a lever-assist member may be added to assist in the mating between two connector housings as is needed depending upon a number of connector terminals loaded and the mating force between them. The lever-assist member is also locked in place by the interaction of the pivot-assist member and the corresponding latching structure of the connectors. The lever-assist member, when moved into the disconnection condition, has a projection which holds the cantilever beam arm of the latch in a position allowing the two connectors to be disconnected, which does not require the user to continue depressing the latch at the same time as rotating the pivot-assist member.",TYCO ELECTRONICS CORP,SCOTT BUCHTER BRADLEY;;RAYMOND SHUEY JOHN;;RICHARD FOLTZ KEITH,,https://lens.org/146-131-238-146-865,Granted Patent,no,0,0,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R13/629,,0,0,,,,INACTIVE
59,ES,T3,ES 2324182 T3,000-417-742-146-249,2009-07-31,2009,ES 06737512 T,2006-03-06,US 7559605 A,2005-03-09,MONTAJE DE CONECTOR ELECTRICO QUE INCORPORA UNA ASISTENCIA POR PALANCA CON UN MECANISMO DE PESTILLO DE MANTENIMIENTO HACIA ABAJO.,"Montaje de conector eléctrico (2), que comprende un primer conector (4) que tiene una primera carcasa de conector (20) para su conexión con un conector acoplable (8) que tiene una segunda carcasa de conector acoplable (120), teniendo una de dichas carcasas de conector un miembro de pestillo (150) para enganchar entre sí dicho primer conector y dicho conector acoplable, teniendo la otra de dichas carcasas de conector un miembro de asistencia de acoplamiento (6) para asistir a la reunión conjunta de dichas carcasas de conector, estando el montaje de conector caracterizado por: comprender dicho miembro de asistencia de acoplamiento (6) una superficie contorneada (78), y el pestillo (50) comprende una superficie (172), en el que la superficie contorneada (78) coopera con la superficie de pestillo (172) para mantener hacia abajo el pestillo (150) durante una contrarrotación del miembro de asistencia de acoplamiento (6).",TYCO ELECTRONICS CORP,BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,,https://lens.org/000-417-742-146-249,Granted Patent,no,0,0,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R13/629,,0,0,,,,ACTIVE
60,US,A,US 5073488 A,025-810-765-791-695,1991-12-17,1991,US 27730588 A,1988-11-29,US 27730588 A,1988-11-29,RAPID METHOD FOR DETERMINING EFFICACY OF A STERILIZATION CYCLE AND RAPID READ-OUT BIOLOGICAL INDICATOR,"A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product.",MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,3M INNOVATIVE PROPERTIES COMPANY (2002-03-28);;MINNESOTA MINING AND MANUFACTURING COMPANY A CORP. OF DE (1988-11-29),https://lens.org/025-810-765-791-695,Granted Patent,yes,29,187,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,435/31;;435/38,17,14,101-627-427-868-409;;132-604-543-178-619;;003-052-556-881-426;;069-546-987-795-188;;059-097-821-340-163;;128-020-145-716-975;;008-820-833-702-213;;043-783-355-192-907;;066-321-154-144-982;;024-833-774-176-761;;023-532-052-619-713;;063-627-138-008-326;;009-142-964-897-483;;003-290-222-786-254,pmc413821;;10.1128/br.37.3.320-342.1973;;4357018;;4145864;;10.1128/jb.114.3.1336-1345.1973;;pmc285397;;10.1002/9780470110355.ch5;;4893470;;pmc238996;;3089149;;10.1128/aem.51.5.969-977.1986;;10.1128/jb.143.1.27-34.1980;;6772628;;pmc294174;;10.1093/oxfordjournals.jbchem.a130278;;4756897;;10.1016/0167-4838(84)90321-2;;13229367;;10.1016/0003-9861(55)90018-7;;pmc169838;;10.1128/aem.31.6.807-812.1976;;7193;;10.1016/0005-2744(76)90092-9;;8145;;10.1016/0167-4838(82)90070-x;;10.1128/br.41.3.711-753.1977;;334155;;pmc414021;;10.1111/j.2042-7158.1982.tb04238.x;;6124601;;10.1016/s0196-6553(80)80029-0;;10297938,"Singleton et al., Proteins from Thermophilic Microorganisms , Bacteriol Rev. 37, 320 42, (1973).;;Wisdon et al., Membranes of Bacillus stearothermophilus: Factors Affecting Protoplast Stability and Thermostability of Alkaline Phosphatase and Reduced Nicotinamide Adenine Dinucleotide Oxidase , J. Bacteriol 114, 1336 45 (1973).;;Roth, M., Fluorimetric Assay of Enzymes , Methods of Biochemical Analysis, vol. 17, pp. 189 285.;;Fluorescence in Enzymology , Quantitative Assay of Enzymes, pp. 312 348.;;Snyder, A. P. et al., Pattern Recognition Analysis of In Vivo Enzyme Substrate Fluorescence Velocities in Microorganism Detection and Identification , Appl. Environ. Microbiol., vol. 51, No. 5, pp. 969 977 (1986).;;Laurence, D. J. R., Fluorescence Techniques for the Enzymologist , Techniques for Characterization of Proteins, pp. 174 212.;;Warth, A. D., Heat Stability of Bacillus cereus Enzymes within Spores and in Extracts , Journal of Bacteriology, vol. 143, No. 1, pp. 27 34 (1980).;;Yutani, K. et al., Comparison of Thermostable Amylases from B. stearothermophilus Grown at Different Temperatures , J. Biochem., 74, pp. 573 579 (1973).;;Suzuki, Y. et al., Assignment of A Nitrophenyl D Glucopyranosidase of Bacillus stearothermophilus ATCC 12016 to a Novel Exo 1,4 Glucosidase Active For Oligomaltosaccharides and Glucans , Biochemica et Biophysica Acta., 787, pp. 281 289 (1984).;;Campbell, Jr., L. L., Purification and Properties of an Amylase from Facultactive Thermophilic Bacteria , Amylase Studies, pp. 154 161.;;Suzuki, Y. et al., Production of Extracellular Glucosidase by a Thermophilic Bacillus Species , Applied and Environmental Microbiology, pp. 807 812 (1976).;;Suzuki, Y. et al., Purification and Properties of Extracellular Glucosidase of a Thermophile, Bacillus thermoglucosidius KP 1006 , Biochimica et Biophysica Acta., 445, pp. 386 397 (1976).;;Suzuki, Y. et al., Assignment of a Nitrophenyl D Glucopyranoside Hydrolyzing Glucosidase of Bacillus stearothermophilus ATCC 12016 to an Exo Oligo 1,6 Glucosidase , Biochemica et Biophysica Acta., 704, pp. 476 483 (1982).;;Warth, A. D., Stabilization of Spore Enzymes to Heat by Reduction in Water Activity , Sporulation and Germination, Proceedings of the Eighth International Spore Conference Woods Hole, Massachusetts, pp. 249 252 (1980).;;Priest, F. G., Extracellular Enzyme Synthesis in the Genus Bacillus , Bacteriological Reviews, pp. 711 753 (1977).;;Hodges, N. A., A Comparison of Heat Resistance in Commercially Available Bacillus stearothermophilus Spore Preparations Used for Monitoring Steam Sterilization , J. Pharm. Pharmacol., 34, pp. 259 260 (1982).;;Starkey, D. H., The Use of Indicators For Quality Control of Sterilizing Processes in Hospital Practice: A Review , American Journal of Infection Control, vol. 8, No. 3, pp. 79 84 (1980).",EXPIRED
61,CA,C,CA 2002902 C,093-871-677-361-009,2001-10-30,2001,CA 2002902 A,1989-11-14,US 27730588 A,1988-11-29,RAPID METHOD FOR DETERMINING EFFICACY OF A STERILIZATION CYCLE AND RAPID READ-OUT BIOLOGICAL INDICATOR,"A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product.",MINNESOTA MINING & MFG,FOLTZ WILLIAM E;;WOODSON LEWIS P;;MATNER RICHARD R,,https://lens.org/093-871-677-361-009,Granted Patent,no,0,0,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
62,KR,B1,KR 0163168 B1,183-385-502-162-162,1998-11-16,1998,KR 890017394 A,1989-11-28,US 27730588 A,1988-11-29,RAPID READ-OUT BIOLOGICAL INDICATOR,,MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,,https://lens.org/183-385-502-162-162,Granted Patent,no,0,0,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
63,JP,A,JP 2010056084 A,034-673-596-496-641,2010-03-11,2010,JP 2009191809 A,2009-08-21,US 20143508 A,2008-08-29,TERMINAL POSITION ASSURING MEMBER FOR ELECTRIC CONNECTOR,"<P>PROBLEM TO BE SOLVED: To solve a problem that a present TPA design indicates the existence of a partially inserted contact but do not indicate the nonexistence of the contact in a housing cavity, and furthermore, to cope with a situation having a better advantage that TPA displacement is prevented by sure engagement between the TPA and a housing, and the breakage of TPA is prevented when an excess force is added. <P>SOLUTION: The connector assembly is constituted of a connector housing 4 and a terminal position assuring member (TPA) 6. The connector housing 4 includes a latch 50 abutting of a tine 72 in the TPA 6. When the terminal is completely inserted, the tine 72 is bent so that the TPA 6 can be moved to a regular lock position. <P>COPYRIGHT: (C)2010,JPO&INPIT",TYCO ELECTRONICS CORP,MARTIN GALEN M;;FOLTZ KEITH RICHARD;;WHITEFOOT JOHN M,,https://lens.org/034-673-596-496-641,Patent Application,no,0,1,3,3,0,H01R13/4365;;H01R13/4365;;H01R13/64;;H01R13/629;;H01R13/639,H01R13/42,,0,0,,,,PENDING
64,US,A,US 5460284 A,128-741-578-337-540,1995-10-24,1995,US 22215994 A,1994-04-01,US 22215994 A,1994-04-01,Capture system employing annular fluid stream,"A method and apparatus are disclosed for capturing coating debris during laser ablation of a photoreceptor comprising: (a) enclosing a predetermined length of a coated substrate in a housing to result in an enclosed coated substrate portion, wherein there exists a gap between the enclosed substrate portion and the housing in communication with air outside the housing; (b) directing high energy radiation at the coating of the enclosed substrate portion; (c) directing a first fluid stream against the coating of the enclosed substrate portion to remove at least part of the coating in the form of coating debris during or subsequent to (b), whereby the first fluid stream may move a portion of the coating debris outside the housing in the absence of (d); (d) directing an annularly-shaped second fluid stream against the first fluid stream in a direction effective for keeping the coating debris inside the housing, thereby minimizing movement of the coating debris into the air outside the housing; and (e) exhausting the coating debris.",XEROX CORP,FOLTZ ROBERT S;;GAITHER RONALD A;;PETRALIA RICHARD C,XEROX CORPORATION (1994-03-24),https://lens.org/128-741-578-337-540,Granted Patent,yes,16,10,1,1,0,B08B7/0042;;B23K26/147;;B23K26/142;;B23K26/1437;;B23K26/1436;;Y10T137/212;;Y10T137/212;;B23K26/147;;B08B7/0042;;B23K26/1437;;B23K26/142;;B23K26/1436,B08B7/00;;B23K26/14,216/65;;216/8;;216/25;;216/66;;156/643.1;;427/555;;427/534;;427/552;;15/302;;15/312.1;;15/345;;137/814;;239/106;;239/433;;219/121.66;;219/121.69;;219/121.84,1,0,,,"Lift off Stencil Created by Laser Ablation , IBM Technical Disclosure Bulletin, vol. 28, No. 5, Oct. 1985, p. 2034.",EXPIRED
65,US,B1,US 6767231 B1,133-481-603-408-930,2004-07-27,2004,US 67067703 A,2003-09-25,US 67067703 A,2003-09-25,Electrical connector with flexible blocking feature,"
    An electrical connector includes a first housing having a first set of electrical contacts and a second housing having a second set of electrical contacts. The first and second housing are configured to be matable with one another to mate the first set of contacts with the second set of contacts. The first and second housings are movable between an initial position wherein the first and second sets of electrical contacts are unmated and a final position wherein the respective first and second sets of electrical contacts are fully mated. A lever member is rotatably mounted to the first housing and configured to engage the second housing when rotated. The lever member is configured to move the first and second housings between the initial and final positions as the lever member is rotated when the lever and the second housing are initially aligned. The lever member includes at least one blocking beam configured to separate the first and second housings as the lever member is rotated when the lever member and the second housing are initially misaligned. 
",TYCO ELECTRONICS CORP,MARTIN GALEN M;;FOLTZ KEITH RICHARD;;GUNDERMANN JAMES E,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/133-481-603-408-930,Granted Patent,yes,11,28,1,1,0,H01R13/62944;;H01R13/62944;;H01R13/6295;;H01R13/6295,H01R13/629,439/157;;439/160;;439/372,0,0,,,,EXPIRED
66,US,A,US 5418167 A,137-356-168-831-197,1995-05-23,1995,US 10681693 A,1993-08-13,US 10681693 A;;US 74832791 A;;US 27730588 A;;US 44382095 A,1988-11-29,Rapid read-out biological indicator,"A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product.",MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,3M INNOVATIVE PROPERTIES COMPANY (2002-03-28),https://lens.org/137-356-168-831-197,Granted Patent,yes,35,137,5,20,0,C12Q1/22;;C12Q1/22;;Y10S435/81;;Y10S435/81,C12Q1/22,435/288;;435/31;;435/38;;435/810;;435/291;;435/18;;435/19;;435/21;;435/23;;435/24;;422/55;;422/56;;422/58;;422/60;;422/61;;422/86,17,15,003-052-556-881-426;;069-546-987-795-188;;009-625-323-557-936;;059-097-821-340-163;;128-020-145-716-975;;008-820-833-702-213;;043-783-355-192-907;;066-321-154-144-982;;024-833-774-176-761;;023-532-052-619-713;;063-627-138-008-326;;009-142-964-897-483;;003-290-222-786-254;;101-627-427-868-409;;132-604-543-178-619,10.1002/9780470110355.ch5;;4893470;;pmc238996;;3089149;;10.1128/aem.51.5.969-977.1986;;10.1016/0076-6879(57)04055-0;;10.1128/jb.143.1.27-34.1980;;6772628;;pmc294174;;10.1093/oxfordjournals.jbchem.a130278;;4756897;;10.1016/0167-4838(84)90321-2;;13229367;;10.1016/0003-9861(55)90018-7;;pmc169838;;10.1128/aem.31.6.807-812.1976;;7193;;10.1016/0005-2744(76)90092-9;;8145;;10.1016/0167-4838(82)90070-x;;10.1128/br.41.3.711-753.1977;;334155;;pmc414021;;10.1111/j.2042-7158.1982.tb04238.x;;6124601;;10.1016/s0196-6553(80)80029-0;;10297938;;pmc413821;;10.1128/br.37.3.320-342.1973;;4357018;;4145864;;10.1128/jb.114.3.1336-1345.1973;;pmc285397,"Roth, M. Fluorimetric Assay of Enzymes , Methods of Biochemical Analysis, vol. 17, pp. 189 285, Copyright 1969, by John Wiley & Sons, Inc.;;Fluorescence in Enzymology , Quantitative Assay of Enzymes, pp. 312 348. (Fluorescence Assay in Biology and Medicine, vol. 1, 1962).;;Snyder, A. P. et al., Pattern Recognition Analysis of In Vivo Enzyme Substrate Fluorescence Velocities in Microorganism Detection and Identification , Appl. Environ. Microbiol., vol. 51, No. 5, pp. 969 977 (1986).;;Laurence, D. J. R., Fluorescence Techniques for the Enzymologist , Techniques for Characterization of Proteins, pp. 174 212. (Methods in Enzymology, S. Colowick and N. Kaplan, vol. IV, 1957).;;Warth, A. D., Heat Stability of Bacillus cereus Enzymes Within Spores and in Extracts , Journal of Bacteriology, vol. 143, No. 1, pp. 27 34 (1980).;;Yutani, K. et al., Comparison of Thermostable Amylases from B. stearothermophilus Grown at Different Temperatures , J. Biochem., 74, pp. 573 579 (1973).;;Suzuki, Y. et al., Assignment of a p Nitrophenyl D Glucopyranosidase of Bacillus Stearothermophilus ATCC 12016 to A Novel Exo 1,4 Glucosidase Active For Oligomaltosaccharides and Glucans , Biochemica et Biophysica Acta., 787 pp. 281 289 (1984).;;Campbell, L. L. Jr., Purification and Properties of an Amylase from Facultactive Thermophilic Bacteria , Amylase Studies, pp. 154 161. (Apr. 1954).;;Suzuki, Y. et al., Production of Extracellular Glucosidase by A Thermophilic Bacillus Species, Applied and Environmental Microbiology , pp. 807 812 (1976).;;Suzuki, Y. et al., Purification and Properties of Extracellular Glucosidase of A Thermophile, Bacillus Thermoglucosidius KP 1006 , Biochimica et Biophysical Acta., 445, pp. 386 397 (1976).;;Suzuki, Y. et al., Assignment of A p Nitrophenyl D Glucopyranoside Hydrolyzing Glucosidase of Bacillus Stearothermophilus ATCC 12016 to An Exo Oligo 1,6 Glucosidase , Biochemica et Biophysics Acta., 704, pp. 476 483 (1982).;;Warth, A. D., Stabilization of Spore Enzymes to Heat by Reduction in Water Activity , Sporulation and Germination, Proceedings of the Eighth International Spore Conference Woods Hole, Mass., pp. 249 252 (1980).;;Priest, F. G., Extracellular Enzyme Synthesis in the Genus Bacillus , Bacteriological Reviews, pp. 711 753 (1977).;;Hodges, N. A., A Comparison of Heat Resistance in Commercially Available Bacillus stearothermophilus Spore Preparations Used for Monitoring Steam Sterilization , J. Pharm. Pharmacol., 34, pp. 259 260 (1982).;;Starkey, D. H., The Use of Indicators For Quality Control of Sterilizing Processes in Hospital Practice: A Review , American Journal of Infection Control, vol. 8, No. 3, pp. 79 84 (1980).;;Singleton et al., Proteins from Thermophilic Microorganisms , Bacteriol Rev. 37, 320 42 (1973).;;Wisdom et al., Membranes of Bacillus Stoarothermophilus: Factors Affecting Protoplast Stability and Thermostability of Alkaline Phosphatase and Reduced Nicotinamide Adenine Dinucleotide Oxidase , J. Baceriol. 114, 1336 45 (1973).",EXPIRED
67,EP,B1,EP 0371682 B1,169-869-130-428-890,1996-05-22,1996,EP 89312101 A,1989-11-22,US 27730588 A,1988-11-29,Rapid method for determining efficacy of a sterilization cycle and rapid read-out biological indicator,,MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,,https://lens.org/169-869-130-428-890,Granted Patent,yes,4,2,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
68,DE,D1,DE 602006006809 D1,095-711-327-374-686,2009-06-25,2009,DE 602006006809 T,2006-03-06,US 7559605 A;;US 2006/0008345 W,2005-03-09,ELEKTRISCHE VERBINDERANORDNUNG MIT EINEM HEBEL DER EINE VORRICHTUNG ZUM NIEDERHALTEN EINER VERRIEGELUNG HAT,,TYCO ELECTRONICS CORP,BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,,https://lens.org/095-711-327-374-686,Granted Patent,no,0,0,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R13/629,,0,0,,,,ACTIVE
69,US,A1,US 2003/0157588 A1,079-720-395-848-569,2003-08-21,2003,US 44382095 A,1995-05-18,US 44382095 A;;US 10681693 A;;US 74832791 A;;US 27730588 A,1988-11-29,RAPID READ-OUT BIOLOGICAL INDICATOR,"
   A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product. 
",MATNER RICHARD R.;;FOLTZ WILLIAM E.;;WOODSON LEWIS P.,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,3M INNOVATIVE PROPERTIES COMPANY (2002-03-28);;MINNESOTA MINING AND MANUFACTURING COMPANY (1995-05-17),https://lens.org/079-720-395-848-569,Patent Application,yes,0,21,5,20,0,C12Q1/22;;C12Q1/22;;Y10S435/81;;Y10S435/81,C12Q1/22,435/31;;435/287.1,0,0,,,,EXPIRED
70,US,A1,US 2010/0323537 A1,109-469-552-575-699,2010-12-23,2010,US 45679409 A,2009-06-23,US 45679409 A,2009-06-23,Electrical connector having reversible wire dress,"An electrical connector assembly is disclosed having a main housing portion, camming slide mounting in camming slide receiving guides of the main housing portion, a wire guide and a lever. The lever is operably coupled to the camming slides to translate the camming slides upon rotation of the lever. The lever is mounted to the wire guide, and the combination of the wire guide and the lever are reversible to reverse the orientation of the wires in the wire dress.",TYCO ELECTRONICS CORP,VASBINDER ANDREW JACOB;;SHUEY JOHN R;;FOLTZ KEITH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/109-469-552-575-699,Patent Application,yes,8,15,2,2,0,H01R13/62977;;H01R13/62977;;H01R13/62922;;H01R13/62922;;H01R13/62944;;H01R13/62944,H01R12/00;;H01R13/62,439/65;;439/372,0,0,,,,ACTIVE
71,KR,A,KR 20100027008 A,143-521-494-998-420,2010-03-10,2010,KR 20090079126 A,2009-08-26,US 20143508 A,2008-08-29,TERMINAL POSITION ASSURANCE MEMBER FOR ELECTRICAL CONNECTOR,PURPOSE: A terminal position assurance member for an electrical connector is provided to insure a proper location of a terminal in the inside of the electrical connector. CONSTITUTION: A terminal position assurance member for an electrical connector comprises the following: a housing member(4) including a housing main body and a terminal maintaining latch(50); a terminal receiving cavity(10) is extended to the housing main body which limits the terminal receiving cavity; and a terminal position assurance member(6) including a tine(72) extended to the terminal maintaining latch. The terminal maintaining latch is partially overlaps with the terminal receiving cavity.,TYCO ELECTRONICS CORP,MARTIN GALEN M;;FOLTZ KEITH RICHARD;;WHITEFOOT JOHN M,,https://lens.org/143-521-494-998-420,Patent Application,no,0,0,3,3,0,H01R13/4365;;H01R13/4365;;H01R13/64;;H01R13/629;;H01R13/639,H01R13/629;;H01R13/639,,0,0,,,,DISCONTINUED
72,DE,D1,DE 68926529 D1,026-321-181-416-583,1996-06-27,1996,DE 68926529 T,1989-11-22,US 27730588 A,1988-11-29,Schnelle Methode zur Bestimmung der Wirksamkeit eines Sterilisierungs-Zyklus sowie ein schnell arbeitender biologischer Indikator,,MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,,https://lens.org/026-321-181-416-583,Granted Patent,no,0,0,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
73,CA,A1,CA 2002902 A1,163-655-917-881-531,1990-05-29,1990,CA 2002902 A,1989-11-14,US 27730588 A,1988-11-29,RAPID METHOD FOR DETERMINING EFFICACY OF A STERILIZATION CYCLE AND RAPID READ-OUT BIOLOGICAL INDICATOR,"A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product. FM:6",MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,,https://lens.org/163-655-917-881-531,Patent Application,no,0,5,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,D21500015    M,0,0,,,,EXPIRED
74,DE,T2,DE 68926529 T2,017-056-291-077-18X,1997-01-09,1997,DE 68926529 T,1989-11-22,US 27730588 A,1988-11-29,Schnelle Methode zur Bestimmung der Wirksamkeit eines Sterilisierungs-Zyklus sowie ein schnell arbeitender biologischer Indikator,,MINNESOTA MINING & MFG,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,,https://lens.org/017-056-291-077-18X,Granted Patent,no,0,0,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
75,US,B2,US 6623955 B2,041-868-741-689-292,2003-09-23,2003,US 44382095 A,1995-05-18,US 44382095 A;;US 10681693 A;;US 74832791 A;;US 27730588 A,1988-11-29,Rapid read-out biological indicator,"
    A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product. 
",3M INNOVATIVE PROPERTIES CO,MATNER RICHARD R;;FOLTZ WILLIAM E;;WOODSON LEWIS P,3M INNOVATIVE PROPERTIES COMPANY (2002-03-28);;MINNESOTA MINING AND MANUFACTURING COMPANY (1995-05-17),https://lens.org/041-868-741-689-292,Granted Patent,yes,34,74,5,20,0,C12Q1/22;;C12Q1/22;;Y10S435/81;;Y10S435/81,C12Q1/22,435/287.4;;435/31;;435/38;;435/810;;422/55;;422/56;;422/58;;422/60;;422/61;;422/86,17,15,003-052-556-881-426;;069-546-987-795-188;;009-625-323-557-936;;059-097-821-340-163;;128-020-145-716-975;;008-820-833-702-213;;043-783-355-192-907;;066-321-154-144-982;;024-833-774-176-761;;023-532-052-619-713;;063-627-138-008-326;;009-142-964-897-483;;003-290-222-786-254;;101-627-427-868-409;;132-604-543-178-619,10.1002/9780470110355.ch5;;4893470;;pmc238996;;3089149;;10.1128/aem.51.5.969-977.1986;;10.1016/0076-6879(57)04055-0;;10.1128/jb.143.1.27-34.1980;;6772628;;pmc294174;;10.1093/oxfordjournals.jbchem.a130278;;4756897;;10.1016/0167-4838(84)90321-2;;13229367;;10.1016/0003-9861(55)90018-7;;pmc169838;;10.1128/aem.31.6.807-812.1976;;7193;;10.1016/0005-2744(76)90092-9;;8145;;10.1016/0167-4838(82)90070-x;;10.1128/br.41.3.711-753.1977;;334155;;pmc414021;;10.1111/j.2042-7158.1982.tb04238.x;;6124601;;10.1016/s0196-6553(80)80029-0;;10297938;;pmc413821;;10.1128/br.37.3.320-342.1973;;4357018;;4145864;;10.1128/jb.114.3.1336-1345.1973;;pmc285397,"Roth, M., ""Fluorimetric Assay of Enzymes,"" Methods of Biochemical Analysis, vol. 17, pp. 189-285, Copyright 1969, by John Wiley & Sons, Inc.;;Udenfriend, S., ""Fluorescence in Enzymology,"" Fluorescence Assay in Biology and Medicine, vol. 1, 1962, pp. 312-348.;;Snyder, A.P. et al., ""Pattern Recognition Analysis of In Vivo Enzyme-Substrate Fluorescence Velocities in Microorganism Detection and Identification,"" Appl. Environ. Microbiol., vol. 51, No. 5, pp. 969-977 (1986).;;Laurence, D.J.R., ""Fluorescence Techniques for the Enzymologist,"" Techniques for Characterization of Proteins, Methods in Enzymology, S. Colowick and N. Kaplan, vol. IV, 1957, pp. 174-212.;;Warth, A.D., ""Heat Stability of Bacillus cereus Enzymes Within Spores and in Extracts,"" Journal of Bacteriology, vol. 143, No. 1, pp. 27-34 (1980).;;Yutani, K. et al., ""Comparison of Thermostable alpha-Amylases from B. stearothermophilus Grown at Different Temperatures,"" J. Biochem., 74, pp. 573-579 (1973).;;Suzuki, Y., et al., ""Assignment of A p-Nitrophenyl alpha-D-Glucopyranosidase of Bacillus Stearothermophilus ATCC 12016 to A Novel Exo-alpha-1,4-Glucosidase Active For Oligomaltosaccharides and alpha-Glucans,"" Biochemica et Biophysica Acta., 787, pp. 281-289 (1984).;;Campbell, L.L., Jr., ""Purification and Properties of an alpha-Amylase from Facultactive Thermophilic Bacteria,"" alpha-Amylase Studies, pp. 154-161 (Apr., 1954).;;Suzuki, Y. et al., Production of Extracellular alpha-Glucosidase by a Thermophilic Bacillus Species, Applied and Environment Microbiology, pp. 807-812 (1976).;;Suzuki, Y. et al., ""Purification and Properties of Extracellular alpha-Glucosidase of A Thermophile, Bacillus Thermoglucosidius KP 1006,"" Biochimica et Biophysical Acta., 445, pp. 386-397 (1976).;;Suzuki, Y. et al., Assignment of A p-Nitrophenyl-alpha-D-Glucopyranoside-Hydrolyzing alpha-Glucosidase of Bacillus Cereus ATCC 7064 to an Exo-Oligo-1,6-Glucosidase, Biochemica et Biophysics Acta., 704, pp. 476-483 (1982).;;Warth, A.D., ""Stabilization of Spore Enzymes to Heat by Reduction in Water Activity,"" Sporulation and Germination, Proceedings of the Eighth International Spore Conference, Woods Hole, Massachusetts, pp. 249-252 (1980).;;Priest, F.G., ""Extracelluar Enzyme Synthesis in the Genus bacillus,"" Bacteriological Reviews, pp. 711-753 (1977).;;Hodges, N.A., ""A comparison of heat resistance in commercially available Bacillus stearothermophisu spore preparations used for monitoring Steam sterilization,"" J. Pharm. Pharmacol., 34, pp. 259-260 (1982).;;Starkey, D.H., ""The use of indicators for quality control of sterilizing processes in hospital practice: A review,"" American Journal of Infection Control, vol. 8, No. 3, pp. 79-84 (1980).;;Singleton, R. et al., ""Proteins from Thermophilic Microoganisms,"" Bacteriological Reviews, 37, 320-42 (1973).;;Wisdom, C. et al., ""Membranes of Bacillus stearothermophilus: Factors Affecting Protoplast Stability and Thermostability of Alkaline Phosphatase and Reduce Nicotinamide Adenine Dinucleotide Oxidase,"" J. Bacteriology., vol 114, No. 3, pp. 1336-1345 (1973).",EXPIRED
76,BR,A,BR 0300681 A,134-152-503-433-548,2004-08-10,2004,BR 0300681 A,2003-03-17,US 10038902 A,2002-03-18,"Dispositivo para posicionamento de terminal, aparelho, métodos e artigos de fabricação para firmar conectores macho vedados","""DISPOSITIVO PARA POSICIONAMENTO DE TERMINAL, APARELHO, MéTODOS E ARTIGOS DE FABRICAçãO PARA FIRMAR CONECTORES MACHO VEDADOS"". Aparelho, métodos e artigos de fabricação para garantia de posicionamento do terminal são mostrados, compreendidos de um alojamento com contato de pino e dispositivo de garantia de posicionamento do terminal. O dispositivo de garantia de posicionamento de terminal, quando ele é instalado dentro do alojamento, proporciona uma projeção que engata um dedo dentro do alojamento, dessa maneira conduzindo o dedo para dentro de um recesso dentro do contato de pino, e assim acomodando o contato de pino dentro do alojamento. Se mais do que um contato de pino está dentro do alojamento, mais do que uma projeção e dedo são proporcionados. o dispositivo de garantia de posicionamento do terminal adicionalmente contém um recesso para recuperação, de modo que ele pode ser recuperado na eventualidade de manutenção, desmontagem, etc. no conector.",TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/134-152-503-433-548,Patent Application,no,0,0,8,8,0,H01R13/4223;;H01R13/4364;;H01R13/64;;H01R13/4364;;H01R13/4223,H01R13/42;;H01R13/422;;H01R13/436,,0,0,,,,DISCONTINUED
77,US,A,US 5223401 A,014-975-652-563-30X,1993-06-29,1993,US 27757088 A,1988-11-29,US 27757088 A,1988-11-29,Rapid read-out sterility indicator,"A unitary sterility indicator and a method for its use, the indicator comprising an outer container having liquid impermeable and gas non-absorptive walls, and having a gas-transmissive, bacteria impermeable opening therein; contained within the outer container, a detectable amount of a source of active enzyme and/or another microorganism commonly used to monitor sterilization; a sealed, openable gas and liquid impermeable inner container containing an aqueous medium and/or a nutrient growth medium, disposed in the outer container; an enzyme substrate system capable of reacting with active enzyme to produce a detectable enzyme-modified product and/or a detector material sensitive to microorganism growth, contained in one of the containers; and means contained within the outer container for restricting the area in which enzyme-modified product and/or growing microorganisms are contained, after the inner container is opened, to an area which is less than the volume of aqueous solution contained in the inner container.",MINNESOTA MINING & MFG,FOLTZ WILLIAM E;;MATNER RICHARD R;;WOODSON LEWIS P,MINNESOTA MINING AND MANUFACTURING COMPANY A CORP. OF DE (1988-11-29),https://lens.org/014-975-652-563-30X,Granted Patent,yes,30,118,1,1,0,C12Q1/22;;C12Q1/22;;Y10S435/808;;Y10S435/808;;Y10S435/81;;Y10S435/81;;Y10S436/805;;Y10S436/805,C12Q1/22,435/18;;435/4;;435/288;;435/291;;435/295;;435/808;;435/810;;435/31;;435/19;;435/21;;435/23;;435/24;;422/55;;422/56;;422/58;;422/60;;422/61;;422/83;;422/86;;422/101;;436/501;;436/805;;935/38;;935/60;;935/76,15,13,009-625-323-557-936;;043-783-355-192-907;;003-052-556-881-426;;069-546-987-795-188;;059-097-821-340-163;;128-020-145-716-975;;008-820-833-702-213;;066-321-154-144-982;;024-833-774-176-761;;023-532-052-619-713;;063-627-138-008-326;;009-142-964-897-483;;003-290-222-786-254,10.1016/0076-6879(57)04055-0;;13229367;;10.1016/0003-9861(55)90018-7;;10.1002/9780470110355.ch5;;4893470;;pmc238996;;3089149;;10.1128/aem.51.5.969-977.1986;;10.1128/jb.143.1.27-34.1980;;6772628;;pmc294174;;10.1093/oxfordjournals.jbchem.a130278;;4756897;;10.1016/0167-4838(84)90321-2;;pmc169838;;10.1128/aem.31.6.807-812.1976;;7193;;10.1016/0005-2744(76)90092-9;;8145;;10.1016/0167-4838(82)90070-x;;10.1128/br.41.3.711-753.1977;;334155;;pmc414021;;10.1111/j.2042-7158.1982.tb04238.x;;6124601;;10.1016/s0196-6553(80)80029-0;;10297938,"Laurence, D. J. R., Fluorescence Techniques for the Enzymologist , Methods in Enzymology, vol. IV, pp. 174 212 (1957).;;Campbell, L. L. Jr., Purification and Properties of an Amylase from Facultative Thermophilic Bacteria , Archives of Biochemistry and Biophysics, vol. 54(1), pp. 154 161 (1955).;;Roth, M., Fluorimetric Assay of Enzymes , Methods of Biochemical Anaylsis, vol. 17, pp. 189 285 (1969).;;Udenfriend, S., Fluorescence in Enzymology , Fluorescence Assay in Biology and Medicine, Academic Press, New York, pp. 312 348 (1962).;;Snyder, A. P. et al., Pattern Recognition Analysis of In Vivo Enzyme Substrate Fluorescence Velocities in Microorganism Detection and Identification , Appl. Environ. Microbiol., vol. 51, No. 5, pp. 969 977 (1986).;;Warth, A. D., Heat Stability of Bacillus cereus Enzymes Within Spores and in Extracts , Journal of Bacteriology, vol. 143, No. 1, pp. 27 34 (1980).;;Yutani, K. et al., Comparison of thermostable Amylases from B. stearothermophilus Grown at Different Temperatures , J. Biochem., 74, pp. 573 579 (1973).;;Suzuki, Y. et al., Assignment of A Nitrophenyl D Glucopyranosidase of Bacillus Stearothermophilus ATCC 12016 to A Novel Exo 1,4 Glucosidase Active For Oligomaltosaccharides and Glucans , Biochemica et Biophysica Acta., 787 pp. 281 289 (1984).;;Suzuki, Y. et al., Production of Extracellular Glucosidase by A Thermophilic Bacillus Species , Applied and Environmental Microbiology, pp. 807 812 (1976).;;Suzuki, Y. et al., Purification and properties of Extracellular Glucosidase of A Thermophile, Bacillus Thermoglucosidius KP 1006 , Biochimica et Biophysica Acta., 445, pp. 386 397 (1976).;;Suzuki, Y. et al., Assignment of A Nitrophenyl D Glucopyranoside Hydrolyzing Glucosidase of Bacillus Stearothermophilus ATCC 12016 to An Exo Oligo 1,6 Glucosidase , Biochemica et Biophysica Acta., 704, pp. 476 483 (1982).;;Warth, A. D., Stabilization of Spore Enzymes to Heat by Reduction in Water Activity , Sporulation and Germination, Proceedings of the Eighth International Spore Conference, Woods Hole, Mass., pp. 249 252 (1980).;;Priest, F. G., Extracellular Enzyme Synthesis in the Genus Bacillus , Bacteriological Reviews, pp. 711 753 (1977).;;Hodges, N. A., A Comparison of Heat Resistance in Commercially Available Bacillus stearothermophilus Spore Preparations Used For Monitoring Steam Sterilization , J. Phram. Pharmacol., 34, 259 260 (1982).;;Starkey, D. H., The Use of Indicators for Quality Control of Sterilizing Processes in Hospital Practice: A Review , American Journal of Infection Control, vol. 8, No. 3, pp. 79 84 (1980).",EXPIRED
78,AU,A,AU 1989/044695 A,068-622-904-197-488,1990-06-07,1990,AU 1989/044695 A,1989-11-14,US 27730588 A,1988-11-29,RAPID METHOD FOR DETERMINING EFFICACY OF A STERILIZATION CYCLE AND RAPID READ-OUT BIOLOGICAL INDICATOR,,MINNESOTA MINING & MFG,MATNER RICHARD REYNOLD;;FOLTZ WILLIAM EDWARD;;WOODSON LEWIS PAYNE,,https://lens.org/068-622-904-197-488,Patent Application,no,0,0,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
79,EP,A1,EP 1856771 A1,172-937-196-118-588,2007-11-21,2007,EP 06737512 A,2006-03-06,US 2006/0008345 W;;US 7559605 A,2005-03-09,ELECTRICAL CONNECTOR ASSEMBLY HAVING LEVER ASSIST WITH LATCH HOLD DOWN MECHANISM,,TYCO ELECTRONICS CORP,BUCHTER BRADLEY SCOTT;;FOLTZ KEITH RICHARD;;SHUEY JOHN RAYMOND,,https://lens.org/172-937-196-118-588,Patent Application,yes,0,0,11,11,0,H01R13/62955;;H01R13/62955;;H01R13/6272;;H01R13/6272;;H01R13/62944;;H01R13/62944;;H01R13/633;;H01R13/633,H01R13/629,,1,0,,,See references of WO 2006099007A1,ACTIVE
80,JP,A,JP 2003282174 A,185-312-404-881-257,2003-10-03,2003,JP 2003071494 A,2003-03-17,US 10038902 A,2002-03-18,ELECTRIC CONNECTOR,"<P>PROBLEM TO BE SOLVED: To provide an electric connector having a terminal position guarantee device for seating a male type pin in a waterproof male type connector. <P>SOLUTION: This electric connector 10 has a housing having a pin contact 50 and a terminal position guarantee means (TPA) 30. When the TPA is attached in the housing, it provides a tab for engaging with a fingerlike part 15 in the housing. For this reason, the fingerlike part is forced into a recess 51 of the pin contact to seat the pin contact in the housing. When there are two pin contacts or more in the housing, two tabs and fingerlike parts or more are provided. Since the TPA has a recess 61 for recovery further, the connector can be recovered when performing maintenance and disassembly of the connector. <P>COPYRIGHT: (C)2004,JPO",TYCO ELECTRONICS CORP,HALL JOHN WESLEY JR;;FOLTZ-KEITH RICHARD;;BUCHTER BRADLEY S,,https://lens.org/185-312-404-881-257,Patent Application,no,0,0,8,8,0,H01R13/4223;;H01R13/4364;;H01R13/64;;H01R13/4364;;H01R13/4223,H01R13/422;;H01R13/42;;H01R13/436,,0,0,,,,PENDING
81,US,B2,US 10468786 B2,187-994-091-434-31X,2019-11-05,2019,US 201715457487 A,2017-03-13,EP 16160927 A,2016-03-17,"Electrical connection device, a method of manufacturing an electrical cable and a manufactured electrical coaxial cable","An electrical connection device comprises a cable, a ferrule, and a first electrical contact. The cable has an outer conductor surrounding an inner conductor. The ferrule is mechanically connected to the outer conductor. The first electrical contact is electrically connected to the inner conductor.",TE CONNECTIVITY GERMANY GMBH;;TE CONNECTIVITY CORP,DE CLOET OLIVIER;;SCHRETTLINGER CHRISTIAN;;MUELLER WOLFGANG;;FOLTZ KEITH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2019-09-12);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01);;TE CONNECTIVITY GERMANY GMBH (2017-02-23),https://lens.org/187-994-091-434-31X,Granted Patent,yes,9,8,6,6,0,H01R13/506;;H01R13/6277;;H01R24/38;;H01R24/60;;H01R43/26;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R43/04;;H01R2103/00;;H01R12/596;;H01R13/6592;;H01R9/05;;H01R13/59;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R4/20;;H01R24/38;;H01R43/04;;H01R2103/00,H01R9/05;;H01R4/18;;H01R4/20;;H01R12/59;;H01R13/59;;H01R13/6592;;H01R24/38;;H01R24/40;;H01R43/04;;H01R103/00,,5,0,,,"European Search Report, dated Jul. 26, 2016, 9 pages.;;Abstract of JP2006310135, dated Nov. 9, 2006, 1 page.;;Abstract of JP2006302824, dated Nov. 2, 2006, 1 page.;;Abstract of JP11176527, dated Jul. 2, 1999, 1 page.;;Abstract of JP2003317882, dated Nov. 7, 2003, 1 page.",ACTIVE
82,JP,A,JP 2017168440 A,059-608-439-967-194,2017-09-21,2017,JP 2017047401 A,2017-03-13,EP 16160927 A,2016-03-17,"ELECTRICAL CONNECTION DEVICE, METHOD OF ASSEMBLING ELECTRICAL CABLE AND ASSEMBLED ELECTRICAL COAXIAL CABLE","PROBLEM TO BE SOLVED: To provide a mini coaxial connection device, and an improved connector or a mating connector, preferably a mini connector or a mini mating connector, which are small, simple in structure, and/or easy to handle, and also to efficiently implement a method of assembling an electrical cable in a flexible process management, for example, optionally at a customer's facility.SOLUTION: An electrical connection device 100 includes at least two individual parts. A first part 200 has a form of a ferrule 200 capable of being provided on a cable 60, and a second part 300 has a form of electrical contact means. The ferrule 200 can be at least mechanically and reliably connected to a second conductor 640 of the cable 60, and the contact means can be electromechanically and reliably connected to a first conductor of the cable.SELECTED DRAWING: Figure 18",TE CONNECTIVITY GERMANY GMBH;;TE CONNECTIVITY CORP,OLIVIER DE CLOET;;CHRISTIAN SCHRETTLINGER;;WOLFGANG MUELLER;;KEITH RICHARD FOLTZ,,https://lens.org/059-608-439-967-194,Patent Application,no,9,9,6,6,0,H01R13/506;;H01R13/6277;;H01R24/38;;H01R24/60;;H01R43/26;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R43/04;;H01R2103/00;;H01R12/596;;H01R13/6592;;H01R9/05;;H01R13/59;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R4/20;;H01R24/38;;H01R43/04;;H01R2103/00,H01R24/38,,0,0,,,,PENDING
83,CN,A,CN 103368000 A,121-550-156-495-93X,2013-10-23,2013,CN 201310209282 A,2013-03-25,US 201213428981 A,2012-03-23,Coaxial connector,"A coaxial connector (302) comprises a socket contact (310) having a contact wall (340), the contact wall (340) extends around a central contact axis (328) and limits a contact cavity (342) formed to receive a pin contact (410) of a connector (402). The contact wall is provided with a wall edge (376) limiting a contact opening (378) extending to the contact cavity. A dielectric plugging member (312) is provided with a central hole (341) receiving and keeping the socket contact. The dielectric plugging member comprises a main body portion (372) around the socket contact and a cover portion (374) protruding inwards from the main body portion in a radial direction, so the cover portion can cover the wall edge and guide the pin contact into the contact cavity in a matching process.",TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;QIN JIE;;FOLTZ KEITH RICHARD;;WEIDNER KEVIN,,https://lens.org/121-550-156-495-93X,Patent Application,no,0,1,2,11,0,,H01R13/631;;H01R24/38,,0,0,,,,DISCONTINUED
84,EP,A1,EP 3220483 A1,062-353-357-433-742,2017-09-20,2017,EP 16160927 A,2016-03-17,EP 16160927 A,2016-03-17,"ELECTRIC CONNECTION DEVICE, METHOD OF ASSEMBLING AN ELECTRICAL CABLE AND ASSEMBLED ELECTRICAL COAXIAL CABLE","The invention relates to an electric connection device (100), preferably a mini-coaxial connection device (100) for a cable (60), in particular a copper (60) and/or an aluminium cable (60) for the automotive industry, comprising at least two separate parts (200, 300), wherein a first part (200) is in the form of a ferrule (200) that can be provided on/at the cable (60), and a second part (300) is in the form of an electric contact means (300) that can be provided on/at the cable (60), and the ferrule (200) is able to be connected securely, at least mechanically, to a second electric conductor (640) of the cable (60), and the contact means (300) is able to be securely connected electromechanically to a first electric conductor (630) of the cable (60). Furthermore, the invention relates to a method of assembling an electrical cable (60), preferably a copper and/or aluminium coaxial cable (60) for the automotive industry, wherein in a first step (I), a second electric conductor (640) of the cable (60) is mechanically fixed by means of a ferrule (200), and in a second step (II) chronologically following the first step (I), a first electric conductor (630) of the cable (60) is contacted electromechanically by means of an electric contact means (300).
 
",TE CONNECTIVITY GERMANY GMBH;;TE CONNECTIVITY CORP,DE CLOET OLIVIER;;SCHRETTLINGER CHRISTIAN;;MUELLER WOLFGANG;;FOLTZ KEITH RICHARD,TE CONNECTIVITY SOLUTIONS GMBH (2023-09-27);;TE CONNECTIVITY GERMANY GMBH (2023-09-27),https://lens.org/062-353-357-433-742,Patent Application,yes,8,6,6,6,0,H01R13/506;;H01R13/6277;;H01R24/38;;H01R24/60;;H01R43/26;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R43/04;;H01R2103/00;;H01R12/596;;H01R13/6592;;H01R9/05;;H01R13/59;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R4/20;;H01R24/38;;H01R43/04;;H01R2103/00,H01R9/05;;H01R4/18;;H01R24/40;;H01R43/04;;H01R103/00,,0,0,,,,PENDING
85,CN,A,CN 114401630 A,096-481-786-181-58X,2022-04-26,2022,CN 202080064589 A,2020-08-18,US 201916544685 A;;US 202016872617 A;;US 2020/0046776 W,2019-08-19,Livestock health monitoring system and method of use,"Systems and methods for determining animal health using an animal health notification system include attaching an animal health notification system component to an animal, monitoring a body temperature of the animal to determine whether the body temperature of the animal remains outside a selected temperature range for a selected duration, and providing a notification if the body temperature of the animal remains outside the selected temperature range for the selected duration.",FRIETAMIUS LTD RESPONSIBILITY COMPANY,GREER JODY MILTON;;CRIDER RICHARD A JR;;FOLTZ ANDREW C,,https://lens.org/096-481-786-181-58X,Patent Application,no,5,0,6,42,0,A01K29/005;;A01K11/001;;A01K11/004;;G01K13/223;;A01K29/005;;A61B5/0008;;A61B5/01;;A61B5/6816;;A61B2503/40;;A01K11/001,A01K29/00;;A01K11/00;;G01K13/20,,1,0,,,"窦培武: ""《兽医工作指南》"", 上海科学技术出版社, pages: 16 - 18",PENDING
86,EP,A3,EP 1347536 A3,058-286-668-896-742,2005-08-03,2005,EP 03251648 A,2003-03-18,US 10038902 A,2002-03-18,"Terminal position device apparatus, methods and articles of manufacture for securing sealed male connectors",One or more pin contacts (50) are each retained in a housing (10) of an electrical connector (1) by means of a housing finger (15) which is displaced by a tab (31) of a terminal or contact position assurance device (30) which is insertable into the housing (10). A single position assurance device (30) may be provided with a plurality of tabs (31) for urging a plurality of housing fingers into contact with a plurality of pin contacts (50). The position assurance device (30) may include a recess in a floor thereof for facilitating withdrawal from the housing (10).,TYCO ELECTRONICS CORP,HALL JOHN WESLEY JR;;FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/058-286-668-896-742,Search Report,yes,2,0,8,8,0,H01R13/4223;;H01R13/4364;;H01R13/64;;H01R13/4364;;H01R13/4223,H01R13/422;;H01R13/42;;H01R13/436,,0,0,,,,DISCONTINUED
87,US,A1,US 2013/0157505 A1,074-531-083-047-290,2013-06-20,2013,US 201213428981 A,2012-03-23,US 201213428981 A;;US 201113330874 A;;US 201113330978 A,2011-12-20,COAXIAL CONNECTOR,"A coaxial connector including a socket contact having a mating end, a terminating end, and a central contact axis extending therebetween. The socket contact includes a contact wall that extends around the contact axis and defines a contact cavity. The contact wall has a wall edge at the mating end that defines a contact opening to the contact cavity. The coaxial connector also includes a dielectric insert that holds the socket contact. The dielectric insert includes a mating face that has an insert opening providing access to the bore. The dielectric insert includes a body portion that surrounds the socket contact and a hood portion that defines the insert opening. The hood portion projects radially inward from the body portion so that the hood portion covers the wall edge. The hood portion is configured to direct a pin contact of a mating connector into the contact cavity.",SYKES MICHAEL TIMOTHY;;QIN JIE;;FOLTZ KEITH RICHARD;;WEIDNER KEVIN;;TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;QIN JIE;;FOLTZ KEITH RICHARD;;WEIDNER KEVIN,TYCO ELECTRONICS CORPORATION (2012-03-16),https://lens.org/074-531-083-047-290,Patent Application,yes,5,18,1,11,0,H01R9/05;;H01R9/05;;H01R12/724;;H01R12/724;;H01R13/424;;H01R13/424,H01R9/05,439/578,0,0,,,,DISCONTINUED
88,CN,A,CN 107204537 A,084-293-554-885-330,2017-09-26,2017,CN 201710159879 A,2017-03-17,EP 16160927 A,2016-03-17,"Electrical Connection Device, A Method of Manufacturing an Electrical Cable and A Manufactured Electrical Coaxial Cable","The invention relates to an electric connection device (100), preferably a mini-coaxial connection device (100) for a cable (60), in particular a copper (60) and/or an aluminium cable (60) for the automotive industry, comprising at least two separate parts (200, 300), wherein a first part (200) is in the form of a ferrule (200) that can be provided on/at the cable (60), and a second part (300) is in the form of an electric contact means (300) that can be provided on/at the cable (60), and the ferrule (200) is able to be connected securely, at least mechanically, to a second electric conductor (640) of the cable (60), and the contact means (300) is able to be securely connected electromechanically to a first electric conductor (630) of the cable (60). Furthermore, the invention relates to a method of assembling an electrical cable (60), preferably a copper and/or aluminium coaxial cable (60) for the automotive industry, wherein in a first step (I), a second electric conductor (640) of the cable (60) is mechanically fixed by means of a ferrule (200), and in a second step (II) chronologically following the first step (I), a first electric conductor (630) of the cable (60) is contacted electromechanically by means of an electric contact means (300).",TE CONNECTIVITY GERMANY GMBH;;TE CONNECTIVITY CORP,CHRISTIAN SCHRETTLINGER;;OLIVIER DE CLOET;;WOLFGANG MUELLER;;KEITH RICHARD FOLTZ,,https://lens.org/084-293-554-885-330,Patent Application,no,20,9,6,6,0,H01R13/506;;H01R13/6277;;H01R24/38;;H01R24/60;;H01R43/26;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R43/04;;H01R2103/00;;H01R12/596;;H01R13/6592;;H01R9/05;;H01R13/59;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R4/20;;H01R24/38;;H01R43/04;;H01R2103/00,H01R13/506;;H01R13/627;;H01R24/38;;H01R24/60;;H01R43/26,,0,0,,,,ACTIVE
89,US,A1,US 2017/0271784 A1,151-113-859-121-830,2017-09-21,2017,US 201715457487 A,2017-03-13,EP 16160927 A,2016-03-17,"Electrical Connection Device, A Method of Manufacturing an Electrical Cable and A Manufactured Electrical Coaxial Cable","An electrical connection device comprises a cable, a ferrule, and a first electrical contact. The cable has an outer conductor surrounding an inner conductor. The ferrule is mechanically connected to the outer conductor. The first electrical contact is electrically connected to the inner conductor.",TE CONNECTIVITY GERMANY GMBH;;TE CONNECTIVITY CORP,DE CLOET OLIVIER;;SCHRETTLINGER CHRISTIAN;;MUELLER WOLFGANG;;FOLTZ KEITH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2019-09-12);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01);;TE CONNECTIVITY GERMANY GMBH (2017-02-23),https://lens.org/151-113-859-121-830,Patent Application,yes,8,6,6,6,0,H01R13/506;;H01R13/6277;;H01R24/38;;H01R24/60;;H01R43/26;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R43/04;;H01R2103/00;;H01R12/596;;H01R13/6592;;H01R9/05;;H01R13/59;;H01R4/188;;H01R9/0503;;H01R9/0518;;H01R24/40;;H01R2201/26;;H01R4/20;;H01R24/38;;H01R43/04;;H01R2103/00,H01R4/20;;H01R24/38;;H01R43/04,,0,0,,,,ACTIVE
90,EP,A2,EP 1347536 A2,156-296-074-713-736,2003-09-24,2003,EP 03251648 A,2003-03-18,US 10038902 A,2002-03-18,"Terminal position device apparatus, methods and articles of manufacture for securing sealed male connectors",One or more pin contacts (50) are each retained in a housing (10) of an electrical connector (1) by means of a housing finger (15) which is displaced by a tab (31) of a terminal or contact position assurance device (30) which is insertable into the housing (10). A single position assurance device (30) may be provided with a plurality of tabs (31) for urging a plurality of housing fingers into contact with a plurality of pin contacts (50). The position assurance device (30) may include a recess in a floor thereof for facilitating withdrawal from the housing (10).,TYCO ELECTRONICS CORP,HALL JOHN WESLEY JR;;FOLTZ KEITH RICHARD;;BUCHTER BRADLEY SCOTT,,https://lens.org/156-296-074-713-736,Patent Application,yes,0,0,8,8,0,H01R13/4223;;H01R13/4364;;H01R13/64;;H01R13/4364;;H01R13/4223,H01R13/422;;H01R13/42;;H01R13/436,,0,0,,,,DISCONTINUED
91,CA,A1,CA 2422386 A1,036-388-417-793-852,2003-09-18,2003,CA 2422386 A,2003-03-17,US 10038902 A,2002-03-18,"TERMINAL POSITION DEVICE APPARATUS, METHODS AND ARTICLES OF MANUFACTURE FOR SECURING SEALED MALE CONNECTORS","Apparatus, methods and articles of manufacture for terminal position assuran ce are shown, comprised of a housing with pin contact and terminal position assurance means. The terminal position assurance means, as it is installed within the housing, provides a tab that engages a finger within the housing, thereby driving the finger into a recess within the pin contact, and so seating the pin contact within the housing. If more than one pin contact is within the housing, more than one tab and finger are provided. The terminal position assurance means further contains a recess for retrieva l so it may be retrieved in the event of maintenance, disassembly, etc. on the connector.</ SDOAB>",TYCO ELECTRONICS CORP,BUCHTER BRADLEY SCOTT;;HALL JOHN WESLEY JR;;FOLTZ KEITH RICHARD,,https://lens.org/036-388-417-793-852,Patent Application,no,0,0,8,8,0,H01R13/4223;;H01R13/4364;;H01R13/64;;H01R13/4364;;H01R13/4223,H01R13/42;;H01R13/422;;H01R13/436,,0,0,,,,DISCONTINUED
92,TW,A,TW 201347319 A,044-282-986-418-061,2013-11-16,2013,TW 102109995 A,2013-03-21,US 201213428981 A,2012-03-23,Coaxial connector,A coaxial connector (302) comprises a socket contact (310) having a contact wall (340) that extends around a central contact axis (328) and defines a contact cavity (342) configured to receive a pin contact (410) of a mating connector (402). The contact wall has a wall edge (376) that defines a contact opening (378) to the contact cavity. A dielectric insert (312) has a central bore (341) that receives and holds the socket contact. The dielectric insert includes a body portion (372) that surrounds the socket contact and a hood portion (374) that projects radially inward from the body portion such that the hood portion covers the wall edge and directs the pin contact into the contact cavity during mating.,TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;QIN JIE;;FOLTZ KEITH RICHARD;;WEIDNER KEVIN EDWARD,,https://lens.org/044-282-986-418-061,Patent of Addition,no,0,1,2,11,0,,H01R13/631;;H01R24/40,,0,0,,,,PENDING
93,CA,A1,CA 2417065 A1,087-627-408-509-376,2003-07-25,2003,CA 2417065 A,2003-01-24,US 5670002 A,2002-01-25,COAXIAL CABLE CONNECTOR,"Apparatus, methods and articles of manufacture for a coaxial cable connector that allows variable wire termination orientations are disclosed. A connector housing is used to install the embodiments upon a mating connector, with a cable housing providing contact for a coax cable. A core member provides connection for an inner conductor, and a cap is used to seal the connector, once the cable is installed within the cable housing.",TYCO ELECTRONICS CORP,HARDY DOUGLAS JOHN;;HALL JOHN WESLEY;;RAUDENBUSH JAMES MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/087-627-408-509-376,Patent Application,no,0,0,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,EXPIRED
94,EP,A2,EP 1331702 A2,006-439-644-303-859,2003-07-30,2003,EP 03250438 A,2003-01-24,US 5670002 A,2002-01-25,Coaxial cable connector,A coaxial cable connector is provided which allows variable wire termination orientations. It comprises a connector housing (30) for interfacing with a mating connector and a cable housing (20) connected to the connector housing for coupling a coax cable to the connector housing. A core member (50) provides connection for an inner conductor of the coax cable and a cap (40) is used to seal the connector once the cable is installed within the cable housing.,TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;HARDY DOUGLAS JOHN;;RAUDENBUSH JAMES MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/006-439-644-303-859,Patent Application,yes,2,1,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,EXPIRED
95,DE,D1,DE 69635469 D1,188-414-000-934-507,2005-12-29,2005,DE 69635469 T,1996-09-20,US 53329695 A,1995-09-25,Synchronisierung zwischen verschiedenen Computeranbieterumgebungen,,IBM,FOLTZ RICHARD C;;LIN SY LONG;;MEEGAN JOHN VINCENT;;WADOOD SYED ABDUL,,https://lens.org/188-414-000-934-507,Granted Patent,no,0,0,8,8,0,H04L63/20;;H04L67/1095;;G06F16/10;;H04L63/20;;Y10S707/99952;;H04L67/1095;;G06F16/10;;H04L9/40,G06F12/00;;G06F17/30;;H04L29/06;;H04L29/08,,0,0,,,,EXPIRED
96,EP,A3,EP 1331702 A3,055-918-861-453-955,2004-06-09,2004,EP 03250438 A,2003-01-24,US 5670002 A,2002-01-25,Coaxial cable connector,A coaxial cable connector is provided which allows variable wire termination orientations. It comprises a connector housing (30) for interfacing with a mating connector and a cable housing (20) connected to the connector housing for coupling a coax cable to the connector housing. A core member (50) provides connection for an inner conductor of the coax cable and a cap (40) is used to seal the connector once the cable is installed within the cable housing.,TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;HARDY DOUGLAS JOHN;;RAUDENBUSH JAMES MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/055-918-861-453-955,Search Report,yes,3,0,14,14,0,H01R9/05;;H01R13/5213;;H01R24/44;;H01R2103/00;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R24/44;;H01R2103/00,H01R13/52;;H01R9/05;;H01R24/44,,0,0,,,,EXPIRED
97,DE,T2,DE 69635469 T2,108-406-575-534-588,2006-07-27,2006,DE 69635469 T,1996-09-20,US 53329695 A,1995-09-25,Synchronisierung zwischen verschiedenen Computeranbieterumgebungen,,IBM,FOLTZ RICHARD C;;LIN SY LONG;;MEEGAN JOHN VINCENT;;WADOOD SYED ABDUL,,https://lens.org/108-406-575-534-588,Granted Patent,no,0,0,8,8,0,H04L63/20;;H04L67/1095;;G06F16/10;;H04L63/20;;Y10S707/99952;;H04L67/1095;;G06F16/10;;H04L9/40,G06F12/00;;G06F17/30;;H04L29/06;;H04L29/08,,0,0,,,,EXPIRED
98,JP,A,JP 2003217755 A,036-735-325-699-918,2003-07-31,2003,JP 2003016846 A,2003-01-27,US 5670002 A,2002-01-25,COAXIAL CABLE CONNECTOR AND ITS INSTALLATION METHOD,"<P>PROBLEM TO BE SOLVED: To provide an improved coaxial cable connector and its installation method for allowing press-fitting or the soldering connection having an angle or for in-line use. <P>SOLUTION: This coaxial cable connector has a connector housing 30 to be connected to a mating connector m, a cable housing 20 connected to the connector housing 30, and contacting with a coaxial cable w, a core member 50 connected to an internal conductor i, and a cap member 40 for sealing a recessed part 26 having opening one end when installing the coaxial cable w once in the cable housing 20. <P>COPYRIGHT: (C)2003,JPO",TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;RAUDENBUSH JAMES MICHAEL;;HARDY DOUGLAS JOHN;;FOLTZ KEITH RICHARD,,https://lens.org/036-735-325-699-918,Patent Application,no,0,4,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,EXPIRED
99,US,A,US 5978813 A,092-623-502-016-79X,1999-11-02,1999,US 53329695 A,1995-09-25,US 53329695 A,1995-09-25,System for providing synchronization between a local area network and a distributing computer environment,"A database synchronization system for synchronizing a plurality of local databases in a plurality of distributed computing systems is disclosed. The plurality of distributed computing systems form a distributed computing environment (DCE). The synchronization system includes a system server, a registry database, coupled to the system server, a local area network (LAN) synchronization server, coupled to the system server, a LAN server synchronization library, coupled to the system server, and a LAN server, coupled to the LAN synchronization server and selected ones of the plurality distributed computing systems forming a LAN. Synchronization between the LAN and the DCE registry occurs when registry modifications in the registry database affecting at least one of the plurality of local LAN databases invokes the LAN server synchronization library to synchronize the affected database. The synchronization system utilizes a registry database coupled to each of the local databases. A primary replica is coupled to the registry database that synchronizes each local database within the DCE with the registry database. A secondary replica is then coupled to the primary replica, that synchronizes at least one local area network (LAN) server that includes selected ones of the plurality of computing systems and their respective databases with the registry database.",IBM,FOLTZ RICHARD C;;LIN SY LONG;;MEEGAN JOHN VINCENT;;WADOOD SYED ABDUL,INTERNATIONAL BUSINESS MACHINES CORPORATION (1995-09-25),https://lens.org/092-623-502-016-79X,Granted Patent,yes,6,142,8,8,0,H04L63/20;;H04L67/1095;;G06F16/10;;H04L63/20;;Y10S707/99952;;H04L67/1095;;G06F16/10;;H04L9/40,G06F12/00;;G06F17/30;;H04L29/06;;H04L29/08,707/201,2,0,,,"Understanding DCE, 1992, W. Rosenberry et al., Chapter 1, DCE: The Network as Computer .;;Understanding DCE, 1992, W. Rosenberry et al., Chapter 5, DCE Security Service: Protecting Resources .",EXPIRED
100,ES,T3,ES 2312724 T3,118-777-755-283-160,2009-03-01,2009,ES 03250438 T,2003-01-24,US 5670002 A,2002-01-25,CONECTOR DE CABLE COAXIAL.,"Un conector de cable coaxial que comprende un alojamiento del conector (30) para conectar con un conector de acoplamiento, un alojamiento del cable (21) que conecta con dicho alojamiento del conector y tiene un hueco abierto (26), un miembro central (50) que tiene medios de guía (13) y que se extiende dentro de dicho alojamiento para el conector y dicho alojamiento para el cable y se extiende también al menos parcialmente a través de dicho hueco abierto (26) para que dicho medio de guía sea accesible a través de dicho hueco abierto para recibir un conductor interior (i) de un cable coaxial, y un casquillo (40) para sellar dicho hueco abierto tras la instalación de dicho conductor interior de dicho cable coaxial, caracterizado porque recortes o aberturas (28,29) bordean el hueco abierto (26) y están situados en lados opuestos del alojamiento para el cable (21).",TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;HARDY DOUGLAS JOHN;;RAUDENBUSH JAMES MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/118-777-755-283-160,Granted Patent,no,0,0,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,EXPIRED
101,EP,A3,EP 0765062 A3,031-626-385-238-422,2004-02-25,2004,EP 96306844 A,1996-09-20,US 53329695 A,1995-09-25,Synchronization between dissimilar computer server environments,"A database synchronization system for synchronizing a plurality of local databases in a plurality of distributed computing systems is disclosed. The plurality of distributed computing systems form a distributed computing environment (DCE). The synchronization system includes a system server, a registry database, coupled to the system server, a local area network (LAN) synchronization server, coupled to the system server, a LAN server synchronization library, coupled to the system server, and a LAN server, coupled to the LAN synchronization server and selected ones of the plurality distributed computing systems forming a LAN. Synchronization between the LAN and the DCE registry occurs when registry modifications in the registry database affecting at least one of the plurality of local LAN databases invokes the LAN server synchronization library to synchronize the affected database. The synchronization system utilizes a registry database coupled to each of the local databases. A primary replica is coupled to the registry database that synchronizes each local database within the DCE with the registry database. A secondary replica is then coupled to the primary replica, that synchronizes at least one local area network (LAN) server that includes selected ones of the plurality of computing systems and their respective databases with the registry database.",IBM,FOLTZ RICHARD C;;LIN SY LONG;;MEEGAN JOHN VINCENT;;WADOOD SYED ABDUL,,https://lens.org/031-626-385-238-422,Search Report,yes,2,0,8,8,0,H04L63/20;;H04L67/1095;;G06F16/10;;H04L63/20;;Y10S707/99952;;H04L67/1095;;G06F16/10;;H04L9/40,G06F12/00;;G06F17/30;;H04L29/06;;H04L29/08,,2,0,,,"ANUPAM BHIDE: ""Experiences with two high availability designs"", IEEE, April 1992 (1992-04-01), pages 51 - 54, XP002265332, Retrieved from the Internet <URL:http://ieeexplore.ieee.org/iel2/446/6238/00242618.pdf?isNumber=6238&prod=IEEE+CNF&arnumber=242618&arSt=51&ared=54&arAuthor=Bhide%2C+A.%3B> [retrieved on 20031216];;""UPDATING LOOSELY-COUPLED SQL/DS DATABASES"", IBM TECHNICAL DISCLOSURE BULLETIN, IBM CORP. NEW YORK, US, vol. 33, no. 6B, 1 November 1990 (1990-11-01), pages 395 - 396, XP000108923, ISSN: 0018-8689",EXPIRED
102,BR,A,BR 0300360 A,173-599-096-303-660,2003-09-09,2003,BR 0300360 A,2003-01-24,US 5670002 A,2002-01-25,Conector de cabo coaxial,"""CONECTOR DE CABO COAXIAL"". Um aparelho, métodos e artigos de fabricação para um conector de cabo coaxial que permite orientações de terminação de fio variáveis são apresentados. Um alojamento de conector é usado de modo a instalar as modalidades em um conector correspondente, com um alojamento de cabo provendo contato para um cabo coaxial. Um membro de núcleo provê conexão para um condutor interno, e uma capa é usada de modo a vedar o conector, quando o cabo é instalado dentro do alojamento de cabo.",TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;RAUDENBUSH JAMES WESLEY;;HARDY DOUGLAS JOHN;;FOLTZ KEITH RICHARD,,https://lens.org/173-599-096-303-660,Patent Application,no,0,0,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,DISCONTINUED
103,CA,C,CA 2417065 C,180-300-882-490-429,2010-03-30,2010,CA 2417065 A,2003-01-24,US 5670002 A,2002-01-25,COAXIAL CABLE CONNECTOR,"Apparatus, methods and articles of manufacture for a coaxial cable connector that allows variable wire termination orientations are disclosed. A connector housing is used to install the embodiments upon a mating connector, with a cable housing providing contact for a coax cable. A core member provides connection for an inner conductor, and a cap is used to seal the connector, once the cable is installed within the cable housing.",TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;RAUDENBUSH JAMES MICHAEL;;HARDY DOUGLAS JOHN;;FOLTZ KEITH RICHARD,,https://lens.org/180-300-882-490-429,Granted Patent,no,0,0,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,EXPIRED
104,EP,B1,EP 1331702 B1,028-398-840-271-495,2008-08-20,2008,EP 03250438 A,2003-01-24,US 5670002 A,2002-01-25,Coaxial cable connector,,TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;HARDY DOUGLAS JOHN;;RAUDENBUSH JAMES MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/028-398-840-271-495,Granted Patent,yes,3,0,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,EXPIRED
105,EP,A2,EP 0765062 A2,161-984-124-963-689,1997-03-26,1997,EP 96306844 A,1996-09-20,US 53329695 A,1995-09-25,Synchronization between dissimilar computer server environments,"A database synchronization system for synchronizing a plurality of local databases in a plurality of distributed computing systems is disclosed. The plurality of distributed computing systems form a distributed computing environment (DCE). The synchronization system includes a system server, a registry database, coupled to the system server, a local area network (LAN) synchronization server, coupled to the system server, a LAN server synchronization library, coupled to the system server, and a LAN server, coupled to the LAN synchronization server and selected ones of the plurality distributed computing systems forming a LAN. Synchronization between the LAN and the DCE registry occurs when registry modifications in the registry database affecting at least one of the plurality of local LAN databases invokes the LAN server synchronization library to synchronize the affected database. The synchronization system utilizes a registry database coupled to each of the local databases. A primary replica is coupled to the registry database that synchronizes each local database within the DCE with the registry database. A secondary replica is then coupled to the primary replica, that synchronizes at least one local area network (LAN) server that includes selected ones of the plurality of computing systems and their respective databases with the registry database.",IBM,FOLTZ RICHARD C;;LIN SY LONG;;MEEGAN JOHN VINCENT;;WADOOD SYED ABDUL,,https://lens.org/161-984-124-963-689,Patent Application,yes,0,11,8,8,0,H04L63/20;;H04L67/1095;;G06F16/10;;H04L63/20;;Y10S707/99952;;H04L67/1095;;G06F16/10;;H04L9/40,G06F12/00;;G06F17/30;;H04L29/06;;H04L29/08,,0,0,,,,EXPIRED
106,DE,D1,DE 60322987 D1,010-490-855-732-598,2008-10-02,2008,DE 60322987 T,2003-01-24,US 5670002 A,2002-01-25,Koaxialkabelverbinder,,TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;HARDY DOUGLAS JOHN;;RAUDENBUSH JAMES MICHAEL;;FOLTZ KEITH RICHARD,,https://lens.org/010-490-855-732-598,Granted Patent,no,0,0,14,14,0,H01R9/05;;H01R9/05;;H01R9/05;;H01R13/5213;;H01R13/5213;;H01R24/44;;H01R24/44;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R13/52;;H01R24/44,,0,0,,,,EXPIRED
107,EP,A1,EP 1345290 A1,048-873-363-314-784,2003-09-17,2003,EP 03100619 A,2003-03-11,US 9809802 A,2002-03-13,Apparatus and Method for Electrical Connector Cable Retention,The invention is a FAKRA connector having cable retention means. The retention means is comprised of an extended housing (20) and either a groove-projection assembly (21-23) integrated with the extended housing or a cable clip external to the extended housing.,TYCO ELECTRONICS CORP,HALL JOHN WESLEY;;RAUDENBUSH JAMES MICHAEL;;HARDY DOUGLAS JOHN;;FOLTZ KEITH RICHARD,,https://lens.org/048-873-363-314-784,Patent Application,yes,6,7,3,3,0,H01R13/60;;H01R13/60,H01R13/58;;H01R13/46;;H01R13/60,,1,0,,,"PRESS XPRESS: ""SUMMARY:OSRAM SYLVANIA announces FAKRA SMB connector products"", OSRAM SYLVANIA - HOME PAGE, 15 June 2001 (2001-06-15), York,PA, XP002240633, Retrieved from the Internet <URL:http://www.sylvania.com/press/06152001.html> [retrieved on 20030509]",DISCONTINUED
108,EP,B1,EP 0765062 B1,018-389-622-814-554,2005-11-23,2005,EP 96306844 A,1996-09-20,US 53329695 A,1995-09-25,Synchronization between dissimilar computer server environments,,IBM,FOLTZ RICHARD C;;LIN SY LONG;;MEEGAN JOHN VINCENT;;WADOOD SYED ABDUL,,https://lens.org/018-389-622-814-554,Granted Patent,yes,2,5,8,8,0,H04L63/20;;H04L67/1095;;G06F16/10;;H04L63/20;;Y10S707/99952;;H04L67/1095;;G06F16/10;;H04L9/40,G06F12/00;;G06F17/30;;H04L29/06;;H04L29/08,,2,0,,,"ANUPAM BHIDE: ""Experiences with two high availability designs"" IEEE, [Online] April 1992 (1992-04), pages 51-54, XP002265332 Retrieved from the Internet: &lt;URL:http://ieeexplore.ieee.org/iel2/446/6 238/00242618.pdf?isNumber=6238&prod=IEEE+C NF&arnumber=242618&arSt=51&ared=54&arAutho r=Bhide%2C+A.%3B&gt; [retrieved on 2003-12-16];;""UPDATING LOOSELY-COUPLED SQL/DS DATABASES"" IBM TECHNICAL DISCLOSURE BULLETIN, IBM CORP. NEW YORK, US, vol. 33, no. 6B, 1 November 1990 (1990-11-01), pages 395-396, XP000108923 ISSN: 0018-8689",EXPIRED
109,JP,A,JP 2003272752 A,102-087-055-761-900,2003-09-26,2003,JP 2003067623 A,2003-03-13,US 9809802 A,2002-03-13,ELECTRICAL CONNECTOR AND METHOD FOR CONNECTING CABLE WITH ELECTRICAL CONNECTOR,"<P>PROBLEM TO BE SOLVED: To provide an electrical connector for minimizing a required space for a multi-polar FAKRA cable assembly within the scheme of FAKRA SMB standard, and simply binding FAKRA connectors in a multi-polar cable assembly, and a method for manufacturing the electrical connector. <P>SOLUTION: An apparatus and a method for electrical connector cable retention are disclosed, comprised of an FAKRA connector with a cable retention means. The cable retention means comprises an extended housing 20 with a means for retaining a cable i, and in a preferred embodiment, comprises an assembly of a groove 21 and projections 22, 23 integrated with the extended housing 20, or a cable clip outside the extended housing 20. Various embodiments are provided for various cable diameters. <P>COPYRIGHT: (C)2003,JPO",TYCO ELECTRONICS CORP,HALL JOHN WESLEY JR;;RAUDENBUSH JAMES MICHAEL;;HARDY DOUGLAS JOHN;;FOLTZ-KEITH RICHARD,,https://lens.org/102-087-055-761-900,Patent Application,no,0,5,3,3,0,H01R13/60;;H01R13/60,H01R13/58;;H01R13/46;;H01R13/60,,0,0,,,,PENDING
110,EP,A3,EP 1104048 A3,007-344-073-227-657,2003-12-17,2003,EP 00309514 A,2000-10-27,US 16199699 P,1999-10-28,Blind mate electrical connector with mechanical assist means,"An electrical connector assembly (2) includes a first connector in the form of a printed circuit board header (10) and a second connector in the form of a plug connector that can be attached to wires in a wiring harness. One of the connectors is mounted in an opening (6) in a panel so that the connectors is free to float in an X and a Y direction. A protruding alignment post (30) on one connector is received within an alignment cavity (70) on the other connectors so that the connector positioned in the panel opening (6) will shift laterally so that pin terminals (22) in one connector will be aligned with receptacle terminals in terminal cavities of the other connector will be aligned before they are mated. A mechanical assist member, such as a bolt extends through a central opening (32) in the alignment post (30) and through the mating alignment cavity (70) to increase the force available to mate the two connectors.",TYCO ELECTRONICS CORP,CHRISTIANSEN MICHAEL JOHN;;FOLTZ KEITH RICHARD;;BECK JR HOY SMITH;;MYER JOHN MARK,,https://lens.org/007-344-073-227-657,Search Report,yes,10,0,3,3,0,H01R13/6215;;H01R13/6315;;H01R13/6315;;H01R13/6215,H01R12/71;;H01R13/621;;H01R13/631,,0,0,,,,DISCONTINUED
111,EP,A2,EP 1104048 A2,014-436-717-526-903,2001-05-30,2001,EP 00309514 A,2000-10-27,US 16199699 P,1999-10-28,Blind mate electrical connector with mechanical assist means,"An electrical connector assembly (2) includes a first connector in the form of a printed circuit board header (10) and a second connector in the form of a plug connector that can be attached to wires in a wiring harness. One of the connectors is mounted in an opening (6) in a panel so that the connectors is free to float in an X and a Y direction. A protruding alignment post (30) on one connector is received within an alignment cavity (70) on the other connectors so that the connector positioned in the panel opening (6) will shift laterally so that pin terminals (22) in one connector will be aligned with receptacle terminals in terminal cavities of the other connector will be aligned before they are mated. A mechanical assist member, such as a bolt extends through a central opening (32) in the alignment post (30) and through the mating alignment cavity (70) to increase the force available to mate the two connectors.",TYCO ELECTRONICS CORP,CHRISTIANSEN MICHAEL JOHN;;FOLTZ KEITH RICHARD;;BECK JR HOY SMITH;;MYER JOHN MARK,,https://lens.org/014-436-717-526-903,Patent Application,yes,0,2,3,3,0,H01R13/6215;;H01R13/6315;;H01R13/6315;;H01R13/6215,H01R12/71;;H01R13/621;;H01R13/631,,0,0,,,,DISCONTINUED
112,US,B1,US 6435891 B1,103-488-201-772-485,2002-08-20,2002,US 69856500 A,2000-10-27,US 69856500 A;;US 16199699 P,1999-10-28,Mechanically assisted blind mate electrical connector,"
    An electrical connector assembly (  2  ) includes a first connector in the form of a printed circuit board header (  10  ) and a second connector in the form of a plug connector that can be attached to wires in a wiring harness. One of the connectors is mounted in an opening (  6  ) in a panel so that the connector is free to float in an X and a Y direction. A protruding alignment post (  30  ) on one connector is received within an alignment cavity (  70  ) on the other connectors so that the connector positioned in the panel opening (  6  ) will shift laterally so that pin terminals (22) in one connector will be aligned with receptacle terminals (  50  ) in terminal cavities of the other connector will be aligned before they are mated. A mechanical assist member, such as a bolt (  90  ) extends through a central opening (  32  ) in the alignment post (  30  ) and through the mating alignment cavity (  70  ) to increase the force available to mate the two connectors. 
",TYCO ELECTRONICS CORP,BECK JR HOY SMITH;;CHRISTIANSEN MICHAEL JOHN;;FOLTZ KEITH RICHARD;;MYER JOHN MARK,TYCO ELECTRONICS CORPORATION (2000-10-27),https://lens.org/103-488-201-772-485,Granted Patent,yes,18,27,3,3,0,H01R13/6215;;H01R13/6315;;H01R13/6315;;H01R13/6215,H01R12/71;;H01R13/621;;H01R13/631,439/248;;439/364;;439/587,0,0,,,,EXPIRED
113,US,B1,US 7896655 B1,081-483-923-486-81X,2011-03-01,2011,US 54125209 A,2009-08-14,US 54125209 A,2009-08-14,Multi-port connector system,"An electrical connector assembly includes a housing, a connector and a conductor. The housing extends from a mating interface to a back end along a longitudinal axis and from a top side to a mounting interface along a vertical axis. The connector is disposed at the mating interface and is configured to mate with a mating connector. The conductor extends from the electrical connector to the mounting interface to provide a conductive pathway between the mating connector and the circuit board. The conductor includes a mating portion oriented along the longitudinal axis and a mounting portion oriented along the vertical axis. One of the mating portion and the mounting portion includes a bifurcated end having opposing contact tips and the other of the mating portion and the mounting portion includes an interconnection end that is received between the contact tips to electrically couple the mating portion and the mounting portion.",TYCO ELECTRONICS CORP,BLASICK FRANCIS J;;WALLACE DARON;;WEIDNER KEVIN EDWARD;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL;;EVERTS DAVID,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/081-483-923-486-81X,Granted Patent,yes,11,21,4,4,0,H01R12/585;;H01R13/112;;H01R24/50;;H01R43/16;;H01R2103/00;;H01R12/724;;H01R24/545;;H01R24/50;;H01R12/724;;H01R24/545;;H01R43/16;;H01R2103/00;;H01R12/585;;H01R13/112,H01R12/00,439/63;;439/581,0,0,,,,ACTIVE
114,CN,B,CN 102074812 B,106-825-851-780-341,2015-04-01,2015,CN 201010530123 A,2010-08-16,US 54125209 A,2009-08-14,Multi-port connector system,,TYCO ELECTRONICS CORP,BLASICK FRANCIS J;;WALLACE DARON;;WEIDNER KEVIN E;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL;;EVERTS DAVID,,https://lens.org/106-825-851-780-341,Granted Patent,no,0,0,4,4,0,H01R12/585;;H01R13/112;;H01R24/50;;H01R43/16;;H01R2103/00;;H01R12/724;;H01R24/545;;H01R24/50;;H01R12/724;;H01R24/545;;H01R43/16;;H01R2103/00;;H01R12/585;;H01R13/112,H01R12/52;;H01R12/55;;H01R13/02;;H01R13/46;;H01R13/652,,0,0,,,,ACTIVE
115,US,A1,US 2011/0039423 A1,123-622-173-028-877,2011-02-17,2011,US 54125209 A,2009-08-14,US 54125209 A,2009-08-14,MULTI-PORT CONNECTOR SYSTEM,"An electrical connector assembly includes a housing, a connector and a conductor. The housing extends from a mating interface to a back end along a longitudinal axis and from a top side to a mounting interface along a vertical axis. The connector is disposed at the mating interface and is configured to mate with a mating connector. The conductor extends from the electrical connector to the mounting interface to provide a conductive pathway between the mating connector and the circuit board. The conductor includes a mating portion oriented along the longitudinal axis and a mounting portion oriented along the vertical axis. One of the mating portion and the mounting portion includes a bifurcated end having opposing contact tips and the other of the mating portion and the mounting portion includes an interconnection end that is received between the contact tips to electrically couple the mating portion and the mounting portion.",TYCO ELECTRONICS CORP,BLASICK FRANCIS J;;WALLACE DARON;;WEIDNER KEVIN E;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL;;EVERTS DAVID,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/123-622-173-028-877,Patent Application,yes,11,8,4,4,0,H01R12/585;;H01R13/112;;H01R24/50;;H01R43/16;;H01R2103/00;;H01R12/724;;H01R24/545;;H01R24/50;;H01R12/724;;H01R24/545;;H01R43/16;;H01R2103/00;;H01R12/585;;H01R13/112,H01R12/00,439/65,0,0,,,,ACTIVE
116,CN,A,CN 102074812 A,089-509-694-213-79X,2011-05-25,2011,CN 201010530123 A,2010-08-16,US 54125209 A,2009-08-14,Multi-port connector system,"An electrical connector assembly (102) includes a housing (114), connectors (132, 166) and a conductor (200). The housing (114) extends from a mating interface (106) to a back end (120) along a longitudinal axis (122) and from a top side (124) to a mounting interface (108) along a vertical axis(126). The connectors (132, 166) are disposed at the mating interface and are configured to mate with a mating connector (104). The conductor (200) extends from the electrical connector to the mounting interface to provide a conductive pathway between the mating connector and the circuit board. The conductor includes a mating portion (202) oriented along the longitudinal axis and a mounting portion (204) oriented along the vertical axis. One of the mating portion and the mounting portion includes a bifurcated end (304) having opposing contact tips (310, 312) and the other of the mating portion and the mounting portion includes an interconnection end (402) that is received between the contact tips to electrically couple the mating portion and the mounting portion.",TYCO ELECTRONICS CORP,BLASICK FRANCIS J;;DARON WALLACE;;WEIDNER KEVIN E;;RICHARD FOLTZ KEITH;;MICHAEL BLOCK;;DAVID EVERTS,,https://lens.org/089-509-694-213-79X,Patent Application,no,9,1,4,4,0,H01R12/585;;H01R13/112;;H01R24/50;;H01R43/16;;H01R2103/00;;H01R12/724;;H01R24/545;;H01R24/50;;H01R12/724;;H01R24/545;;H01R43/16;;H01R2103/00;;H01R12/585;;H01R13/112,H01R12/52;;H01R12/55;;H01R13/02;;H01R13/46;;H01R13/652,,0,0,,,,ACTIVE
117,US,A,US 5298292 A,006-973-550-933-243,1994-03-29,1994,US 89109192 A,1992-06-01,US 89109192 A,1992-06-01,Method for applying a coating solution,"A method for applying a coating solution onto a substrate to form a coated portion thereon includes a dipping device for dipping and removing the substrate into and from the coating solution; and a heating device for inductively heating the substrate while the dipping device removes the substrate from the coating solution to uniformly dry an inner surface of the coated portion, the inner surface being adjacent to the substrate. The method advantageously may include a drying device for blowing hot gases onto the coated portion of the substrate while the dipping device removes the substrate from the coating solution. The drying device for blowing hot gases onto the coated portion of the substrate includes a plurality of slits arranged so that a plurality of hot gas streams flowing through corresponding ones of the plurality of slits impinge and exert a gas pressure on the coated portion, the plurality of slits being arranged so that a collective gas pressure from all hot gas streams is uniformly applied across the coated portion along a transverse direction so that the coated portion is squeezed to a uniform thickness as the dipping device removes the substrate.",XEROX CORP,DILKO JOHN T;;FOLTZ ROBERT S;;O'DELL GENE;;RICH DAVID;;MANZOLATI RICHARD J;;DARCY JOHN J,XEROX CORPORATION A NY CORP (1992-05-20),https://lens.org/006-973-550-933-243,Granted Patent,yes,12,6,3,3,0,B05D1/18;;B05D3/0209;;B05D3/0281;;B05D3/0413;;B05D3/0413;;B05D3/0281;;B05D1/18;;B05D3/0209,B05C3/09;;B05C3/05;;B05C9/14;;B05D1/18;;B05D3/02;;B05D3/04;;G03G5/05,427/543;;427/58;;427/348;;427/372.2;;427/443.2;;427/544;;427/591,2,0,,,"Kirk Othmer, Encyclopedia of Chemica Technology; 3rd Ed.; Supplement Volume, J. Willey & Sons, 1984, pp. 846 873.;;Perry s Chemical Engineer s Handbook 5th Ed; McGraw Hill Book Company; pp. 20 78; 20 80 to 20 82; 20 84; 20 86 to 20 89; 20 91 to 20 95; 20 98 to 20 103.",EXPIRED
118,US,B1,US 6197461 B1,127-321-633-812-133,2001-03-06,2001,US 44934299 A,1999-11-24,US 44934299 A,1999-11-24,Multiple-seam electrostatographic imaging member and method of making electrostatographic imaging member,"Multiple-seam electrostatographic imaging member belts include two or more imaging member portions joined together by two or more seams. The belts can be formed from imaging member web that either includes or does not include an anti-curl backing layer, and that includes a charge transport layer that is substantially stress free.",XEROX CORP,FOLTZ ROBERT S;;MILLONZI RICHARD P;;YU ROBERT C U;;DARCY JOHN J;;LANGLOIS EDOUARD E,XEROX CORPORATION (1999-11-23),https://lens.org/127-321-633-812-133,Granted Patent,yes,31,10,2,2,0,G03G5/04;;G03G5/043;;G03G5/10;;Y10T428/192;;Y10T156/1079;;Y10T428/192;;Y10T156/1079;;G03G5/043;;G03G5/04;;G03G5/10,G03G5/04;;G03G5/043;;G03G5/10,430/56;;430/127;;428/58;;156/94,0,0,,,,EXPIRED
119,US,B1,US 6277534 B1,125-881-393-417-363,2001-08-21,2001,US 69950900 A,2000-10-31,US 69950900 A;;US 44934299 A,1999-11-24,Multiple-seam electrostatographic imaging member and method of making electrostatographic imaging member,"Multiple-seam electrostatographic imaging member belts include two or more imaging member portions joined together by two or more seams. The belts can be formed from imaging member web that either includes or does not include an anti-curl backing layer, and that includes a charge transport layer that is substantially stress free.",XEROX CORP,FOLTZ ROBERT S;;MILLONZI RICHARD P;;YU ROBERT C U;;DARCY JOHN J;;LANGLOIS EDOUARD E,,https://lens.org/125-881-393-417-363,Granted Patent,yes,32,11,2,2,0,G03G5/04;;G03G5/043;;G03G5/10;;Y10T428/192;;Y10T156/1079;;Y10T428/192;;Y10T156/1079;;G03G5/043;;G03G5/04;;G03G5/10,G03G5/04;;G03G5/043;;G03G5/10,430/56;;430/127;;430/130;;430/69;;156/73.4;;156/189;;156/266;;156/304.6,0,0,,,,EXPIRED
120,US,A,US 5307637 A,127-313-719-237-707,1994-05-03,1994,US 91091192 A,1992-07-09,US 91091192 A,1992-07-09,Angled multi-hole film cooled single wall combustor dome plate,"A gas turbine engine combustor is provided with a combustor dome plate film cooling means having an annular slotted ring to provide a film starting means upstream of a multi-hole film cooled single wall metal dome plate which is annular in shape. One particular embodiment provides a starting slot in the form of a plurality of rings surrounding the edges of the air/fuel nozzle inlet apertures in the dome plate. The cooling holes are disposed in concentric circles about the apertures and angled along radii emanating from the center of the apertures. This produces a cooling film emanating radially from the ring like circular slots around each air/fuel nozzle inlet aperture in the dome plate. Another embodiment provides a starting slot in the form of circumferential rails circumferentially disposed about the inner and outer circumferential edges of dome plate. The cooling holes are arranged in two section, the first to feed a radially inward directed cooling film that is initiated from an outer starting slot on a radially outer circumferential edge of the plate. The second sections has film cooling holes angled radially outward to feed a radially outward directed cooling film emanating an inner starting slot on a radially inward circumferential edge of the plate.",GEN ELECTRIC,STICKLES RICHARD W;;FOLTZ HOWARD L;;TAYLOR KEITH K;;COOK GEORGE E;;MACLEAN THOMAS;;DODDS WILLARD J,GENERAL ELECTRIC COMPANY (1992-06-09),https://lens.org/127-313-719-237-707,Granted Patent,yes,21,123,1,1,0,F05B2260/202;;F23R3/002;;F23R3/10;;F23R3/50;;F23R2900/03042;;Y02T50/60;;F23R3/10;;F05B2260/202;;F23R3/50;;F23R3/002;;F23R2900/03042;;Y02T50/60,F23R3/00;;F23R3/10;;F23R3/50,60/756;;60/755,4,0,,,"Advanced Low Emissions Catalytic Combustor Program Phase 1 Final Report , by Dr. G. J. Sturgess, Prepared for NASA, Jun. 1981 NASA CR 159656.;;Alternate Cooling Configuration for Gas Turbine Combustion Systems , by D. A. Nealy, S. B. Reider, & H. C. Mongia, Prepared for Advisory Group for Aerospace Research and Development Propulsion and Energetics Panel, May, 1985.;;Film Cooling , by Richard J. Goldstein, pp. 321 379, prepared for Department of Mechanical Engineering, University of Minnesota, Minneapolis, Minn.;;Influence of Coolant Tube Curvature on Film Cooling Effectiveness as Detected by Infrared Imagery , by S. Stephen Papell, Robert W. Graham, and Richard P. Cagezo, prepared for Lewis Research Center, Cleveland, Ohio, 1979, NASA T.P. No. 1546.",EXPIRED
121,EP,A2,EP 0371682 A2,018-263-877-672-814,1990-06-06,1990,EP 89312101 A,1989-11-22,US 27730588 A,1988-11-29,Rapid method for determining efficacy of a sterilization cycle and rapid read-out biological indicator.,"A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product.",MINNESOTA MINING & MFG,MATNER RICHARD R C O MINNESOTA;;FOLTZ WILLIAM E C O MINNESOTA;;WOODSON LEWIS P C O MINNESOTA,,https://lens.org/018-263-877-672-814,Patent Application,yes,0,18,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
122,US,B1,US 6627002 B1,088-002-078-017-315,2003-09-30,2003,US 62886500 A,2000-07-28,US 62886500 A,2000-07-28,Hollow cylindrical imaging member treatment process with solid carbon dioxide pellets,"
    A process for treating an electrostatographic imaging member including providing a hollow cylindrical electrostatographic imaging member having an interior surface, a coated outer surface, a first end and a second end, the interior surface at at least the first end having a coating of adhesive material securing a first end flange to the first end, and propelling solid carbon dioxide pellets against the first end flange and coating of adhesive material with sufficient force to remove the first end flange and coating of adhesive material from the interior surface at at least the first end of the hollow cylindrical electrostatographic imaging member. 
",XEROX CORP,MILLONZI RICHARD P;;FOLTZ ROBERT S;;PETRALIA RICHARD C;;CACCAMISE LESLIE W;;HAMMOND HAROLD F;;CRUMP DAVID P;;MCCUMISKEY ROBERT E;;WILLIAMS EDWARD C,XEROX CORPORATION (2000-09-06),https://lens.org/088-002-078-017-315,Granted Patent,yes,20,3,1,1,0,B08B9/0321;;B08B9/0321;;B08B7/0092;;B08B7/0092;;G03G15/751;;G03G15/751,B08B7/00;;B08B9/02;;G03G15/00,134/7;;134/8;;134/34;;451/40;;451/53,0,0,,,,EXPIRED
123,TW,A,TW 201330399 A,193-907-968-868-704,2013-07-16,2013,TW 101139667 A,2012-10-26,US 201113284577 A,2011-10-28,Coaxial connector,"A coaxial connector (300) comprises an outer contact (314) having a mating end (360) configured to be mated to a mating connector, and a terminating end (362) configured to be mounted to a circuit board (302). A central cavity (364) extends between the mating end and the terminating end. A center contact (310) is disposed in the central cavity and is configured to be terminated to the circuit board. A circuit board mount (316) is coupled to the terminating end and is configured to mechanically and electrically connect the outer contact to the circuit board. A dielectric insert (312) is received in the central cavity, and the dielectric insert has a bore (340) that receives and holds the center contact. The dielectric insert has structural features (346) extending axially along an exterior of the dielectric insert, and air gaps (348) are defined between the structural features. The structural features engage the outer contact (314) to secure the dielectric insert (312) in the central cavity (364).",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM R,,https://lens.org/193-907-968-868-704,Patent of Addition,no,0,0,6,6,0,H01R9/0515;;H01R9/0524;;H01R24/44;;H01R24/50;;H01R24/44;;H01R9/0515;;H01R9/0524;;H01R24/50,H01R24/38;;H01R13/514,,0,0,,,,PENDING
124,US,B2,US 8641447 B2,156-005-522-422-340,2014-02-04,2014,US 201113330874 A,2011-12-20,US 201113330874 A,2011-12-20,Coaxial connector,"A coaxial connector includes a center contact electrically connected to a conductor of a cable. The center contact extends along a contact axis oriented generally perpendicular to an axis of the conductor of the cable. An outer contact has a cavity and the center contact is disposed in the cavity. The outer contact has a separable interface end and a terminating end. The separable interface end and terminating end are oriented generally perpendicular to one another. A dielectric insert is received in the cavity. The dielectric insert has a bore that receives and holds the center contact. The dielectric insert has structural features extending axially along an exterior of the dielectric insert, with air gaps defined between the structural features. The structural features engage the outer contact to secure the dielectric insert in the cavity.",SYKES MICHAEL TIMOTHY;;SCHEIGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP;;TYCO ELECTRONICS LOGISTICS AG,SYKES MICHAEL TIMOTHY;;SCHEIGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-15);;TE CONNECTIVITY CORPORATION (2011-12-14),https://lens.org/156-005-522-422-340,Granted Patent,yes,13,12,4,11,0,H01R24/44;;H01R24/545;;H01R24/44;;H01R24/545,H01R9/05,439/582;;439/855,0,0,,,,INACTIVE
125,US,S,US D0712840 S,184-670-120-989-438,2014-09-09,2014,US 201129405154 F,2011-10-28,US 201129405154 F,2011-10-28,Coaxial connector,,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP;;TYCO ELECTRONICS LOGISTICS AG,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-20);;TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01);;TYCO ELECTRONICS COPORATION (2011-10-24),https://lens.org/184-670-120-989-438,Design Right,no,0,16,1,1,0,,,1303;;D13/151,0,0,,,,ACTIVE
126,US,A1,US 2013/0157503 A1,192-252-281-039-140,2013-06-20,2013,US 201113330874 A,2011-12-20,US 201113330874 A,2011-12-20,COAXIAL CONNECTOR,"A coaxial connector includes a center contact electrically connected to a conductor of a cable. The center contact extends along a contact axis oriented generally perpendicular to an axis of the conductor of the cable. An outer contact has a cavity and the center contact is disposed in the cavity. The outer contact has a separable interface end and a terminating end. The separable interface end and terminating end are oriented generally perpendicular to one another. A dielectric insert is received in the cavity. The dielectric insert has a bore that receives and holds the center contact. The dielectric insert has structural features extending axially along an exterior of the dielectric insert, with air gaps defined between the structural features. The structural features engage the outer contact to secure the dielectric insert in the cavity.",SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-15);;TE CONNECTIVITY CORPORATION (2011-12-14),https://lens.org/192-252-281-039-140,Patent Application,yes,0,7,4,11,0,H01R24/44;;H01R24/545;;H01R24/44;;H01R24/545,H01R9/05,439/578,0,0,,,,INACTIVE
127,CN,A,CN 103311684 A,093-812-335-223-423,2013-09-18,2013,CN 201210599339 A,2012-12-20,US 201113330874 A,2011-12-20,Coaxial connector,"A coaxial connector includes a center contact electrically connected to a conductor of a cable. The center contact extends along a contact axis oriented generally perpendicular to an axis of the conductor of the cable. An outer contact has a cavity and the center contact is disposed in the cavity. The outer contact has a separable interface end and a terminating end. The separable interface end and terminating end are oriented generally perpendicular to one another. A dielectric insert is received in the cavity. The dielectric insert has a bore that receives and holds the center contact. The dielectric insert has structural features extending axially along an exterior of the dielectric insert, with air gaps defined between the structural features. The structural features engage the outer contact to secure the dielectric insert in the cavity.",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,,https://lens.org/093-812-335-223-423,Patent Application,no,5,1,4,11,0,H01R24/44;;H01R24/545;;H01R24/44;;H01R24/545,H01R9/05,,0,0,,,,DISCONTINUED
128,US,S,US D0675995 S,090-216-702-078-767,2013-02-12,2013,US 201129405151 F,2011-10-28,US 201129405151 F,2011-10-28,Coaxial connector,,TYCO ELECTRONICS CORP;;TYCO ELECTRONICS LOGISTICS AG;;SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-20);;TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01);;TYCO ELECTRONICS COPORATION (2011-10-24),https://lens.org/090-216-702-078-767,Design Right,no,0,3,1,1,0,,,1303;;D13/151,0,0,,,,ACTIVE
129,US,A,US 5740422 A,108-619-216-865-405,1998-04-14,1998,US 53476295 A,1995-09-27,US 53476295 A,1995-09-27,Method and apparatus for resource management for a lan server enterprise,"A method and architecture for the administration of large cells in an Open System Foundation/Distributed Computing Environment (OSF/DCE). The architecture organizes the Cell Directory Service (CDS) name space of the OSF/DCE to allow a network administrator to easily determine network resources under their control, and work with a subset of the network resources. The OSF/DCE name space is organized as resource realms having a CDS component and a registry component. The CDS component of the resource realms has a fixed portion containing at least two roots describing sub-systems and realm resources (e.g., printer, serial devices, etc.). The CDS component also contains individual realms defined directly below the fixed portions. The registry component has a root consisting of the security, group and realm portions. Individual realms are defined as directories below the root. The resulting resource manager which allows the OSF/DCE name space to be organized/partitioned into separate, administrable name spaces which allows easy determination as to what resources are controlled by the administrator, and easily administrable subsets of network resources.",IBM,FOLTZ RICHARD CAMPBELL;;GENGLER WILLIAM HAROLD;;LUCAS JR JOSEPH CHRISTOPHER;;MEEGAN JOHN VINCENT;;REISH TROY GARY;;ROLETTE JR JAMES MICHAEL,INTERNATIONAL BUSINESS MACHINES CORPORATION (1995-09-25),https://lens.org/108-619-216-865-405,Granted Patent,yes,4,28,1,1,0,H04L61/45;;H04L61/00;;H04L61/45;;H04L61/00,G06F17/30;;H04L29/12,395/609;;395/200.59,0,0,,,,EXPIRED
130,EP,A1,EP 2587590 A1,098-959-445-142-710,2013-05-01,2013,EP 12190259 A,2012-10-26,US 201113284553 A,2011-10-28,Coaxial connector,"A coaxial connector (100) comprises an outer contact (114) having a separable interface end (166) configured to be mated to a mating connector, and a terminating end (186). A central cavity (164) extends between the separable interface end (166) and the terminating end (186). A dielectric insert (112) is received in the central cavity (164), and the dielectric insert (112) has a bore (140) that holds a center contact (110). The dielectric insert (112) has structural features (146) extending axially along an exterior of the dielectric insert (112), and air gaps (148) are defined between the structural features (146). The structural features (146) engage the outer contact (114) to secure the dielectric insert (112) in the central cavity (164).
",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM R,,https://lens.org/098-959-445-142-710,Patent Application,yes,10,2,6,6,0,H01R24/44;;H01R24/44;;H01R9/0521;;H01R9/0521;;H01R9/0524;;H01R9/0524;;H01R24/50;;H01R24/50;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R24/44,,0,0,,,,DISCONTINUED
131,TW,A,TW 201332231 A,008-695-277-430-99X,2013-08-01,2013,TW 101148005 A,2012-12-18,US 201113330874 A,2011-12-20,Coaxial connector,"A coaxial connector (100) comprises a center contact (110), an outer contact (114) having a cavity (164), the center contact being disposed in the cavity. The outer contact has a separable interface end (166) configured to be mated to the mating connector, and a terminating end (186) configured to be terminated to an end of a cable. The separable interface end and the terminating end are oriented perpendicular to one another. A dielectric insert (112) is received in the cavity. The dielectric insert has a bore (140) that receives and holds the center contact. The dielectric insert has structural features (146) extending axially along an exterior of the dielectric insert, air gaps (148) are defined between the structural features, and the structural features engage the outer contact to secure the dielectric insert in the cavity.",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM ROBERT;;SCHEGGIA MATTIA,,https://lens.org/008-695-277-430-99X,Patent of Addition,no,0,0,4,11,0,H01R24/44;;H01R24/545;;H01R24/44;;H01R24/545,H01R24/38,,0,0,,,,PENDING
132,CN,A,CN 103094766 A,024-566-622-597-424,2013-05-08,2013,CN 201210448190 A,2012-10-29,US 201113284577 A,2011-10-28,Coaxial Connector,"A coaxial connector (300) comprises an outer contact (314) having a mating end (360) configured to be mated to a mating connector, and a terminating end (362) configured to be mounted to a circuit board. A central cavity (364) extends between the mating end (360) and the terminating end (362). A center contact (310) is disposed in the central cavity (364) and is configured to be terminated to the circuit board. A circuit board mount (316) is coupled to the terminating end (362) and is configured to mechanically and electrically connect the outer contact (314) to the circuit board. A dielectric insert (312) is received in the central cavity (364), and the dielectric insert (312) has a bore (340) that receives and holds the center contact (310). The dielectric insert (312) has structural features (346) extending axially along an exterior of the dielectric insert (312), and air gaps (348) are defined between the structural features (346). The structural features (346) engage the outer contact (314) to secure the dielectric insert (312) in the central cavity (364).",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM R,,https://lens.org/024-566-622-597-424,Patent Application,no,4,1,6,6,0,H01R9/0515;;H01R9/0524;;H01R24/44;;H01R24/50;;H01R24/44;;H01R9/0515;;H01R9/0524;;H01R24/50,H01R13/46;;H01R9/05;;H01R13/40;;H01R24/50;;H01R103/00,,0,0,,,,INACTIVE
133,EP,A1,EP 2587591 A1,145-493-755-136-165,2013-05-01,2013,EP 12190274 A,2012-10-26,US 201113284577 A,2011-10-28,Coaxial connector,"A coaxial connector (300) comprises an outer contact (314) having a mating end (360) configured to be mated to a mating connector, and a terminating end (362) configured to be mounted to a circuit board. A central cavity (364) extends between the mating end (360) and the terminating end (362). A center contact (310) is disposed in the central cavity (364) and is configured to be terminated to the circuit board. A circuit board mount (316) is coupled to the terminating end (362) and is configured to mechanically and electrically connect the outer contact (314) to the circuit board. A dielectric insert (312) is received in the central cavity (364), and the dielectric insert (312) has a bore (340) that receives and holds the center contact (310). The dielectric insert (312) has structural features (346) extending axially along an exterior of the dielectric insert (312), and air gaps (348) are defined between the structural features (346). The structural features (346) engage the outer contact (314) to secure the dielectric insert (312) in the central cavity (364).
",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM R,,https://lens.org/145-493-755-136-165,Patent Application,yes,8,1,6,6,0,H01R9/0515;;H01R9/0524;;H01R24/44;;H01R24/50;;H01R24/44;;H01R9/0515;;H01R9/0524;;H01R24/50,H01R24/44;;H01R9/05;;H01R24/50,,0,0,,,,DISCONTINUED
134,US,A1,US 2013/0109231 A1,120-823-108-150-43X,2013-05-02,2013,US 201113284553 A,2011-10-28,US 201113284553 A,2011-10-28,COAXIAL CONNECTOR,"A coaxial connector includes a center contact, an outer contact and a dielectric insert received in the outer contact and holding the center contact. The dielectric insert may have structural features that extend axially along an exterior of the dielectric insert with air gaps between the structural features. The outer contact may include a rear housing that is interchangeably coupled to either a plug housing or a jack housing at the housing interface. The center contact may be configured to be terminated by a plurality of different termination techniques in different applications.",SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-20);;TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/120-823-108-150-43X,Patent Application,yes,9,8,6,6,0,H01R24/44;;H01R24/44;;H01R9/0521;;H01R9/0521;;H01R9/0524;;H01R9/0524;;H01R24/50;;H01R24/50;;H01R2103/00;;H01R2103/00,H01R9/05,439/585;;439/578,0,0,,,,INACTIVE
135,US,B2,US 8636522 B2,063-691-534-482-384,2014-01-28,2014,US 201113284577 A,2011-10-28,US 201113284577 A,2011-10-28,Coaxial connector,A coaxial connector includes a center contact and an outer contact. The outer contact has a central cavity and the center contact is disposed in the central cavity. The outer contact has a mating end configured to be mated to a mating connector and a terminating end configured to be mounted to a circuit board. A circuit board mount is coupled to the terminating end and is configured to mechanically and electrically connect the outer contact to the circuit board. A dielectric insert is received in the central cavity and holds the center contact. The dielectric insert has structural features extending axially along an exterior of the dielectric insert with air gaps therebetween. The structural features engage the outer contact to secure the dielectric insert in the central cavity.,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-20);;TE CONNECTIVITY CORPORATION (2017-01-01),https://lens.org/063-691-534-482-384,Granted Patent,yes,11,21,6,6,0,H01R9/0515;;H01R9/0524;;H01R24/44;;H01R24/50;;H01R24/44;;H01R9/0515;;H01R9/0524;;H01R24/50,H01R12/00,439/63,1,0,,,"European Search Report, European Application No. 12190274.6, European Filing Date Oct. 26, 2012.",INACTIVE
136,US,B2,US 8647128 B2,163-496-017-878-913,2014-02-11,2014,US 201113330978 A,2011-12-20,US 201113330978 A,2011-12-20,Coaxial connector,A coaxial connector includes a center contact and a board contact coupled to the center contact that is terminated to a circuit board. An outer contact has a cavity that receives the center contact and board contact. The outer contact has a separable interface end mated to a mating connector and a terminating end mounted to the circuit board. A circuit board mount is coupled to the terminating end and electrically connects the outer contact to the circuit board. A dielectric insert is received in the cavity and includes a bore that receives and holds either the center contact or the board contact. The dielectric insert has structural features extending axially along an exterior of the dielectric insert with air gaps being defined between the structural features. The structural features engage the outer contact to secure the dielectric insert in the cavity.,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP;;TYCO ELECTRONICS LOGISTICS AG,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-15);;TE CONNECTIVITY CORPORATION (2011-12-14),https://lens.org/163-496-017-878-913,Granted Patent,yes,6,14,4,11,0,H01R24/44;;H01R24/44,H01R9/05,439/63;;439/578,0,0,,,,INACTIVE
137,CN,A,CN 103094765 A,199-248-593-238-408,2013-05-08,2013,CN 201210448175 A,2012-10-29,US 201113284553 A,2011-10-28,Coaxial Connector,"A coaxial connector (100) comprises an outer contact (114) having a separable interface end (166) configured to be mated to a mating connector, and a terminating end (186). A central cavity (164) extends between the separable interface end (166) and the terminating end (186). A dielectric insert (112) is received in the central cavity (164), and the dielectric insert (112) has a bore (140) that holds a center contact (110). The dielectric insert (112) has structural features (146) extending axially along an exterior of the dielectric insert (112), and air gaps (148) are defined between the structural features (146). The structural features (146) engage the outer contact (114) to secure the dielectric insert (112) in the central cavity (164).",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM R,,https://lens.org/199-248-593-238-408,Patent Application,no,6,2,6,6,0,H01R24/44;;H01R24/44;;H01R9/0521;;H01R9/0521;;H01R9/0524;;H01R9/0524;;H01R24/50;;H01R24/50;;H01R2103/00;;H01R2103/00,H01R13/46;;H01R9/05;;H01R13/40;;H01R24/50;;H01R103/00,,0,0,,,,INACTIVE
138,US,B2,US 8727807 B2,099-830-040-793-282,2014-05-20,2014,US 201113284553 A,2011-10-28,US 201113284553 A,2011-10-28,Coaxial connector,"A coaxial connector includes a center contact, an outer contact and a dielectric insert received in the outer contact and holding the center contact. The dielectric insert may have structural features that extend axially along an exterior of the dielectric insert with air gaps between the structural features. The outer contact may include a rear housing that is interchangeably coupled to either a plug housing or a jack housing at the housing interface. The center contact may be configured to be terminated by a plurality of different termination techniques in different applications.",SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP;;TYCO ELECTRONICS LOGISTICS AG,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-20);;TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/099-830-040-793-282,Granted Patent,yes,18,12,6,6,0,H01R24/44;;H01R24/44;;H01R9/0521;;H01R9/0521;;H01R9/0524;;H01R9/0524;;H01R24/50;;H01R24/50;;H01R2103/00;;H01R2103/00,H01R9/05;;H01R24/44,439/578;;439/63,1,0,,,"European Search Report, European Application No. 12190259,7, European Filing Date Oct. 26, 2012.",INACTIVE
139,CN,A,CN 103311759 A,175-875-845-990-498,2013-09-18,2013,CN 201210599338 A,2012-12-20,US 201113330978 A,2011-12-20,Coaxial connector,"A coaxial connector (200) includes an outer contact (214) with a cavity (264), a center contact (210) which is arranged in the chamber and is constructed to match with the coaxial connector, a board contact (209) which is arranged in the chamber and is constructed for wiring jointing with a circuit board (204), and a circuit board mounting frame (215) which is coupled to the outer contact and is constructed for electrically connecting the outer contact with the circuit board. The center contact and the board contact are separated components which are electrically connected with each other in the chamber. A front dielectric insert (212) is received in the chamber and is provided with a bore (240) which receives and holds the board contact. The front dielectric insert and the bottom dielectric insert have structural features (246) which extend along the outer axial direction of the front dielectric insert and the bottom dielectric. Air gaps (248) are defined among the structural features. Furthermore the structural features are jointed with the outer contact for fixing the front dielectric insert and the bottom dielectric in the cavity.",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM ROBERT;;SCHEGGIA MATTIA,,https://lens.org/175-875-845-990-498,Patent Application,no,3,8,4,11,0,H01R24/44;;H01R24/44,H01R24/50;;H01R13/02;;H01R103/00,,0,0,,,,DISCONTINUED
140,US,A1,US 2013/0109228 A1,192-457-921-040-57X,2013-05-02,2013,US 201113284577 A,2011-10-28,US 201113284577 A,2011-10-28,COAXIAL CONNECTOR,A coaxial connector includes a center contact and an outer contact. The outer contact has a central cavity and the center contact is disposed in the central cavity. The outer contact has a mating end configured to be mated to a mating connector and a terminating end configured to be mounted to a circuit board. A circuit board mount is coupled to the terminating end and is configured to mechanically and electrically connect the outer contact to the circuit board. A dielectric insert is received in the central cavity and holds the center contact. The dielectric insert has structural features extending axially along an exterior of the dielectric insert with air gaps therebetween. The structural features engage the outer contact to secure the dielectric insert in the central cavity.,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-20);;TE CONNECTIVITY CORPORATION (2017-01-01),https://lens.org/192-457-921-040-57X,Patent Application,yes,3,25,6,6,0,H01R9/0515;;H01R9/0524;;H01R24/44;;H01R24/50;;H01R24/44;;H01R9/0515;;H01R9/0524;;H01R24/50,H01R9/05,439/578,0,0,,,,INACTIVE
141,US,A1,US 2013/0157504 A1,094-456-272-637-175,2013-06-20,2013,US 201113330978 A,2011-12-20,US 201113330978 A,2011-12-20,COAXIAL CONNECTOR,A coaxial connector includes a center contact and a board contact coupled to the center contact that is terminated to a circuit board. An outer contact has a cavity that receives the center contact and board contact. The outer contact has a separable interface end mated to a mating connector and a terminating end mounted to the circuit board. A circuit board mount is coupled to the terminating end and electrically connects the outer contact to the circuit board. A dielectric insert is received in the cavity and includes a bore that receives and holds either the center contact or the board contact. The dielectric insert has structural features extending axially along an exterior of the dielectric insert with air gaps being defined between the structural features. The structural features engage the outer contact to secure the dielectric insert in the cavity.,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R;;TYCO ELECTRONICS CORP,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL J;;WEIDNER KEVIN E;;ORNER JEFFREY K;;CHEVALIER TIM R,TYCO ELECTRONICS LOGISTICS AG (2011-12-15);;TE CONNECTIVITY CORPORATION (2011-12-14),https://lens.org/094-456-272-637-175,Patent Application,yes,0,8,4,11,0,H01R24/44;;H01R24/44,H01R9/05,439/578,0,0,,,,INACTIVE
142,TW,A,TW 201338308 A,097-063-696-423-13X,2013-09-16,2013,TW 101148006 A,2012-12-18,US 201113330978 A,2011-12-20,Coaxial connector,"A coaxial connector (200) comprises an outer contact (214) having a cavity (264), a center contact (210) disposed in the cavity and configured to be mated with a center contact of a mating coaxial connector, a board contact (209) disposed in the cavity and configured to be terminated to a circuit board (204), and a circuit board mount (215) coupled to the outer contact and configured to electrically connect the outer contact to the circuit board. The center contact and the board contact are separate components electrically connected to one another in the cavity. A front dielectric insert (212) is received in the cavity and has a bore (240) that receives and holds the center contact. A bottom dielectric insert (211) is received in the cavity and has a bore that receives and holds the board contact. The front dielectric insert and the bottom dielectric insert each have structural features (246) extending axially along a respective exterior of the front dielectric insert and the bottom dielectric insert, air gaps (248) are defined between the structural features, and the structural features engage the outer contact to secure the front dielectric insert and the bottom dielectric insert in the cavity.",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM ROBERT;;SCHEGGIA MATTIA,,https://lens.org/097-063-696-423-13X,Patent of Addition,no,0,0,4,11,0,H01R24/44;;H01R24/44,H01R24/40,,0,0,,,,PENDING
143,TW,A,TW 201334305 A,041-949-231-815-687,2013-08-16,2013,TW 101139666 A,2012-10-26,US 201113284553 A,2011-10-28,Coaxial connector,"A coaxial connector (100) comprises an outer contact (114) having a separable interface end (166) configured to be mated to a mating connector, and a terminating end (186). A central cavity (164) extends between the separable interface end and the terminating end. A dielectric insert (112) is received in the central cavity, and the dielectric insert has a bore (140) that holds a center contact (110). The dielectric insert has structural features (146) extending axially along an exterior of the dielectric insert, and air gaps (148) are defined between the structural features. The structural features engage the outer contact (114) to secure the dielectric insert (112) in the central cavity (164).",TYCO ELECTRONICS CORP;;TE CONNECTIVITY SOLUTIONS GMBH,SYKES MICHAEL TIMOTHY;;SCHEGGIA MATTIA;;FOLTZ KEITH RICHARD;;BLOCK MICHAEL JON;;WEIDNER KEVIN EDWARD;;ORNER JEFFREY KENNETH;;CHEVALIER TIM R,,https://lens.org/041-949-231-815-687,Patent of Addition,no,0,0,6,6,0,H01R24/44;;H01R24/44;;H01R9/0521;;H01R9/0521;;H01R9/0524;;H01R9/0524;;H01R24/50;;H01R24/50;;H01R2103/00;;H01R2103/00,H01R13/514;;H01R24/38,,0,0,,,,PENDING
144,DE,D1,DE 602006013551 D1,169-188-221-482-020,2010-05-27,2010,DE 602006013551 T,2006-08-09,US 70682505 P,2005-08-09,Elektrischer Verbindungsadapter und Verfahren zur Herstellung,,TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KIETH RICHARD;;REVAK DAVID MICHAEL;;AMAZON ALAN JAY;;GRUBBS JIMMY GLENN;;SWARTWOOD DAVIV A;;LAUB MICHAEL FREDRICK,,https://lens.org/169-188-221-482-020,Granted Patent,no,0,0,7,7,0,H01R13/502;;H01R13/502;;H01R24/58;;H01R24/58;;H01R31/06;;H01R31/06;;H01R43/16;;H01R43/16;;H01R2103/00;;H01R2103/00;;H01R2107/00;;H01R2107/00,H01R24/58,,0,0,,,,ACTIVE
145,EP,B1,EP 1753095 B1,073-797-341-832-868,2010-04-14,2010,EP 06118688 A,2006-08-09,US 70682505 P,2005-08-09,Electrical connector adapter and method of manufacture,,TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KIETH RICHARD;;REVAK DAVID MICHAEL;;AMAZON ALAN JAY;;GRUBBS JIMMY GLENN;;SWARTWOOD DAVIV A;;LAUB MICHAEL FREDRICK,,https://lens.org/073-797-341-832-868,Granted Patent,yes,3,0,7,7,0,H01R13/502;;H01R13/502;;H01R24/58;;H01R24/58;;H01R31/06;;H01R31/06;;H01R43/16;;H01R43/16;;H01R2103/00;;H01R2103/00;;H01R2107/00;;H01R2107/00,H01R24/58,,0,0,,,,ACTIVE
146,EP,A1,EP 1753095 A1,197-755-200-003-354,2007-02-14,2007,EP 06118688 A,2006-08-09,US 70682505 P,2005-08-09,Electrical connector adapter and method of manufacture,"An electrical connector adapter (40) for electrically interconnecting a portable electronic component such as an MP3 player, CD player, or other portable device with sound or other equipment in a vehicle. The adapter (40) includes a one-piece insulating housing (60) having a system mating end (42) for interconnecting to a vehicle's electrical system and a component mating end (44) for interconnecting to a portable electrical component. Three electrical contacts (62, 64, 68) are retained in three openings (90, 92, 94) respectively in the housing (60) and are arranged to electrically mate with a plug of a portable electrical component.
",TYCO ELECTRONICS CORP,MARTIN GALEN MONROE;;FOLTZ KIETH RICHARD;;REVAK DAVID MICHAEL;;AMAZON ALAN JAY;;GRUBBS JIMMY GLENN;;SWARTWOOD DAVIV A;;LAUB MICHAEL FREDRICK,,https://lens.org/197-755-200-003-354,Patent Application,yes,5,1,7,7,0,H01R13/502;;H01R13/502;;H01R24/58;;H01R24/58;;H01R31/06;;H01R31/06;;H01R43/16;;H01R43/16;;H01R2103/00;;H01R2103/00;;H01R2107/00;;H01R2107/00,H01R24/58,,0,0,,,,ACTIVE
147,US,B2,US 7503807 B2,038-473-616-404-513,2009-03-17,2009,US 50077306 A,2006-08-08,US 50077306 A;;US 70682505 P,2005-08-09,Electrical connector adapter and method for making,"An electrical connector adapter ( 40 ) is disclosed for electrically interconnecting a portable electronic component such as an MP3 player, CD player, or other portable device with sound or other equipment in a vehicle. The adapter ( 40 ) includes a one-piece insulating housing ( 60 ) having a system mating end ( 42 ) for interconnecting to a vehicle's electrical system and a component mating end ( 44 ) for interconnecting to a portable electrical component. Three electric contacts ( 62, 64, 68 ) are retained in three openings ( 90, 92, 94 ) respectively in the housing ( 60 ) and are arranged to electrically mate with a plug ( 54 ) of a portable electrical component.",TYCO ELECTRONICS CORP,MARTIN GALEN M;;FOLTZ KEITH RICHARD;;REVAK DAVID MICHAEL;;AMAZON ALAN JAY;;GRUBBS JIMMY GLENN;;SWARTWOOD DAVID A;;LAUB MICHAEL F,TE CONNECTIVITY CORPORATION (2006-07-27),https://lens.org/038-473-616-404-513,Granted Patent,yes,14,15,7,7,0,H01R13/502;;H01R13/502;;H01R24/58;;H01R24/58;;H01R31/06;;H01R31/06;;H01R43/16;;H01R43/16;;H01R2103/00;;H01R2103/00;;H01R2107/00;;H01R2107/00,H01R24/58;;H01R25/00,439/638;;439/668,3,0,,,"Ford Motor Co., Drawing No. 357T-19A164-AB, Mar. 22, 2002, 1 pg.;;Lumberg Connect-Customized Solutions, Lumberg Catalog, 12 pgs.;;European Patent Office Search Report, EP 06 11 8688, Nov. 9, 2006.",ACTIVE
148,EP,A3,EP 0371682 A3,190-290-349-388-609,1991-05-29,1991,EP 89312101 A,1989-11-22,US 27730588 A,1988-11-29,RAPID METHOD FOR DETERMINING EFFICACY OF A STERILIZATION CYCLE AND RAPID READ-OUT BIOLOGICAL INDICATOR,"A rapid method of determining the efficacy of a sterilization cycle, and an indicator adapted to perform such method, comprising subjecting to the sterilization cycle a source of active enzyme having activity which correlates with the viability of a microorganism commonly used to monitor sterilization, and incubating the enzyme source, following the completion of the sterilization cycle, with an effective amount of a substrate system capable of reacting with any residual active enzyme to produce a detectable enzyme-modified product.",MINNESOTA MINING AND MANUFACTURING COMPANY,"MATNER, RICHARD R. C/O MINNESOTA MINING AND;;FOLTZ, WILLIAM E. C/O MINNESOTA MINING AND;;WOODSON, LEWIS P. C/O MINNESOTA MINING AND",,https://lens.org/190-290-349-388-609,Search Report,yes,4,0,15,20,0,C12Q1/22;;C12Q1/22;;C12Q1/22,A61L2/26;;C12Q1/22;;C12Q1/25,,0,0,,,,EXPIRED
149,US,A,US 5655182 A,064-578-014-400-738,1997-08-05,1997,US 48508095 A,1995-06-07,US 48508095 A,1995-06-07,Method and apparatus for reusing a photoreceptor and gear assembly,"A reusable photoreceptor assembly has a gear assembly removable from a photoreceptor. A square leaf spring or ring is used to secure and remove the gear assembly to and from the photoreceptor, thereby avoiding damage to both the gear assembly and photoreceptor during the removal of the gear assembly. The undamaged gear assembly and photoreceptor may then be reused.",XEROX CORP,SANCHEZ ISMAEL R;;BRYDGES WARREN F;;FOLTZ ROBERT S;;HAMMOND WILLIAM A;;PETRALIA RICHARD C;;SWAIN EUGENE A;;VO THONG H;;WILLIAMS JOHN K,XEROX CORPORATION (1995-06-02),https://lens.org/064-578-014-400-738,Granted Patent,yes,14,18,2,2,0,G03G15/751;;G03G15/751,G03G21/00;;G03G15/00,399/117;;399/167,0,0,,,,EXPIRED
150,WO,A1,WO 2021/181325 A1,073-251-282-604-835,2021-09-16,2021,IB 2021052031 W,2021-03-11,US 202062988143 P,2020-03-11,CONNECTOR ASSEMBLY,"A connector assembly (20) includes an outer conductive body (22) having a first end (23) configured to mate with a corresponding electrical connector, and a conductive center contact (30) arranged within the outer conductive body (22). The center contact (30) comprises a first end (32) configured to mate with the corresponding electrical connector and a second end (38) electrically connecting with a first electrical contact (52) of a circuit board (50). An outer contact (40) is slidably attached to a second end (26) of the outer conductive body (22) and electrically connects with a second electrical contact (54) of the circuit board (50). An elastic element (44) is provided for biasing the outer contact (40) in a direction away from the outer conductive body (22) and toward the circuit board (50).",TE CONNECTIVITY CORP;;TE CONNECTIVITY SERVICES GMBH,BRANDT CHRISTIAN PERRY;;BAKER JESSE ALAN;;FOLTZ KEITH RICHARD;;SCHROLL NEIL;;EVANS NICHOLAS LEE;;HALL JOHN WESLEY;;SWANGER NATHAN;;RAUDENBUSH JAMES MICHAEL;;CUESTA EMILIO,,https://lens.org/073-251-282-604-835,Patent Application,yes,3,0,7,7,0,H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R13/5219;;H01R13/6315;;H01R24/50;;H01R24/52;;H01R13/5219,H01R12/91;;H01R12/71;;H01R13/14;;H01R13/631;;H01R24/50;;H01R24/52;;H04N5/225;;H05K5/00,,0,0,,,,PENDING
151,US,B2,US 9912737 B2,099-093-194-000-356,2018-03-06,2018,US 201514826343 A,2015-08-14,US 201514826343 A;;US 201462042374 P,2014-08-27,Method and system for modular interoperable distributed control,"A distributed control system (DCS) for controlling an industrial process using a plurality of distributed control nodes (DCNs) can include a plurality of Device DCNs, each Device DCN including an I/O interface coupled with a field device for single channel input or output, a plurality of Application DCNs, and one or more Ethernet switches. The plurality of Device DCNs and the plurality of Application DCNs can be adapted to host a software runtime and communicatively coupled via the one or more Ethernet switches. The DCS architecture can include of two types of DCNs; Application DCNs and Device DCNs. The software runtime can be configured to selectively provide control application level communication and function block execution services.",PATIN DAVID LLOYD;;BITAR SALEEM STEPHEN;;BARTUSIAK RAYMOND DONALD;;FOLTZ DENNIS J;;THAKE ANDREW J;;DEBARI DAVID L;;CARO RICHARD J;;BRANDL DENNIS LEE;;EXXONMOBIL RES & ENG CO,PATIN DAVID LLOYD;;BITAR SALEEM STEPHEN;;BARTUSIAK RAYMOND DONALD;;FOLTZ DENNIS J;;THAKE ANDREW J;;DEBARI DAVID L;;CARO RICHARD J;;BRANDL DENNIS LEE,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2015-06-22),https://lens.org/099-093-194-000-356,Granted Patent,yes,7,14,2,2,0,H04L67/10;;H04L67/10;;H04L49/351;;H04L49/351;;H04L67/12;;H04L67/12,G06F15/16;;H04L12/931;;H04L29/08,,3,0,,,"HI302 Hart/Foundation Fieldbus Interface, http://www.smar.com/en/product/hi302-hart-foundation-fieldbus-interface, downloaded from the internet on Jul. 7, 2015.;;Fieldbus Foundation—DF51 HSE, http://www.fieldbus.org/index.php?option=com—mtree&task=viewlink&link—id=959&ffbstatus=Registered&Itemid=324, downloaded from the internet on Jul. 7, 2015.;;Foundation for Remove Operations Management, http://www.fieldbus.org/images/stories/enduserresources/technicalreferences/documents/foundation—for—remote—operations—management, downloaded from the Internet on Jul. 7, 2015.",ACTIVE
152,MX,A,MX 9603863 A,169-520-751-842-689,1997-03-29,1997,MX 9603863 A,1996-09-04,US 53603395 A,1995-09-29,IMAGING MEMBER END FLANGE AND END FLANGE ASSEMBLY.,"A hollow cylindrical electrostatographic imaging member supporting end flange including a disk shaped member, a supporting hub extending axially from the disk shaped member and a metal disk coaxially secured to the hub, the disk comprising a plurality of rectangular tabs extending radially from the disk in a direction away from an imaginary axis of the hub for engagement with the hollow cylindrical electrostatographic imaging member upon insertion of the hub and disk shaped member into one end of the hollow cylindrical electrostatographic imaging member. When this end flange is inserted into one end of the hollow cylindrical electrostatographic imaging member, the plurality of rectangular tabs extending radially from the disk engage the inner surface of the hollow cylindrical electrostatographic imaging member.",XEROX CORP,SANCHEZ ISMAEL R;;FOLTZ ROBERT S;;BRYDGES WARREN F;;HOMMOND WILLIAM A;;SWAIN EUGENE A;;WILLIAMS JOHN K;;PETRALIA RICHARD C;;VO THONG H,,https://lens.org/169-520-751-842-689,Patent Application,no,0,0,4,4,0,G03G15/751;;G03G15/751,G03G15/00;;G03G21/00;;G03G21/16,,0,0,,,,EXPIRED
153,BR,A,BR 9603933 A,176-882-301-448-061,1998-06-09,1998,BR 9603933 A,1996-09-27,US 53603395 A,1995-09-29,Membro de formação de imagens eletrostatográficas cilíndrico oco apoiando a flanges de extremidade conjunto de membro de formação de imagens eletrostatográficas compreendendo um membro de formação de imagens eletrostatográficas cilíndrico oco e processo para fixar um flange de extremidade reutilizável a um membro de formação de imagens eletrostatográficas cilíndrico oco tendo uma superfície interna,,XEROX CORP,PETRALIA RICHARD C;;SWAIN EUGENE A;;VO THONG H;;HAMMOND WILLIAM A;;WILLIAMS JOHN K;;BRYDGES WARREN F;;FOLTZ ROBERT S;;SANCHEZ ISMAEL R,,https://lens.org/176-882-301-448-061,Patent Application,no,0,0,4,4,0,G03G15/751;;G03G15/751,G03G21/00;;G03G15/00;;G03G21/16,,0,0,,,,DISCONTINUED
154,US,A,US 5752136 A,180-350-312-600-126,1998-05-12,1998,US 53603395 A,1995-09-29,US 53603395 A,1995-09-29,Imaging member end flange and end flange assembly,"A hollow cylindrical electrostatographic imaging member supporting end flange including a disk shaped member, a supporting hub extending axially from the disk shaped member and a metal disk coaxially secured to the hub, the disk comprising a plurality of rectangular tabs extending radially from the disk in a direction away from an imaginary axis of the hub for engagement with the hollow cylindrical electrostatographic imaging member upon insertion of the hub and disk shaped member into one end of the hollow cylindrical electrostatographic imaging member. When this end flange is inserted into one end of the hollow cylindrical electrostatographic imaging member, the plurality of rectangular tabs extending radially from the disk engage the inner surface of the hollow cylindrical electrostatographic imaging member.",XEROX CORP,SANCHEZ ISMAEL R;;FOLTZ ROBERT S;;BRYDGES WARREN F;;HAMMOND WILLIAM A;;SWAIN EUGENE A;;WILLIAMS JOHN K;;PETRALIA RICHARD C;;VO THONG H,XEROX CORPORATION (1995-11-28),https://lens.org/180-350-312-600-126,Granted Patent,yes,20,29,4,4,0,G03G15/751;;G03G15/751,G03G15/00;;G03G21/00;;G03G21/16,399/117;;399/167;;492/47,0,0,,,,EXPIRED
155,US,A1,US 2016/0065656 A1,082-606-888-354-398,2016-03-03,2016,US 201514826343 A,2015-08-14,US 201514826343 A;;US 201462042374 P,2014-08-27,METHOD AND SYSTEM FOR MODULAR INTEROPERABLE DISTRIBUTED CONTROL,"A distributed control system (DCS) for controlling an industrial process using a plurality of distributed control nodes (DCNs) can include a plurality of Device DCNs, each Device DCN including an I/O interface coupled with a field device for single channel input or output, a plurality of Application DCNs, and one or more Ethernet switches. The plurality of Device DCNs and the plurality of Application DCNs can be adapted to host a software runtime and communicatively coupled via the one or more Ethernet switches. The DCS architecture can include of two types of DCNs; Application DCNs and Device DCNs. The software runtime can be configured to selectively provide control application level communication and function block execution services.",PATIN DAVID LLOYD;;BITAR SALEEM STEPHEN;;BARTUSIAK RAYMOND DONALD;;FOLTZ DENNIS J;;THAKE ANDREW J;;DEBARI DAVID L;;CARO RICHARD J;;BRANDL DENNIS LEE;;EXXONMOBIL RES & ENG CO,PATIN DAVID LLOYD;;BITAR SALEEM STEPHEN;;BARTUSIAK RAYMOND DONALD;;FOLTZ DENNIS J;;THAKE ANDREW J;;DEBARI DAVID L;;CARO RICHARD J;;BRANDL DENNIS LEE,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2015-06-22),https://lens.org/082-606-888-354-398,Patent Application,yes,7,48,2,2,0,H04L67/10;;H04L67/10;;H04L49/351;;H04L49/351;;H04L67/12;;H04L67/12,H04L29/08;;H04L12/931,,0,0,,,,ACTIVE
156,CN,A,CN 115398752 A,043-665-418-730-649,2022-11-25,2022,CN 202180027358 A,2021-03-11,US 202062988143 P;;IB 2021052031 W,2020-03-11,Connector assembly,"A connector assembly (20) includes an outer conductive body (22) having a first end (23) configured to mate with a corresponding electrical connector, and a conductive center contact (30) disposed within the outer conductive body (22). The center contact (30) includes a first end (32) configured to mate with a corresponding electrical connector and a second end (38) electrically connected with a first electrical contact (52) of a circuit board (50). An external contact (40) is slidably attached to the second end (26) of the external conductive body (22) and electrically connected with a second electrical contact (54) of the circuit board (50). A resilient element (44) is provided for biasing the external contact (40) in a direction away from the external conductive body (22) and towards the circuit board (50).",TE CONNECTIVITY SOLUTIONS GMBH,BRANDT CHRISTIAN PERRY;;BAKER JAMES A;;KEITH RICHARD FOLTZ;;SCHROLL NEIL FRANKLIN;;EVANS NICHOLAS LEE;;HALL JOHN WESLEY;;SWANGER NATHAN WILLIAM;;RAUDENBUSH JAMES MICHAEL;;CUESTA EMILIO,,https://lens.org/043-665-418-730-649,Patent Application,no,0,0,7,7,0,H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R13/5219;;H01R13/6315;;H01R24/50;;H01R24/52;;H01R13/5219,H01R12/91;;H01R12/71;;H01R13/14;;H01R13/631;;H01R24/50;;H01R24/52;;H04N5/225;;H05K5/00,,0,0,,,,PENDING
157,DE,T5,DE 112021001561 T5,195-721-680-747-898,2023-01-12,2023,DE 112021001561 T,2021-03-11,US 202062988143 P;;IB 2021052031 W,2020-03-11,Schwimmender Wannenstecker und Leiterplatten-Anordnung,"Eine Steckverbinder-Anordnung (20) weist einen äußeren leitfähigen Körper (22) mit einem ersten Ende (23) auf, das dazu konfiguriert ist, dass es mit einem entsprechenden elektrischen Steckverbinder zusammengefügt wird, und einen leitfähigen Mittelkontakt (30), der innerhalb des äußeren leitfähigen Körpers (22) angeordnet ist. Der Mittelkontakt (30) umfasst ein erstes Ende (32), das dazu konfiguriert ist, dass es mit dem entsprechenden elektrischen Steckverbinder zusammengefügt wird, und ein zweites Ende (38), das mit einem ersten elektrischen Kontakt (52) einer gedruckten Leiterplatte (50) elektrisch verbunden wird. Ein äußerer Kontakt (40) ist an einem zweiten Ende (26) des äußeren leitfähigen Körpers (22) verschiebbar angebracht und ist mit einem zweiten elektrischen Kontakt (54) der gedruckten Leiterplatte (50) elektrisch verbunden. Ein elastisches Element (44) ist vorgesehen, um den äußeren Kontakt (40) in einer Richtung weg von dem äußeren leitfähigen Körper (22) und hin zu der gedruckten Leiterplatte (50) vorzuspannen.",TE CONNECTIVITY SOLUTIONS GMBH,BRANDT CHRISTIAN PERRY;;BAKER JESSE ALAN;;FOLTZ KEITH RICHARD;;SCHROLL NEIL FRANKLIN;;EVANS NICHOLAS LEE;;HALL JOHN WESLEY;;SWANGER NATHAN WILLIAM;;RAUDENBUSH JAMES MICHAEL;;CUESTA EMILIO,,https://lens.org/195-721-680-747-898,Patent Application,no,0,0,7,7,0,H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R13/5219;;H01R13/6315;;H01R24/50;;H01R24/52;;H01R13/5219,H01R12/91;;H01R12/71,,0,0,,,,PENDING
158,KR,A,KR 20220160013 A,022-842-655-537-132,2022-12-05,2022,KR 20227035322 A,2021-03-11,US 202062988143 P;;IB 2021052031 W,2020-03-11,커넥터 조립체,"커넥터 조립체(20)는, 대응하는 전기 커넥터와 정합하도록 구성된 제1 단부(23)를 갖는 외측 전도성 본체(22), 및 외측 전도성 본체(22) 내에 배치된 전도성 중심 접촉부(30)를 포함한다. 중심 접촉부(30)는, 대응하는 전기 커넥터와 정합하도록 구성된 제1 단부(32) 및 회로 기판(50)의 제1 전기 접촉부(52)와 전기적으로 연결되도록 구성된 제2 단부(38)를 포함한다. 외측 접촉부(40)는, 외측 전도성 본체(22)의 제2 단부(26)에 활주 가능하게 부착되고, 회로 기판(50)의 제2 전기 접촉부(54)와 전기적으로 연결된다. 회로 기판(50)을 향하여 외측 전도성 본체(22)로부터 멀어지는 방향으로 외측 접촉부(40)를 편향시키기 위한 탄성 요소(44)가 제공된다.",TE CONNECTIVITY SOLUTIONS GMBH,BRANDT CHRISTIAN PERRY;;BAKER JESSE ALAN;;FOLTZ KEITH RICHARD;;SCHROLL NEIL FRANKLIN;;EVANS NICHOLAS LEE;;HALL JOHN WESLEY;;SWANGER NATHAN WILLIAM;;RAUDENBUSH JAMES MICHAEL;;CUESTA EMILIO,,https://lens.org/022-842-655-537-132,Patent Application,no,0,0,7,7,0,H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R24/50;;H01R12/91;;H01R13/14;;H01R13/6315;;H01R24/52;;H01R12/714;;H04N23/57;;H01R13/5219;;H01R13/6315;;H01R24/50;;H01R24/52;;H01R13/5219,H01R24/50;;H01R12/71;;H01R12/91;;H01R13/14;;H01R13/52;;H01R13/631;;H01R24/52;;H04N5/225,,0,0,,,,PENDING
159,DE,T2,DE 69707170 T2,148-082-778-633-562,2002-03-14,2002,DE 69707170 T,1997-02-26,US 60936896 A,1996-03-01,Vorrichtung zum Tauchbeschichten mit einem einzigen Beschichtungsbehälter,,XEROX CORP,PETROPOULOS MARK C;;FOLEY GEOFFREY M T;;SWAIN EUGENE A;;KILMER DAVID J;;THOMAS MARK S;;PIETRZYKOWSKI JR;;FOLTZ ROBERT S;;SCHMITT PETER J;;MILLONZI RICHARD P,,https://lens.org/148-082-778-633-562,Granted Patent,no,0,1,6,6,0,B05C3/09;;B05C3/09;;G03G5/0525;;G03G5/0525,B05C3/10;;B05C3/09;;B05C11/10;;B05C13/00;;G03G5/05,,0,0,,,,EXPIRED
160,DE,D1,DE 69707170 D1,151-972-958-296-922,2001-11-15,2001,DE 69707170 T,1997-02-26,US 60936896 A,1996-03-01,Vorrichtung zum Tauchbeschichten mit einem einzigen Beschichtungsbehälter,,XEROX CORP,PETROPOULOS MARK C;;FOLEY GEOFFREY M T;;SWAIN EUGENE A;;KILMER DAVID J;;THOMAS MARK S;;PIETRZYKOWSKI JR;;FOLTZ ROBERT S;;SCHMITT PETER J;;MILLONZI RICHARD P,,https://lens.org/151-972-958-296-922,Granted Patent,no,0,0,6,6,0,B05C3/09;;B05C3/09;;G03G5/0525;;G03G5/0525,B05C3/10;;B05C3/09;;B05C11/10;;B05C13/00;;G03G5/05,,0,0,,,,EXPIRED
161,EP,B1,EP 0792697 B1,033-783-863-453-824,2001-10-10,2001,EP 97301276 A,1997-02-26,US 60936896 A,1996-03-01,Dip coating apparatus having a single coating vessel,,XEROX CORP,PETROPOULOS MARK C;;FOLEY GEOFFREY M T;;SWAIN EUGENE A;;KILMER DAVID J;;THOMAS MARK S;;PIETRZYKOWSKI STANLEY J JR;;FOLTZ ROBERT S;;SCHMITT PETER J;;MILLONZI RICHARD P,,https://lens.org/033-783-863-453-824,Granted Patent,yes,4,2,6,6,0,B05C3/09;;B05C3/09;;G03G5/0525;;G03G5/0525,B05C3/10;;B05C3/09;;B05C11/10;;B05C13/00;;G03G5/05,,4,0,,,"PATENT ABSTRACTS OF JAPAN vol. 014, no. 150 (P-1025), 22 March 1990 & JP 02 012155 A (MITA IND CO LTD), 17 January 1990,;;PATENT ABSTRACTS OF JAPAN vol. 012, no. 446 (C-546), 24 November 1988 & JP 63 171669 A (FUJI XEROX CO LTD), 15 July 1988,;;PATENT ABSTRACTS OF JAPAN vol. 18, no. 412 (P-1780), 2 August 1994 & JP 06 123989 A (MATSUSHITA ELECTRIC IND CO LTD), 5 June 1994,;;PATENT ABSTRACTS OF JAPAN vol. 017, no. 207 (P-1525), 22 April 1993 & JP 04 346354 A (KONICA CORP), 2 December 1992,",EXPIRED
162,US,A,US 5725667 A,119-478-274-898-830,1998-03-10,1998,US 60936896 A,1996-03-01,US 60936896 A,1996-03-01,Dip coating apparatus having a single coating vessel,"There is disclosed a dip coating apparatus including: (a) a single coating vessel capable of containing a batch of substrates vertically positioned in the vessel, wherein there is absent vessel walls defining a separate compartment for each of the substrates; (b) a coating solution disposed in the vessel, wherein the solution is comprised of materials employed in a photosensitive member and including a solvent that gives off a solvent vapor; and (c) a solvent vapor uniformity control apparatus which minimizes any difference in solvent vapor concentration encountered by the batch of the substrates in the air adjacent the solution surface, thereby improving coating uniformity of the substrates.",XEROX CORP,PETROPOULOS MARK C;;FOLEY GEOFFREY M T;;SWAIN EUGENE A;;KILMER DAVID J;;THOMAS MARK S;;PIETRZYKOWSKI JR STANLEY J;;FOLTZ ROBERT S;;SCHMITT PETER J;;MILLONZI RICHARD P,XEROX CORPORATION (1996-02-27),https://lens.org/119-478-274-898-830,Granted Patent,yes,21,29,6,6,0,B05C3/09;;B05C3/09;;G03G5/0525;;G03G5/0525,B05C3/10;;B05C3/09;;B05C11/10;;B05C13/00;;G03G5/05,118/407;;118/423;;118/429;;118/500,5,0,,,"European Search Report for EP 97 30 1276.;;Patent Abstracts of Japan, vol. 014, No. 150 (P 1025), Mar. 22, 1990 & JP 02 012155 A (Mita Ind Co Ltd), Jan. 17, 1990.;;Patent Abstracts of Japan, vol. 012, No. 446 (C 546), Nov. 24, 1988 & JP 63 171669 A (Fuji Xerox Co Ltd), Jul. 15, 1988.;;Patent Abstracts of Japan, vol. 018, No. 412 (P 1780), Aug. 2, 1994 & JP 06 123989 A (Matsushita Electric Ind Co Ltd), Jun. 5, 1994.;;Patent Abstracts of Japan, vol. 017, No. 207 (P 1525), Apr. 22, 1993 & JP 04 346354 A (Konica Corp), Dec. 2, 1992.",EXPIRED
163,JP,A,JP H10407 A,044-849-029-213-982,1998-01-06,1998,JP 4508097 A,1997-02-28,US 60936896 A,1996-03-01,DIP COATING APPARATUS,"PROBLEM TO BE SOLVED: To provide an inexpensive dip coating apparatus capable of accommodating a large quantity batch size. SOLUTION: A manifold assembly 2 is disposed outside a single coating container 4 born by supports 6. A solution is introduced by a pump within the container 4 from a container bottom through manifold provided with fluid outlets 8. The manifold assembly 2 and the fluid outlets 8 evenly distribute fluid into the container 4. The solution overflowing along container sides enters an overflow area 10 and returns to the container 4 by being communicated with the manifold assembly 2 by a suitable pump. A group of substrates 12 (processed in a batch), carried on and by the carrier pallet 14 into the container 4, is shown in Figure. The carrier pallets 14 include plural chuck assemblies 16 for holding substrates 12 and are capable of transferring a group of substrates into or from the container 4 nearly simultaneously.",XEROX CORP,PETROPOULOS MARK C;;FOLEY GEOFFREY M T;;SWAIN EUGINE A;;KILMER DAVID J;;THOMAS MARK S;;PIETRZYKOWSKI STANLEY J JR;;FOLTZ ROBERT S;;SCHMITT PETER J;;MILLONZI RICHARD P,,https://lens.org/044-849-029-213-982,Patent Application,no,0,3,6,6,0,B05C3/09;;B05C3/09;;G03G5/0525;;G03G5/0525,B05C3/10;;B05C3/09;;B05C11/10;;B05C13/00;;G03G5/05,,0,0,,,,PENDING
164,EP,A1,EP 0792697 A1,137-003-954-330-716,1997-09-03,1997,EP 97301276 A,1997-02-26,US 60936896 A,1996-03-01,Dip coating apparatus having a single coating vessel,"There is disclosed a dip coating apparatus including: (a) a single coating vessel (4) capable of containing a batch of substrates (12) vertically positioned in the vessel (4), wherein there is absent vessel walls defining a separate compartment for each of the substrates (12); (b) a coating solution disposed in the vessel (4), wherein the solution is comprised of photosensitive materials and including a solvent that gives off a solvent vapor; and (c) a solvent vapor uniformity control apparatus (22) which minimizes any difference in solvent vapor concentration encountered by the batch of the substrates (12) in the air adjacent the solution surface, thereby improving coating uniformity of the substrates (12).",XEROX CORP,PETROPOULOS MARK C;;FOLEY GEOFFREY M T;;SWAIN EUGINE A;;KILMER DAVID J;;THOMAS MARK S;;PIETRZYKOWSKI STANLEY J JR;;FOLTZ ROBERT S;;SCHMITT PETER J;;MILLONZI RICHARD P,,https://lens.org/137-003-954-330-716,Patent Application,yes,12,3,6,6,0,B05C3/09;;B05C3/09;;G03G5/0525;;G03G5/0525,B05C3/10;;B05C3/09;;B05C11/10;;B05C13/00;;G03G5/05,,4,0,,,"PATENT ABSTRACTS OF JAPAN vol. 014, no. 150 (P - 1025) 22 March 1990 (1990-03-22);;PATENT ABSTRACTS OF JAPAN vol. 012, no. 446 (C - 546) 24 November 1988 (1988-11-24);;PATENT ABSTRACTS OF JAPAN vol. 18, no. 412 (P - 1780) 2 August 1994 (1994-08-02);;PATENT ABSTRACTS OF JAPAN vol. 017, no. 207 (P - 1525) 22 April 1993 (1993-04-22)",EXPIRED
165,CN,A,CN 104119439 A,060-621-462-488-070,2014-10-29,2014,CN 201410050615 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/060-621-462-488-070,Patent Application,no,0,3,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;A61P35/00;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
166,KR,A,KR 20140142311 A,142-010-699-916-117,2014-12-11,2014,KR 20147029678 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KLAKAMP SCOTT L;;RAYA ROBERT;;KANG JASPAL;;SU QIAOJUAN JANE;;KING CHADWICK T;;RATHANASWAMI PALANI,,https://lens.org/142-010-699-916-117,Patent Application,no,0,0,84,87,286,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
167,AU,A1,AU 2015/242981 A1,008-335-174-799-672,2015-11-05,2015,AU 2015/242981 A,2015-10-13,AU 2015/242981 A;;AU 2012/268864 A;;AU 2010/202054 A,2010-05-20,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRVI. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LUI YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/008-335-174-799-672,Patent Application,no,0,1,2,4,0,,C07K16/22;;A61K39/395;;A61K39/44;;A61K47/48;;C07H21/04;;C07K14/71;;C07K16/28;;C07K16/42;;C07K17/00;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,0,0,,,,ACTIVE
168,AU,B2,AU 2012/268864 B2,042-617-895-510-996,2016-01-21,2016,AU 2012/268864 A,2012-12-21,AU 2010/202054 A;;AU 2012/268864 A,2010-05-20,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvILI. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. LOi t E-0 est a4P F4 --I C)0 rX4CXwQu C >-fE-UCtD N Fzw M 4 IH Pd CM ?ZE~ F4 ""P cn Q c-1 ~~oo rE E-1 CQ XZ E-4 N> -r- - 8L) mN l0 6 - > C U)c C' >uZ ) L 1.4ZulZo & -E-",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/042-617-895-510-996,Granted Patent,no,2,0,2,4,0,,C07K16/22;;A61K39/395;;A61K39/44;;A61K47/48;;C07H21/04;;C07K14/71;;C07K16/28;;C07K16/42;;C07K17/00;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,1,1,044-355-372-029-744,11255078;;10.1016/s1040-8428(00)00134-7,"Yang et al (2001) Critical Reviews in Oncology Hematology, 38:17-23",ACTIVE
169,KR,A,KR 20160003332 A,082-459-671-070-127,2016-01-08,2016,KR 20157036166 A,2004-06-25,US 48314503 P;;US 56245304 P;;US 52557003 P;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"본 발명은 신규한 항체, 특히 상피 성장 인자 수용체의 결실 돌연변이체 지향성 항체, 및 특히 Ⅲ형 결실 돌연변이체 EGFRvⅢ에 관한 것이다. 또한, 본 발명은 상피 성장 인자 수용체의 결실 돌연변이체에 지향성인 인간 단클론성 항체 및 특히 EGFRvⅢ에 관한 것이다. 이러한 항체의 진단 및 치료 제형, 및 이들 항체의 면역 접합체가 또한 제공된다.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/082-459-671-070-127,Patent Application,no,0,0,84,87,286,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53;;G01N33/532;;G01N33/574,,0,0,,,,DISCONTINUED
170,AU,A1,AU 2014/203036 A1,101-957-937-477-928,2014-07-03,2014,AU 2014/203036 A,2014-06-04,AU 2011/265359 A;;AU 2014/203036 A,2011-12-20,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"This invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion 5 mutant, EGFRvHI. The embodiments also relate to human monoclonal antibodies directed against deletion mutants of epidermal growth factor and particularly to EGFRvIII. The embodiments also relate to variants of such antibodies. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,KEYT BRUCE;;KING CHADWICK T;;FOLTZ IAN;;KANG JASPAL;;GUDAS JEAN;;CORVALAN JOSE;;GREEN LARRY;;FOORD ORIT;;RATHANASWAMI PALANI;;SU QIAOJUAN JANE;;WEBER RICHARD;;RAYA ROBERT;;KLAKAMP SCOTT L;;FENG XIAO;;YANG XIAO DONG;;JIA XIAO-CHI;;LIU YING,,https://lens.org/101-957-937-477-928,Patent Application,no,0,2,1,1,0,,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;G01N33/53,,0,0,,,,DISCONTINUED
171,EP,B1,EP 3011971 B1,161-182-441-494-017,2021-07-21,2021,EP 15193910 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;EP 04777034 A;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/161-182-441-494-017,Granted Patent,yes,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,1,1,045-904-151-504-498,10.1016/s0969-8051(98)00120-6;;10382844,"REIST C J ET AL: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[<211>At]astato-3-pyridinecarboxylate - Preservation of immunoreactivity and in vivo localizing capacity"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 26, no. 4, 1 May 1999 (1999-05-01), pages 405 - 411, XP004167074, ISSN: 0969-8051, DOI: 10.1016/S0969-8051(98)00120-6",ACTIVE
172,CA,C,CA 2530285 C,048-238-928-784-773,2019-12-24,2019,CA 2530285 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;JIA XIAO-CHI;;KANG JASPAL;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;FOLTZ IAN;;KING CHADWICK T;;RATHANASWAMI PALANISWAMI,,https://lens.org/048-238-928-784-773,Granted Patent,no,0,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,ACTIVE
173,AU,A1,AU 2010/202054 A1,086-642-769-662-965,2010-06-10,2010,AU 2010/202054 A,2010-05-20,AU 2004/260936 A;;AU 2010/202054 A;;US 52557003 P;;US 48314503 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/086-642-769-662-965,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K39/44;;A61K47/48;;C07H21/04;;C07K14/71;;C07K16/22;;C07K16/28;;C07K16/42;;C07K17/00;;C12N/;;C12N5/06;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,0,0,,,,DISCONTINUED
174,EP,B1,EP 1639092 B1,172-118-142-908-614,2016-01-06,2016,EP 04777147 A,2004-06-25,US 2004/0020564 W;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC. (2012-10-31),https://lens.org/172-118-142-908-614,Granted Patent,yes,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,1,1,045-904-151-504-498,10.1016/s0969-8051(98)00120-6;;10382844,"REIST C J ET AL: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[<211>At]astato-3-pyridinecarboxylate - Preservation of immunoreactivity and in vivo localizing capacity"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 26, no. 4, 1 May 1999 (1999-05-01), pages 405 - 411, XP004167074, ISSN: 0969-8051, DOI: 10.1016/S0969-8051(98)00120-6",ACTIVE
175,KR,A,KR 20140024046 A,185-470-478-506-728,2014-02-27,2014,KR 20147000817 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/185-470-478-506-728,Patent Application,no,1,4,84,87,250,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53;;G01N33/532;;G01N33/574,,1,1,084-140-179-723-657,10.1007/bf02482738;;11210174,"Brain Tumor Pathol. Vol. 17, Pages 71-78(2000).*",INACTIVE
176,BR,A,BR PI0411852 A,091-557-219-818-616,2006-05-23,2006,BR PI0411852 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos,"""ANTICORPOS DIRIGIDOS AOS MUTANTES DE DELEçãO DE RECEPTOR DE FATOR DE CRESCIMENTO EPIDéRMICO E SEUS USOS"". A presente invenção se refere a anticorpos inovadores, particularmente anticorpos dirigidos contra mutantes de deleção de receptor de fator de crescimento epidérmico e particularmente contra mutante de deleção do tipo III, EGFRvIII. A invenção também se refere a anticorpos monoclonais humanos dirigidos contra mutantes de deleção de receptor de fator de crescimento epidérmico e particularmente a EGFRvIII. Formulações de diagnóstico, e terapêuticas, de tais anticorpos, e seus imunoconjugados, também são providas.",ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/091-557-219-818-616,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
177,EP,A2,EP 1639092 A2,107-193-304-468-336,2006-03-29,2006,EP 04777147 A,2004-06-25,US 2004/0020564 W;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC. (2012-10-31),https://lens.org/107-193-304-468-336,Patent Application,yes,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,ACTIVE
178,IN,A,IN 313DEN2012 A,135-953-026-051-307,2015-05-08,2015,IN 313DEN2012 A,2012-01-11,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/135-953-026-051-307,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,PENDING
179,EP,B1,EP 1638606 B1,167-480-343-026-221,2016-01-06,2016,EP 04777034 A,2004-06-25,US 2004/0020295 W;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC. (2012-10-31),https://lens.org/167-480-343-026-221,Granted Patent,yes,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,2,2,010-953-281-569-514;;045-904-151-504-498,10.1038/nbt1135;;16151405;;10.1016/s0969-8051(98)00120-6;;10382844,"LONBERG NILS: ""Human antibodies from transgenic animals"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 9, 1 September 2005 (2005-09-01), pages 1117 - 1125, XP002442149, ISSN: 1087-0156, DOI: 10.1038/NBT1135;;REIST C J ET AL: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[<211>At]astato-3-pyridinecarboxylate - Preservation of immunoreactivity and in vivo localizing capacity"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 26, no. 4, 1 May 1999 (1999-05-01), pages 405 - 411, XP004167074, ISSN: 0969-8051, DOI: 10.1016/S0969-8051(98)00120-6",ACTIVE
180,JP,A,JP 2017222711 A,172-163-069-205-172,2017-12-21,2017,JP 2017175574 A,2017-09-13,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES TO RECOGNIZE THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"PROBLEM TO BE SOLVED: To provide tumor specific molecules to aid in better diagnosis and treatment of human and animal cancer.SOLUTION: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII.SELECTED DRAWING: None",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/172-163-069-205-172,Patent Application,no,2,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,7,0,,,"CANCER RES., vol. 55, no. 14, JPN6010025376, 15 July 1995 (1995-07-15), pages 3140 - 3148, ISSN: 0003971346;;BRAIN TUMOR PATHOL., vol. 17, no. 2, JPN6010025377, 2000, pages 71 - 78, ISSN: 0003971347;;CRIT. REV. ONCOL. HEMATOL., vol. 38, no. 1, JPN6010025378, April 2001 (2001-04-01), pages 17 - 23, ISSN: 0003971348;;NAT. BIOTECHNOL., vol. 21, no. 7, JPN6010025380, 1 June 2003 (2003-06-01), pages 778 - 784, ISSN: 0003971349;;IMMUNOLOGICAL REVIEWS, vol. 129, no. 1, JPN6014009562, October 1992 (1992-10-01), pages 57 - 80, ISSN: 0003971350;;CLIN. CANCER RES., vol. 1, no. 8, JPN6010025379, August 1995 (1995-08-01), pages 859 - 864, ISSN: 0003856544;;HUAWEI: ""Multiplexing of Multicast/Broadcast and Unicast Services"", 3GPP R1-051431, JPN6013003402, 7 November 2005 (2005-11-07), ISSN: 0003856545",PENDING
181,EP,A2,EP 1638606 A2,183-046-179-743-648,2006-03-29,2006,EP 04777034 A,2004-06-25,US 2004/0020295 W;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC. (2012-10-31),https://lens.org/183-046-179-743-648,Patent Application,yes,0,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,ACTIVE
182,CN,A,CN 104059147 A,055-918-306-566-352,2014-09-24,2014,CN 201410050583 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/055-918-306-566-352,Patent Application,no,0,2,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;A61P35/00;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
183,WO,A2,WO 2005/010151 A2,080-986-083-035-36X,2005-02-03,2005,US 2004/0020295 W,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC;;WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/080-986-083-035-36X,Patent Application,yes,0,79,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,PENDING
184,CA,A1,CA 2530172 A1,022-638-236-220-087,2005-02-10,2005,CA 2530172 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic an d therapeutic formulations of such antibodies, and immunoconjugates thereof, a re also provided.",ABGENIX INC,FENG XIAO;;KEYT BRUCE;;YANG XIAO DONG;;CORVALAN JOSE;;RAYA ROBERT;;LIU YING;;WEBER RICHARD;;SU QIAOJUAN JANE;;KLAKAMP SCOTT L;;GREEN LARRY;;FOORD ORIT;;GUDAS JEAN;;JIA XIAO-CHI;;FOLTZ IAN;;KING CHADWICK T;;RATHANASWAMI PALANI;;KANG JASPAL,,https://lens.org/022-638-236-220-087,Patent Application,no,0,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C12N15/13;;A61K39/395;;A61K47/48;;C07K14/71;;C07K16/22;;C07K16/28;;C07K17/00;;C07K19/00;;C12N/;;C12N5/06;;C12N5/12;;C12N5/16;;G01N33/53;;G01N33/533;;G01N33/534;;G01N33/535,,0,0,,,,DISCONTINUED
185,KR,A,KR 20130065723 A,043-260-363-626-952,2013-06-19,2013,KR 20137011483 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/043-260-363-626-952,Patent Application,no,0,0,84,87,252,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/18;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53;;G01N33/532;;G01N33/574,,0,0,,,,DISCONTINUED
186,JP,A,JP 2019206524 A,141-739-821-756-859,2019-12-05,2019,JP 2019107945 A,2019-06-10,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"To provide tumor specific molecules to aid in better diagnosis and treatment of human and animal cancer.SOLUTION: The present invention provides an isolated human monoclonal antibody that specifically binds to EGFRvIII, the type III deletion mutant, of an epidermal growth factor receptor.SELECTED DRAWING: None",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/141-739-821-756-859,Patent Application,no,3,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;A61P35/00;;C07K14/82;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,5,1,033-261-430-402-230,1560463;;10.1016/0022-2836(92)91010-m,"CANCER RES., vol. 55, no. 14, JPN6010025376, 15 July 1995 (1995-07-15), pages 3140 - 3148, ISSN: 0004599791;;BRAIN TUMOR PATHOL., vol. 17, no. 2, JPN6010025377, 2000, pages 71 - 78, ISSN: 0004599792;;CRIT. REV. ONCOL. HEMATOL., vol. 38, no. 1, JPN6010025378, April 2001 (2001-04-01), pages 17 - 23, ISSN: 0004599793;;CLIN. CANCER RES., vol. 1, no. 8, JPN6010025379, August 1995 (1995-08-01), pages 859 - 864, ISSN: 0004599789;;""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops"", JOURNAL OF MOLECULAR BIOLOGY, vol. 224, no. 2, JPN7013003402, 1992, pages 487 - 499, ISSN: 0004599790",ACTIVE
187,WO,A3,WO 2005/010151 A3,025-230-745-521-62X,2005-09-15,2005,US 2004/0020295 W,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC;;WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/025-230-745-521-62X,Search Report,yes,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,1,1,077-163-323-456-652,10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#;;9506533,"SCHMIDT M. ET AL: ""Expression of an Oncogenic Mutant EGF Receptor Markedly Increased the Sensivity of Cells to an EGF-Receptor-Specific Antibody-Toxin."", INT.J.CANCER., vol. 75, 16 March 1998 (1998-03-16), pages 878 - 884, XP001016349",PENDING
188,AU,A1,AU 2011/265359 A1,077-023-797-033-219,2012-01-19,2012,AU 2011/265359 A,2011-12-20,AU 2004/259398 A;;AU 2011/265359 A,2004-06-25,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"C \NRPonblDCC\RR\4)550A4_l DOC.15/12/2011 This invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion 5 mutant, EGFRvIII. The embodiments also relate to human monoclonal antibodies directed against deletion mutants of epidermal growth factor and particularly to EGFRvIII. The embodiments also relate to variants of such antibodies. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,KEYT BARRY;;KING CHADWICK T;;FOLTZ IAN;;KANG JASPAL;;GUDAS JEAN;;CORVALAN JOSE;;GREEN LARRY;;FOORD ORIT;;RATHANASWAMI PALANI;;SU QIAOJUAN JANE;;WEBER RICHARD;;RAYA ROBERT;;KLAKAMP SCOTT L;;FENG XIAO;;YANG XIAO DONG;;JIA XIAO-CHI;;LIU YING,,https://lens.org/077-023-797-033-219,Patent Application,no,0,0,3,3,0,,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;G01N33/53,,0,0,,,,ACTIVE
189,JP,A,JP 2011042683 A,133-437-958-355-470,2011-03-03,2011,JP 2010252825 A,2010-11-11,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODY DIRECTED TO DELETION MUTANT OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"<P>PROBLEM TO BE SOLVED: To provide a tumor-specific molecule for encouraging better diagnosis and better treating of cancer of a human and animal. <P>SOLUTION: The present invention relates to new antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. <P>COPYRIGHT: (C)2011,JPO&INPIT",ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/133-437-958-355-470,Patent Application,no,2,3,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/32;;A61K39/395;;A61K47/48;;A61P35/00;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;C12N15/09;;G01N33/53,,7,2,135-943-065-643-592;;033-261-430-402-230,10.1111/j.1600-065x.1992.tb01419.x;;1464422;;1560463;;10.1016/0022-2836(92)91010-m,"CANCER RES., vol. 55, no. 14, JPN6010025376, 15 July 1995 (1995-07-15), pages 3140 - 3148, ISSN: 0002430090;;BRAIN TUMOR PATHOL., vol. 17, no. 2, JPN6010025377, 2000, pages 71 - 78, ISSN: 0002430091;;CRIT. REV. ONCOL. HEMATOL., vol. 38, no. 1, JPN6010025378, April 2001 (2001-04-01), pages 17 - 23, ISSN: 0002430092;;NAT. BIOTECHNOL., vol. 21, no. 7, JPN6010025380, 1 June 2003 (2003-06-01), pages 778 - 784, ISSN: 0002430093;;IMMUNOLOGICAL REVIEWS, vol. 129, no. 1, JPN6014009562, October 1992 (1992-10-01), pages 57 - 80, ISSN: 0002761963;;""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops"", JOURNAL OF MOLECULAR BIOLOGY, vol. 224, no. 2, JPN7013003402, 1992, pages 487 - 499, ISSN: 0002643114;;CLIN. CANCER RES., vol. 1, no. 8, JPN6010025379, August 1995 (1995-08-01), pages 859 - 864, ISSN: 0002830269",ACTIVE
190,EP,A4,EP 1638606 A4,124-647-306-939-226,2009-06-03,2009,EP 04777034 A,2004-06-25,US 2004/0020295 W;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC. (2012-10-31),https://lens.org/124-647-306-939-226,Search Report,no,3,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,8,8,001-201-806-511-780;;084-140-179-723-657;;017-985-977-936-133;;044-355-372-029-744;;004-272-966-072-139;;016-435-611-136-112;;045-082-353-678-357;;128-683-050-479-273,7606735;;10.1007/bf02482738;;11210174;;10.1023/a:1011177318162;;11484948;;11255078;;10.1016/s1040-8428(00)00134-7;;10.1038/nbt832;;12778055;;9816055;;pmc16575;;10.1073/pnas.130166597;;10852962;;10.1073/pnas.87.11.4207;;1693434;;pmc54077,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71 - 78, XP001016320, ISSN: 0914-8108;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06-01), pages 745 - 760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17 - 23, XP002963604, ISSN: 1040-8428;;DORONINA SVETLANA O ET AL: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy."", NATURE BIOTECHNOLOGY JUL 2003, vol. 21, no. 7, 1 June 2003 (2003-06-01), pages 778 - 784, XP002524202, ISSN: 1087-0156;;LORIMER I A ET AL: ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 1995, vol. 1, no. 8, August 1995 (1995-08-01), pages 859 - 864, XP002524203, ISSN: 1078-0432;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7503 - 7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424",ACTIVE
191,JP,A,JP 2014088414 A,134-371-627-385-728,2014-05-15,2014,JP 2013272029 A,2013-12-27,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES RECOGNIZING DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"PROBLEM TO BE SOLVED: To provide a method of killing target cells by antibodies coupled to toxins.SOLUTION: The method comprises bringing target cells, particularly cancer cells, into contact with antibodies coupled to toxins. The antibodies are coupled to peptide LEEKKGNY. The target cells express the peptide of said sequence. The toxins are selected from the group consisting of AEFP, MMAE, DM-1 and ZAP, and kill the target cells. The antibodies are preferably coupled to the toxins by peptide linkers.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/134-371-627-385-728,Patent Application,no,4,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,7,1,033-261-430-402-230,1560463;;10.1016/0022-2836(92)91010-m,"CANCER RES., vol. 55, no. 14, JPN6010025376, 15 July 1995 (1995-07-15), pages 3140 - 3148, ISSN: 0003051689;;BRAIN TUMOR PATHOL., vol. 17, no. 2, JPN6010025377, 2000, pages 71 - 78, ISSN: 0003051690;;CRIT. REV. ONCOL. HEMATOL., vol. 38, no. 1, JPN6010025378, April 2001 (2001-04-01), pages 17 - 23, ISSN: 0003051691;;NAT. BIOTECHNOL., vol. 21, no. 7, JPN6010025380, 1 June 2003 (2003-06-01), pages 778 - 784, ISSN: 0003051692;;IMMUNOLOGICAL REVIEWS, vol. 129, no. 1, JPN6014009562, October 1992 (1992-10-01), pages 57 - 80, ISSN: 0003051693;;CLIN. CANCER RES., vol. 1, no. 8, JPN6010025379, August 1995 (1995-08-01), pages 859 - 864, ISSN: 0003051694;;""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops"", JOURNAL OF MOLECULAR BIOLOGY, vol. 224, no. 2, JPN7013003402, 1992, pages 487 - 499, ISSN: 0003051695",ACTIVE
192,KR,A,KR 20140033239 A,074-409-653-020-50X,2014-03-17,2014,KR 20147004191 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KLAKAMP SCOTT L;;RAYA ROBERT;;KANG JASPAL;;SU QIAOJUAN JANE;;KING CHADWICK T;;RATHANASWAMI PALANI,,https://lens.org/074-409-653-020-50X,Patent Application,no,0,0,84,87,250,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
193,AU,A1,AU 2004/260936 A1,156-618-722-722-104,2005-02-10,2005,AU 2004/260936 A,2004-06-25,US 52557003 P;;US 48314503 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,,ABGENIX INC,FOORD ORIT;;RATHANASWAMI PALANI;;FOLTZ IAN;;KLAKAMP SCOTT L;;GREEN LARRY;;JIA XIAO-CHI;;RAYA ROBERT;;KING CHADWICK T;;KEYT BRUCE;;FENG XIAO;;YANG XIAO DONG;;WEBER RICHARD;;KANG JASPAL;;LIU YING;;CORVALAN JOSE;;GUDAS JEAN;;SU QIAOJUAN JANE,,https://lens.org/156-618-722-722-104,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,G01N33/53;;A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06,,0,0,,,,ACTIVE
194,JP,A,JP 2017210486 A,175-092-482-842-734,2017-11-30,2017,JP 2017163089 A,2017-08-28,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES TO RECOGNIZE THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"PROBLEM TO BE SOLVED: To provide tumor specific molecules to aid in better diagnosis and treatment of human and animal cancer.SOLUTION: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII.SELECTED DRAWING: None",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/175-092-482-842-734,Patent Application,no,1,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/30;;A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;C12N15/09;;G01N33/53,,5,1,033-261-430-402-230,1560463;;10.1016/0022-2836(92)91010-m,"CANCER RES., vol. 55, no. 14, JPN6010025376, 15 July 1995 (1995-07-15), pages 3140 - 3148, ISSN: 0003972567;;BRAIN TUMOR PATHOL., vol. 17, no. 2, JPN6010025377, 2000, pages 71 - 78, ISSN: 0003972568;;CRIT. REV. ONCOL. HEMATOL., vol. 38, no. 1, JPN6010025378, April 2001 (2001-04-01), pages 17 - 23, ISSN: 0003972569;;CLIN. CANCER RES., vol. 1, no. 8, JPN6010025379, August 1995 (1995-08-01), pages 859 - 864, ISSN: 0003856582;;""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops"", JOURNAL OF MOLECULAR BIOLOGY, vol. 224, no. 2, JPN7013003402, 1992, pages 487 - 499, ISSN: 0003856583",PENDING
195,EP,A1,EP 2457587 A1,181-731-928-613-676,2012-05-30,2012,EP 11188666 A,2004-06-25,EP 04777147 A;;US 52557003 P;;US 48314503 P;;US 56245304 P,2003-06-27,Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;FENG XIAO;;FOORD ORITUS;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT,AMGEN FREMONT INC. (2012-10-31),https://lens.org/181-731-928-613-676,Patent Application,yes,151,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,154,116,001-201-806-511-780;;084-140-179-723-657;;017-985-977-936-133;;044-355-372-029-744;;004-272-966-072-139;;016-435-611-136-112;;045-082-353-678-357;;128-683-050-479-273;;093-272-820-060-870;;045-751-499-875-041;;040-622-347-677-457;;049-182-911-054-623;;032-441-846-127-844;;002-538-287-083-621;;112-409-472-179-059;;067-857-455-571-760;;019-845-050-845-357;;027-389-935-773-753;;028-036-828-526-370;;103-963-954-821-085;;004-905-691-936-256;;005-419-140-766-345;;031-946-967-022-35X;;154-572-677-438-265;;090-683-249-679-734;;040-622-347-677-457;;008-822-347-989-692;;064-678-224-734-734;;008-822-347-989-692;;009-417-133-046-629;;001-201-806-511-780;;150-632-545-202-265;;046-385-127-360-775;;043-637-817-489-241;;011-171-559-635-599;;025-279-035-199-960;;084-140-179-723-657;;117-357-237-248-341;;003-420-832-784-996;;045-904-151-504-498;;072-377-861-372-36X;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;053-206-529-796-448;;124-275-393-571-41X;;016-219-576-017-946;;044-355-372-029-744;;073-659-966-706-479;;087-448-981-335-707;;168-332-656-193-807;;007-780-042-541-484;;040-224-280-888-095;;022-668-203-716-884;;106-109-254-812-280;;032-728-154-591-070;;085-764-009-624-439;;106-794-363-564-085;;052-835-629-769-725;;105-521-401-667-801;;056-196-705-544-876;;087-448-981-335-707;;049-134-753-209-354;;024-995-475-936-443;;040-577-067-037-463;;104-212-297-137-759;;085-277-440-303-853;;016-219-576-017-946;;033-688-911-017-272;;023-767-491-654-250;;035-318-090-591-262;;054-354-046-619-106;;004-517-823-944-609;;087-098-327-694-214;;064-075-380-054-48X;;125-735-714-799-644;;004-986-447-228-415;;087-806-501-008-318;;033-509-048-623-004;;111-679-382-231-89X;;006-626-459-797-838;;013-447-454-196-187;;029-269-446-589-556;;069-165-512-595-028;;044-866-756-228-616;;000-831-802-795-392;;060-720-804-641-033;;002-495-630-767-098;;073-196-766-890-197;;093-698-369-612-279;;123-535-669-081-393;;048-664-799-869-659;;021-262-590-615-162;;102-103-218-931-722;;068-082-778-319-717;;084-646-990-422-712;;093-183-016-210-781;;003-280-353-877-595;;004-272-966-072-139;;014-234-489-298-615;;117-906-457-481-371;;112-312-727-891-46X;;128-901-299-587-74X;;082-984-043-695-164;;089-633-612-001-004;;023-137-217-763-01X;;003-653-620-396-243;;008-717-257-689-35X;;052-664-611-823-937;;119-625-566-432-941;;195-002-437-063-479;;087-448-981-335-707;;067-782-603-238-967;;041-969-682-554-154;;001-779-867-387-972;;024-995-475-936-443,7606735;;10.1007/bf02482738;;11210174;;10.1023/a:1011177318162;;11484948;;11255078;;10.1016/s1040-8428(00)00134-7;;10.1038/nbt832;;12778055;;9816055;;pmc16575;;10.1073/pnas.130166597;;10852962;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1038/309418a0;;6328312;;10.1038/307521a0;;6320011;;10.1038/313144a0;;2981413;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;2834047;;2103507;;21566922;;10.3892/ijo.4.2.277;;6305505;;10.1016/0092-8674(83)90417-8;;10.1016/0092-8674(83)90153-8;;6309409;;10.1016/s0092-8674(85)80052-0;;2988784;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;10.1016/0092-8674(85)90209-0;;2982500;;10.1016/0092-8674(85)90210-7;;2982501;;2986110;;pmc397542;;10.1073/pnas.82.8.2287;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1038/313144a0;;2981413;;3258189;;3367154;;10.1097/00005072-198805000-00001;;3258189;;10.1677/erc.0.0080083;;11397666;;7606735;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1002/ijc.10224;;11920586;;7585629;;8391918;;10.1002/ijc.11007;;12640678;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;11352579;;10.1006/jmbi.2001.4628;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;12515857;;10.1073/pnas.232686499;;pmc141049;;12810643;;10.1038/ng0297-146;;9020839;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1093/nar/14.22.9081;;3786144;;pmc311930;;10.1021/ja00332a054;;pmc336489;;10.1093/nar/16.8.3209;;2836790;;1772569;;10.1021/cr00102a001;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1126/science.1853201;;1853201;;10.1038/354105a0;;1944583;;10.1021/jm00390a019;;2885419;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/ng0594-13;;8075633;;10.1038/ng0297-146;;9020839;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;8069530;;10.1006/immu.1994.1009;;1428404;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;3457627;;2430705;;10.1007/bf00199811;;2428468;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;6206272;;10.1093/jnci/73.3.721;;10.1021/jm00378a013;;6209394;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;10.1016/0006-291x(81)91644-2;;7306187;;3262420;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;4044586;;10.1016/s0021-9258(17)38981-0;;2908625;;10.1007/978-1-4613-1083-9_12;;2451562;;10.1016/s0021-9258(17)39118-4;;4030773;;8324745;;10.1021/jm00199a006;;563462;;10.1038/270721a0;;593392;;6441645;;1241159;;10.1126/science.1241159;;1238093;;10.1016/0006-2952(75)90017-9;;4609809;;pmc1185838;;708370;;10.1042/bj1730723;;7495477;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1038/nbt832;;12778055;;10.1182/blood-2003-01-0039;;12714494;;12213074;;10.1021/jm020149g;;9873732;;10.1016/s0960-894x(98)00610-6;;10.1002/jbm.820150212;;7348718;;6201207;;10.1002/bip.360220167;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;11067777;;10.1006/rtph.2000.1421;;10967427;;10.1016/s0378-5173(00)00423-3;;10.1002/1520-6017(200008)89:8<967::aid-jps1>3.0.co;2-r;;10906720;;9846074;;9584952;;10.3109/13550289809114515;;113458;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;8845302;;10.1002/ijc.10189;;11920591;;10.1006/jmbi.1999.3192;;10543973;;10.1038/342877a0;;2687698,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71 - 78, XP001016320, ISSN: 0914-8108;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06-01), pages 745 - 760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17 - 23, XP002963604, ISSN: 1040-8428;;DORONINA SVETLANA O ET AL: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy."", NATURE BIOTECHNOLOGY JUL 2003, vol. 21, no. 7, 1 June 2003 (2003-06-01), pages 778 - 784, XP002524202, ISSN: 1087-0156;;LORIMER I A ET AL: ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 1995, vol. 1, no. 8, August 1995 (1995-08-01), pages 859 - 864, XP002524203, ISSN: 1078-0432;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7503 - 7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424;;ULLRICH ET AL.: ""Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells"", NATURE, vol. 309, 1984, pages 418 - 425, XP000650082, DOI: doi:10.1038/309418a0;;DOWNWARD ET AL.: ""Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence"", NATURE, vol. 307, 1984, pages 521 - 527, XP002026327, DOI: doi:10.1038/307521a0;;HALEY ET AL.: ""Oncogenes, Genes, and Growth Factors"", 1987, WILEY, article ""The Epidermal Growth Factor Receptor Gene"", pages: 40 - 76;;LIBERMANN ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;WONG ET AL.: ""Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification"", PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 6899 - 6903;;YAMAZAKI ET AL.: ""Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB"", HUMAN BRAIN TUMORS. MOLECULAR AND CELLULAR BIOLOGY, vol. 8, 1988, pages 1816 - 1820;;MALDEN ET AL.: ""Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme"", CANCER RESEARCH, vol. 4, 1988, pages 2711 - 2714;;MENDELSOHN CANCER CELLS, vol. 7, 1989, pages 359;;MENDELSOHN CANCER BIOLOGY, vol. 1, 1990, pages 339 - 344;;MODJTAHEDI, DEAN, INT'L J. ONCOLOGY, vol. 4, 1994, pages 277 - 296;;FUNG ET AL.: ""Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus"", CELL, vol. 33, 1984, pages 357 - 368, XP000645035, DOI: doi:10.1016/0092-8674(83)90417-8;;YAMAMOTO ET AL.: ""A New Avain Erythroblastosis Virus, AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma"", CELL, vol. 34, 1983, pages 225 - 232;;NILSEN ET AL.: ""c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor"", CELL, vol. 41, 1985, pages 719 - 726;;GAMMETT ET AL.: ""Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes"", PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 6053 - 6057;;GILMORE ET AL.: ""Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro"", CELL, vol. 40, 1985, pages 609 - 618;;KRIS ET AL.: ""Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein"", CELL, vol. 40, 1985, pages 619 - 625;;RAINES ET AL.: ""c-erbB Activation in Avian Leukosis Virus-Induced Erythroblastosis: Clustered Integration Sites and the Arrangement of Provirus in the c-erbB Alleles"", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 2287 - 2291;;PELLEY ET AL.: ""Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication--Competent Retrovirus Containing the Activated c-erbB"", JOURNAL OF VIROLOGY, vol. 62, 1988, pages 1840 - 1844;;WELLS ET AL.: ""Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB"", PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 7597 - 7601;;YAMAZAKI ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;HUMPHREY ET AL.: ""Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts"", CANCER RESEARCH, vol. 48, 1988, pages 2231 - 2238;;BIGNER ET AL., J. NEUROPATHOL. EXP. NEUROL., vol. 47, 1988, pages 191 - 205;;HUMPHREY ET AL.: ""Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts"", CANCER RES., vol. 48, no. 8, 1988, pages 2231 - 8;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy"", ENDOCR RELAT CANCER., vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;WIKSTRAND, CJ. ET AL.: ""Monoclonal antibodies against EGFR,,III are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148;;OLAPADE-OLAOPA, EO. ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer"", BR J CANCER., vol. 82, no. 1, 2000, pages 186 - 94;;GE H. ET AL.: ""Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis"", INT J CANCER, vol. 98, no. 3, 2002, pages 357 - 61, XP002967805, DOI: doi:10.1002/ijc.10224;;MOSCATELLO, G. ET AL.: ""Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors"", CANCER RES., vol. 55, no. 23, 1995, pages 5536 - 9, XP002943271;;GARCIA DE PALAZZO, IE. ET AL.: ""Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas"", CANCER RES., vol. 53, no. 14, 1993, pages 3217 - 20, XP002153548;;LUO ET AL., INT. J. CANCER., vol. 104, no. 6, 2003, pages 716 - 21;;KUAN ET AL.: ""EGFRvIII as a promising target for antibody-based brain tumor therapy"", BRAIN TUMOR PATHOL., vol. 17, no. 2, 2000, pages 71 - 78, XP001016320;;KUAN ET AL.: ""Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv"", INTERNATIONAL JOURNAL OF CANCER., vol. 88, no. 6, 2000, pages 962 - 969, XP002176481, DOI: doi:10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U;;LANDRY ET AL.: ""Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII"", JOURNAL OF MOLECULAR BIOLOGY, vol. 308, no. 5, 2001, pages 883 - 893, XP004466169, DOI: doi:10.1006/jmbi.2001.4628;;REIST ET AL.: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate"", NUCLEAR MEDICINE AND BIOLOGY, vol. 26, no. 4, 1999, pages 405 - 411, XP004167074, DOI: doi:10.1016/S0969-8051(98)00120-6;;REIST ET AL.: ""In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent"", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 7, 1997, pages 639 - 647, XP004092552, DOI: doi:10.1016/S0969-8051(97)00080-2;;WIKSTRAND ET AL.: ""Generation of anti- idiotypic reagents in the EGFRvIII tumor-associated antigen system"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 50, no. 12, 2002, pages 639 - 652;;WIKSTRAND ET AL.: ""Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148, XP002074673;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target"", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158, XP055000817, DOI: doi:10.3109/13550289809114515;;JUNGBLUTH ET AL.: ""A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor"", PROC NATL ACAD SCI USA., vol. 100, no. 2, 2003, pages 639 - 44;;MAMOT ET AL.: ""Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells"", CANCER RESEARCH, vol. 63, 2003, pages 3154 - 3161;;MENDEZ ET AL.: ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice"", NAT GENET., vol. 15, no. 2, 1997, pages 146 - 56, XP002918152, DOI: doi:10.1038/ng0297-146;;YANG X ET AL.: ""Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRIT REV ONCOL HEMATO, vol. 38, no. 1, 2001, pages 17 - 23, XP002330089, DOI: doi:10.1016/S1040-8428(00)00134-7;;YANG X-D ET AL.: ""Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy"", CANCER RESEARCH, vol. 59, no. 6, 1999, pages 1236 - 1243;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy"", ENDOCR RELAT CANCER, vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;BABCOOK ET AL.: ""A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities"", PROC NATL ACAD SCI U S A., vol. 93, no. 15, 1996, pages 7843 - 8, XP000608647, DOI: doi:10.1073/pnas.93.15.7843;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual(2d ed"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;LAPLANCHE ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 9081;;STEC ET AL., J AM. CHEM. SOC., vol. 106, 1984, pages 6077;;STEIN ET AL., NUCL. ACIDS RES., vol. 16, 1988, pages 3209;;ZON ET AL.: ""Anti-Cancer Drug Design"", vol. 6, 1991, pages: 539;;ZON ET AL.: ""Oligonucleotides and Analogues: A Practical Approach"", 1991, OXFORD UNIVERSITY PRESS, pages: 87 - 108;;UHLMANN, PEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543;;DAYHOFF, M.O.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1972, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 101 - 110,1-10;;SMITH, WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMAN, WUNSCH, J MOL. BIOL., vol. 48, 1970, pages 443;;PEARSON, LIPMAN, PROC. NATL. ACAD. SCI. (US.A., vol. 85, 1988, pages 2444;;E.S. GOLUB AND D.R. GREN,: ""Immunology - A Synthesis(2d Edition,"", 1991, SINAUER ASSOCIATES;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164;;CREIGHTON,: ""Proteins, Structures and Molecular Principles"", 1984, W. H. FREEMAN AND COMPANY;;C. BRANDEN AND J. TOOZE,: ""Introduction to Protein Structure"", 1991, GARLAND PUBLISHING;;THORNTON, NATURE, vol. 354, 1991, pages 105;;FAUCHERE, J ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBER, FREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J MED. CHEM., vol. 30, 1987, pages 1229;;RIZO, GIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;PARKER, S.,: ""The McGraw-Hill Dictionary of Chemical Terms"", 1985, MCGRAW-HILL;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. I93, 1996, pages 7843 - 7848;;PAUL, W.,: ""Fundamental Immunology, 2nd ed"", 1989, RAVEN PRESS;;KABAT: ""Sequences of Proteins of Immunological Interest"", 1987, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA, LESK, J MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;SONGSIVILAI, LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;BROOKS, B. R., BRUCCOLERI, R. E., OLAFSON, B. D., STATES, D. J., SWAMINATHAN, S., KARPLUS, M., J. COMP. CHEM, vol. 4, 1983, pages 187;;GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;GREEN, JAKOBOVITS, J EXP. MED., vol. 188, 1998, pages 483 - 495;;FANGER ET AL., IMMUNOL METHODS, vol. 4, 1994, pages 72 - 81;;TRAUNECKER ET AL., INT. J CANCER (SUPPL., vol. 7, 1992, pages 51 - 52;;VALERIUS ET AL., BLOOD, vol. 90, 1997, pages 4485 - 4492;;VITETTA, IMMUNOL TODAY, vol. 14, 1993, pages 252;;JUNGHANS ET AL.: ""Cancer Chemotherapy and Biotherapy(2d edition,"", 1996, LIPPINCOTT RAVEN, pages: 655 - 686;;SELA ET AL.: ""Immunoconjugates"", 1987, pages: 189 - 216;;GHOSE ET AL.: ""Targeted Drugs"", 1983, pages: 1 - 22;;DIENER ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 1 - 23;;PIETERSZ ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 25 - 53;;BUMOL ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 55 - 79;;GARNETT ET AL., CANCER RES., vol. 46, 1986, pages 2407 - 2412;;OHKAWA ET AL., CANCER IMMUMOL. IMMUNOTHER., vol. 23, 1986, pages 81 - 86;;ENDO ET AL., CANCER RES., vol. 47, 1980, pages 1076 - 1080;;HURWITZ ET AL., APPL. BIOCHEM., vol. 2, 1980, pages 25 - 35;;MANABI ET AL., BIOCHEM. PHARMACOL., vol. 34, 1985, pages 289 - 291;;DILLMAN ET AL., CANCER RES., vol. 46, 1986, pages 4886 - 4891;;SHOVAL ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 8276 - 8280;;TSUKADA ET AL., J. NATL. CANC. INST., vol. 73, 1984, pages 721 - 729;;KATO ET AL., J. MED. CHEM., vol. 27, 1984, pages 1602 - 1607;;TSUKADA ET AL., BR. J. CANCER, vol. 52, 1985, pages 111 - 116;;BIOCHEM. BIOPHYS. RES. COMMUN., vol. 102, 1981, pages 1048 - 1054;;J. NATL. CANC. INST., vol. 80, 1988, pages 1154 - 1159;;CANCER RES., vol. 48, 1988, pages 6097 - 6102;;PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 626 - 629;;LAMBERT ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 12035 - 12041;;LAMBERT ET AL.: ""Immunotoxins"", 1988, pages: 175 - 209;;GHETIE ET AL., CANCER RES., vol. 48, 1988, pages 2610 - 2617;;J. BIOL. CHEM., vol. 260, 1985, pages 10905 - 10908;;MENENDEZ ET AL.: ""Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer"", 1989;;HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342;;KUPCHAN ET AL., J. MED. CHEM., vol. 21, 1978, pages 31 - 37;;HIGASHIDE ET AL., NATURE, vol. 270, 1977, pages 721 - 722;;KAWAI ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 3441 - 3451;;CHEM. PHARM. BULL., vol. 12, 1984, pages 3441;;SIEBER ET AL.: ""Comparative Leukemia Research"", BIBL. HAEMAT., vol. 43, 1975, pages 495 - 500;;REMILLARD ET AL., SCIENCE, vol. 189, 1975, pages 1002 - 1005;;WOLPERT-DEFILLIPPES ET AL., BIOCHEM. PHARMACOL., vol. 24, 1975, pages 1735 - 1738;;KUPCHAN, PED. PROC., vol. 33, 1974, pages 2288 - 2295;;CARLSSON ET AL., BIOCHEM. J., vol. 173, 1978, pages 723 - 737;;PETTIT ET AL.: ""Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications"", ANTICANCER DRUG DES., vol. 10, no. 7, 1995, pages 529 - 44;;WOYKE ET AL.: ""In vitro activities and postantifungal effects of the potent dolastatin 10 structural modification auristatin PHE"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, 2001, pages 3580 - 3584;;PETTIT ET AL.: ""Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, 1998, pages 2961 - 2965;;DORONINA ET AL.: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy"", NATURE BIOTECHNOLOGY., 2003;;FRANCISCO ET AL.: ""cAClO-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;DORONINA ET AL.: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy"", NATURE BIOTECHNOLOGY, 2003;;KING ET AL.: ""Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains"", J MED CHEM., vol. 45, no. 19, 2002, pages 4336 - 43, XP001193748, DOI: doi:10.1021/jm020149g;;DUBOWCHIK ET AL.: ""Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin"", BIOORG MED CHEM LETT., vol. 8, no. 23, 1998, pages 3347 - 52, XP004143756, DOI: doi:10.1016/S0960-894X(98)00610-6;;MAYER, A.M.S.: ""Marine Pharmacology in 1998: Antitumor and Cytotoxic Compounds"", THE PHARMACOLOGIST., vol. 41, no. 4, 1999, pages 159 - 164;;""Remington's Pharmaceutical Sciences (18th"", 1990, MACK PUBLISHING COMPANY;;LANGER ET AL., J BIOMED MATER. RES., vol. 15, 1981, pages 167 - 277;;LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105;;SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 - 3692;;HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 - 4034;;""Remington's Pharmaceutical Sciences(18th ed,"", 1990, MACK PUBLISHING COMPANY, article BLOCK, LAWRENCE;;BALDRICK P.: ""Pharmaceutical excipient development: the need for preclinical guidance"", REGUL. TOXICOL. PHARMACOL., vol. 32, no. 2, 2000, pages 210 - 8;;WANG W.: ""Lyophilization and development of solid protein pharmaceuticals"", INT. J PHARM., vol. 203, no. 1-2, 2000, pages 1 - 60, XP002428586, DOI: doi:10.1016/S0378-5173(00)00423-3;;CHARMAN WN: ""Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts"", J PHARM SCI, vol. 89, no. 8, 2000, pages 967 - 78, XP008099512;;POWELL ET AL.: ""Compendium of excipients for parenteral formulations"", PDA J PHARM SCI TECHNOL., vol. 52, 1998, pages 238 - 311, XP009119027;;WIKSTRAND ET AL., J NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 58;;YANG ET AL., CRIT REV ONCOL HEMATOL., vol. 38, no. 1, 2001, pages 17 - 23;;KEARNEY ET AL., J. IMMUNOL., vol. 123, 1979, pages 1548 - 1550;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7843 - 7848;;BATRA ET AL.: ""Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene"", CELL GROWTH DIFFER., vol. 6, no. 10, 1995, pages 1251 - 9;;JOHNS ET AL., INT. J. CANCER., vol. 98, 2002, pages 398;;CHEN, Y ET AL., J MOL BIOL., vol. 293, no. 4, 1999, pages 865 - 81;;J. MOL. BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17;;CHOTHIA ET AL., NATURE, vol. 342, no. 6252, 21 December 1989 (1989-12-21), pages 877 - 83;;MARTIN ET AL., J MOL BIOL., vol. 263, no. 5, 15 November 1996 (1996-11-15), pages 800 - 15",DISCONTINUED
196,JP,A,JP 2011088901 A,190-324-091-131-656,2011-05-06,2011,JP 2010262796 A,2010-11-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,"ANTIBODY RECOGNIZING DELETION MUTANT OF EPIDERMAL GROWTH FACTOR RECEPTOR, AND USE THEREOF","<P>PROBLEM TO BE SOLVED: To obtain tumor-specific molecules for promoting good diagnosis and treatment of human and animal cancers. <P>SOLUTION: There is provided novel antibodies, particularly, antibodies directed to deletion mutants of epidermal growth factor receptors and particularly to the type III deletion mutants, and EGFRvIII. <P>COPYRIGHT: (C)2011,JPO&INPIT",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/190-324-091-131-656,Patent Application,no,1,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;A61P35/00;;C07K16/22;;C07K16/46;;C07K17/00;;C12N/;;C12N5/06;;C12N15/09;;C12P21/08;;G01N33/53,,4,0,,,"CANCER RES., vol. 55, no. 14, JPN6010027877, 15 July 1995 (1995-07-15), pages 3140 - 3148, ISSN: 0002434903;;BRAIN TUMOR PATHOL., vol. 17, no. 2, JPN6010027878, 2000, pages 71 - 78, ISSN: 0002434904;;CRIT. REV. ONCOL. HEMATOL., vol. 38, no. 1, JPN6010027879, April 2001 (2001-04-01), pages 17 - 23, ISSN: 0002434905;;CLIN. CANCER RES., vol. 1, no. 8, JPN6010027880, August 1995 (1995-08-01), pages 859 - 864, ISSN: 0002830457",ACTIVE
197,EP,A1,EP 2457586 A1,070-671-844-782-142,2012-05-30,2012,EP 11188665 A,2004-06-25,EP 04777034 A;;US 52557003 P;;US 48314503 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT,AMGEN FREMONT INC. (2012-10-31),https://lens.org/070-671-844-782-142,Patent Application,yes,150,10,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;B82Y5/00;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,157,116,001-201-806-511-780;;084-140-179-723-657;;017-985-977-936-133;;044-355-372-029-744;;004-272-966-072-139;;016-435-611-136-112;;045-082-353-678-357;;128-683-050-479-273;;093-272-820-060-870;;045-751-499-875-041;;040-622-347-677-457;;049-182-911-054-623;;032-441-846-127-844;;002-538-287-083-621;;112-409-472-179-059;;067-857-455-571-760;;019-845-050-845-357;;027-389-935-773-753;;028-036-828-526-370;;103-963-954-821-085;;004-905-691-936-256;;005-419-140-766-345;;031-946-967-022-35X;;154-572-677-438-265;;090-683-249-679-734;;040-622-347-677-457;;008-822-347-989-692;;064-678-224-734-734;;008-822-347-989-692;;009-417-133-046-629;;001-201-806-511-780;;150-632-545-202-265;;046-385-127-360-775;;043-637-817-489-241;;011-171-559-635-599;;025-279-035-199-960;;084-140-179-723-657;;117-357-237-248-341;;003-420-832-784-996;;045-904-151-504-498;;072-377-861-372-36X;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;053-206-529-796-448;;124-275-393-571-41X;;016-219-576-017-946;;044-355-372-029-744;;073-659-966-706-479;;087-448-981-335-707;;168-332-656-193-807;;040-224-280-888-095;;022-668-203-716-884;;106-109-254-812-280;;032-728-154-591-070;;085-764-009-624-439;;106-794-363-564-085;;052-835-629-769-725;;105-521-401-667-801;;056-196-705-544-876;;087-448-981-335-707;;049-134-753-209-354;;024-995-475-936-443;;040-577-067-037-463;;104-212-297-137-759;;085-277-440-303-853;;016-219-576-017-946;;033-688-911-017-272;;023-767-491-654-250;;035-318-090-591-262;;054-354-046-619-106;;004-517-823-944-609;;087-098-327-694-214;;064-075-380-054-48X;;125-735-714-799-644;;004-986-447-228-415;;087-806-501-008-318;;033-509-048-623-004;;111-679-382-231-89X;;006-626-459-797-838;;013-447-454-196-187;;029-269-446-589-556;;069-165-512-595-028;;044-866-756-228-616;;000-831-802-795-392;;060-720-804-641-033;;002-495-630-767-098;;073-196-766-890-197;;093-698-369-612-279;;123-535-669-081-393;;048-664-799-869-659;;021-262-590-615-162;;102-103-218-931-722;;068-082-778-319-717;;084-646-990-422-712;;093-183-016-210-781;;003-280-353-877-595;;004-272-966-072-139;;014-234-489-298-615;;014-234-489-298-615;;117-906-457-481-371;;112-312-727-891-46X;;128-901-299-587-74X;;082-984-043-695-164;;089-633-612-001-004;;023-137-217-763-01X;;003-653-620-396-243;;008-717-257-689-35X;;052-664-611-823-937;;119-625-566-432-941;;195-002-437-063-479;;087-448-981-335-707;;067-782-603-238-967;;041-969-682-554-154;;001-779-867-387-972;;024-995-475-936-443,7606735;;10.1007/bf02482738;;11210174;;10.1023/a:1011177318162;;11484948;;11255078;;10.1016/s1040-8428(00)00134-7;;10.1038/nbt832;;12778055;;9816055;;pmc16575;;10.1073/pnas.130166597;;10852962;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1038/309418a0;;6328312;;10.1038/307521a0;;6320011;;10.1038/313144a0;;2981413;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;2834047;;2103507;;21566922;;10.3892/ijo.4.2.277;;6305505;;10.1016/0092-8674(83)90417-8;;10.1016/0092-8674(83)90153-8;;6309409;;10.1016/s0092-8674(85)80052-0;;2988784;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;10.1016/0092-8674(85)90209-0;;2982500;;10.1016/0092-8674(85)90210-7;;2982501;;2986110;;pmc397542;;10.1073/pnas.82.8.2287;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1038/313144a0;;2981413;;3258189;;3367154;;10.1097/00005072-198805000-00001;;3258189;;10.1677/erc.0.0080083;;11397666;;7606735;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1002/ijc.10224;;11920586;;7585629;;8391918;;10.1002/ijc.11007;;12640678;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;11352579;;10.1006/jmbi.2001.4628;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;12515857;;10.1073/pnas.232686499;;pmc141049;;12810643;;10.1038/ng0297-146;;9020839;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1093/nar/14.22.9081;;3786144;;pmc311930;;pmc336489;;10.1093/nar/16.8.3209;;2836790;;1772569;;10.1021/cr00102a001;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1126/science.1853201;;1853201;;10.1038/354105a0;;1944583;;10.1021/jm00390a019;;2885419;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/ng0594-13;;8075633;;10.1038/ng0297-146;;9020839;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;8069530;;10.1006/immu.1994.1009;;1428404;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;3457627;;2430705;;10.1007/bf00199811;;2428468;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;6206272;;10.1093/jnci/73.3.721;;10.1021/jm00378a013;;6209394;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;10.1016/0006-291x(81)91644-2;;7306187;;3262420;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;4044586;;10.1016/s0021-9258(17)38981-0;;2908625;;10.1007/978-1-4613-1083-9_12;;2451562;;10.1016/s0021-9258(17)39118-4;;4030773;;8324745;;10.1021/jm00199a006;;563462;;10.1038/270721a0;;593392;;6441645;;1241159;;10.1126/science.1241159;;1238093;;10.1016/0006-2952(75)90017-9;;4609809;;pmc1185838;;708370;;10.1042/bj1730723;;7495477;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1038/nbt832;;12778055;;10.1182/blood-2003-01-0039;;12714494;;10.1182/blood-2003-01-0039;;12714494;;12213074;;10.1021/jm020149g;;9873732;;10.1016/s0960-894x(98)00610-6;;10.1002/jbm.820150212;;7348718;;6201207;;10.1002/bip.360220167;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;11067777;;10.1006/rtph.2000.1421;;10967427;;10.1016/s0378-5173(00)00423-3;;10.1002/1520-6017(200008)89:8<967::aid-jps1>3.0.co;2-r;;10906720;;9846074;;9584952;;10.3109/13550289809114515;;113458;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;8845302;;10.1002/ijc.10189;;11920591;;10.1006/jmbi.1999.3192;;10543973;;10.1038/342877a0;;2687698,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71 - 78, XP001016320, ISSN: 0914-8108;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06-01), pages 745 - 760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17 - 23, XP002963604, ISSN: 1040-8428;;DORONINA SVETLANA O ET AL: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy."", NATURE BIOTECHNOLOGY JUL 2003, vol. 21, no. 7, 1 June 2003 (2003-06-01), pages 778 - 784, XP002524202, ISSN: 1087-0156;;LORIMER I A ET AL: ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 1995, vol. 1, no. 8, August 1995 (1995-08-01), pages 859 - 864, XP002524203, ISSN: 1078-0432;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7503 - 7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424;;ULLRICH ET AL.: ""Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells"", NATURE, vol. 309, 1984, pages 418 - 425, XP000650082, DOI: doi:10.1038/309418a0;;DOWNWARD ET AL.: ""Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence"", NATURE, vol. 307, 1984, pages 521 - 527, XP002026327, DOI: doi:10.1038/307521a0;;GUROFF, G.: ""Oncogenes, Genes, and Growth Factors,12th Edition"", 1987, WILEY, article HALEY ET AL.: ""The Epidermal Growth Factor Receptor Gene"", pages: 40 - 76;;LIBERMANN ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;WONG ET AL.: ""Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification"", PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 6899 - 6903;;YAMAZAKI ET AL.: ""Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors"", MOLECULAR AND CELLULAR BIOLOGY, vol. 8, 1988, pages 1816 - 1820;;MALDEN ET AL.: ""Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme"", CANCER RESEARCH, vol. 4, 1988, pages 2711 - 2714;;MENDELSOHN CANCER CELLS, vol. 7, 1989, pages 359;;MENDELSOHN CANCER BIOLOGY, vol. 1, 1990, pages 339 - 344;;MODJTAHEDI, DEAN, INT'L J. ONCOLOGY, vol. 4, 1994, pages 277 - 296;;FUNG ET AL.: ""Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus"", CELL, vol. 33, 1984, pages 357 - 368, XP000645035, DOI: doi:10.1016/0092-8674(83)90417-8;;YAMAMOTO ET AL.: ""A New Avain Erythroblastosis Virus, AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma"", CELL, vol. 34, 1983, pages 225 - 232;;NILSEN ET AL.: ""c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor"", CELL, vol. 41, 1985, pages 719 - 726;;GAMMETT ET AL.: ""Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes"", PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 6053 - 6057;;GILMORE ET AL.: ""Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro"", CELL, vol. 40, 1985, pages 609 - 618;;KRIS ET AL.: ""Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein"", CELL, vol. 40, 1985, pages 619 - 625;;RAINES ET AL.: ""c-erbB Activation in Avian Leukosis Virus-Induced Erythroblastosis: Clustered Integration Sites and the Arrangement of Provirus in the c-erbB Alleles"", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 2287 - 2291;;PELLEY ET AL.: ""Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication-Competent Retrovirus Containing the Activated c-erbB"", JOURNAL OF VIROLOGY, vol. 62, 1988, pages 1840 - 1844;;WELLS ET AL.: ""Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB"", PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 7597 - 7601;;YAMAZAKI ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;HUMPHREY ET AL.: ""Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts"", CANCER RESEARCH, vol. 48, 1988, pages 2231 - 2238;;BIGNER ET AL., J. NEUROPATHOL. EXP. NEUROL., vol. 47, 1988, pages 191 - 205;;HUMPHREY ET AL.: ""Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts"", CANCER RES., vol. 48, no. 8, 1988, pages 2231 - 8;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy"", ENDOCR RELAT CANCER, vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;WIKSTRAND, CJ. ET AL.: ""Monoclonal antibodies against EGFR,,III are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148;;OLAPADE-OLAOPA, EO. ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer"", BR J CANCER, vol. 82, no. 1, 2000, pages 186 - 94;;GE H. ET AL.: ""Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis"", INT J CANCER, vol. 98, no. 3, 2002, pages 357 - 61, XP002967805, DOI: doi:10.1002/ijc.10224;;MOSCATELLO, G. ET AL.: ""Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors"", CANCER RES., vol. 55, no. 23, 1995, pages 5536 - 9, XP002943271;;GARCIA DE PALAZZO, IE ET AL.: ""Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas"", CANCER RES., vol. 53, no. 14, 1993, pages 3217 - 20, XP002153548;;OLAPADE-OLAOPA, EO ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer"", BR J CANCER, vol. 82, no. 1, 2000, pages 186 - 94;;LUO ET AL., INT. J. CANCER, vol. 104, no. 6, 2003, pages 716 - 21;;KUAN ET AL.: ""EGFRvIII as a promising target for antibody-based brain tumor therapy"", BRAIN TUMOR PATHOL., vol. 17, no. 2, 2000, pages 71 - 78, XP001016320;;KUAN ET AL.: ""Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv"", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 6, 2000, pages 962 - 969, XP002176481, DOI: doi:10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U;;LANDRY ET AL.: ""Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor"", EGFRVIII. JOURNAL OF MOLECULAR BIOLOGY, vol. 308, no. 5, 2001, pages 883 - 893, XP004466169, DOI: doi:10.1006/jmbi.2001.4628;;REIST ET AL.: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate"", NUCLEAR MEDICINE AND BIOLOGY, vol. 26, no. 4, 1999, pages 405 - 411, XP004167074, DOI: doi:10.1016/S0969-8051(98)00120-6;;REIST ET AL.: ""In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent"", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 7, 1997, pages 639 - 647, XP004092552, DOI: doi:10.1016/S0969-8051(97)00080-2;;WIKSTRAND ET AL.: ""Generation of anti- idiotypic reagents in the EGFRvIII tumor-associated antigen system"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 50, no. 12, 2002, pages 639 - 652;;WIKSTRAND ET AL.: ""Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148, XP002074673;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target"", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158, XP055000817, DOI: doi:10.3109/13550289809114515;;JUNGBLUTH ET AL.: ""A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor"", PROC NATL ACAD SCI USA., vol. 100, no. 2, 2003, pages 639 - 44;;MAMOT ET AL.: ""Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells"", CANCER RESEARCH, vol. 63, 2003, pages 3154 - 3161;;MENDEZ ET AL.: ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice"", NAT GENET, vol. 15, no. 2, 1997, pages 146 - 56, XP002918152, DOI: doi:10.1038/ng0297-146;;YANG X ET AL.: ""Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRIT REV ONCOL HEMATO, vol. 38, no. 1, 2001, pages 17 - 23, XP002330089, DOI: doi:10.1016/S1040-8428(00)00134-7;;YANG X-D ET AL.: ""Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy"", CANCER RESEARCH, vol. 59, no. 6, 1999, pages 1236 - 1243;;BABCOOK ET AL.: ""A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities"", PROC NATL ACAD SCI U S A., vol. 93, no. 15, 1996, pages 7843 - 8, XP000608647, DOI: doi:10.1073/pnas.93.15.7843;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual(2d ed.,"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;LAPLANCHE ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 9081;;J AM. CHEM. SOC., vol. 106, 1984, pages 6077;;STEIN ET AL., NUCL. ACIDS RES., vol. 16, 1988, pages 3209;;ZON ET AL., ANTI-CANCER DRUG DESIGN, vol. 6, 1991, pages 539;;ZON ET AL.: ""Oligonucleotides and Analogues: A Practical Approach"", 1991, OXFORD UNIVERSITY PRESS, pages: 87 - 108;;UHLMANN, PEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543;;DAYHOFF, M.O.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1972, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 101 - 110;;SMITH, WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMAN, WUNSCH, J MOL. BIOL., vol. 48, 1970, pages 443;;PEARSON, LIPMAN, PROC. NATL. ACAD. SCI. (US.A., vol. 85, 1988, pages 2444;;E.S. GOLUB AND D.R. GREN,: ""Immunology - A Synthesis(2'"" Edition,"", 1991, SINAUER ASSOCIATES, SUNDERLAND;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164;;CREIGHTON,: ""Proteins, Structures and Molecular Principles"", 1984, W. H. FREEMAN AND COMPANY;;C. BRANDEN AND J. TOOZE,: ""Introduction to Protein Structure"", 1991, GARLAND PUBLISHING;;THORNTON, NATURE, vol. 354, 1991, pages 105;;FAUCHERE, J ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBER, FREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J MED. CHEM., vol. 30, 1987, pages 1229;;RIZO, GIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;PARKER, S.,: ""The McGraw-Hill Dictionary of Chemical Terms"", 1985, MCGRAW-HILL;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. I93, 1996, pages 7843 - 7848;;PAUL, W.,: ""Fundamental Immunology, 2nd ed."", 1989, RAVEN PRESS;;KABAT: ""Sequences of Proteins of Immunological Interest"", 1987, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA, LESK, J MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;SONGSIVILAI, LACHMANN, CLIN. EXP. IMMUNOL, vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;BROOKS, B. R., BRUCCOLERI, R. E, OLAFSON, B. D., STATES, D. J., SWAMINATHAN, S., KARPLUS, M., J. COMP. CHEM, vol. 4, 1983, pages 187;;GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;GREEN, JAKOBOVITS, J EXP. MED., vol. 188, 1998, pages 483 - 495;;FANGER ET AL., IMMUNOL METHODS, vol. 4, 1994, pages 72 - 81;;TRAUNECKER ET AL., INT. J CANCER (SUPPL., vol. 7, 1992, pages 51 - 52;;DEO ET AL., MICROMET'S BITE TECHNOLOGY, vol. 18, 1997, pages 127;;VALERIUS ET AL., BLOOD, vol. 90, 1997, pages 4485 - 4492;;VITETTA IMMUNOL TODAY, vol. 14, 1993, pages 252;;JUNGHANS ET AL.: ""Cancer Chemotherapy and Biotherapy(2d edition"", 1996, LIPPINCOTT RAVEN, pages: 655 - 686;;SELA ET AL.: ""Immunoconjugates"", 1987, pages: 189 - 216;;GHOSE ET AL.: ""Targeted Drugs"", 1983, pages: 1 - 22;;DIENER ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 1 - 23;;PIETERSZ ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 25 - 53;;BUMOL ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 55 - 79;;GARNETT ET AL., CANCER RES., vol. 46, 1986, pages 2407 - 2412;;OHKAWA ET AL., CANCER IMMUMOL. IMMUNOTHER, vol. 23, 1986, pages 81 - 86;;ENDO ET AL., CANCER RES., vol. 47, 1980, pages 1076 - 1080;;HURWITZ ET AL., APPL. BIOCHEM., vol. 2, 1980, pages 25 - 35;;MANABI ET AL., BIOCHEM. PHARMACOL, vol. 34, 1985, pages 289 - 291;;DILLMAN ET AL., CANCER RES., vol. 46, 1986, pages 4886 - 4891;;SHOVAL ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 8276 - 8280;;TSUKADA ET AL., J. NATL. CANC. INST., vol. 73, 1984, pages 721 - 729;;KATO ET AL., J. MED. CHEM., vol. 27, 1984, pages 1602 - 1607;;TSUKADA ET AL., BR. J. CANCER, vol. 52, 1985, pages 111 - 116;;BIOCHEM. BIOPHYS. RES. COMMUN, vol. 102, 1981, pages 1048 - 1054;;J. NATL. CANC. INST., vol. 80, 1988, pages 1154 - 1159;;CANCER RES., vol. 48, 1988, pages 6097 - 6102;;PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 626 - 629;;LAMBERT ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 12035 - 12041;;LAMBERT ET AL.: ""Immunotoxins"", 1988, pages: 175 - 209;;GHETIE ET AL., CANCER RES., vol. 48, 1988, pages 2610 - 2617;;J. BIOL. CHEM., vol. 260, 1985, pages 10905 - 10908;;MENENDEZ ET AL., FOURTH INTERNATIONAL CONFERENCE ON MONOCLONAL ANTIBODY IMMUNOCONJUGATES FOR CANCER, SAN DIEGO, 1989;;HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342;;KUPCHAN ET AL., J. MED. CHEM., vol. 21, 1978, pages 31 - 37;;HIGASHIDE ET AL., NATURE, vol. 270, 1977, pages 721 - 722;;KAWAI ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 3441 - 3451;;CHEM. PHARM. BULL., vol. 12, no. 3441, 1984;;SIEBER ET AL.: ""Comparative Leukemia Research 1975"", BIBL. HAEMAT., vol. 43, 1976, pages 495 - 500;;REMILLARD ET AL., SCIENCE, vol. 189, 1975, pages 1002 - 1005;;WOLPERT-DEFILLIPPES ET AL., BIOCHEM. PHARMACOL, vol. 24, 1975, pages 1735 - 1738;;KUPCHAN, PED. PROC., vol. 33, 1974, pages 2288 - 2295;;CARLSSON ET AL., BIOCHEM. J., vol. 173, 1978, pages 723 - 737;;PETTIT ET AL.: ""Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications"", ANTICANCER DRUG DES., vol. 10, no. 7, 1995, pages 529 - 44;;WOYKE ET AL.: ""In vitro activities and postantifungal effects of the potent dolastatin 10 structural modification auristatin PHE"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, 2001, pages 3580 - 3584;;PETTIT ET AL.: ""Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, 1998, pages 2961 - 2965;;DORONINA ET AL.: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy"", NATURE BIOTECHNOLOGY, 2003;;FRANCISCO ET AL.: ""cAClO-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;FRANCISCO ET AL.: ""cAClO-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 8 May 2003 (2003-05-08);;FRANCISCO ET AL.: ""cAClO-vcMMAE, an anti-CD30- monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 8 May 2003 (2003-05-08);;KING ET AL.: ""Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains"", J MED CHEM., vol. 45, no. 19, 2002, pages 4336 - 43, XP001193748, DOI: doi:10.1021/jm020149g;;DUBOWCHIK ET AL.: ""Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin"", BIOORG MED CHEM LETT., vol. 8, no. 23, 1998, pages 3347 - 52, XP004143756, DOI: doi:10.1016/S0960-894X(98)00610-6;;MAYER, A.M.S.: ""Marine Pharmacology in 1998: Antitumor and Cytotoxic Compounds"", THE PHARMACOLOGIST, vol. 41, no. 4, 1999, pages 159 - 164;;""Remington's Pharmaceutical Sciences(18'"" ed,"", 1990, MACK PUBLISHING COMPANY;;LANGER ET AL., J BIOMED MATER. RES., vol. 15, 1981, pages 167 - 277;;LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105;;SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 - 3692;;HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 - 4034;;BLOCK, LAWRENCE: ""Remington's Pharmaceutical Sciences(18'"" ed,"", 1990, MACK PUBLISHING COMPANY;;BALDRICK P: ""Pharmaceutical excipient development: the need for preclinical guidance"", REGUL. TOXICOL. PHARMACOL., vol. 32, no. 2, 2000, pages 210 - 8;;WANG W.: ""Lyophilization and development of solid protein pharmaceuticals"", INT. J PHARM., vol. 203, no. 1-2, 2000, pages 1 - 60, XP002428586, DOI: doi:10.1016/S0378-5173(00)00423-3;;CHARMAN WN: ""Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts"", J PHARM SCI ., vol. 89, no. 8, 2000, pages 967 - 78, XP008099512;;POWELL ET AL.: ""Compendium of excipients for parenteral formulations"", PDA J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311, XP009119027;;WIKSTRAND ET AL., J NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 58;;YANG ET AL., CRIT REV ONCOL HEMATOL., vol. 38, no. 1, 2001, pages 17 - 23;;KEARNEY ET AL., J. IMMUNOL., vol. 123, 1979, pages 1548 - 1550;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7843 - 7848;;BATRA ET AL.: ""Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene"", CELL GROWTH DIFFER, vol. 6, no. 10, 1995, pages 1251 - 9;;BATRA ET AL.: ""Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene"", CELL GROWTH DIFFER., vol. 6, no. 10, 1995, pages 1251 - 9;;JOHNS ET AL., INT. J. CANCER., vol. 98, 2002, pages 398;;CHEN, Y ET AL., J MOL BIOL., vol. 293, no. 4, 1999, pages 865 - 81;;J. MOL. BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17;;CHOTHIA ET AL., NATURE, vol. 342, no. 6252, 21 December 1989 (1989-12-21), pages 877 - 83;;MARTIN ET AL., J MOL BIOL., vol. 263, no. 5, 15 November 1996 (1996-11-15), pages 800 - 15",DISCONTINUED
198,KR,A,KR 20120098932 A,115-289-529-637-66X,2012-09-05,2012,KR 20127019601 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/115-289-529-637-66X,Patent Application,no,0,4,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/18;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53;;G01N33/532;;G01N33/574,,0,0,,,,DISCONTINUED
199,AU,A1,AU 2004/259398 A1,147-809-066-291-371,2005-02-03,2005,AU 2004/259398 A,2004-06-25,US 56245304 P;;US 48314503 P;;US 52557003 P;;US 2004/0020295 W,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,,AMGEN FREMONT INC,KING CHADWICK T;;GUDAS JEAN;;FOLTZ IAN;;RATHANASWAMI PALANI;;GREEN LARRY;;KLAKAMP SCOTT L;;LIU YING;;JIA XIAO-CHI;;FOORD ORIT;;SU QIAOJUAN JANE;;KEYT BRUCE;;YANG XIAO DONG;;KANG JASPAL;;FENG XIAO;;WEBER RICHARD;;CORVALAN JOSE;;RAYA ROBERT,,https://lens.org/147-809-066-291-371,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
200,AU,B9,AU 2011/265359 B9,176-537-390-678-952,2014-04-10,2014,AU 2011/265359 A,2011-12-20,AU 2004/259398 A;;AU 2011/265359 A,2004-06-25,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"C \NRPonblDCC\RR\4)550A4_l DOC.15/12/2011 This invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion 5 mutant, EGFRvIII. The embodiments also relate to human monoclonal antibodies directed against deletion mutants of epidermal growth factor and particularly to EGFRvIII. The embodiments also relate to variants of such antibodies. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,KEYT BARRY;;KING CHADWICK T;;FOLTZ IAN;;KANG JASPAL;;GUDAS JEAN;;CORVALAN JOSE;;GREEN LARRY;;FOORD ORIT;;RATHANASWAMI PALANI;;SU QIAOJUAN JANE;;WEBER RICHARD;;RAYA ROBERT;;KLAKAMP SCOTT L;;FENG XIAO;;YANG XIAO DONG;;JIA XIAO-CHI;;LIU YING,,https://lens.org/176-537-390-678-952,Amended Patent,no,1,0,3,3,0,,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;G01N33/53,,0,0,,,,ACTIVE
201,WO,A2,WO 2005/012479 A2,055-673-786-763-052,2005-02-10,2005,US 2004/0020564 W,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC;;WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/055-673-786-763-052,Patent Application,yes,0,8,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,PENDING
202,KR,A,KR 20060073540 A,092-068-311-453-137,2006-06-28,2006,KR 20057024871 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KLAKAMP SCOTT L;;RAYA ROBERT;;KANG JASPAL;;SU QIAOJUAN JANE;;KING CHADWICK T;;RATHANASWAMI PALANI,,https://lens.org/092-068-311-453-137,Patent Application,no,0,0,84,87,288,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,INACTIVE
203,AU,B2,AU 2004/260936 B2,019-822-535-982-163,2010-06-10,2010,AU 2004/260936 A,2004-06-25,US 52557003 P;;US 48314503 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,,AMGEN FREMONT INC,FOORD ORIT;;RATHANASWAMI PALANI;;FOLTZ IAN;;KLAKAMP SCOTT L;;GREEN LARRY;;JIA XIAO-CHI;;RAYA ROBERT;;KING CHADWICK T;;KEYT BRUCE;;FENG XIAO;;YANG XIAO DONG;;WEBER RICHARD;;KANG JASPAL;;LIU YING;;CORVALAN JOSE;;GUDAS JEAN;;SU QIAOJUAN JANE,,https://lens.org/019-822-535-982-163,Granted Patent,no,2,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K39/44;;A61K47/48;;C07H21/04;;C07K14/71;;C07K16/22;;C07K16/28;;C07K16/42;;C07K17/00;;C12N/;;C12N5/06;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,1,1,044-355-372-029-744,11255078;;10.1016/s1040-8428(00)00134-7,"YANG X-D et al, 'Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy' Critical Reviews in Oncology/Hematology 38(2001) 17-23",ACTIVE
204,BR,A,BR PI0411803 A,008-985-175-592-037,2006-05-23,2006,BR PI0411803 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos,"""ANTICORPOS DIRIGIDOS AOS MUTANTES DE DELEçãO DE RECEPTOR DE FATOR DE CRESCIMENTO EPIDéRMICO E SEUS USOS"". A presente invenção se refere a anticorpos inovadores, particularmente anticorpos dirigidos contra mutantes de deleção de receptor de fator de crescimento epidérmico e particularmente contra mutante de deleção do tipo III, EGFRvIII. A invenção também se refere a anticorpos monoclonais humanos dirigidos contra mutantes de deleção de receptor de fator de crescimento epidérmico e particularmente a EGFRvIII. Formulações de diagnóstico, e terapêuticas, de tais anticorpos e de seus imunoconjugados, também são providas.",ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/008-985-175-592-037,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
205,EP,A1,EP 3037105 A1,043-632-605-070-550,2016-06-29,2016,EP 15193917 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;EP 04777147 A;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/043-632-605-070-550,Patent Application,yes,150,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,165,123,001-201-806-511-780;;084-140-179-723-657;;117-357-237-248-341;;045-904-151-504-498;;054-707-943-234-995;;017-985-977-936-133;;044-355-372-029-744;;045-082-353-678-357;;128-683-050-479-273;;093-272-820-060-870;;045-751-499-875-041;;040-622-347-677-457;;049-182-911-054-623;;032-441-846-127-844;;002-538-287-083-621;;112-409-472-179-059;;067-857-455-571-760;;019-845-050-845-357;;027-389-935-773-753;;028-036-828-526-370;;103-963-954-821-085;;004-905-691-936-256;;005-419-140-766-345;;031-946-967-022-35X;;154-572-677-438-265;;090-683-249-679-734;;049-182-911-054-623;;040-622-347-677-457;;008-822-347-989-692;;064-678-224-734-734;;008-822-347-989-692;;009-417-133-046-629;;009-417-133-046-629;;001-201-806-511-780;;150-632-545-202-265;;046-385-127-360-775;;043-637-817-489-241;;011-171-559-635-599;;025-279-035-199-960;;084-140-179-723-657;;117-357-237-248-341;;003-420-832-784-996;;045-904-151-504-498;;072-377-861-372-36X;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;119-625-566-432-941;;053-206-529-796-448;;124-275-393-571-41X;;016-219-576-017-946;;044-355-372-029-744;;073-659-966-706-479;;087-448-981-335-707;;168-332-656-193-807;;007-780-042-541-484;;040-224-280-888-095;;022-668-203-716-884;;106-109-254-812-280;;032-728-154-591-070;;085-764-009-624-439;;106-794-363-564-085;;052-835-629-769-725;;105-521-401-667-801;;056-196-705-544-876;;087-448-981-335-707;;049-134-753-209-354;;024-995-475-936-443;;040-577-067-037-463;;104-212-297-137-759;;085-277-440-303-853;;016-219-576-017-946;;033-688-911-017-272;;023-767-491-654-250;;035-318-090-591-262;;054-354-046-619-106;;004-517-823-944-609;;087-098-327-694-214;;064-075-380-054-48X;;125-735-714-799-644;;004-986-447-228-415;;087-806-501-008-318;;033-509-048-623-004;;111-679-382-231-89X;;006-626-459-797-838;;013-447-454-196-187;;029-269-446-589-556;;069-165-512-595-028;;044-866-756-228-616;;000-831-802-795-392;;060-720-804-641-033;;002-495-630-767-098;;073-196-766-890-197;;093-698-369-612-279;;123-535-669-081-393;;048-664-799-869-659;;021-262-590-615-162;;102-103-218-931-722;;068-082-778-319-717;;084-646-990-422-712;;093-183-016-210-781;;003-280-353-877-595;;004-272-966-072-139;;014-234-489-298-615;;014-234-489-298-615;;014-234-489-298-615;;117-906-457-481-371;;112-312-727-891-46X;;128-901-299-587-74X;;082-984-043-695-164;;089-633-612-001-004;;023-137-217-763-01X;;003-653-620-396-243;;008-717-257-689-35X;;052-664-611-823-937;;087-448-981-335-707;;119-625-566-432-941;;195-002-437-063-479;;087-448-981-335-707;;067-782-603-238-967;;041-969-682-554-154;;001-779-867-387-972;;024-995-475-936-443,7606735;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;10.1016/s0969-8051(98)00120-6;;10382844;;pmc2034020;;10.1038/bjc.1995.435;;7547242;;10.1023/a:1011177318162;;11484948;;11255078;;10.1016/s1040-8428(00)00134-7;;pmc16575;;10.1073/pnas.130166597;;10852962;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1038/309418a0;;6328312;;10.1038/307521a0;;6320011;;10.1038/313144a0;;2981413;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;2834047;;2103507;;21566922;;10.3892/ijo.4.2.277;;6305505;;10.1016/0092-8674(83)90417-8;;10.1016/0092-8674(83)90153-8;;6309409;;10.1016/s0092-8674(85)80052-0;;2988784;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;10.1016/0092-8674(85)90209-0;;2982500;;10.1016/0092-8674(85)90210-7;;2982501;;2986110;;pmc397542;;10.1073/pnas.82.8.2287;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1038/313144a0;;2981413;;3258189;;3367154;;10.1097/00005072-198805000-00001;;3258189;;10.1677/erc.0.0080083;;11397666;;10.1677/erc.0.0080083;;11397666;;7606735;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1002/ijc.10224;;11920586;;7585629;;8391918;;10.1002/ijc.11007;;12640678;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;11352579;;10.1006/jmbi.2001.4628;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;9584952;;10.3109/13550289809114515;;12515857;;10.1073/pnas.232686499;;pmc141049;;12810643;;10.1038/ng0297-146;;9020839;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1093/nar/14.22.9081;;3786144;;pmc311930;;10.1021/ja00332a054;;pmc336489;;10.1093/nar/16.8.3209;;2836790;;1772569;;10.1021/cr00102a001;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1126/science.1853201;;1853201;;10.1038/354105a0;;1944583;;10.1021/jm00390a019;;2885419;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/ng0594-13;;8075633;;10.1038/ng0297-146;;9020839;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;8069530;;10.1006/immu.1994.1009;;1428404;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;3457627;;2430705;;10.1007/bf00199811;;2428468;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;6206272;;10.1093/jnci/73.3.721;;10.1021/jm00378a013;;6209394;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;10.1016/0006-291x(81)91644-2;;7306187;;3262420;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;4044586;;10.1016/s0021-9258(17)38981-0;;2908625;;10.1007/978-1-4613-1083-9_12;;2451562;;10.1016/s0021-9258(17)39118-4;;4030773;;8324745;;10.1021/jm00199a006;;563462;;10.1038/270721a0;;593392;;6441645;;1241159;;10.1126/science.1241159;;1238093;;10.1016/0006-2952(75)90017-9;;4609809;;pmc1185838;;708370;;10.1042/bj1730723;;7495477;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1038/nbt832;;12778055;;10.1182/blood-2003-01-0039;;12714494;;10.1182/blood-2003-01-0039;;12714494;;10.1182/blood-2003-01-0039;;12714494;;12213074;;10.1021/jm020149g;;9873732;;10.1016/s0960-894x(98)00610-6;;10.1002/jbm.820150212;;7348718;;6201207;;10.1002/bip.360220167;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;11067777;;10.1006/rtph.2000.1421;;10967427;;10.1016/s0378-5173(00)00423-3;;10.1002/1520-6017(200008)89:8<967::aid-jps1>3.0.co;2-r;;10906720;;9846074;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;9584952;;10.3109/13550289809114515;;113458;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;8845302;;10.1002/ijc.10189;;11920591;;10.1006/jmbi.1999.3192;;10543973;;10.1038/342877a0;;2687698,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71 - 78, XP001016320, ISSN: 0914-8108;;KUAN C-T: ""INCREASED BINDING AFFINITY ENHANCES TARGETING OF GLIOMA XENOGRAFTS BY EGFRVIII-SPECIFIC SCFV"", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 88, no. 6, 15 December 2000 (2000-12-15), pages 962 - 969, XP001024149, ISSN: 0020-7136, DOI: 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U;;REIST C J ET AL: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[<211>At]astato-3-pyridinecarboxylate - Preservation of immunoreactivity and in vivo localizing capacity"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 26, no. 4, 1 May 1999 (1999-05-01), pages 405 - 411, XP004167074, ISSN: 0969-8051, DOI: 10.1016/S0969-8051(98)00120-6;;NEGRI D R ET AL: ""In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody"", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 72, no. 4, 1 October 1995 (1995-10-01), pages 928 - 933, XP002744679, ISSN: 0007-0920;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06-01), pages 745 - 760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17 - 23, XP002963604, ISSN: 1040-8428;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7503 - 7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424;;ULLRICH ET AL.: ""Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells"", NATURE, vol. 309, 1984, pages 418 - 425, XP000650082, DOI: doi:10.1038/309418a0;;DOWNWARD ET AL.: ""Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence"", NATURE, vol. 307, 1984, pages 521 - 527, XP002026327, DOI: doi:10.1038/307521a0;;HALEY ET AL.: ""Oncogenes, Genes, and Growth Factors, 12th ed."", 1987, WILEY, article ""The Epidermal Growth Factor Receptor Gene"", pages: 40 - 76;;LIBERMANN ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;WONG ET AL.: ""Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification"", PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 6899 - 6903;;YAMAZAKI ET AL.: ""Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors"", MOLECULAR AND CELLULAR BIOLOGY, vol. 8, 1988, pages 1816 - 1820;;MALDEN ET AL.: ""Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme"", CANCER RESEARCH, vol. 4, 1988, pages 2711 - 2714;;""EGF-r has been demonstrated to be overexpressed on many types of human solid tumors"", MENDELSOHN CANCER CELLS, vol. 7, 1989, pages 359;;MENDELSOHN CANCER BIOLOGY, vol. 1, 1990, pages 339 - 344;;MODJTAHEDI; DEAN, INT'L J. ONCOLOGY, vol. 4, 1994, pages 277 - 296;;FUNG ET AL.: ""Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus"", CELL, vol. 33, 1984, pages 357 - 368, XP000645035, DOI: doi:10.1016/0092-8674(83)90417-8;;YAMAMOTO ET AL.: ""A New Avain Erythroblastosis Virus, AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma"", CELL, vol. 34, 1983, pages 225 - 232;;NILSEN ET AL.: ""c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor"", CELL, vol. 41, 1985, pages 719 - 726;;GAMMETT ET AL.: ""Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes"", PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 6053 - 6057;;GILMORE ET AL.: ""Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro"", CELL, vol. 40, 1985, pages 609 - 618;;KRIS ET AL.: ""Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein"", CELL, vol. 40, 1985, pages 619 - 625;;RAINES ET AL.: ""c-erbB Activation in Avian Leukosis Virus-Induced Erythroblastosis: Clustered Integration Sites and the Arrangement of Provirus in the c-erbB Alleles"", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 2287 - 2291;;PELLEY ET AL.: ""Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication--Competent Retrovirus Containing the Activated c-erbB"", JOURNAL OF VIROLOGY, vol. 62, 1988, pages 1840 - 1844;;WELLS ET AL.: ""Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB"", PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 7597 - 7601;;WON ET AL.: ""Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification"", PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 6899 - 6903;;YAMAZAKI ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;HUMPHREY ET AL.: ""Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts"", CANCER RESEARCH, vol. 48, 1988, pages 2231 - 2238;;BIGNER ET AL., J. NEUROPATHOL. EXP. NEUROL., vol. 47, 1988, pages 191 - 205;;HUMPHREY ET AL.: ""Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts"", CANCER RES., vol. 48, no. 8, 1988, pages 2231 - 8;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy"", ENDOCR RELAT CANCER., vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;KUANET: ""EGF mutant receptor vill as a molecular target in cancer therapy"", ENDOCR RELAT CANCER, vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy"", ENDOCR RELAT CANCER, vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;WIKSTRAND, CJ ET AL.: ""Monoclonal antibodies against EGFR III are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148;;OLAPADE-OLAOPA, EO ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer"", BR J CANCER, vol. 82, no. 1, 2000, pages 186 - 94, XP055333157, DOI: doi:10.1054/bjoc.1999.0898;;GE H ET AL.: ""Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis"", INT J CANCER, vol. 98, no. 3, 2002, pages 357 - 61, XP002967805, DOI: doi:10.1002/ijc.10224;;WIKSTRAND, CJ ET AL.: ""Monoclonal antibodies against EGFR,,III are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148;;MOSCATELLO, G ET AL.: ""Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors"", CANCER RES., vol. 55, no. 23, 1995, pages 5536 - 9, XP002943271;;GARCIA DE PALAZZO, IE ET AL.: ""Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas"", CANCER RES., vol. 53, no. 14, 1993, pages 3217 - 20, XP002153548;;MOSCATELLO, G. ET AL.: ""Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors"", CANCER RES., vol. 55, no. 23, 1995, pages 5536 - 9, XP002943271;;OLAPADE-OLAOPA, EO. ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer"", BR J CANCER, vol. 82, no. 1, 2000, pages 186 - 94, XP055333157, DOI: doi:10.1054/bjoc.1999.0898;;LUO ET AL., INT. J. CANCER, vol. 104, no. 6, 2003, pages 716 - 21;;KUAN ET AL.: ""EGFRvIII as a promising target for antibody-based brain tumor therapy"", BRAIN TUMOR PATHOL., vol. 17, no. 2, 2000, pages 71 - 78, XP001016320;;KUAN ET AL.: ""Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv"", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 6, 2000, pages 962 - 969, XP002176481, DOI: doi:10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U;;LANDRY ET AL.: ""Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII"", JOURNAL OF MOLECULAR BIOLOGY, vol. 308, no. 5, 2001, pages 883 - 893, XP004466169, DOI: doi:10.1006/jmbi.2001.4628;;REIST ET AL.: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate"", NUCLEAR MEDICINE AND BIOLOGY, vol. 26, no. 4, 1999, pages 405 - 411, XP004167074, DOI: doi:10.1016/S0969-8051(98)00120-6;;REIST ET AL.: ""In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent"", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 7, 1997, pages 639 - 647, XP004092552, DOI: doi:10.1016/S0969-8051(97)00080-2;;WIKSTRAND ET AL.: ""Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunology"", IMMUNOTHERAPY, vol. 50, no. 12, 2002, pages 639 - 652;;WIKSTRAND ET AL.: ""Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148, XP002074673;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFR III): characterization and utilization as an immunotherapeutic target"", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target"", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158, XP055000817, DOI: doi:10.3109/13550289809114515;;JUNGBLUTH ET AL.: ""A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor"", PROC NATL ACAD SCI USA., vol. 100, no. 2, 2003, pages 639 - 44;;MAMOT ET AL.: ""Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvin-overexpressing Tumor Cells"", CANCER RESEARCH, vol. 63, 2003, pages 3154 - 3161;;MENDEZ ET AL.: ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice"", NAT GENET., vol. 15, no. 2, 1997, pages 146 - 56, XP002918152, DOI: doi:10.1038/ng0297-146;;YANG X ET AL.: ""Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRIT REV ONCOL HEMATO, vol. 38, no. 1, 2001, pages 17 - 23, XP002330089, DOI: doi:10.1016/S1040-8428(00)00134-7;;YANG X-D ET AL.: ""Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy"", CANCER RESEARCH, vol. 59, no. 6, 1999, pages 1236 - 1243;;BABCOOK ET AL.: ""A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities"", PROC NATL ACAD SCI U S A., vol. 93, no. 15, 1996, pages 7843 - 8, XP000608647, DOI: doi:10.1073/pnas.93.15.7843;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual, 2nd ed."", 1989, COLD SPRING HARBOR LABORATORY PRESS;;LAPLANCHE ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 9081;;STEC ET AL., J AM. CHEM. SOC., vol. 106, 1984, pages 6077;;STEIN ET AL., NUCL. ACIDS RES., vol. 16, 1988, pages 3209;;ZON ET AL., ANTI-CANCER DRUG DESIGN, vol. 6, 1991, pages 539;;ZON ET AL.: ""Oligonucleotides and Analogues: A Practical Approach"", 1991, OXFORD UNIVERSITY PRESS, pages: 87 - 108;;UHLMANN; PEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543;;DAYHOFF, M.O.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1972, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 101 - 110;;DAYHOFF, M.O.: ""ATLAS OF PROTEIN SEQUENCE AND STRUCTURE"", vol. SUPPL. T, pages: 1 - 10;;SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMAN; WUNSCH, 1. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. (US.A.), vol. 85, 1988, pages 2444;;E.S. GOLUB AND D.R. GREN: ""Immunology - A Synthesis, 2nd ed."", 1991, SINAUER ASSOCIATES;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164;;CREIGHTON: ""Proteins, Structures and Molecular Principles"", 1984, W. H. FREEMAN AND COMPANY;;C. BRANDEN AND J. TOOZE: ""Introduction to Protein Structure"", 1991, GARLAND PUBLISHING;;THORNTON ET AL., NATURE, vol. 354, - 1991, pages 105;;FAUCHERE, J., ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBER; FREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J. MED. CHEM., vol. 30, 1987, pages 1229;;RIZO; GIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;PARKER, S.: ""The McGraw-Hill Dictionary of Chemical Terms"", 1985, MCGRAW-HILL;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 193, 1996, pages 7843 - 7848;;PAUL, W: ""Fundamental Immunology, 2nd ed."", 1989, RAVEN PRESS, article ""chapter 7"";;KABAT: ""Sequences of Proteins of Immunological Interest"", 1987, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA; LESK, J MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;BROOKS, B. R.; BRUCCOLERI, R. E.; OLAFSON, B. D.; STATES, D. J.; SWAMINATHAN, S.; KARPLUS, M., J. COMP. CHEM, vol. 4, 1983, pages 187;;GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;GREEN; JAKOBOVITS, J. EXP. MED., vol. 188, 1998, pages 483 - 495;;FANGER ET AL., IMMUNOL METHODS, vol. 4, 1994, pages 72 - 81;;TRAUNECKER ET AL., INT. J. CANCER (SUPPL.), vol. 7, 1992, pages 51 - 52;;VALERIUS ET AL., BLOOD, vol. 90, 1997, pages 4485 - 4492;;VITETTA, IMMUNOL TODAY, vol. 14, 1993, pages 252;;JUNGHANS ET AL.: ""Cancer Chemotherapy and Biotherapy, 2nd ed."", 1996, LIPPINCOTT RAVEN, pages: 655 - 686;;SELA ET AL.: ""Immunoconjugates"", 1987, pages: 189 - 216;;GHOSE ET AL.: ""Targeted Drugs"", 1983, pages: 1 - 22;;DIENER ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 1 - 23;;PIETERSZ ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 25 - 53;;BUMOL ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 55 - 79;;GARNETT ET AL., CANCER RES., vol. 46, 1986, pages 2407 - 2412;;OHKAWA ET AL., CANCER IMMUMOL. IMMUNOTHER, vol. 23, 1986, pages 81 - 86;;ENDO ET AL., CANCER RES., vol. 47, 1980, pages 1076 - 1080;;HURWITZ ET AL., APPL. BIOCHEM., vol. 2, 1980, pages 25 - 35;;MANABI ET AL., BIOCHEM. PHARMACOL., vol. 34, 1985, pages 289 - 291;;DILLMAN ET AL., CANCER RES., vol. 46, 1986, pages 4886 - 4891;;SHOVAL ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 8276 - 8280;;TSUKADA ET AL., J. NATL. CANC. INST., vol. 73, 1984, pages 721 - 729;;KATO ET AL., J. MED. CHEM., vol. 27, 1984, pages 1602 - 1607;;TSUKADA ET AL., BR. J. CANCER, vol. 52, 1985, pages 111 - 116;;BIOCHEM. BIOPHYS. RES. COMMUN., vol. 102, 1981, pages 1048 - 1054;;J. NATL. CANC. INST., vol. 80, 1988, pages 1154 - 1159;;CANCER RES., vol. 48, 1988, pages 6097 - 6102;;PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 626 - 629;;LAMBERT ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 12035 - 12041;;LAMBERT ET AL.: ""Immunotoxins"", 1988, pages: 175 - 209;;GHETIE ET AL., CANCER RES., vol. 48, 1988, pages 2610 - 2617;;J. BIOL. CHEM., vol. 260, 1985, pages 10905 - 10908;;MENENDEZ ET AL., FOURTH INTERNATIONAL CONFERENCE ON MONOCLONAL ANTIBODY IMMUNOCONJUGATES FOR CANCER, 1989;;HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342;;KUPCHAN ET AL., J. MED. CHEM., vol. 21, 1978, pages 31 - 37;;HIGASHIDE ET AL., NATURE, vol. 270, 1977, pages 721 - 722;;KAWAI ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 3441 - 3451;;CHEM. PHARM. BULL., vol. 12, 1984, pages 3441;;SIEBER ET AL., COMPARATIVE LEUKEMIA RESEARCH, vol. 43, 1975;;BIBL. HAEMAT., 1976, pages 495 - 500;;REMILLARD ET AL., SCIENCE, vol. 189, 1975, pages 1002 - 1005;;WOLPERT-DEFILLIPPES ET AL., BIOCHEM. PHARMACOL., vol. 24, 1975, pages 1735 - 1738;;KUPCHAN, PED. PROC., vol. 33, 1974, pages 2288 - 2295;;CARLSSON ET AL., BIOCHEM. J., vol. 173, 1978, pages 723 - 737;;PETTIT ET AL.: ""Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications"", ANTICANCER DRUG DES., vol. 10, no. 7, 1995, pages 529 - 44;;WOYKE ET AL.: ""In vitro activities and postantifungal effects of the potent dolastatin 10 structural modification auristatin PHE"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, 2001, pages 3580 - 3584;;PETTIT ET AL.: ""Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, 1998, pages 2961 - 2965;;DORONINA ET AL.: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy"", NATURE BIOTECHNOLOGY, 2003;;FRANCISCO ET AL.: ""cAC10- CMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;FRANCISCO ET AL.: ""cAClO-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;FRANCISCO ET AL.: ""cACI0-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;KING ET AL.: ""Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains"", J MED CHEM., vol. 45, no. 19, 2002, pages 4336 - 43, XP001193748, DOI: doi:10.1021/jm020149g;;DUBOWCHIK ET AL.: ""Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin"", BIOORG MED CHEM LETT., vol. 8, no. 23, 1998, pages 3347 - 52, XP004143756, DOI: doi:10.1016/S0960-894X(98)00610-6;;MAYER, A.M.S.: ""Marine Pharmacology in 1998: Antitumor and Cytotoxic Compounds"", THE PHARMACOLOGIST, vol. 41, no. 4, 1999, pages 159 - 164;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING COMPANY;;LANGER ET AL., J. BIOMED MATER. RES., vol. 15, 1981, pages 167 - 277;;LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105;;SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 - 3692;;HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 - 4034;;BLOCK, LAWRENCE: ""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING COMPANY, article ""particularly Chapter 87"";;BALDRICK P: ""Pharmaceutical excipient development: the need for preclinical guidance"", REGUL. TOXICOL. PHARMACOL., vol. 32, no. 2, 2000, pages 210 - 8;;WANG W: ""Lyophilization and development of solid protein pharmaceuticals"", INT. 1. PHARM., vol. 203, no. 1-2, 2000, pages 1 - 60, XP002428586, DOI: doi:10.1016/S0378-5173(00)00423-3;;CHARMAN WN: ""Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts"", J PHARM SCI ., vol. 89, no. 8, 2000, pages 967 - 78, XP008099512;;POWELL ET AL.: ""Compendium of excipients for parenteral formulations"", PDA J PHARM SCI TECHNOL., vol. 52, 1998, pages 238 - 3 1 1;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. I93, 1996, pages 7843 - 7848;;WIKSTRAND ET AL., J NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 58;;YANG ET AL., CRIT REV ONCOL HEMATOL., vol. 38, no. 1, 2001, pages 17 - 23;;KEARNEY ET AL., J. IMMUNOL., vol. 123, 1979, pages 1548 - 1550;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7843 - 7848;;BATRA ET AL.: ""Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene"", CELL GROWTH DIFFER., vol. 6, no. 10, 1995, pages 1251 - 9, XP055367769;;JOHNS ET AL., INT. J. CANCER., vol. 98, 2002, pages 398;;CHEN, Y ET AL., J MOL BIOL., vol. 293, no. 4, 1999, pages 865 - 81;;J. MOL. BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17;;CHOTHIA ET AL., NATURE, vol. 342, no. 6252, 21 December 1989 (1989-12-21), pages 877 - 83;;MARTIN ET AL., J MOL BIOL., vol. 263, no. 5, 15 November 1996 (1996-11-15), pages 800 - 15",ACTIVE
206,EP,A4,EP 1639092 A4,196-279-000-484-201,2009-06-03,2009,EP 04777147 A,2004-06-25,US 2004/0020564 W;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC. (2012-10-31),https://lens.org/196-279-000-484-201,Search Report,no,3,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,8,8,001-201-806-511-780;;084-140-179-723-657;;017-985-977-936-133;;044-355-372-029-744;;004-272-966-072-139;;016-435-611-136-112;;045-082-353-678-357;;128-683-050-479-273,7606735;;10.1007/bf02482738;;11210174;;10.1023/a:1011177318162;;11484948;;11255078;;10.1016/s1040-8428(00)00134-7;;10.1038/nbt832;;12778055;;9816055;;pmc16575;;10.1073/pnas.130166597;;10852962;;10.1073/pnas.87.11.4207;;1693434;;pmc54077,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71 - 78, XP001016320, ISSN: 0914-8108;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06-01), pages 745 - 760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17 - 23, XP002963604, ISSN: 1040-8428;;DORONINA SVETLANA O ET AL: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy."", NATURE BIOTECHNOLOGY JUL 2003, vol. 21, no. 7, 1 June 2003 (2003-06-01), pages 778 - 784, XP002524202, ISSN: 1087-0156;;LORIMER I A ET AL: ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 1995, vol. 1, no. 8, August 1995 (1995-08-01), pages 859 - 864, XP002524203, ISSN: 1078-0432;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7503 - 7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424",ACTIVE
207,AU,A1,AU 2012/268864 A1,192-527-338-819-659,2013-01-17,2013,AU 2012/268864 A,2012-12-21,AU 2010/202054 A;;AU 2012/268864 A,2010-05-20,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. w (5SIO In ouje co 4 4 CL) Oz AP4N 1- 4=O8 inn Q o8o amo a >S z >-E1C2 C'4 NN 4 U) U) r P NlwwZ EICnE4 m'l iC O P mM ~ I4 ,-H OO>1 rcP 04I :I P- FA' U) L) P (I) II40 F, NEl 4 O>1k""O D>mow Nl H 4 6 C - 80 ""L)0",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/192-527-338-819-659,Patent Application,no,0,0,2,4,0,,C07K14/71;;A61K39/395;;A61K39/44;;A61K47/48;;C07H21/04;;C07K16/22;;C07K16/28;;C07K16/42;;C07K17/00;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,0,0,,,,ACTIVE
208,AU,B2,AU 2015/242981 B2,018-305-581-219-503,2017-10-19,2017,AU 2015/242981 A,2015-10-13,AU 2015/242981 A;;AU 2012/268864 A;;AU 2010/202054 A,2010-05-20,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRVI. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LUI YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI,,https://lens.org/018-305-581-219-503,Granted Patent,no,2,0,2,4,0,,C07K16/22;;A61K39/395;;A61K39/44;;C07H21/04;;C07K14/71;;C07K16/28;;C07K16/42;;C07K17/00;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,2,2,044-355-372-029-744;;054-707-943-234-995,11255078;;10.1016/s1040-8428(00)00134-7;;pmc2034020;;10.1038/bjc.1995.435;;7547242,"Yang et al (2001) Critical Reviews in Oncology Hematology, 38:17-23;;DRM NEGRI et al British Journal of Cancer, Vol.72, No. 4, page 928-933. 1995.",ACTIVE
209,EP,A1,EP 3679951 A1,079-021-318-262-908,2020-07-15,2020,EP 20155925 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;EP 15193917 A;;EP 04777147 A;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/079-021-318-262-908,Patent Application,yes,149,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,135,110,001-201-806-511-780;;084-140-179-723-657;;117-357-237-248-341;;045-904-151-504-498;;054-707-943-234-995;;017-985-977-936-133;;044-355-372-029-744;;045-082-353-678-357;;128-683-050-479-273;;093-272-820-060-870;;045-751-499-875-041;;049-182-911-054-623;;040-622-347-677-457;;032-441-846-127-844;;002-538-287-083-621;;112-409-472-179-059;;067-857-455-571-760;;019-845-050-845-357;;027-389-935-773-753;;028-036-828-526-370;;103-963-954-821-085;;004-905-691-936-256;;005-419-140-766-345;;031-946-967-022-35X;;154-572-677-438-265;;090-683-249-679-734;;008-822-347-989-692;;064-678-224-734-734;;008-822-347-989-692;;009-417-133-046-629;;001-201-806-511-780;;150-632-545-202-265;;046-385-127-360-775;;001-201-806-511-780;;043-637-817-489-241;;011-171-559-635-599;;025-279-035-199-960;;084-140-179-723-657;;117-357-237-248-341;;003-420-832-784-996;;045-904-151-504-498;;072-377-861-372-36X;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;119-625-566-432-941;;053-206-529-796-448;;124-275-393-571-41X;;016-219-576-017-946;;044-355-372-029-744;;073-659-966-706-479;;087-448-981-335-707;;024-995-475-936-443;;168-332-656-193-807;;007-780-042-541-484;;040-224-280-888-095;;022-668-203-716-884;;106-794-363-564-085;;106-109-254-812-280;;032-728-154-591-070;;085-764-009-624-439;;087-806-501-008-318;;052-835-629-769-725;;105-521-401-667-801;;056-196-705-544-876;;087-448-981-335-707;;049-134-753-209-354;;040-577-067-037-463;;104-212-297-137-759;;085-277-440-303-853;;016-219-576-017-946;;033-688-911-017-272;;023-767-491-654-250;;035-318-090-591-262;;054-354-046-619-106;;004-517-823-944-609;;082-984-043-695-164;;004-986-447-228-415;;125-735-714-799-644;;064-075-380-054-48X;;033-509-048-623-004;;111-679-382-231-89X;;000-831-802-795-392;;002-495-630-767-098;;073-196-766-890-197;;093-698-369-612-279;;123-535-669-081-393;;048-664-799-869-659;;021-262-590-615-162;;102-103-218-931-722;;068-082-778-319-717;;084-646-990-422-712;;093-183-016-210-781;;003-280-353-877-595;;004-272-966-072-139;;014-234-489-298-615;;117-906-457-481-371;;112-312-727-891-46X;;128-901-299-587-74X;;089-633-612-001-004;;023-137-217-763-01X;;003-653-620-396-243;;008-717-257-689-35X;;052-664-611-823-937;;119-625-566-432-941;;195-002-437-063-479;;067-782-603-238-967;;041-969-682-554-154;;001-779-867-387-972;;024-995-475-936-443,7606735;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;10.1016/s0969-8051(98)00120-6;;10382844;;pmc2034020;;10.1038/bjc.1995.435;;7547242;;10.1023/a:1011177318162;;11484948;;11255078;;10.1016/s1040-8428(00)00134-7;;pmc16575;;10.1073/pnas.130166597;;10852962;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1038/309418a0;;6328312;;10.1038/307521a0;;6320011;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1038/313144a0;;2981413;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;2834047;;2103507;;21566922;;10.3892/ijo.4.2.277;;6305505;;10.1016/0092-8674(83)90417-8;;10.1016/0092-8674(83)90153-8;;6309409;;10.1016/s0092-8674(85)80052-0;;2988784;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;10.1016/0092-8674(85)90209-0;;2982500;;10.1016/0092-8674(85)90210-7;;2982501;;2986110;;pmc397542;;10.1073/pnas.82.8.2287;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;3258189;;3367154;;10.1097/00005072-198805000-00001;;3258189;;10.1677/erc.0.0080083;;11397666;;7606735;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1002/ijc.10224;;11920586;;7606735;;7585629;;8391918;;10.1002/ijc.11007;;12640678;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;11352579;;10.1006/jmbi.2001.4628;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;9584952;;10.3109/13550289809114515;;12515857;;10.1073/pnas.232686499;;pmc141049;;12810643;;10.1038/ng0297-146;;9020839;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1038/342877a0;;2687698;;10.1093/nar/14.22.9081;;3786144;;pmc311930;;10.1021/ja00332a054;;pmc336489;;10.1093/nar/16.8.3209;;2836790;;1772569;;10.1126/science.1853201;;1853201;;10.1021/cr00102a001;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;6206272;;10.1093/jnci/73.3.721;;10.1038/354105a0;;1944583;;10.1021/jm00390a019;;2885419;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/0022-2836(87)90412-8;;3681981;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/ng0594-13;;8075633;;10.1038/ng0297-146;;9020839;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;8069530;;10.1006/immu.1994.1009;;1428404;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;6201207;;10.1002/bip.360220167;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;2428468;;2430705;;10.1007/bf00199811;;10.1021/jm00378a013;;6209394;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;2451562;;8324745;;10.1021/jm00199a006;;563462;;10.1038/270721a0;;593392;;6441645;;1241159;;10.1126/science.1241159;;1238093;;10.1016/0006-2952(75)90017-9;;4609809;;pmc1185838;;708370;;10.1042/bj1730723;;7495477;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1038/nbt832;;12778055;;10.1182/blood-2003-01-0039;;12714494;;12213074;;10.1021/jm020149g;;9873732;;10.1016/s0960-894x(98)00610-6;;10.1002/jbm.820150212;;7348718;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;11067777;;10.1006/rtph.2000.1421;;10967427;;10.1016/s0378-5173(00)00423-3;;10.1002/1520-6017(200008)89:8<967::aid-jps1>3.0.co;2-r;;10906720;;9846074;;9584952;;10.3109/13550289809114515;;113458;;8845302;;10.1002/ijc.10189;;11920591;;10.1006/jmbi.1999.3192;;10543973;;10.1038/342877a0;;2687698,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71 - 78, XP001016320, ISSN: 0914-8108;;KUAN C-T: ""INCREASED BINDING AFFINITY ENHANCES TARGETING OF GLIOMA XENOGRAFTS BY EGFRVIII-SPECIFIC SCFV"", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 88, no. 6, 15 December 2000 (2000-12-15), pages 962 - 969, XP001024149, ISSN: 0020-7136, DOI: 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U;;REIST C J ET AL: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[<211>At]astato-3-pyridinecarboxylate - Preservation of immunoreactivity and in vivo localizing capacity"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 26, no. 4, 1 May 1999 (1999-05-01), pages 405 - 411, XP004167074, ISSN: 0969-8051, DOI: 10.1016/S0969-8051(98)00120-6;;NEGRI D R ET AL: ""In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific mono-clonal antibody"", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 72, no. 4, 1 October 1995 (1995-10-01), pages 928 - 933, XP002744679, ISSN: 0007-0920;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06-01), pages 745 - 760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17 - 23, XP002963604, ISSN: 1040-8428;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7503 - 7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424;;ULLRICH ET AL.: ""Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells"", NATURE, vol. 309, 1984, pages 418 - 425, XP000650082, DOI: 10.1038/309418a0;;DOWNWARD ET AL.: ""Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence"", NATURE, vol. 307, 1984, pages 521 - 527, XP002026327, DOI: 10.1038/307521a0;;WONG ET AL.: ""Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification"", PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 6899 - 6903;;LIBERMANN ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;YAMAZAKI ET AL.: ""Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors"", MOLECULAR AND CELLULAR BIOLOGY, vol. 8, 1988, pages 1816 - 1820;;MAIDEN ET AL.: ""Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme"", CANCER RESEARCH, vol. 4, 1988, pages 2711 - 2714;;MENDELSOHN, CANCER CELLS, vol. 7, 1989, pages 359;;MENDELSOHN, CANCER BIOLOGY, vol. 1, 1990, pages 339 - 344;;MODJTAHEDIDEAN, INT'L J. ONCOLOGY, vol. 4, 1994, pages 277 - 296;;FUNG ET AL.: ""Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus"", CELL, vol. 33, 1984, pages 357 - 368, XP000645035, DOI: 10.1016/0092-8674(83)90417-8;;YAMAMOTO ET AL.: ""A New Avain Erythroblastosis Virus, AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma"", CELL, vol. 34, 1983, pages 225 - 232;;NILSEN ET AL.: ""c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor"", CELL, vol. 41, 1985, pages 719 - 726;;GAMMETT ET AL.: ""Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes"", PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 6053 - 6057;;GILMORE ET AL.: ""Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro"", CELL, vol. 40, 1985, pages 609 - 618;;KRIS ET AL.: ""Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein"", CELL, vol. 40, 1985, pages 619 - 625;;RAINES ET AL.: ""c-erbB Activation in Avian Leukosis Virus-Induced Erythroblastosis: Clustered Integration Sites and the Arrangement of Provirus in the c-erbB Alleles"", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 2287 - 2291;;PELLEY ET AL.: ""Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication--Competent Retrovirus Containing the Activated c-erbB"", JOURNAL OF VIROLOGY, vol. 62, 1988, pages 1840 - 1844;;WELLS ET AL.: ""Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB"", PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 7597 - 7601;;HUMPHREY ET AL.: ""Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts"", CANCER RESEARCH, vol. 48, 1988, pages 2231 - 2238;;BIGNER ET AL., J. NEUROPATHOL. EXP. NEUROL., vol. 47, 1988, pages 191 - 205;;HUMPHREY ET AL.: ""Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts"", CANCER RES., vol. 48, no. 8, 1988, pages 2231 - 8;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy"", ENDOCR RELAT CANCER, vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: 10.1677/erc.0.0080083;;KUAN ET AL.: ""EGF mutant receptor vIΠ as a molecular target in cancer therapy"", ENDOCR RELAT CANCER, vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: 10.1677/erc.0.0080083;;WIKSTRAND, CJ. ET AL.: ""Monoclonal antibodies against EGFR III are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148;;OLAPADE-OLAOPA, EO. ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer"", BR J CANCER, vol. 82, no. 1, 2000, pages 186 - 94, XP055333157, DOI: 10.1054/bjoc.1999.0898;;GE H. ET AL.: ""Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis"", INT J CANCER, vol. 98, no. 3, 2002, pages 357 - 61, XP002967805, DOI: 10.1002/ijc.10224;;WIKSTRAND, CJ. ET AL.: ""Monoclonal antibodies against EGFR II are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148, XP002074673;;MOSCATELLO, G. ET AL.: ""Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors"", CANCER RES., vol. 55, no. 23, 1995, pages 5536 - 9, XP002943271;;GARCIA DE PALAZZO, IE. ET AL.: ""Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas"", CANCER RES., vol. 5 3, no. 14, 1993, pages 3217 - 20, XP002153548;;LUO ET AL., INT. J. CANCER, vol. 104, no. 6, 2003, pages 716 - 21;;KUAN ET AL.: ""EGFRvIII as a promising target for antibody-based brain tumor therapy"", BRAIN TUMOR PATHOL., vol. 17, no. 2, 2000, pages 71 - 78, XP001016320;;KUAN ET AL.: ""Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv"", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 6, 2000, pages 962 - 969, XP002176481, DOI: 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U;;LANDRY ET AL.: ""Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII"", JOURNAL OF MOLECULAR BIOLOGY, vol. 308, no. 5, 2001, pages 883 - 893, XP004466169, DOI: 10.1006/jmbi.2001.4628;;REIST ET AL.: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[21 lAt]astato-3-pyridinecarboxylate"", NUCLEAR MEDICINE AND BIOLOGY, vol. 26, no. 4, 1999, pages 405 - 411, XP004167074, DOI: 10.1016/S0969-8051(98)00120-6;;REIST ET AL.: ""In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent"", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 7, 1997, pages 639 - 647, XP004092552, DOI: 10.1016/S0969-8051(97)00080-2;;WIKSTRAND ET AL.: ""Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 50, no. 12, 2002, pages 639 - 652;;WIKSTRAND ET AL.: ""Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148, XP002074673;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFR III): characterization and utilization as an immunotherapeutic target"", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target"", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158, XP055000817, DOI: 10.3109/13550289809114515;;JUNGBLUTH ET AL.: ""A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor"", PROC NATL ACAD SCI USA, vol. 100, no. 2, 2003, pages 639 - 44;;MAMOT ET AL.: ""Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells"", CANCER RESEARCH, vol. 63, 2003, pages 3154 - 3161, XP002509423;;MENDEZ ET AL.: ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice"", NAT GENET., vol. 15, no. 2, 1997, pages 146 - 56, XP002067603, DOI: 10.1038/ng0297-146;;YANG X ET AL.: ""Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRIT REV ONCOL HEMATO, vol. 38, no. 1, 2001, pages 17 - 23, XP002330089, DOI: 10.1016/S1040-8428(00)00134-7;;YANG X-D ET AL.: ""Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy"", CANCER RESEARCH, vol. 59, no. 6, 1999, pages 1236 - 1243;;BABCOOK ET AL.: ""A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities"", PROC NATL ACAD SCI U S A., vol. 93, no. 15, 1996, pages 7843 - 8, XP000608647, DOI: 10.1073/pnas.93.15.7843;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;LAPLANCHE ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 9081;;STEC ET AL., J. AM. CHEM. SOC., vol. 106, 1984, pages 6077;;STEIN ET AL., NUCL. ACIDS RES., vol. 16, 1988, pages 3209;;ZON ET AL., ANTI-CANCER DRUG DESIGN, vol. 6, 1991, pages 539;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164 - 108;;UHLMANNPEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543;;DAYHOFF, M.O.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1972, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 101 - 110;;SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSONLIPMAN, PROC. NATL. ACAD. SCI. (U.S.A.), vol. 85, 1988, pages 2444;;TSUKADA ET AL., J. NATL. CANC. INST., vol. 73, 1984, pages 721 - 729;;THORNTON, NATURE, vol. 354, 1991, pages 105;;FAUCHERE, J. ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBERFREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J. MED. CHEM., vol. 30, 1987, pages 1229;;RIZOGIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;MANABI ET AL., BIOCHEM. PHARMACOL., vol. 34, 1985, pages 289 - 291;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. i93, 1996, pages 7843 - 7848;;CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;BROOKS, B. R.BRUCCOLERI, R. E.OLAFSON, B. D.STATES, D. J.SWAMINATHAN, S.KARPLUS, M., J. COMP. CHEM, vol. 4, 1983, pages 187;;GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;GREENJAKOBOVITS, J. EXP. MED., vol. 188, 1998, pages 483 - 495;;FANGER ET AL., IMMUNOL METHODS, vol. 4, 1994, pages 72 - 81;;TRAUNECKER ET AL., INT. J. CANCER, vol. 7, 1992, pages 51 - 52;;VALERIUS ET AL., BLOOD, vol. 90, 1997, pages 4485 - 4492;;VITETTA, IMMUNOL TODAY, vol. 14, 1993, pages 252;;JUNGHANS ET AL.: ""Cancer Chemotherapy and Biotherapy"", 1996, LIPPINCOTT RAVEN, pages: 655 - 686;;SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556;;SHOVAL ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 8276 - 8280;;DILLMAN ET AL., CANCER RES., vol. 46, 1986, pages 4886 - 4891;;OHKAWA ET AL., CANCER IMMUMOL. IMMUNOTHER., vol. 23, 1986, pages 81 - 86;;ENDO ET AL., CANCER RES., vol. 47, 1980, pages 1076 - 1080;;HURWITZ ET AL., APPL. BIOCHEM., vol. 2, 1980, pages 25 - 35;;KATO ET AL., J. MED. CHEM., vol. 27, 1984, pages 1602 - 1607;;TSUKADA ET AL., BR. J. CANCER, vol. 52, 1985, pages 111 - 116;;SHENRYSER: ""introduced this method for the preparation of conjugates of daunorubicin with macromolecular carriers"", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 102, 1981, pages 1048 - 1054;;YANGREISFELD: ""used the same technique to conjugate daunorubicin to an anti-melanoma antibody"", J. NATL. CANC. INST., vol. 80, 1988, pages 1154 - 1159;;DILLMAN ET AL.: ""also used an acid-labile linker in a similar fashion to prepare conjugates of daunorubicin with an anti-T cell antibody"", CANCER RES., vol. 48, 1988, pages 6097 - 6102;;TROUET ET AL.: ""involved linking daunorubicin to an antibody via a peptide spacer arm"", PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 626 - 629;;LAMBERT ET AL.: ""described the conversion of methotrexate into a mercaptoethylamide derivative followed by conjugation with poly-D-lysine via a disulfide bond"", J. BIOL. CHEM., vol. 260, 1985, pages 10905 - 10908;;GHETIE ET AL., CANCER RES., vol. 48, 1988, pages 2610 - 2617;;MENENDEZ ET AL., FOURTH INTERNATIONAL CONFERENCE ON MONOCLONAL ANTIBODY IMMUNOCONJUGATES FOR CANCER, 1989;;HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342;;KUPCHAN ET AL., J. MED. CHEM., vol. 21, 1978, pages 31 - 37;;HIGASHIDE ET AL., NATURE, vol. 270, 1977, pages 721 - 722;;KAWAI ET AL., CHEM. PHARM. BULL., vol. 12, 1984, pages 3441 - 3451;;SIEBER ET AL.: ""Comparative Leukemia Research 1975"", BIBL. HAEMAT., vol. 43, 1976, pages 495 - 500;;REMILLARD ET AL., SCIENCE, vol. 189, 1975, pages 1002 - 1005;;WOLPERT-DEFILLIPPES ET AL., BIOCHEM. PHARMACOL., vol. 24, 1975, pages 1735 - 1738;;KUPCHAN, PED. PROC., vol. 33, 1974, pages 2288 - 2295;;CARLSSON ET AL., BIOCHEM. J., vol. 173, 1978, pages 723 - 737;;PETTIT ET AL.: ""Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications"", ANTICANCER DRUG DES., vol. 10, no. 7, 1995, pages 529 - 44;;WOYKE ET AL.: ""In vitro activities and postantifungal effects of the potent dolastatin 10 structural modification auristatin PHE"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, 2001, pages 3580 - 3584;;PETTIT ET AL.: ""Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 42, 1998, pages 2961 - 2965;;DORONINA ET AL.: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy"", NATURE BIOTECHNOLOGY, 2003;;FRANCISCO ET AL.: ""cAClO-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 8 May 2003 (2003-05-08);;KING ET AL.: ""Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains"", J MED CHEM., vol. 45, no. 19, 2002, pages 4336 - 43, XP001193748, DOI: 10.1021/jm020149g;;DUBOWCHIK ET AL.: ""Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin"", BIOORG MED CHEM LETT., vol. 8, no. 23, 1998, pages 3347 - 52, XP004143756, DOI: 10.1016/S0960-894X(98)00610-6;;MAYER, A.M.S.: ""Marine Pharmacology in 1998: Antitumor and Cytotoxic Compounds"", THE PHARMACOLOGIST, vol. 41, no. 4, 1999, pages 159 - 164;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING COMPANY;;LANGER ET AL., J. BIOMED MATER. RES., vol. 15, 1981, pages 167 - 277;;LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 - 3692;;HWANG ET AL., PROC. NATL. A CAD. SCI. USA, vol. 77, 1980, pages 4030 - 4034;;BALDRICK P.: ""Pharmaceutical excipient development: the need for preclinical guidance"", REGUL. TOXICOL. PHARMACOL., vol. 32, no. 2, 2000, pages 210 - 8;;WANG W.: ""Lyophilization and development of solid protein pharmaceuticals"", INT. J. PHARM., vol. 203, no. 1-2, 2000, pages 1 - 60, XP002428586, DOI: 10.1016/S0378-5173(00)00423-3;;CHARMAN WN: ""Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts"", J PHARM SCI, vol. 89, no. 8, 2000, pages 967 - 78, XP008099512;;POWELL ET AL.: ""Compendium of excipients for parenteral formulations"", PDA J PHARM SCI TECHNOL., vol. 52, 1998, pages 238 - 311, XP009119027;;WIKSTRAND ET AL., J NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 58;;YANG ET AL., CRIT REV ONCOL HEMATOL., vol. 38, no. 1, 2001, pages 17 - 23;;KEARNEY ET AL., J. IMMUNOL., vol. 123, 1979, pages 1548 - 1550;;BATRA ET AL.: ""Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene"", CELL GROWTH DIFFER., vol. 6, no. 10, 1995, pages 1251 - 9, XP055367769;;JOHNS ET AL., INT. J. CANCER, vol. 98, 2002, pages 398;;CHEN, Y ET AL., J MOL BIOL., vol. 293, no. 4, 1999, pages 865 - 81;;CHOTHIA ET AL.: ""have described antibody structure in terms of ''canonical classes'' for the hypervariable regions of each immunoglobulin chain"", J. MOL. BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17;;CHOTHIA ET AL., NATURE, vol. 342, no. 6252, 21 December 1989 (1989-12-21), pages 877 - 83;;MARTIN ET AL., J MOL BIOL., vol. 263, no. 5, 15 November 1996 (1996-11-15), pages 800 - 15",PENDING
210,CA,A1,CA 2530285 A1,122-390-433-877-853,2005-02-03,2005,CA 2530285 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic an d therapeutic formulations of such antibodies, and immunoconjugates thereof, a re also provided.",ABGENIX INC,KANG JASPAL;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;JIA XIAO-CHI;;LIU YING;;CORVALAN JOSE;;RAYA ROBERT;;YANG XIAO DONG;;GUDAS JEAN;;GREEN LARRY;;KEYT BRUCE;;WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;KING CHADWICK T;;RATHANASWAMI PALANI;;FOLTZ IAN,,https://lens.org/122-390-433-877-853,Patent Application,no,0,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,ACTIVE
211,EP,A1,EP 3011971 A1,147-960-391-982-75X,2016-04-27,2016,EP 15193910 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;EP 04777034 A;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/147-960-391-982-75X,Patent Application,yes,147,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,162,119,001-201-806-511-780;;084-140-179-723-657;;017-985-977-936-133;;044-355-372-029-744;;004-272-966-072-139;;016-435-611-136-112;;045-082-353-678-357;;128-683-050-479-273;;093-272-820-060-870;;045-751-499-875-041;;040-622-347-677-457;;049-182-911-054-623;;032-441-846-127-844;;002-538-287-083-621;;112-409-472-179-059;;067-857-455-571-760;;019-845-050-845-357;;027-389-935-773-753;;028-036-828-526-370;;103-963-954-821-085;;004-905-691-936-256;;005-419-140-766-345;;031-946-967-022-35X;;154-572-677-438-265;;090-683-249-679-734;;040-622-347-677-457;;008-822-347-989-692;;064-678-224-734-734;;008-822-347-989-692;;009-417-133-046-629;;001-201-806-511-780;;150-632-545-202-265;;001-201-806-511-780;;046-385-127-360-775;;043-637-817-489-241;;011-171-559-635-599;;025-279-035-199-960;;084-140-179-723-657;;117-357-237-248-341;;003-420-832-784-996;;045-904-151-504-498;;072-377-861-372-36X;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;119-625-566-432-941;;053-206-529-796-448;;124-275-393-571-41X;;009-417-133-046-629;;016-219-576-017-946;;044-355-372-029-744;;073-659-966-706-479;;087-448-981-335-707;;168-332-656-193-807;;007-780-042-541-484;;040-224-280-888-095;;022-668-203-716-884;;106-109-254-812-280;;032-728-154-591-070;;085-764-009-624-439;;106-794-363-564-085;;052-835-629-769-725;;056-196-705-544-876;;087-448-981-335-707;;049-134-753-209-354;;024-995-475-936-443;;040-577-067-037-463;;104-212-297-137-759;;085-277-440-303-853;;016-219-576-017-946;;033-688-911-017-272;;023-767-491-654-250;;035-318-090-591-262;;054-354-046-619-106;;004-517-823-944-609;;087-098-327-694-214;;064-075-380-054-48X;;125-735-714-799-644;;004-986-447-228-415;;087-806-501-008-318;;033-509-048-623-004;;111-679-382-231-89X;;006-626-459-797-838;;013-447-454-196-187;;029-269-446-589-556;;069-165-512-595-028;;044-866-756-228-616;;000-831-802-795-392;;060-720-804-641-033;;002-495-630-767-098;;073-196-766-890-197;;093-698-369-612-279;;123-535-669-081-393;;048-664-799-869-659;;021-262-590-615-162;;102-103-218-931-722;;068-082-778-319-717;;084-646-990-422-712;;093-183-016-210-781;;003-280-353-877-595;;004-272-966-072-139;;014-234-489-298-615;;014-234-489-298-615;;117-906-457-481-371;;112-312-727-891-46X;;128-901-299-587-74X;;082-984-043-695-164;;089-633-612-001-004;;023-137-217-763-01X;;003-653-620-396-243;;008-717-257-689-35X;;052-664-611-823-937;;119-625-566-432-941;;195-002-437-063-479;;087-448-981-335-707;;067-782-603-238-967;;041-969-682-554-154;;001-779-867-387-972;;024-995-475-936-443,7606735;;10.1007/bf02482738;;11210174;;10.1023/a:1011177318162;;11484948;;11255078;;10.1016/s1040-8428(00)00134-7;;10.1038/nbt832;;12778055;;9816055;;pmc16575;;10.1073/pnas.130166597;;10852962;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1038/309418a0;;6328312;;10.1038/307521a0;;6320011;;10.1038/313144a0;;2981413;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;2834047;;2103507;;21566922;;10.3892/ijo.4.2.277;;6305505;;10.1016/0092-8674(83)90417-8;;10.1016/0092-8674(83)90153-8;;6309409;;10.1016/s0092-8674(85)80052-0;;2988784;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;10.1016/0092-8674(85)90209-0;;2982500;;10.1016/0092-8674(85)90210-7;;2982501;;2986110;;pmc397542;;10.1073/pnas.82.8.2287;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1038/313144a0;;2981413;;3258189;;3367154;;10.1097/00005072-198805000-00001;;3258189;;10.1677/erc.0.0080083;;11397666;;7606735;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;7606735;;10.1002/ijc.10224;;11920586;;7585629;;8391918;;10.1002/ijc.11007;;12640678;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;11352579;;10.1006/jmbi.2001.4628;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;9584952;;10.3109/13550289809114515;;12515857;;10.1073/pnas.232686499;;pmc141049;;12810643;;10.1677/erc.0.0080083;;11397666;;10.1038/ng0297-146;;9020839;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1093/nar/14.22.9081;;3786144;;pmc311930;;10.1021/ja00332a054;;pmc336489;;10.1093/nar/16.8.3209;;2836790;;1772569;;10.1021/cr00102a001;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1126/science.1853201;;1853201;;10.1038/354105a0;;1944583;;10.1146/annurev.bi.61.070192.002131;;1497316;;10.1146/annurev.biochem.61.1.387;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/ng0594-13;;8075633;;10.1038/ng0297-146;;9020839;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;8069530;;10.1006/immu.1994.1009;;1428404;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;3457627;;2430705;;10.1007/bf00199811;;2428468;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;6206272;;10.1093/jnci/73.3.721;;10.1021/jm00378a013;;6209394;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;10.1016/0006-291x(81)91644-2;;7306187;;3262420;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;4044586;;10.1016/s0021-9258(17)38981-0;;2908625;;10.1007/978-1-4613-1083-9_12;;2451562;;10.1016/s0021-9258(17)39118-4;;4030773;;8324745;;10.1021/jm00199a006;;563462;;10.1038/270721a0;;593392;;6441645;;1241159;;10.1126/science.1241159;;1238093;;10.1016/0006-2952(75)90017-9;;4609809;;pmc1185838;;708370;;10.1042/bj1730723;;7495477;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1038/nbt832;;12778055;;10.1182/blood-2003-01-0039;;12714494;;10.1182/blood-2003-01-0039;;12714494;;12213074;;10.1021/jm020149g;;9873732;;10.1016/s0960-894x(98)00610-6;;10.1002/jbm.820150212;;7348718;;6201207;;10.1002/bip.360220167;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;11067777;;10.1006/rtph.2000.1421;;10967427;;10.1016/s0378-5173(00)00423-3;;10.1002/1520-6017(200008)89:8<967::aid-jps1>3.0.co;2-r;;10906720;;9846074;;9584952;;10.3109/13550289809114515;;113458;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;8845302;;10.1002/ijc.10189;;11920591;;10.1006/jmbi.1999.3192;;10543973;;10.1038/342877a0;;2687698,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140 - 3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71 - 78, XP001016320, ISSN: 0914-8108;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06-01), pages 745 - 760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17 - 23, XP002963604, ISSN: 1040-8428;;DORONINA SVETLANA O ET AL: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy."", NATURE BIOTECHNOLOGY JUL 2003, vol. 21, no. 7, 1 June 2003 (2003-06-01), pages 778 - 784, XP002524202, ISSN: 1087-0156;;LORIMER I A ET AL: ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 1995, vol. 1, no. 8, August 1995 (1995-08-01), pages 859 - 864, XP002524203, ISSN: 1078-0432;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20), pages 7503 - 7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207 - 4211, XP000133024, ISSN: 0027-8424;;ULLRICH ET AL.: ""Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells"", NATURE, vol. 309, 1984, pages 418 - 425, XP000650082, DOI: doi:10.1038/309418a0;;DOWNWARD ET AL.: ""Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence"", NATURE, vol. 307, 1984, pages 521 - 527, XP002026327, DOI: doi:10.1038/307521a0;;GUROFF, G.: ""Oncogenes, Genes, and Growth Factors, 12th ed."", 1987, WILEY, article HALEY ET AL.: ""The Epidermal Growth Factor Receptor Gene (Chapter 2)"", pages: 40 - 76;;LIBERMANN ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin"", NATURE, vol. 313, 1985, pages 144 - 147;;WONG ET AL.: ""Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification"", PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 6899 - 6903;;YAMAZAKI ET AL.: ""Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors"", MOLECULAR AND CELLULAR BIOLOGY, vol. 8, 1988, pages 1816 - 1820;;MALDEN ET AL.: ""Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme"", CANCER RESEARCH, vol. 4, 1988, pages 2711 - 2714;;MENDELSOHN: ""EGF-r has been demonstrated to be overexpressed on many types of human solid tumors"", CANCER CELLS, vol. 7, 1989, pages 359;;MENDELSOHN, CANCER BIOLOGY, vol. 1, 1990, pages 339 - 344;;MODJTAHEDI; DEAN, INT'L J. ONCOLOGY, vol. 4, 1994, pages 277 - 296;;FUNG ET AL.: ""Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus"", CELL, vol. 33, 1984, pages 357 - 368, XP000645035, DOI: doi:10.1016/0092-8674(83)90417-8;;YAMAMOTO ET AL.: ""A New Avain Erythroblastosis Virus, AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma."", CELL, vol. 34, 1983, pages 225 - 232;;NILSEN ET AL.: ""c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor"", CELL, vol. 41, 1985, pages 719 - 726;;GAMMETT ET AL.: ""Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes"", PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 6053 - 6057;;GILMORE ET AL.: ""Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro"", CELL, vol. 40, 1985, pages 609 - 618;;KRIS ET AL.: ""Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein"", CELL, vol. 40, 1985, pages 619 - 625;;NILSEN ET AL.: ""c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor."", CELL, vol. 41, 1985, pages 719 - 726;;GAMMETT ET AL.: ""Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes."", PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 6053 - 6057;;RAINES ET AL.: ""c-erbB Activation in Avian Leukosis Virus-Induced Erythroblastosis: Clustered Integration Sites and the Arrangement of Provirus in the c-erbB Alleles"", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 2287 - 2291;;PELLEY ET AL.: ""Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication--Competent Retrovirus Containing the Activated c-erbB."", JOURNAL OF VIROLOGY, vol. 62, 1988, pages 1840 - 1844;;WELLS ET AL.: ""Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB"", PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 7597 - 7601;;YAMAZAKI ET AL.: ""Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin."", NATURE, vol. 313, 1985, pages 144 - 147;;HUMPHREY ET AL.: ""Amplification and Expression of the,Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts."", CANCER RESEARCH, vol. 48, 1988, pages 2231 - 2238;;BIGNER ET AL., J. NEUROPATHOL. EXP. NEUROL., vol. 47, 1988, pages 191 - 205;;HUMPHREY ET AL.: ""Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts"", CANCER RES., vol. 48, no. 8, 1988, pages 2231 - 8;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy"", ENDOCR RELAT CANCER., vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;KUAN ET AL.: ""EGF mutant receptor vIII as a molecular target in cancer therapy."", ENDOCR RELAT CANCER., vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;WIKSTRAND, CJ. ET AL.: ""Monoclonal antibodies against EGFR,,III are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148;;OLAPADE-OLAOPA, EO. ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer."", BR J CANCER., vol. 82, no. 1, 2000, pages 186 - 94, XP055333157, DOI: doi:10.1054/bjoc.1999.0898;;WIKSTRAND, CJ. ET AL.: ""Monoclonal antibodies against EGFR II are tumor specific and react with breast and lung carcinomas malignant gliomas."", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148, XP002074673;;GE H. ET AL.: ""Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis."", INT J CANCER., vol. 98, no. 3, 2002, pages 357 - 61, XP002967805, DOI: doi:10.1002/ijc.10224;;WIKSTRAND, CJ. ET AL.: ""Monoclonal antibodies against EGFR III are tumor specific and react with breast and lung carcinomas malignant gliomas."", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148;;MOSCATELLO, G. ET AL.: ""Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors"", CANCER RES., vol. 55, no. 23, 1995, pages 5536 - 9, XP002943271;;GARCIA DE PALAZZO, IE. ET AL.: ""Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas."", CANCER RES., vol. 53, no. 14, 1993, pages 3217 - 20, XP002153548;;OLAPADE-OLAOPA, EO. ET AL.: ""Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer."", BR J CANCER, vol. 82, no. 1, 2000, pages 186 - 94, XP055333157, DOI: doi:10.1054/bjoc.1999.0898;;LUO ET AL., INT. J. CANCER., vol. 104, no. 6, 2003, pages 716 - 21;;KUAN ET AL.: ""EGFRvIII as a promising target for antibody-based brain tumor therapy."", BRAIN TUMOR PATHOL., vol. 17, no. 2, 2000, pages 71 - 78, XP001016320;;KUAN ET AL.: ""Increased binding affmity enhances targeting of glioma xenografts by EGFRvHI-specific scFv."", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 6, 2000, pages 962 - 969;;LANDRY ET AL.: ""Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII"", JOURNAL OF MOLECULAR BIOLOGY, vol. 308, no. 5, 2001, pages 883 - 893, XP004466169, DOI: doi:10.1006/jmbi.2001.4628;;REIST ET AL.: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate"", NUCLEAR MEDICINE AND BIOLOGY., vol. 26, no. 4, 1999, pages 405 - 411, XP004167074, DOI: doi:10.1016/S0969-8051(98)00120-6;;REIST ET AL.: ""In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIIImonoclonal antibody: comparison with its murine parent"", NUCLEAR MEDICINE AND BIOLOGY., vol. 24, no. 7, 1997, pages 639 - 647, XP004092552, DOI: doi:10.1016/S0969-8051(97)00080-2;;WIKSTRAND ET AL.: ""Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system."", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 50, no. 12, 2002, pages 639 - 652;;WIKSTRAND ET AL.: ""Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas malignant gliomas"", CANCER RESEARCH, vol. 55, no. 14, 1995, pages 3140 - 3148, XP002074673;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFR III): characterization and utilization as an immunotherapeutic target."", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158;;WIKSTRAND ET AL.: ""The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target."", J.NEUROVIROL., vol. 4, no. 2, 1998, pages 148 - 158, XP055000817, DOI: doi:10.3109/13550289809114515;;JUNGBLUTH ET AL.: ""A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor"", PROC NATL ACAD SCI U S A., vol. 100, no. 2, 2003, pages 639 - 44;;MAMOT ET AL.: ""Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells."", CANCER RESEARCH, vol. 63, 2003, pages 3154 - 3161, XP002509423;;KUAN ET AL.: ""EGF mutant receptor vin as a molecular target in cancer therapy."", ENDOCR RELAT CANCER., vol. 8, no. 2, 2001, pages 83 - 96, XP001022539, DOI: doi:10.1677/erc.0.0080083;;MENDEZ ET AL.: ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice."", NAT GENET., vol. L5, no. 2, 1997, pages 146 - 56, XP002918152, DOI: doi:10.1038/ng0297-146;;YANG X ET AL.: ""Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy."", CRIT REV ONCOL HEMATO, vol. 38, no. 1, 2001, pages 17 - 23, XP002330089, DOI: doi:10.1016/S1040-8428(00)00134-7;;YANG X-D ET AL.: ""Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy"", CANCER RESEARCH, vol. 59, no. 6, 1999, pages 1236 - 1243;;BABCOOK ET AL.: ""A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities"", PROC NATL ACAD SCI U S A., vol. 93, no. 15, 1996, pages 7843 - 8, XP000608647, DOI: doi:10.1073/pnas.93.15.7843;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual, 2nd ed."", 1989, COLD SPRING HARBOR LABORATORY PRESS;;LAPLANCHE ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 9081;;STEC ET AL., J. AM. CHEM. SOC., vol. 106, 1984, pages 6077;;STEIN ET AL., NUCL. ACIDS RES., vol. 16, 1988, pages 3209;;ZON ET AL., ANTICANCER DRUG DESIGN, vol. 6, 1991, pages 539;;ZON ET AL.: ""Oligonucleotides and Analogues: A Practical Approach"", 1991, OXFORD UNIVERSITY PRESS, pages: 87 - 108;;UHLMANN; PEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543;;DAYHOFF, M.O.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1972, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 101 - 110;;SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. (US.A.), vol. 85, 1988, pages 2444;;E.S. GOLUB AND D.R. GREN: ""Immunology - A Synthesis"", 1991, SINAUER ASSOCIATES;;BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164;;CREIGHTON: ""Proteins, Structures and Molecular Principles"", 1984, W. H. FREEMAN AND COMPANY;;C. BRANDEN AND J. TOOZE: ""Introduction to Protein Structure"", 1991, GARLAND PUBLISHING;;THORNTON, NATURE, vol. 354, 1991, pages 105;;FAUCHERE, J. ADV. DRUG RES., vol. 15, 1986, pages 29;;VEBER; FREIDINGER, TINS, 1985, pages 392;;EVANS ET AL., J. MED. CHERN., vol. 30, 1987, pages 1229;;RIZO; GIERASCH, ANN. REV. BIOCHEM., vol. 61, 1992, pages 387;;PARKER, S.: ""The McGraw-Hill Dictionary of Chemical Terms"", 1985, MCGRAW-HILL;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. I93, 1996, pages 7843 - 7848;;PAUL, W.: ""Fundamental Immunology, 2nd ed."", 1989, RAVEN PRESS, article ""Ch.7"";;KABAT: ""Sequences of Proteins of Inanaunological Interest"", 1987, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL, vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;BROOKS, B. R.; BRUCCOLERI, R. E.; OLAFSON, B. D.; STATES, D. J.; SWAMINATHAN, S.; KARPLUS, M., J. COMP. CHEM, vol. 4, 1983, pages 187;;GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;GREEN; JAKOBOVITS, J. EXP. MED., vol. 188, 1998, pages 483 - 495;;FANGER ET AL., IMMUNOL METHODS, vol. 4, 1994, pages 72 - 81;;TRAUNECKER ET AL., INT. J CANCER, vol. 7, 1992, pages 51 - 52;;VALERIUS, BLOOD, vol. 90, 1997, pages 4485 - 4492;;VITETTA, IMMUNOL TODAY, vol. 14, 1993, pages 252;;JUNGHANS ET AL.: ""Cancer Chemotherapy and Biotherapy, 2nd ed."", 1996, LIPPINCOTT RAVEN, pages: 655 - 686;;SELA ET AL.: ""Immunoconjugates"", 1987, pages: 189 - 216;;GHOSE ET AL.: ""Targeted Drugs"", 1983, pages: 1 - 22;;DIENER ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 1 - 23;;PIETERSZ ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 25 - 53;;BUMOL ET AL.: ""Antibody Mediated Delivery Systems"", 1988, pages: 55 - 79;;GARNETT ET AL., CANCER RES., vol. 46, 1986, pages 2407 - 2412;;OHKAWA ET AL., CANCER IMMUMOL. IMMUNOTHER., vol. 23, 1986, pages 81 - 86;;ENDO ET AL., CANCER RES., vol. 47, 1980, pages 1076 - 1080;;HURWITZ ET AL., APPL. BIOCHEM., vol. 2, 1980, pages 25 - 35;;MANABI ET AL., BIOCHEM. PHARMACOL, vol. 34, 1985, pages 289 - 291;;DILLMAN ET AL., CANCER RES., vol. 46, 1986, pages 4886 - 4891;;SHOVAL ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 8276 - 8280;;TSUKADA ET AL., J. NATL. CANC. INST, vol. 73, 1984, pages 721 - 729;;KATO ET AL., J. MED. CHEM., vol. 27, 1984, pages 1602 - 1607;;TSUKADA ET AL., BR. J. CANCER, vol. 52, 1985, pages 111 - 116;;BIOCHEM. BIOPHYS. RES. COMMUN, vol. 102, 1981, pages 1048 - 1054;;J. NATL. CANC. INST, vol. 80, 1988, pages 1154 - 1159;;CANCER RES., vol. 48, 1988, pages 6097 - 6102;;PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 626 - 629;;LAMBERT ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 12035 - 12041;;LAMBERT ET AL.: ""Immunotoxins"", 1988, pages: 175 - 209;;GHETIE ET AL., CANCER RES., vol. 48, 1988, pages 2610 - 2617;;J. BIOL. CHEM., vol. 260, 1985, pages 10905 - 10908;;MENENDEZ ET AL., FOURTH INTERNATIONAL CONFERENCE ON MONOCLONAL ANTIBODY IMMUNOCONJUGATES FOR CANCER, 1989;;HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342;;KUPCHAN ET AL., J. MED. CHEM., vol. 21, 1978, pages 31 - 37;;HIGASHIDE ET AL., NATURE, vol. 270, 1977, pages 721 - 722;;KAWAI ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 3441 - 3451;;CHEM. PHARM. BULL., vol. 12, 1984, pages 3441;;SIEBER ET AL., COMPARATIVE LEUKEMIA RESEARCH 1975, BIBL. HAEMAT., vol. 43, 1976, pages 495 - 500;;REMILLARD ET AL., SCIENCE, vol. 189, 1975, pages 1002 - 1005;;WOLPERT-DEFILLIPPES ET AL., BIOCHEM. PHARMACOL, vol. 24, 1975, pages 1735 - 1738;;KUPCHAN, PED. PROC., vol. 33, 1974, pages 2288 - 2295;;CARLSSON ET AL., BIOCHEM. J., vol. 173, 1978, pages 723 - 737;;PETTIT ET AL.: ""Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications"", ANTICANCER DRUG DES., vol. 10, no. 7, 1995, pages 529 - 44;;WOYKE ET AL.: ""In vitro activities and postantifungal effects of the potent dolastatin 10 structural modification auristatin PHE."", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, 2001, pages 3580 - 3584;;PETTIT ET AL.: ""Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans."", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY., vol. 42, 1998, pages 2961 - 2965;;DORONINA ET AL.: ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy."", NATURE BIOTECHNOLOGY, 2003;;FRANCISCO ET AL.: ""cAC10-VCMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;FRANCISCO ET AL.: ""cAC 10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;FRANCISCO ET AL.: ""cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity"", BLOOD, 24 April 2003 (2003-04-24);;KING ET AL.: ""Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains"", J MED CHEM., vol. 45, no. 19, 2002, pages 4336 - 43, XP001193748, DOI: doi:10.1021/jm020149g;;DUBOWCHIK ET AL.: ""Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin"", BIOORG MED CHEM LETT., vol. 8, no. 23, 1998, pages 3347 - 52, XP004143756, DOI: doi:10.1016/S0960-894X(98)00610-6;;MAYER, A.M.S.: ""Marine Pharmacology in 1998: Antitumor and Cytotoxic Compounds"", THE PHARMACOLOGIST, vol. 41, no. 4, 1999, pages 159 - 164;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING COMPANY;;LANGER ET AL., J BIOMED MATER. RES., vol. 15, 1981, pages 167 - 277;;LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105;;SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 - 3692;;HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 - 4034;;BLOCK; LAWRENCE: ""Remington's Pharmaceutical Sciences, 18th ed."", 1990, MACK PUBLISHING COMPANY;;BALDRICK P.: ""Pharmaceutical excipient development: the need for preclinical guidance"", REGUL. TOXICOL. PHARMACAL., vol. 32, 2000, pages 210 - 8;;WANG W.: ""Lyophilization and development of solid protein pharmaceuticals"", INT. J. PHARM., vol. 203, no. 1-2, 2000, pages 1 - 60, XP002428586, DOI: doi:10.1016/S0378-5173(00)00423-3;;CHARMAN WN: ""Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts"", J PHARM SCI ., vol. 89, no. 8, 2000, pages 967 - 78, XP008099512;;POWELL ET AL.: ""Compendium of excipients for parenteral formulations"", PDA J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311, XP009119027;;WIKSTRAND ET AL., J NEUROVIROL, vol. 4, no. 2, 1998, pages 148 - 58;;YANG ET AL., CRIT REV ONCOL HEMATOL., vol. 38, no. 1, 2001, pages 17 - 23;;KEARNEY ET AL., J. IMMUNOL., vol. 123, 1979, pages 1548 - 1550;;BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7843 - 7848;;BATRA ET AL.: ""Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene"", CELL GROWTH DIFFER., vol. 6, no. 10, 1995, pages 1251 - 9, XP055367769;;JOHNS ET AL., INT. J. CANCER., vol. 98, 2002, pages 398;;CHEN, Y ET AL., J MOL BIOL., vol. 293, no. 4, 1999, pages 865 - 81;;J. MOL. BIOL., vol. 196, no. 4, 20 August 1987 (1987-08-20), pages 901 - 17;;CHOTHIA ET AL., NATURE, vol. 342, no. 6252, 21 December 1989 (1989-12-21), pages 877 - 83;;MARTIN ET AL., J MOL BIOL., vol. 263, no. 5, 15 November 1996 (1996-11-15), pages 800 - 15",ACTIVE
212,JP,A,JP 2014113150 A,149-874-915-894-710,2014-06-26,2014,JP 2013272028 A,2013-12-27,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES THAT RECOGNIZE DELETION MUTANT OF EPIDERMAL GROWTH FACTOR RECEPTOR AND THEIR USE,"PROBLEM TO BE SOLVED: To provide a tumor specific molecule that recognizes deletion mutants of epidermal growth factor receptor (EGFR) for better diagnosis and treatment of human and animal cancer.SOLUTION: Provided is an isolated human monoclonal antibody that specifically binds to a deletion mutant of EGFR, especially, to type III deletion mutant(EGFRvIII) and peptides including LEEKKGNYVVTDHC sequence. Also provided is a therapeutic agent for cancer associated with epidermal cell growth, using the antibody to which a toxin is combined. Also provided are a method for inhibiting cell growth related to expression of EGFRvIII, and a method for treating mammals including humans suffering from cancer associated with epidermal cell growth by using the antibody.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/149-874-915-894-710,Patent Application,no,1,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C12N15/09;;A61K39/395;;A61K47/48;;A61P35/00;;A61P43/00;;C07K14/715;;C07K14/82;;C07K16/22;;C07K16/28;;C07K16/30;;C07K16/46;;C07K17/00;;C12N/;;C12N5/06;;C12N5/10;;C12N15/02;;C12P21/08;;G01N33/50;;G01N33/53;;G01N33/532;;G01N33/574;;G01N33/577,,5,1,033-261-430-402-230,1560463;;10.1016/0022-2836(92)91010-m,"CANCER RES., vol. 55, no. 14, JPN6010025376, 15 July 1995 (1995-07-15), pages 3140 - 3148, ISSN: 0003051684;;BRAIN TUMOR PATHOL., vol. 17, no. 2, JPN6010025377, 2000, pages 71 - 78, ISSN: 0003051685;;CRIT. REV. ONCOL. HEMATOL., vol. 38, no. 1, JPN6010025378, April 2001 (2001-04-01), pages 17 - 23, ISSN: 0003051686;;CLIN. CANCER RES., vol. 1, no. 8, JPN6010025379, August 1995 (1995-08-01), pages 859 - 864, ISSN: 0003051687;;""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops"", JOURNAL OF MOLECULAR BIOLOGY, vol. 224, no. 2, JPN7013003402, 1992, pages 487 - 499, ISSN: 0003051688",ACTIVE
213,WO,A1,WO 2013/019343 A1,002-337-633-132-81X,2013-02-07,2013,US 2012/0044459 W,2012-06-27,US 201113197750 A,2011-08-03,MOLYBDENUM COMPOSITE HYBRID LAMINATES AND METHODS,"In an embodiment of the disclosure, there is provided a molybdenum composite hybrid laminate. The laminate has a plurality of composite material layers. The laminate further has a plurality of surface treated molybdenum foil layers interweaved between the composite material layers. The laminate further has a plurality of adhesive layers disposed between and bonding adjacent layers of the composite material layers and the molybdenum foil layers.",BOEING CO;;MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,,https://lens.org/002-337-633-132-81X,Patent Application,yes,14,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B7/12;;B32B3/06;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,0,0,,,,PENDING
214,EP,B1,EP 2739466 B1,046-120-166-040-105,2019-02-06,2019,EP 12735384 A,2012-06-27,US 201113197750 A;;US 2012/0044459 W,2011-08-03,MOLYBDENUM COMPOSITE HYBRID LAMINATES AND METHODS,,BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,,https://lens.org/046-120-166-040-105,Granted Patent,yes,9,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/06;;B29C73/10;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B37/14,,0,0,,,,ACTIVE
215,US,A1,US 2009/0240038 A1,062-097-917-185-741,2009-09-24,2009,US 39631309 A,2009-03-02,US 39631309 A;;US 87777304 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/062-097-917-185-741,Patent Application,yes,69,29,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/18;;A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,530/391.7,0,0,,,,ACTIVE
216,US,B2,US 9090043 B2,095-683-061-249-697,2015-07-28,2015,US 201113197750 A,2011-08-03,US 201113197750 A,2011-08-03,Molybdenum composite hybrid laminates and methods,"In an embodiment of the disclosure, there is provided a molybdenum composite hybrid laminate. The laminate has a plurality of composite material layers. The laminate further has a plurality of surface treated molybdenum foil layers interweaved between the composite material layers. The laminate further has a plurality of adhesive layers disposed between and bonding adjacent layers of the composite material layers and the molybdenum foil layers.",MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A;;BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,THE BOEING COMPANY (2011-07-28),https://lens.org/095-683-061-249-697,Granted Patent,yes,18,9,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/00;;B32B7/00;;B32B3/06;;B32B3/14;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,1,0,,,"PCT International Search Report and Written Opinion of the International Searching Authority, Sep. 3, 2012, for corresponding International Application No. PCT/US2012/044459 of The Boeing Company, 9 pages.",ACTIVE
217,CA,C,CA 2841071 C,120-650-569-379-920,2016-01-12,2016,CA 2841071 A,2012-06-27,US 201113197750 A;;US 2012/0044459 W,2011-08-03,MOLYBDENUM COMPOSITE HYBRID LAMINATES AND METHODS,"In an embodiment of the disclosure, there is provided a molybdenum composite hybrid laminate. The laminate has a plurality of composite material layers. The laminate further has a plurality of surface treated molybdenum foil layers interweaved between the composite material layers. The laminate further has a plurality of adhesive layers disposed between and bonding adjacent layers of the composite material layers and the molybdenum foil layers.",BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,,https://lens.org/120-650-569-379-920,Granted Patent,no,0,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/06;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,0,0,,,,ACTIVE
218,US,A1,US 2009/0155282 A1,158-707-658-240-692,2009-06-18,2009,US 26835208 A,2008-11-10,US 26835208 A;;US 87777404 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/158-707-658-240-692,Patent Application,yes,69,41,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07H21/04;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/02;;C12N5/06;;G01N33/53,424/139.1;;435/375;;536/23.53,0,0,,,,ACTIVE
219,KR,A,KR 20120060788 A,016-056-361-170-130,2012-06-12,2012,KR 20117031662 A,2004-06-25,US 2004/0020295 W;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KLAKAMP SCOTT L;;RAYA ROBERT;;KANG JASPAL;;SU QIAOJUAN JANE;;KING CHADWICK T;;RATHANASWAMI PALANI,,https://lens.org/016-056-361-170-130,Patent Application,no,0,1,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
220,WO,A3,WO 2005/012479 A3,037-027-371-062-263,2006-10-12,2006,US 2004/0020564 W,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC;;WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/037-027-371-062-263,Search Report,yes,2,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K39/44;;A61K47/48;;C07H21/04;;C07K14/71;;C07K16/22;;C07K16/42;;C07K17/00;;C12N/;;C12N5/06;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,1,1,044-355-372-029-744,11255078;;10.1016/s1040-8428(00)00134-7,"YANG ET AL.: ""Development of ABX-EGF, a Fully Human Anti-EGF Receptor Monoclonal Antibody, for Cancer Therapy"", CRIT. REV. ONCOL/HEM., vol. 38, April 2001 (2001-04-01), pages 17 - 23, XP002963604",PENDING
221,AU,A1,AU 2010/219363 A1,025-387-516-034-962,2010-09-30,2010,AU 2010/219363 A,2010-09-09,AU 2004/260936 A;;AU 2010/219363 A;;US 2004/0020564 W;;US 56245304 P;;US 48314503 P;;US 52557003 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/025-387-516-034-962,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K14/71;;A61K39/395;;A61K39/44;;A61K47/48;;C07H21/04;;C07K16/22;;C07K16/28;;C07K16/42;;C07K17/00;;C12N/;;C12N5/06;;C12N5/12;;C12P21/08;;G01N33/53;;G01N33/552;;G01N33/577,,0,0,,,,DISCONTINUED
222,EP,B1,EP 3037105 B1,060-527-858-111-877,2021-03-17,2021,EP 15193917 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;EP 04777147 A;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/060-527-858-111-877,Granted Patent,yes,2,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,9,0,,,"WIKSTRAND C J ET AL: ""MONOCLONAL ANTIBODIES AGAINST EGFRVIII ARE TUMOR SPECIFIC AND REACT WITH BREAST AND LUNG CARCINOMAS AND MALIGNANT GLIOMAS"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 55, 15 July 1995 (1995-07-15), pages 3140-3148, XP002074673, ISSN: 0008-5472;;KUAN C-T ET AL: ""EGFRVLLL AS A PROMISING TARGET FOR ANTIBODY-BASED BRAIN TUMOR THERAPY"", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 17, no. 2, 1 January 2000 (2000-01-01), pages 71-78, XP001016320, ISSN: 0914-8108;;KUAN C-T: ""INCREASED BINDING AFFINITY ENHANCES TARGETING OF GLIOMA XENOGRAFTS BY EGFRVIII-SPECIFIC SCFV"", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 88, no. 6, 15 December 2000 (2000-12-15), pages 962-969, XP001024149, ISSN: 0020-7136, DOI: 10.1002/1097-0215(20001215)88:6<962::AID-I JC20>3.0.CO;2-U;;REIST C J ET AL: ""Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[<211>At]astato-3-pyridinecarboxylate - Preservation of immunoreactivity and in vivo localizing capacity"", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 26, no. 4, 1 May 1999 (1999-05-01), pages 405-411, XP004167074, ISSN: 0969-8051, DOI: 10.1016/S0969-8051(98)00120-6;;NEGRI D R ET AL: ""In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody"", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 72, no. 4, 1 October 1995 (1995-10-01), pages 928-933, XP002744679, ISSN: 0007-0920;;PEDERSEN M W ET AL: ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO JUN 2001, vol. 12, no. 6, June 2001 (2001-06), pages 745-760, XP002524201, ISSN: 0923-7534;;YANG X-D ET AL: ""Development of ABX-EGF, a full human anti-EGF receptor monoclonal antibody, for cancer therapy"", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 38, no. 1, 1 April 2001 (2001-04-01), pages 17-23, XP002963604, ISSN: 1040-8428;;SAMPSON J H ET AL: ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20 JUN 2000, vol. 97, no. 13, 20 June 2000 (2000-06-20) , pages 7503-7508, XP002524204, ISSN: 0027-8424;;HUMPHREY P A ET AL: ""ANTI-SYNTHETIC PEPTIDE ANTIBODY REACTING AT THE FUSION JUNCTION OF DELETION-MUTANT EPIDERMAL GROWTH FACTOR RECEPTORS IN HUMAN GLIOBLASTOMA"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 87, no. 11, 1 June 1990 (1990-06-01), pages 4207-4211, XP000133024, ISSN: 0027-8424",ACTIVE
223,KR,A,KR 20060054203 A,080-247-856-060-614,2006-05-22,2006,KR 20057024883 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020564 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",ABGENIX INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/080-247-856-060-614,Patent Application,no,0,1,84,87,288,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/18;;A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,ACTIVE
224,AU,B2,AU 2011/265359 B2,113-761-266-825-127,2014-03-06,2014,AU 2011/265359 A,2011-12-20,AU 2004/259398 A;;AU 2011/265359 A,2004-06-25,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"C \NRPonblDCC\RR\4)550A4_l DOC.15/12/2011 This invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion 5 mutant, EGFRvIII. The embodiments also relate to human monoclonal antibodies directed against deletion mutants of epidermal growth factor and particularly to EGFRvIII. The embodiments also relate to variants of such antibodies. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,KEYT BARRY;;KING CHADWICK T;;FOLTZ IAN;;KANG JASPAL;;GUDAS JEAN;;CORVALAN JOSE;;GREEN LARRY;;FOORD ORIT;;RATHANASWAMI PALANI;;SU QIAOJUAN JANE;;WEBER RICHARD;;RAYA ROBERT;;KLAKAMP SCOTT L;;FENG XIAO;;YANG XIAO DONG;;JIA XIAO-CHI;;LIU YING,,https://lens.org/113-761-266-825-127,Granted Patent,no,1,0,3,3,0,,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;G01N33/53,,0,0,,,,ACTIVE
225,KR,A,KR 20130083463 A,174-580-931-574-699,2013-07-22,2013,KR 20137014050 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P;;US 2004/0020295 W,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KLAKAMP SCOTT L;;RAYA ROBERT;;KANG JASPAL;;SU QIAOJUAN JANE;;KING CHADWICK T;;RATHANASWAMI PALANI,,https://lens.org/174-580-931-574-699,Patent Application,no,0,0,84,87,252,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,DISCONTINUED
226,CN,A,CN 103842168 A,025-430-045-734-989,2014-06-04,2014,CN 201280048832 A,2012-06-27,US 2012/0044459 W;;US 201113197750 A,2011-08-03,Molybdenum Composite Hybrid Laminates and Methods,"In an embodiment of the disclosure, there is provided a molybdenum composite hybrid laminate. The laminate has a plurality of composite material layers. The laminate further has a plurality of surface treated molybdenum foil layers interweaved between the composite material layers. The laminate further has a plurality of adhesive layers disposed between and bonding adjacent layers of the composite material layers and the molybdenum foil layers.",BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GAEGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,,https://lens.org/025-430-045-734-989,Patent Application,no,4,1,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/06;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,0,0,,,,ACTIVE
227,US,B2,US 9862175 B2,027-072-516-039-68X,2018-01-09,2018,US 201514795209 A,2015-07-09,US 201514795209 A;;US 201113197750 A,2011-08-03,Molybdenum composite hybrid laminates and methods,A method of forming a molybdenum composite hybrid laminate is disclosed. The method includes treating a surface of each of a plurality of molybdenum foil layers. The method further includes interweaving the surface treated molybdenum foil layers with a plurality of composite material layers. The method further includes bonding with an adhesive layer each of the surface treated molybdenum foil layers to adjacent composite material layers to form a molybdenum composite hybrid laminate having improved yield strength.,BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,THE BOEING COMPANY (2015-07-01),https://lens.org/027-072-516-039-68X,Granted Patent,yes,20,1,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B37/00;;B29C73/10;;B32B3/06;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00;;B32B37/14,,3,0,,,"European Patent Office Examination Report and Office Action, dated Feb. 22, 2017, for counterpart EP Application No. 12735384.5, The Boeing Company, 4 pages.;;PCT International Search Report and Written Opinion of the International Searching Authority, dated Sep. 3, 2012, 9 pages, for related corresponding International Application No. PCT/US2012/044459 of The Boeing Company, of related parent U.S. Appl. No. 13/197,750.;;Japanese Patent Office Action, Notice of Reasons for Rejection (English Version and Japanese Version), dated Jul. 26, 2016, for related Japanese Application No. 2014-523935, The Boeing Company, 6 pages.",ACTIVE
228,US,B2,US 7736644 B2,079-091-561-862-245,2010-06-15,2010,US 87777404 A,2004-06-25,US 87777404 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/079-091-561-862-245,Granted Patent,yes,58,62,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/00;;A61K39/395;;A61K47/48;;C07K16/00;;C07K16/18;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;C12P21/08;;G01N33/53,424/130.1;;424/142.1;;424/143.1;;424/178.1;;424/181.1;;424/183.1;;435/70.21;;435/810;;530/387.1;;530/388.1;;530/388.15;;530/388.22;;530/391.7,102,75,165-322-209-862-791;;055-904-468-981-551;;103-755-269-224-85X;;112-409-472-179-059;;077-163-323-456-652;;087-448-981-335-707;;067-782-603-238-967;;064-678-224-734-734;;024-995-475-936-443;;050-646-523-937-465;;013-447-454-196-187;;125-735-714-799-644;;004-272-966-072-139;;045-751-499-875-041;;112-312-727-891-46X;;145-103-363-875-640;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;033-688-911-017-272;;008-822-347-989-692;;053-206-529-796-448;;033-509-048-623-004;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;003-420-832-784-996;;040-622-347-677-457;;025-279-035-199-960;;002-538-287-083-621;;124-275-393-571-41X;;087-103-148-426-023;;136-926-314-202-897;;112-409-472-179-059;;016-219-576-017-946;;067-857-455-571-760;;043-637-817-489-241;;028-036-828-526-370;;064-075-380-054-48X;;150-632-545-202-265;;154-572-677-438-265;;045-904-151-504-498;;072-377-861-372-36X;;004-986-447-228-415;;029-269-446-589-556;;111-679-382-231-89X;;087-806-501-008-318;;093-272-820-060-870;;054-354-046-619-106;;004-517-823-944-609;;090-683-249-679-734;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;049-182-911-054-623;;027-389-935-773-753;;032-441-846-127-844;;006-301-071-808-697;;044-355-372-029-744;;073-659-966-706-479;;053-206-529-796-448;;045-082-353-678-357;;085-084-648-067-30X;;021-799-621-392-61X;;041-969-682-554-154;;165-322-209-862-791;;055-904-468-981-551;;021-799-621-392-61X,2005389;;10.4049/jimmunol.146.6.2017;;10.1002/jmr.679;;15227640;;2285602;;10.1016/0960-0760(90)90438-q;;2103507;;10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#;;9506533;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;8845302;;3367154;;10.1097/00005072-198805000-00001;;10.1038/342877a0;;2687698;;10.1016/s0167-5699(97)01007-4;;9078685;;3262420;;2428468;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;9873732;;10.1016/s0960-894x(98)00610-6;;3802092;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;3258189;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1021/jm00378a013;;6209394;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11352579;;10.1006/jmbi.2001.4628;;10.1038/313144a0;;2981413;;10.1002/ijc.11007;;12640678;;2834047;;12810643;;10.1016/0006-2952(85)90140-6;;2578281;;8947577;;10.1006/jmbi.1996.0617;;2103507;;10.1038/ng0297-146;;9020839;;21566922;;10.3892/ijo.4.2.277;;7585629;;10.1016/s0092-8674(85)80052-0;;2988784;;2430705;;10.1007/bf00199811;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;6206272;;10.1093/jnci/73.3.721;;10.1038/309418a0;;6328312;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1016/0092-8674(83)90153-8;;6309409;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;3261803;;10.1093/jnci/80.14.1154;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;12515857;;10.1073/pnas.232686499;;pmc141049;;pmc16575;;10.1073/pnas.130166597;;10852962;;12648464;;10.1016/s0014-4827(02)00098-8;;11454674;;10.1002/ijc.10189;;11920591;;2005389;;10.4049/jimmunol.146.6.2017;;10.1002/jmr.679;;15227640;;11454674,"Janway et al, p. 3:1-3:3, in Immunobiology, 1994.;;Kobrin et al, J Immunology 146: 2017-2020, 1991.;;Barrios et al, J Molecular Recognition 17: 332-338, 2004.;;Mendelsohn, Cancer Cells 7:359 (1989).;;Mendelsohn, ""Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents"", J Steroid Biochem Mol Biol, Dec. 20, 1990; 37 (6):889-92.;;Mendelsohn, The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies, Semin Cancer Biol, Oct. 1990; 1(5):339-44.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;Schmidt et al., Expression of an Oncogenic Mutant EGF Receptor Markedly Increases The Sensitivity of Cells to an EGF-Receptor-Specific Antibody-Toxin, Int. J. Cancer, 75, 878-884 (Mar. 16, 1998).;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati, et al.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovits et al.;;Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):7843-8 (1996).;;Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6(10):1251-9 (1995).;;Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.;;Burnol et al, in Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).;;Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).;;Deo et al. Immunology Today (1997) 18:127.;;Diener et al, in Antibody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).;;Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.;;Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.;;Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.;;Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence. Nature (1984) 307:521-527.;;Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. (1998) 8(23):3347-52.;;Endo et al. Cancer Res. (1980) 47:1076-1080.;;Francisco et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.;;Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).;;Garcia de Palazzo, IE. et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 53(14):3217-20 (1993).;;Garnett et al. Cancer Res. 46:2407-2412 (1986).;;Ge H. et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98(3):357-61 (2002).;;Ghose et al, in Targeted Drugs 1-22 (E. Goldberg, ed. 1983).;;Gilmore et al., (1985). Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro. Cell 40:609-618.;;Green and Jakobovits J. Exp. Med. 188:483-495 (1998).;;Humphrey et al., (1988). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.;;Hurwitz et al. Appl. Biochem. 2:25-35 (1980).;;Jungbluth et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 100(2):639-44 (2003).;;Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996).;;Kato et al. J. Med. Chem. 27:1602-1607 (1984).;;Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.;;Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 8(2):83-96 (2001).;;Kuan et al. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 17(2):71-78 (2000).;;Kuan et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. 88(6):962-969 (2000).;;Lambert et al. in Immunotoxins 175-209 (A. Frankel, ed. 1988).;;Lambert et al. J. Biol. Chem. 260:12035-12041 (1985).;;Landry et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. Journal of Molecular Biology. 308(5):883-893 (2001).;;Libermann et al. (1985). Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 313:144-147.;;Luo et al. Int. J. Cancer. 104(6):716-21 (2003).;;Malden et al., (1988). Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme. Cancer Research 4:2711-2714.;;Mamot et al. Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells. Cancer Research 63:3154-3161 (2003).;;Manabe et al. Biochem. Pharmacol. 34 : 289-291 (1985).;;Martin, et al. J Mol Biol. Nov. 15, 1996;263(5):800-15.;;Mendelsohn J., The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol Oct. 1990;1(5):339-344.;;Mendez et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 15(2):146-56 (1997).;;Modjtahedi and Dean Int'l J. Oncology 4:277-296 (1994).;;Moscatello, G. et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55(23):5536-9 (1995).;;Nilsen et al., (1985). c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor. Cell 41:719-726.;;Ohkawa et al. Cancer Immumol. Immunother. 23:81-86 (1986).;;Olapade-Olaopa, EO. et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 82(1):186-94 (2000).;;Pelley et al., (1988). Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication-Competent Retrovirus Containing the Activated c-erbB. Journal of Virology 62: 1840-1844.;;Pietersz et al, in Antibody Mediated Delivery Systems 25-53 (J. Rodwell, ed. 1988).;;Reist et al. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nuclear Medicine and Biology. 26(4):405-411 (1999).;;Reist et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvlll monoclonal antibody: comparison with its murine parent. Nuclear Medicine and Biology. 24(7):639-647 (1997).;;Sela et al. in Immunoconjugates 189-216 (C. Vogel, ed. 1987).;;Shouval et al. Proc. Natl. Acad. Sci. 85: 8276-8280 (1988).;;Trouet et al. Proc. Natl. Acad. Sci. 79: 626-629 (1982).;;Tsukada et al. Br. J. Cancer 52:111-116 (1985).;;Tsukada et al. J. Natl. Canc. Inst. 73:721-729 (1984).;;Ullrich et al. (1984). Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells. Nature 309:418-425.;;Valerius et al. Blood 90:4485-4492 (1997).;;Vitetta et al. Immunotoxins: magic bullets or misguided missiles? Immunol Today 14:252 (1993).;;Wells et al., (1988). Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB. Proc. Natl. Acad. Sci. USA 85:7597-7601.;;Wikstrand et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunology, Immunotherapy. 50(12):639-652 (2002).;;Wikstrand et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas malignant gliomas. Cancer Research. 55(14):3140-3148 (1995).;;Wikstrand et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J.Neurovirol. 4(2):148-158 (1998).;;Wong et al. (1987). Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification. Proc. Natl. Acad. Sci. USA 84:6899-6903.;;Yamamoto et al., (1983). A New Avain Erythroblastosis Virus, AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma. Cell 34:225-232.;;Yamazaki et al. (1988). Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors. Molecular and Cellular Biology 8:1816-1820.;;Yang and Reisfeld. J. Natl. Canc. Inst. 80:1154-1159 (1988).;;Yang X et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hemato 38(1):17-23 (2001).;;Yang X-D et al. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. Cancer Research 59(6):1236-1243 (1999).;;Green et al. ""Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates"" American Association for Cancer Research Annual Meeting, Mar. 2004.;;Jungbluth et al. ""A monoclonal antibody recognizing human cancers with amplification / overexpression of the human epidermal growth factor receptor"" Proc Nat Acad Sci 100(2): 639-644, Jan. 2003.;;Sampson et al. ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors"" Proc Nat Acad Sci 97(13): 7503-7508, Jun. 2000.;;Jorissen et al. ""Epidermal growth factor receptor: mechanisms of activation and signaling"" Experimental Cell Research 284 (2003) 31-53.;;Luwor et al. Monoclonal Antibody 806 Inhibits the Grownth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR.;;Johns et al. ""Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene"" Int J Cancer 98: 398-408 (2002).;;Kobrin et al. ""A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding"" J Immunol 146(6): 2017-2020, Mar. 1991.;;Barrios et al. ""Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor"" J Mol Recognit 17: 332-338 (2004).;;Examiner's First Report on Australian Patent Application No. 2004260936, dated Aug. 25, 2008, in 2 pages.;;Luwor et al. Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR Cancer research 61: 5355-5561, 2001.;;Doronnina et al. Nature Biteochnology, Jul. 2003, 21(7): 784, 941.",ACTIVE
229,US,A1,US 2015/0306859 A1,112-115-305-365-15X,2015-10-29,2015,US 201514795209 A,2015-07-09,US 201514795209 A;;US 201113197750 A,2011-08-03,MOLYBDENUM COMPOSITE HYBRID LAMINATES AND METHODS,A method of forming a molybdenum composite hybrid laminate is disclosed. The method includes treating a surface of each of a plurality of molybdenum foil layers. The method further includes interweaving the surface treated molybdenum foil layers with a plurality of composite material layers. The method further includes bonding with an adhesive layer each of the surface treated molybdenum foil layers to adjacent composite material layers to form a molybdenum composite hybrid laminate having improved yield strength.,BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,THE BOEING COMPANY (2015-07-01),https://lens.org/112-115-305-365-15X,Patent Application,yes,2,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B7/12;;B32B37/14;;B32B15/08,,0,0,,,,ACTIVE
230,BR,B1,BR 112014002438 B1,103-232-030-276-356,2020-07-28,2020,BR 112014002438 A,2012-06-27,US 2012/0044459 W;;US 201113197750 A,2011-08-03,laminado híbrido compósitos de molibdênio e método de formação de um laminado híbrido compósito de molibdênio,"laminados híbridos compósitos de molibdênio e métodos. a presente invenção refere-se a um laminado híbrido compósito de molibdênio. o laminado tem uma pluralidade de camadas de material compósito. o laminado tem, ainda, uma pluralidade de camadas de folha de molibdênio de superfície tratada entrelaçadas entre as camadas de material compósito. o laminado tem, ainda, uma pluralidade de camadas adesivas dispostas entre e ligando camadas adjacentes das camadas de material compósito e as camadas de folha de molibdênio.",BOEING CO,ALAN EDGAR LANDMANN;;GEOFFREY A BUTLER;;GREGORY ALAN FOLTZ;;JOHN MARK GARDNER;;KAY Y BLOHOWIAK;;LIAM S CAVANAUGH PINGREE;;MARC J PIEHL;;MARC R MATSEN;;MARK A NEGLEY;;RICHARD H BOSSI;;ROBERT A ANDERSON;;ROBERT L CARLSEN;;STEPHEN G MOORE,,https://lens.org/103-232-030-276-356,Granted Patent,no,0,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/06;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,0,0,,,,ACTIVE
231,US,A1,US 2010/0111979 A1,134-208-544-309-236,2010-05-06,2010,US 64917909 A,2009-12-29,US 64917909 A;;US 39631309 A;;US 87777304 A;;US 56245304 P;;US 52557003 P;;US 48314503 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/134-208-544-309-236,Patent Application,yes,63,46,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/18;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/02;;C12N5/06;;G01N33/53,424/183.1;;530/391.7;;435/375,3,3,027-214-641-693-526;;055-904-468-981-551;;013-142-717-038-23X,10.1093/oxfordjournals.jbchem.a003254;;12359067;;10.1002/jmr.679;;15227640;;10556035;;10.1006/jmbi.1999.3141,"Kala et al., J Biochem 132: 535-514, 2002.;;Barrios et al., J Molecular Recognition 17: 332-338, 2004.;;Wu et al., J. Mol. Biol. 294: 151-162, 1999.",ACTIVE
232,US,B2,US 9062113 B2,147-023-719-348-829,2015-06-23,2015,US 26836308 A,2008-11-10,US 26836308 A;;US 87777404 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/147-023-719-348-829,Granted Patent,yes,107,7,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C12P21/08;;A61K39/00;;A61K39/395;;A61K47/48;;B82Y5/00;;C07K14/705;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,99,48,087-448-981-335-707;;055-904-468-981-551;;067-782-603-238-967;;064-678-224-734-734;;024-995-475-936-443;;050-646-523-937-465;;125-735-714-799-644;;013-447-454-196-187;;004-272-966-072-139;;045-751-499-875-041;;112-312-727-891-46X;;145-103-363-875-640;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;165-322-209-862-791;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;003-420-832-784-996;;040-622-347-677-457;;030-080-528-694-129;;115-935-599-414-721;;016-435-611-136-112;;037-531-283-684-284;;025-279-035-199-960;;021-799-621-392-61X;;002-538-287-083-621;;124-275-393-571-41X;;087-103-148-426-023;;017-985-977-936-133;;042-601-433-468-58X;;033-261-430-402-230;;027-477-313-726-928;;038-495-237-294-69X;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;033-688-911-017-272;;008-822-347-989-692;;128-683-050-479-273;;041-969-682-554-154;;085-084-648-067-30X;;053-206-529-796-448,8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/jmr.679;;15227640;;8845302;;3367154;;10.1097/00005072-198805000-00001;;10.1038/342877a0;;2687698;;10.1016/s0167-5699(97)01007-4;;9078685;;2428468;;3262420;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;9873732;;10.1016/s0960-894x(98)00610-6;;3802092;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;2005389;;10.4049/jimmunol.146.6.2017;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11352579;;10.1006/jmbi.2001.4628;;10.1038/313144a0;;2981413;;3017977;;10.1016/s0021-9258(18)67114-5;;11801540;;9816055;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;10.1002/ijc.11007;;12640678;;11454674;;2834047;;12810643;;10.1016/0006-2952(85)90140-6;;2578281;;10.1023/a:1011177318162;;11484948;;15520207;;10.1158/0008-5472.can-04-1722;;1560463;;10.1016/0022-2836(92)91010-m;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1093/jnci/75.1.151;;3859688;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;3258189;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1002/ijc.10189;;11920591;;12648464;;10.1016/s0014-4827(02)00098-8;;12515857;;10.1073/pnas.232686499;;pmc141049,"U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati et al.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovitz et al.;;U.S. Appl. No. 12/396,286, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 12/396,313, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 12/268,352, filed Nov. 10, 2008, Weber et al.;;Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):7843-8 (1996).;;Barrios et al. ""Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor"" J Mol Recognition 17: 332-338 (2004).;;Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6(10):1251-9 (1995).;;Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.;;Bumol et al, in Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).;;Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).;;Deo et al. Immunology Today (1997) 18:127.;;Diener et al, in Antibody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).;;Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.;;Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.;;Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.;;Doronnina et al. Nature Biotechnology, Jul. 2003, 21(7): 784, 941.;;Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence. Nature (1984) 307:521-527.;;Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. (1998) 8(23):3347-52.;;Endo et al. Cancer Res. (1980) 47:1076-1080.;;Examiner's First Report on Australian Patent Application No. 2004260936, dated Aug. 25, 2008, in 2 pages.;;Francisco et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr 24, 2003.;;Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.;;Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).;;Kobrin et al. ""A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding"" J Immunol 146(6): 2017-2020, Mar. 1991.;;Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.;;Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 8(2):83-96 (2001).;;Kuan et al. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 17(2):71-78 (2000).;;Kuan et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. 88(6):962-969 (2000).;;Kuby et al. Immunology, Second Edition, 1994, p. 86-96.;;Lambert et al. in Immunotoxins 175-209 (A. Frankel, ed. 1988).;;Lambert et al. J. Biol. Chem. 260:12035-12041 (1985).;;Landry et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. Journal of Molecular Biology. 308(5):883-893 (2001).;;Libermann et al. (1985). Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 313:144-147.;;Livneh et al. ""Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells"" J Biol Chem., vol. 261, Issue 27, 12490-12497, 09, 1986.;;Lonardo et al. ""Evidence for the Epidermal Growth Factor Receptor As a Target for Lung Cancer Prevention"" Clin Cancer Res, 2002; 8(1): 54-60.;;Lorimer et al. ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."" Clinical Cancer Research, Aug. 1995, 1(8): 859-864.;;Liu et al. Proc. Natl. Acad. Sci. USA, Aug. 1996, 93: 8618-8623.;;Luo et al. Int. J. Cancer. 104(6):716-21 (2003).;;Luwor et al. ""Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR"" Cancer Research 61: 5355-5361, 2001.;;Malden et al., (1988). Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme. Cancer Research 4:2711-2714.;;Mamot et al. Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells. Cancer Research 63:3154-3161 (2003).;;Manabe et al. Biochem. Pharmacol. 34 : 289-291 (1985).;;Pederson et al. ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."" Annals of Oncology / ESMO Jun. 2001, 12(6): 745-760.;;Henry et al. A Prostate-Specific Membrange Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer. Cancer Res. Nov 1, 2004. 64: 7995-8001.;;Roitt et al. p. 5.8 and 5.9, in Immunology second edition, Gower Medical Publishing, New York, 1989.;;Office Action dated Jan. 22, 2013 received in Japanese Patent Application 2010-262796 (with English translation).;;Foote et al., ""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops."" Journal of Molecular Biology 224.2 (1992): 487-499.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Appl. No. 6074/DELNP/2005.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Appl. No. 6073/DELNP/2005.;;Office Action dated Feb. 15, 2011, received in Japanese Patent Appl. No. 2006-517620.;;Office Action dated Feb. 8, 2011, received in Japanese Patent Appl. No. 2006-517700.;;Ghiotto et al., GenBank Acc. # AAK94829, Dec. 31, 2001.;;Office Action dated Mar. 16, 2011 and English summary, received in Mexican Patent Appl. No. PA/a/2005/014152.;;Office Action dated Mar. 24, 2011, received in Canadian Patent Appl. No. 2,530,285.;;Office Action dated Mar. 25, 2011, received in Canadian Patent Appl. No. 2,530,172.;;Rudikoff et al., ""Single Amino Acid Substitution Altering Antigen Binding Specificity"", Proc. Natl. Acad. Sci., 1982, Issue 79, pp. 1979-1983.;;Office Action dated Jun. 9, 2013, received in Chinese Application No. 2011104605368 with English Translation.;;Office Action dated Oct. 8, 2012 received in Mexican Patent Application No. MX/a/2012/001445; (with English translation).;;Office Action dated Oct. 16, 2012 received in Mexican Patent Application No. MX/a/2012/001444; (with English translation).;;Extended European Search Report dated May 4, 2012 for Application No. 11188665.1. 10 pages.;;Extended European Search Report dated May 4, 2012 for Application No. 11188666.9. 11 pages.;;EPO Result of Consultation dated Apr. 26, 2012 for Application No. 04 777 147.2. 3 pages.;;Office Action dated Apr. 10, 2012 received in Korean Application No. 10-2011-7031662.;;Office Action dated May 14, 2012 received in Canadian Application No. 2,530,172.;;Office Action dated Jun. 11, 2012 in Canadian Patent Application No. 2,530,285.;;Office Action received in Korean Patent Application No. 10-2005-7024871, dated Jun. 29, 2012.;;Thorpe et al., ""An Immunotoxin Composed of Monoclonal Anti-Thy 1.1 Antibody and a Ribosome-Inactivating Protein from Saponaria Officinalis: Potent Antitumor Effects in Vitro and in Vivo"", J. Natl. Cancer Inst., 75 pages, 151-159, Jul. 1985.;;Office action dated Jun. 28, 2013 received in Canadian Patent Application 2,530,285.;;Office Action dated Jul. 11, 2013, received in Korean Application No. 10-2013-7011483 with English Translation.;;Garcia De Palazzo, IE. et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 53(14):3217-20 (1993).;;Garnett et al. Cancer Res. 46:2407-2412 (1986).;;Ge H. et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98(3):357-61 (2002).;;Ghose et al, in Targeted Drugs 1-22 (E. Goldberg, ed. 1983).;;Gilmore et al., (1985). Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro. Cell 40:609-618.;;Green and Jakobovits J. Exp. Med. 188:483-495 (1998).;;Green et al. ""Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates"" American Association for Cancer Research Annual Meeting, Mar. 2004.;;Humphrey et al., (1988). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.;;Humphrey et al. ""Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma"" Proceedings of the National Academy of Sciences USA, Jun. 1990, 87 (11): 4207-4211.;;Hurwitz et al. Appl. Biochem. 2:25-35 (1980).;;International Search Report dated Aug. 1, 2005, from International Application No. PCT/US2004/020295.;;International Search Report dated Aug. 14, 2006, from International Application No. PCT/US2004/20564.;;Janeway et al. Immunobiology, 1994, p. 3:1-3:3.;;Johns et al. ""Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene"" Int J Cancer 98: 398-408 (2002).;;Jorissen et al. ""Epidermal growth factor receptor: mechanisms of activation and signaling"" Experimental Cell Research 284 (2003) 31-53.;;Jungbluth et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 100(2):639-644 (2003).",ACTIVE
233,CN,A,CN 102675462 A,091-865-728-667-670,2012-09-19,2012,CN 201110460536 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,RICHARD WEBER;;XIAO FENG;;ORIT FOORD;;LARRY GREEN;;GUDAS JEAN M;;BRUCE KEYT;;YING LIU;;PALANISWAMI RATHANASWAMI;;ROBERT RAYA;;DONG YANG XIAO;;JOSE CORVALAN;;IAN FOLTZ;;XIAO-CHI JIA;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;JANE SU QIAOJUAN,,https://lens.org/091-865-728-667-670,Patent Application,no,2,3,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;A61P35/00;;C07K16/22;;C07K17/00;;C12N/;;C12N5/00;;C12N5/06;;G01N33/53;;G01N33/577,,1,1,044-355-372-029-744,11255078;;10.1016/s1040-8428(00)00134-7,"XIAO-DONG YANG ET AL.: ""Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy"", 《CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY》",DISCONTINUED
234,HK,A1,HK 1203205 A1,094-822-013-764-644,2015-10-23,2015,HK 15103624 A,2015-04-14,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T T;;KLAKAMP SCOTT L L;;SU QIAOJUAN JANE,,https://lens.org/094-822-013-764-644,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K/;;A61K39/395;;A61K47/48;;A61P/;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,PENDING
235,US,A1,US 2005/0053608 A1,133-616-007-266-492,2005-03-10,2005,US 87777304 A,2004-06-25,US 87777304 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M.;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S.;;KING CHADWICK T.;;KLAKAMP SCOTT L.;;SU QIAOJUAN JANE,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/133-616-007-266-492,Patent Application,yes,32,84,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,424/155.1;;424/178.1,0,0,,,,ACTIVE
236,CN,A,CN 102558352 A,198-712-885-060-162,2012-07-11,2012,CN 201110233784 A,2004-06-25,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,RICHARD WEBER;;XIAO FENG;;ORIT FOORD;;LARRY GREEN;;GUDAS JEAN M;;BRUCE KEYT;;YING LIU;;PALANISWAMI RATHANASWAMI;;ROBERT RAYA;;DONG YANG XIAO;;JOSE CORVALAN;;IAN FOLTZ;;XIAO-CHI JIA;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;JANE SU QIAOJUAN,,https://lens.org/198-712-885-060-162,Patent Application,no,0,2,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/395;;A61K47/48;;A61P35/00;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;C12N5/09;;G01N33/53,,0,0,,,,DISCONTINUED
237,BR,A2,BR 112014002438 A2,110-312-932-930-787,2017-02-21,2017,BR 112014002438 A,2012-06-27,US 2012/0044459 W;;US 201113197750 A,2011-08-03,laminados híbridos compósitos de molibdênio e métodos,"resumo patente de invenção: ""laminados híbridos compósitos de molibdênio e métodos"". a presente invenção refere-se a um laminado híbrido compósito de molibdênio. o laminado tem uma pluralidade de camadas de material compósito. o laminado tem, ainda, uma pluralidade de camadas de folha de molibdênio de superfície tratada entrelaçadas entre as camadas de material compósito. o laminado tem, ainda, uma pluralidade de camadas adesivas dispostas entre e ligando camadas adjacentes das camadas de material compósito e as camadas de folha de molibdênio.",BOEING CO,ALAN EDGAR LANDMANN;;GEOFFREY A BUTLER;;GREGORY ALAN FOLTZ;;JOHN MARK GARDNER;;KAY Y BLOHOWIAK;;LIAM S CAVANAUGH PINGREE;;MARC J PIEHL;;MARC R MATSEN;;MARK A NEGLEY;;RICHARD H BOSSI;;ROBERT A ANDERSON;;ROBERT L CARLSEN;;STEPHEN G MOORE,,https://lens.org/110-312-932-930-787,Patent Application,no,0,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/06;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,0,0,,,,ACTIVE
238,CA,A1,CA 2841071 A1,145-670-604-735-763,2013-02-07,2013,CA 2841071 A,2012-06-27,US 201113197750 A;;US 2012/0044459 W,2011-08-03,MOLYBDENUM COMPOSITE HYBRID LAMINATES AND METHODS,"In an embodiment of the disclosure, there is provided a molybdenum composite hybrid laminate. The laminate has a plurality of composite material layers. The laminate further has a plurality of surface treated molybdenum foil layers interweaved between the composite material layers. The laminate further has a plurality of adhesive layers disposed between and bonding adjacent layers of the composite material layers and the molybdenum foil layers.",BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,,https://lens.org/145-670-604-735-763,Patent Application,no,0,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/06;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,0,0,,,,ACTIVE
239,US,A1,US 2005/0059087 A1,124-524-462-595-613,2005-03-17,2005,US 87777404 A,2004-06-25,US 87777404 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M.;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S.;;KING CHADWICK T.;;KLAKAMP SCOTT L.;;SU QIAOJUAN JANE,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/124-524-462-595-613,Patent Application,yes,32,41,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,435/7.1;;435/336;;530/388.25;;530/388.15,0,0,,,,ACTIVE
240,US,A1,US 2009/0156790 A1,129-758-461-860-458,2009-06-18,2009,US 26836308 A,2008-11-10,US 26836308 A;;US 87777404 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/129-758-461-860-458,Patent Application,yes,71,33,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/18;;A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,530/387.9;;530/388.15,0,0,,,,ACTIVE
241,US,B2,US 10118968 B2,035-097-443-811-835,2018-11-06,2018,US 64917909 A,2009-12-29,US 64917909 A;;US 39631309 A;;US 87777304 A;;US 56245304 P;;US 52557003 P;;US 48314503 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,,https://lens.org/035-097-443-811-835,Granted Patent,yes,121,2,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/00;;A61K39/395;;A61K47/48;;B82Y5/00;;C07K16/22;;C07K16/28;;C07K16/30;;C07K17/00;;C12N/;;C12N5/06;;C12P21/08;;G01N33/53,,323,170,027-214-641-693-526;;055-904-468-981-551;;013-142-717-038-23X;;068-033-680-421-173;;017-386-037-070-267;;035-554-935-107-802;;029-611-134-469-353;;012-104-543-895-325;;049-928-993-608-092;;095-334-545-560-259;;025-692-172-883-979;;103-932-348-507-545;;008-019-042-176-997;;027-477-313-726-928;;038-495-237-294-69X;;004-705-560-504-051;;016-265-697-674-181;;020-367-308-901-689;;088-581-950-418-154;;006-553-734-546-212;;057-971-690-843-179;;001-711-151-176-765;;021-182-185-908-148;;103-729-004-244-688;;033-769-003-424-862;;015-399-941-370-866;;072-729-813-791-160;;100-394-462-349-099;;027-477-313-726-928;;087-448-981-335-707;;055-904-468-981-551;;067-782-603-238-967;;064-678-224-734-734;;024-995-475-936-443;;050-646-523-937-465;;125-735-714-799-644;;013-447-454-196-187;;004-272-966-072-139;;045-751-499-875-041;;112-312-727-891-46X;;145-103-363-875-640;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;033-688-911-017-272;;128-683-050-479-273;;008-822-347-989-692;;041-969-682-554-154;;085-084-648-067-30X;;053-206-529-796-448;;033-509-048-623-004;;165-322-209-862-791;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;003-420-832-784-996;;040-622-347-677-457;;037-531-283-684-284;;030-080-528-694-129;;115-935-599-414-721;;016-435-611-136-112;;025-279-035-199-960;;021-799-621-392-61X;;002-538-287-083-621;;124-275-393-571-41X;;087-103-148-426-023;;136-926-314-202-897;;103-755-269-224-85X;;112-409-472-179-059;;016-219-576-017-946;;067-857-455-571-760;;022-890-862-570-978;;043-637-817-489-241;;028-036-828-526-370;;064-075-380-054-48X;;150-632-545-202-265;;017-985-977-936-133;;154-572-677-438-265;;045-904-151-504-498;;072-377-861-372-36X;;045-082-353-678-357;;062-976-245-058-504;;077-163-323-456-652;;004-986-447-228-415;;029-269-446-589-556;;111-679-382-231-89X;;087-806-501-008-318;;093-272-820-060-870;;054-354-046-619-106;;004-517-823-944-609;;090-683-249-679-734;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;049-182-911-054-623;;027-389-935-773-753;;032-441-846-127-844;;006-301-071-808-697;;044-355-372-029-744;;073-659-966-706-479;;077-406-419-134-117;;042-601-433-468-58X;;077-950-844-586-930;;086-617-534-349-291;;033-261-430-402-230;;045-942-104-775-903;;001-779-867-387-972;;014-113-432-888-031;;010-953-281-569-514;;017-903-200-905-934;;045-872-081-200-101;;051-707-000-800-833;;135-943-065-643-592;;012-434-436-039-701;;124-416-510-861-245;;058-648-791-423-620;;157-729-192-316-421;;186-732-989-640-404;;063-634-487-523-604;;165-749-823-188-437;;075-889-605-642-840;;031-970-152-284-72X;;009-483-512-107-343;;094-424-423-768-724;;065-684-269-783-203;;112-811-296-657-597;;128-037-910-947-545;;030-309-956-160-927;;064-021-604-555-029;;031-886-516-535-883;;037-531-283-684-284;;100-216-688-182-170;;086-378-024-269-624;;067-653-203-289-895;;001-075-703-287-400;;065-271-121-674-291;;048-110-926-130-802;;004-402-270-959-674;;057-205-729-571-877;;069-970-853-729-540;;005-038-448-235-576;;152-475-651-861-295;;047-010-764-744-638;;175-134-379-959-97X;;115-916-545-155-724;;092-117-309-419-982;;133-939-910-996-391;;054-707-943-234-995;;145-254-035-276-41X;;053-158-286-316-214;;022-400-834-786-515;;005-461-375-871-624;;034-626-837-626-258;;034-526-119-277-42X;;002-666-993-527-919;;032-214-592-514-94X;;005-461-375-871-624;;142-206-526-949-177;;026-589-266-128-73X;;023-683-904-984-090;;033-870-601-973-366;;042-741-242-328-693;;080-633-663-618-912,10.1093/oxfordjournals.jbchem.a003254;;12359067;;10.1002/jmr.679;;15227640;;10556035;;10.1006/jmbi.1999.3141;;12189730;;10.1007/978-1-4615-0549-5_2;;10.1016/0167-7799(96)80921-8;;8746117;;10.1023/b:pham.0000008042.15988.c0;;14725359;;7516563;;10.1016/s0923-2494(94)80039-1;;7608568;;10.4049/jimmunol.155.2.925;;10656818;;10.1006/jmbi.1999.3444;;10.1006/jmbi.1996.0548;;8876650;;10.1074/jbc.m808802200;;19224862;;pmc2667743;;10.1007/978-1-4684-6831-1_14;;15185369;;10.1002/cbic.200300806;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1093/jnci/75.1.151;;3859688;;8812702;;10.1006/meth.1996.0054;;10.1021/bi00489a001;;2271534;;1961196;;10.1016/0161-5890(91)90003-3;;10.4049/jimmunol.164.3.1432;;10640759;;8424945;;10.1021/bi00055a024;;10.1007/s00262-002-0352-9;;12700948;;9530559;;10.1016/s1380-2933(97)10003-3;;10.2210/pdb1aqk/pdb;;10.2210/pdb1hez/pdb;;10.1016/s0969-2126(01)00630-x;;11587642;;10.1006/jmbi.1997.0950;;9150407;;11000403;;10.1016/s0161-5890(00)00049-3;;10.2210/pdb6fab/pdb;;10.1021/bi00229a022;;2015229;;10.1093/protein/8.8.749;;8637844;;9417940;;10.1006/jmbi.1997.1407;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/jmr.679;;15227640;;8845302;;3367154;;10.1097/00005072-198805000-00001;;10.1038/342877a0;;2687698;;10.1016/s0167-5699(97)01007-4;;9078685;;2428468;;3262420;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;9873732;;10.1016/s0960-894x(98)00610-6;;3802092;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;3258189;;10.1002/ijc.10189;;11920591;;12648464;;10.1016/s0014-4827(02)00098-8;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1021/jm00378a013;;6209394;;2005389;;10.4049/jimmunol.146.6.2017;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11352579;;10.1006/jmbi.2001.4628;;10.1038/313144a0;;2981413;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;3017977;;10.1016/s0021-9258(18)67114-5;;11801540;;9816055;;10.1002/ijc.11007;;12640678;;11454674;;2834047;;12810643;;10.1016/0006-2952(85)90140-6;;2578281;;8947577;;10.1006/jmbi.1996.0617;;2285602;;10.1016/0960-0760(90)90438-q;;2103507;;10.1038/ng0297-146;;9020839;;21566922;;10.3892/ijo.4.2.277;;9607595;;7585629;;10.1016/s0092-8674(85)80052-0;;2988784;;2430705;;10.1007/bf00199811;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1023/a:1011177318162;;11484948;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;pmc16575;;10.1073/pnas.130166597;;10852962;;2855491;;10.1101/sqb.1988.053.01.059;;10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#;;9506533;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;6206272;;10.1093/jnci/73.3.721;;10.1038/309418a0;;6328312;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1016/0092-8674(83)90153-8;;6309409;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;3261803;;10.1093/jnci/80.14.1154;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;10.1016/j.jim.2004.01.024;;15099763;;15520207;;10.1158/0008-5472.can-04-1722;;10.1016/j.molimm.2004.11.003;;15829301;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;1560463;;10.1016/0022-2836(92)91010-m;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1006/jmbi.1999.3192;;10543973;;12218124;;10.4049/jimmunol.169.6.3076;;10.1038/nbt1135;;16151405;;10.1073/pnas.93.25.14815;;8962138;;pmc26219;;pmc297746;;10.1073/pnas.86.15.5938;;2762305;;10.2210/pdb3hfm/pdb;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1111/j.1600-065x.1992.tb01419.x;;1464422;;11560969;;10.1002/ijc.1572;;11774237;;11416113;;10.1093/jnci/93.12.921;;7671250;;10482197;;10.1158/0008-5472.can-16-2269;;27635041;;10.1073/pnas.89.13.5867;;pmc49398;;1352878;;7207595;;10.1038/290145a0;;9626458;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;10837619;;10.1016/s0169-409x(97)00095-1;;1727373;;7237431;;7540106;;10.1128/mcb.9.3.1165-1172.1989;;2566907;;pmc362707;;10.1128/mcb.9.3.1165;;9816191;;8102322;;10.1007/bf01518520;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;15989600;;10.1517/13543784.6.2.169;;10561017;;1680547;;2566965;;2342490;;10.1016/0161-5890(90)90140-u;;9717827;;1967301;;10.1200/jco.1990.8.1.103;;10.1038/sj.onc.1202526;;10327070;;19010901;;10.1158/0008-5472.can-08-1776;;10.1200/jco.1997.15.8.2894;;9256133;;1715033;;10.1016/0161-5890(91)90056-p;;10213223;;10565792;;2470152;;10.1126/science.2470152;;8845823;;10.1248/bpb.18.1279;;7923157;;pmc2034020;;10.1038/bjc.1995.435;;7547242;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1007/s002620050622;;10550550;;8253530;;10.1002/ijc.2910550610;;10.1128/mcb.10.11.6064;;10.1128/mcb.10.11.6064-6068.1990;;pmc361407;;1700279;;8703804;;10.1046/j.1365-2141.1996.d01-1730.x;;pmc2034088;;8519647;;10.1038/bjc.1995.517;;10.1385/1-59259-114-0:87;;11217378;;8258342;;8258341;;10.1002/eji.1830231231;;10.1128/mcb.10.11.6064;;10.1128/mcb.10.11.6064-6068.1990;;pmc361407;;1700279;;12525512;;10.1200/jco.2003.05.137;;10.1182/blood-2002-01-0008;;12200383;;10.1126/science.1083911;;12738866;;10527689;;10.1006/clim.1999.4781;;10.1038/347090a0;;2118596;;14568943;;10.4049/jimmunol.171.9.4680,"Kala et al., J Biochem 132: 535-514, 2002.;;Barrios et al., J Molecular Recognition 17: 332-338, 2004.;;Wu et al., J. Mol. Biol. 294: 151-162, 1999.;;Advisory action dated Feb. 12, 2018 in related case U.S. Appl. No. 14/743,886 (Year: 2018).;;Request for Continued Examination filed on Oct. 11, 2010 in U.S. Appl. No. 12/268,352.;;Request for Continued Examination filed on Oct. 11, 2010 in U.S. Appl. No. 12/268,363.;;Request for Continued Examination filed on Oct. 11, 2010 in U.S. Appl. No. 12/396,286.;;Request for Continued Examination filed on Oct. 11, 2010 in U.S. Appl. No. 12/396,313.;;Akers et al., “Formulation Development of Protein Dosage Forms,” Pharmaceutical Biotechnology, Kluwer, Dordrecht, NL, vol. 14, Jan. 1, 2002, pp. 47-127.;;Chamow et al., “Immunoadhesins: Principles and Applications,” Tibtech, Feb. 1996, pp. 52-60, vol. 14.;;Chen et al., “Influence of Histidine on the Stability and Physical Properties of a Fully Human Antibody in Aqueous and Solid Forms,” Pharmaceutical Research, Dec. 2003, pp. 1952-1960, vol. 20(12).;;Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Res. Immunol., Jan. 1994, pp. 33-36, vol. 145(1).;;Ellis, et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma,” The Journal of Immunology, 1995, pp. 925-937, vol. 155.;;Knappik et al., “Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,” J. Mol. Biol. 2000, pp. 57-86, vol. 296.;;MacCallum et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 1996, pp. 732-745, vol. 262.;;McNutt et al., “Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells,” The Journal of Biological Chemistry, Apr. 17, 2009, pp. 10561-10570, vol. 284(16).;;New England Bio Labs: “Furin,” Ipswich, MA, Jan. 2006.;;Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Teritiary Structure Prediction, 1994, pp. 491-495.;;Paul, “Fundamental Immunology,” Laboratory of Immunology, National Institute of allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 1993, pp. 290-295.;;Piatesi et al., “Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diels-Alder Activity,” ChemBioChem, 2004, pp. 460-466, vol. 5.;;RCSB Protein Data Bank webpage and Fasta Sequence downloaded from http://www.pdb.org/pdb/home/home.do for 1HEZ. Downloaded Jul. 26, 2011.;;RCSB Protein Data Bank webpage and Fasta Sequence downloaded from http://www.pdb.org/pdb/home/home.do for 2H1P. Downloaded Jul. 26, 2011.;;RCSB Protein Data Bank webpage and Fasta Sequence downloaded from http://www.pdb.org/pdb/home/home.do for 1AQK. Downloaded Jul. 26, 2011.;;RCSB Protein Data Bank webpage and Fasta Sequence downloaded from http://www.pdb.org/pdb/home/home.do for 1DQL. Downloaded Jul. 26, 2011.;;RCSB Protein Data Bank webpage and Fasta Sequence downloaded from http://www.pdb.org/pdb/home/home.do for 1MF2. Downloaded Jul. 26, 2011.;;RCSB Protein Data Bank webpage and Fasta Sequence downloaded from http://www.pdb.org/pdb/home/home.do for 1FLR. Downloaded Jul. 26, 2011.;;RCSB Protein Data Bank webpage and Fasta Sequence downloaded from http://www.pdb.org/pdb/home/home.do for 8FAB. Downloaded Jul. 26, 2011.;;Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,” Proc. Natl. Acad. Sci. USA, Mar. 1982, pp. 1979-1983, vol. 79.;;Thorpe et al., “An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo”, J. Natl. Cancer Inst., 75 pages, 151-159. Jul. 1985.;;Van Regenmortel, “Mapping Epitope Structure and Activity: From One-Dimensional Prediction to Four-Dimensional Description of Antigenic Specificity,” A Companion to Methods on Enzymology 9, 1996, pp. 465-472, Article No. 0054.;;Wells, “Additivity of Mutational Effects in Proteins,” The American Chemical Society, Sep. 18, 1990, pp. 8509-8517, vol. 29(37).;;Houghten et al., “Relative Importance of Position and Individual Amino Acid Residues in Peptide Antigen-Antibody Interactions: Implications in the Mechanism of Antigenic Drift and Antigenic Shift,” New Approaches to Immunization, Vaccines 86, Cold Spring Harbor Laboratory, p. 21-25, 1986.;;Lederman et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,” Molecular Immunology, 1991, pp. 1171-1181, vol. 28 (11).;;Li et al., “β-Endorphin Omission Analogs: Dissociation of Immunoreactivity from other Biological Activities,” Proc. Natl. Acad. Sci. USA, Jun. 1980, pp. 3211-3214, vol. 77 (6).;;Tamura, et al., Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only, Journal of Immunology, 2000, vol. 164, pp. 1432-1441.;;Brummell, et al., Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues, Biochemistry, 1993, vol. 32, pp. 1180-1187.;;Trail et al., “Monoclonal Antibody Drug Immunoconjugates for Targeted Treatment of Cancer.” Cancer Immunol Immunother 52 (2003): 328-337.;;Faber et al., “Three-dimensional Structure of a Human Fab with High Affinity for Tetanus Toxoid.” Immunotechnology 3 (1998): 253-270.;;Graille et al., “Complex Between Peptostreptococcus magnus Protein L and a Human Antibody Reveals Structural Convergence in the Interaction Modes of Fab Binding Proteins.” Structure 9 (Aug. 2001): 679-687.;;Lescar et al., “Three-dimensional Structure of an Fab-Peptide Complex: Structural Basis of HIV-1 Protease Inhibition by a Monoclonal Antibody.” J. Mol. Biol. 267 (1997): 1207-1222.;;Ramsland et al., “An Unusual Human IgM Antibody with a Protruding HCDR3 and High Avidity for its Peptide Ligands.” Molecular Immunology 37 (2000): 295-310.;;Strong et al., “Three-Dimensional Structure of Murine Anti-p-azophenylarsonate Fab 36-71. 1. X-ray Crystallography, Site-Directed Mutagenesis, and Modeling of the Complex with Hapten.” Biochemistry 30 (1991): 3739-3748.;;Whitlow et al., “1.85 ÁStructure of Anti-Fluorescein 4-4-20 Fab.” Protein Engineering 8.8 (1995): 749-761.;;Young et al., “The Three-dimensional Structures of a Polysaccharide Binding Antibody to Cryptococcus neoformans and its Complex with a Peptide from a Phage Display Library: Implications for the Identification of Peptide Mimotopes.” J. Mol. Biol. 274 (1997): 622-634.;;Ghiotto et al., GenBank Acc. # AAK94829, Dec. 31, 2001.;;Rudikoff et al., “Single Amino Acid Substitution Altering Antigen Binding Specificity”, Proc. Natl. Acad. Sci., 1982, Issue 79, pp. 1979-1983.;;U.S. Appl. No. 12/268,352, filed Nov. 10, 2008, Weber et al.;;U.S. Appl. No. 12/268,363, filed Nov. 10, 2008, Weber et al.;;U.S. Appl. No. 12/396,286, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 12/396,313, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati et al.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.;;U.S. Appl. No. 08/234,145, filed Aug. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovitz et al.;;Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):7843-8 (1996).;;Barrios et al. “Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor” J Mol Recognition 17: 332-338 (2004).;;Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6(10):1251-9 (1995).;;Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.;;Bumol et al, in Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).;;Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).;;Deo et al. Immunology Today (1997) 18:127.;;Diener et al, in Antibody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).;;Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.;;Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.;;Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.;;Doronnina et al. Nature Biotechnology, Jul. 2003, 21(7): 784, 941.;;Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence. Nature (1984) 307:521-527.;;Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. (1998) 8(23):3347-52.;;Endo et al. Cancer Res. (1980) 47:1076-1080.;;Francisco et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.;;Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).;;Garcia de Palazzo, IE. et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 53(14):3217-20 (1993).;;Garnett et al. Cancer Res. 46:2407-2412 (1986).;;Ge H. et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98(3):357-61 (2002).;;Ghose et al, in Targeted Drugs 1-22 (E. Goldberg, ed. 1983).;;Gilmore et al., (1985). Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro. Cell 40:609-618.;;Green and Jakobovits J. Exp. Med. 188:483-495 (1998).;;Green et al. “Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates” American Association for Cancer Research Annual Meeting, Mar. 2004.;;Humphrey et al. “Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma” Proceedings of the National Academy of Sciences USA, Jun. 1990, 87 (11): 4207-4211.;;Humphrey et al., (1998). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.;;Hurwitz et al. Appl. Biochem. 2:25-35 (1980).;;Janeway et al. Immunobiology, 1994, p. 3:1-3:3.;;Johns et al. “Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene” Int J Cancer 98: 398-408 (2002).;;Jorissen et al. “Epidermal growth factor receptor: mechanisms of activation and signaling” Experimental Cell Research 284 (2003) 31-53.;;Jungbluth et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 100(2):639-644 (2003).;;Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996).;;Kato et al. J. Med. Chem. 27:1602-1607 (1984).;;Kobrin et al. “A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding” J Immunol 146(6): 2017-2020, Mar. 1991.;;Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.;;Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 8(2):83-96 (2001).;;Kuan et al. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 17(2):71-78 (2000).;;Kuan et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. 88(6):962-969 (2000).;;Kuby et al. Immunology, Second Edition, 1994, p. 86-96.;;Lambert et al. in Immunotoxins 175-209 (A. Frankel, ed. 1988).;;Lambert et al. J. Biol. Chem. 260:12035-12041 (1985).;;Landry et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. Journal of Molecular Biology. 308(5):883-893 (2001).;;Libermann et al. (1985). Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 313:144-147.;;Liu et al. Proc. Natl. Acad. Sci. USA, Aug. 1996, 93: 8618-8623.;;Livneh et al. “Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells” J Biol Chem., vol. 261, Issue 27, 12490-12497, 09, 1986.;;Lonardo et al. “Evidence for the Epidermal Growth Factor Receptor as a Target for Lung Cancer Prevention” Clin Cancer Res, 2002; 8(1): 54-60.;;Lorimer et al. “Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.” Clinical Cancer Research, Aug. 1995, 1(8): 859-864.;;Luo et al. Int. J. Cancer. 104(6):716-21 (2003).;;Luwor et al. “Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR” Cancer Research 61: 5355-5361, 2001.;;Malden et al., (1988). Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme. Cancer Research 4:2711-2714.;;Mamot et al. Epidermal Growth Factor Receptor (EGFR)—targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells. Cancer Research 63:3154-3161 (2003).;;Manabe et al. Biochem. Pharmacol. 34 : 289-291 (1985).;;Martin, et al. J Mol Biol. Nov. 15, 1996;263(5):800-15.;;Mendelsohn, “Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents”, J Steroid Biochem Mol Biol, Dec. 20, 1990; 37 (6):889-92.;;Mendelsohn, The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies, Semin Cancer Biol, Oct. 1990; 1(5):339-44.;;Mendelsohn, Cancer Cells 7:359 (1989).;;Mendez et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet.15(2):146-56 (1997).;;Modjtahedi and Dean Int'l J. Oncology 4:277-296 (1994).;;Mohammad et al. Clin Cancer Res, May 1998, 4(5): 1337-1343.;;Moscatello, G. et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55(23):5536-9 (1995).;;Nilsen et al., (1985). c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor. Cell 41:719-726.;;Ohkawa et al. Cancer Immumol. Immunother. 23:81-86 (1986).;;Olapade-Olaopa, EO. et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 82(1):186-94 (2000).;;Pederson et al. “The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy.” Annals of Oncology/ESMO Jun. 2001, 12(6): 745-760.;;Pelley et al., (1988). Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication-Competent Retrovirus Containing the Activated c-erbB. Journal of Virology 62: 1840-1844.;;Pietersz et al, in Antibody Mediated Delivery Systems 25-53 (J. Rodwell, ed. 1988).;;Reist et al. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nuclear Medicine and Biology. 26(4):405-411 (1999).;;Reist et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nuclear Medicine and Biology. 24(7):639-647 (1997).;;Sampson et al. “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors” Proc Nat Acad Sci 97(13): 7503-7508, Jun. 2000.;;Schlessinger et al. “Signal Transduction by Epidermal Growth Factor Receptor”, Cold Spring Harb Symp Quant Biol, Jan. 1, 1988; 53: 515-519.;;Schmidt et al., Expression of an Oncogenic Mutant EGF Receptor Markedly Increases the Sensitivity of Cells to an EGF-Receptor-Specific Antibody-Toxin, Int. J. Cancer, 75, 878-884 (Mar. 16, 1998).;;Sela et al. in lmmunoconjugates 189-216 (C. Vogel, ed. 1987).;;Shouval et al. Proc. Natl. Acad. Sci, 85: 8276-8280 (1988).;;Toki et al. Abstracts of Papers of the American Chemical Society, Apr. 2002, 223(2):A1113, 7-11.;;Trouet et al. Proc. Natl. Acad. Sci. 79: 626-629 (1982).;;Tsukada et al. Br. J. Cancer 52:111-116 (1985).;;Tsukada et al. J. Natl. Canc. Inst. 73:721-729 (1984).;;Ullrich et al. (1984). Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells. Nature 309:418-425.;;Valerius et al. Blood 90:4485-4492 (1997).;;Vitetta et al. Immunotoxins: magic bullets or misguided missiles? Immunol Today 14:252 (1993).;;Wells et al., (1988). Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB. Proc. Natl. Acad. Sci. USA 85:7597-7601.;;Wikstrand et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer immunology, Immunotherapy. 50(12):639-652 (2002).;;Wikstrand et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas malignant gliomas. Cancer Research. 55(14):3140-3148 (1995).;;Wikstrand et al. The class III variant of the epidermal growth factor receptor (EGFRVIII): characterization and utilization as an immunotherapeutic target. J.Neurovirol. 4(2):148-158 (1998).;;Wong et al. (1987). Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is Invariably Associated with Gene Amplification. Proc. Natl. Acad. Sci. USA 84:6899-6903.;;Yamamoto et al., (1983). A New Avain Erythroblastosis Virus, AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma. Cell 34:225-232.;;Yamazaki et al. (1988). Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors. Molecular and Cellular Biology 8:1816-1820.;;Yang and Reisfeld. J. Natl. Canc. Inst. 80:1154-1159 (1988).;;Yang X et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hemato 38(1):17-23 (2001).;;Yang X-D et al. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. Cancer Research 59(6):1236-1243 (1999).;;Cochran et al. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Meth 2004, 287: 147-158.;;Henry et al. A Prostate-Specific Membrange Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer. Cancer Res. Nov. 1, 2004. 64: 7995-8001.;;Reimer et al. Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu—a new method of epitope definition. Mol Immunol, 2005, 42: 1121-1124.;;Roth et al. p. 5.8 and 5.9, in Immunology second edition, Gower Medical Publishing, New York, 1989.;;Stancovski et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA, 1991, 88: 8691-8695.;;Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops.” Journal of Molecular Biology 224.2 (1992) : 487-499.;;Campbell, Chapter 1, Monoclonal Antibody Technology, 1984 pp. 1-32, Elsevier Science Publishers B.V., The Netherlands.;;Casset et al., “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,” Biochemical and Biophysical Research Communications, 2003, vol. 307, pp. 198 205.;;Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity Matured Fab in Complex with Antigen,” J. Mol. Biol., 1999, vol. 293, pp. 865 881.;;De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity Determining Regions Containing Specificity Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” J. Immunol, 2002, vol. 169, pp. 3076-3084.;;Lamminmaki et al., “Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol,” The Journal of Biological Chemistry, vol. 276 (39), Sep. 28, 2001, pp. 36687 36694.;;Lonberg, Human antibodies from transgenic animals, Nature Biotechnology 23: 1117-1125, 2005.;;Lorimer, et al., Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display, Proc. Natl. Acad. Sci. USA 93: 14815-14820, Dec. 1996.;;Notice of Allowance dated Oct. 4, 2013, received in U.S. Appl. No. 12/268,352.;;Notice of Allowance dated Sep. 17, 2013, received in U.S. Appl. No. 12/268,363.;;Office Action dated Aug. 23, 2013 in Chinese Application No. 200480018185.3 (with English translation).;;Office Action dated Aug. 27, 2013, received in Japanese Patent Application No. 2010-252825 (with English translation).;;Office Action dated Aug. 27, 2013, received in Japanese Patent Application No. 2010-262796 (with English translation).;;Office Action dated Aug. 19, 2013, received in Korean Patent App. No. 10-2013-7014050 (with English translation).;;Office Action dated Jul. 29, 2013 , received in Chinese Patent Application No. 20111023384.9 (with English Translation).;;Office Action dated Oct. 7, 2013, received in U.S. Appl. No. 12/396,286.;;Office Action dated Oct. 11, 2013, received in European Pat. App No. 11188665.1.;;Office Action dated Oct. 11, 2013, received in European Pat. App No. 11188666.9.;;Office Action dated Sep. 12, 2013, received in U.S. Appl. No. 12/396,313.;;Oral Proceedings Summons dated Oct. 25, 2013, received in European Pat. App. No. 04777034.2.;;Oral Proceedings Summons dated Oct. 25, 2013, received in European Pat. App. No. 04777147.2.;;Padlan et al., “Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL 10 Fab Lysozyme Complex,” Proc. Natl. Acad. Sci., vol. 86, Aug. 1989, pp. 5938 5942.;;Vajdos et al., “Comprehensive Functional Maps of the Antigen Binding Site of an Anti ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol., 2002, vol. 320, pp. 415 428.;;Office Action dated Apr. 30, 2014 in Chinese Application No. 200480018185.3 with English Translation.;;Office Action dated Jun. 12, 2014 in Canadian Application No. 2530285.;;Office Action dated Jun. 13, 2014 in Chinese Application No. 201110233784.9 with English Translation.;;Office Action dated Jul. 11, 2013, received in Korean Application No. 10-2013-7011483 with English Translation.;;Office Action dated Mar. 10, 2014 in Japanese Application No. 2010-252825 with English Translation.;;Office Action dated Mar. 3, 2014 in Japanese Application No. 2010-262796 with English Translation.;;Pietersz et al., “Antibody Conjugates for the Treatment of Cancer”, Immunological Reviews, 1992, vol. 129, No. 29, pp. 57-80.;;Office Action dated Nov. 19, 2013, received in Mexican Patent Application No. MX/a/2012/001444 (with English Translation).;;Trial Decision dated Jan. 17, 2014 in Korean Patent App. No. 2005-7024882 (with English translation).;;Notice of Allowance dated Apr. 23, 2014 in U.S. Appl. No. 12/396,286.;;Office Action dated Apr. 23, 2014 in Korean Application No. 10-2014-7004191 with English Translation.;;Office Action dated Apr. 23, 2014 in Korean Application No. 10-2014-7000817 with English Translation.;;Final Office Action dated Jan. 31, 2014 in U.S. Appl. No. 12/396,286.;;Notice of Allowance dated Jan. 17, 2014 in U.S. Appl. No. 12/268,363.;;Notice of Allowance dated Feb. 5, 2014 in U.S. Appl. No. 12/268,352.;;Office Action dated Jan. 22, 2013 received in Japanese Patent Application 2010-262796 (with English translation).;;Office Action dated Feb. 17, 2014 in Korean Application No. 10-2005-7024883 with English Translation.;;EPO Notification—Invitation pursuant to Article 94(3) and Rule 71(1) EPC dated Mar. 11, 2014 in European Application No. 04 777 034.2.;;EPO Notification—Invitation pursuant to Article 94(3) and Rule 71(1) EPC dated Mar. 11, 2014 in European Application No. 04 777 147.2.;;Notice of Allowance dated Jul. 1, 2014 in U.S. Appl. No. 12/268,363.;;Office Action dated Jan. 28, 2014 in Chinese Application No. 201110460536.8 with English Translation.;;Office Action dated Mar. 20, 2014, received in Korean Patent Application No. 10-2005-7024871 (with English Translation).;;Office Action dated Jul. 11, 2014 in Canadian Patent App. No. 2,530,172.;;Trial Decision dated Mar. 3, 2014 in Korean Application No. 10-2005-7024871 with English Translation.;;Office Action dated Oct. 13, 2014 in Australian Application No. 2012268864.;;Office Action dated Dec. 3, 2014 in Chinese Application No. 200480018185.3 with English Translation.;;Office Action dated Jan. 15, 2015, received in Korean Patent Application No. 10-2014-7029678 (with English Translation).;;Notice of Allowance dated Feb. 17, 2015, received in U.S. Appl. No. 12/268,363.;;Office Action dated Dec. 18, 2014 in Korean Application No. 10-2005-7024871 with English Translation.;;Arteaga, et al. The Epidermanl Growth Factor Receptor: From Mutant Oncogene in Nonhuman Cancers to Therapeutic Target in Human Neoplasia, Journal of Clinical Oncology, 2001 (Sep. 15 Supplement), vol. 19, No. 18s: pp. 32s-40s.;;Damstrup, et al., Epidermal Growth Factor Receptor Mutation Type III Transfected into a Small Lung Cancer Cell Line is Predominantly Localized at the Cell Surface and Enhances the Malignant Phenotype, Int. J. Cancer, 2002, 97: pp. 7-14.;;Lammering, et al., Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization. Journal of the National Cancer Institute, Jun. 20, 2001, vol. 93, No. 12.;;Notice of Allowance dated Oct. 1, 2014 in U.S. Appl. No. 12/268,352.;;Notice of Allowance dated Oct. 1, 2014 in U.S. Appl. No. 12/396,313.;;Notice of Allowance dated Sep. 26, 2014, received in U.S. Appl. No. 12/396,286.;;Office Action dated Aug. 22, 2014, received in Chinese Application No. 201110460536.8 with English Translation.;;Office Action dated Nov. 28, 2014, received in Korean Patent Application No. 10-2014-7000817 with English translation.;;Office Action dated Sep. 30, 2014 in Indian Patent App. No. 8485/DELNP/2009.;;Reist, et al., Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. Oct. 1, 1995; 55(19): 4375-82.;;“Anti-c-ErbB2/c-Neu (Ab-5), clone TA-1,” http://www.millipore.com/catalogue/item/mabe320, accessed May 28, 2014.;;“Mertansine,” Wikipedia, http://en.wikipedia.org/w/index/php?title=Metansine&oldid=45829581, accessed May 28, 2014.;;“Trastuzumab,” Wikipedia, http://en.wikipeida.org/wiki/Trastuzumab, accessed May 28, 2014.;;Baselga, et al., “Phase II Study of Weekly Intravenous Trastuzumab (Herceptin®) in Patients With HER2/neu- Overexpresing Metastatic Breast Cancer,” Semin. Oncol. 26, Suppl12:78-83 (1999).;;Baselga, et al., “Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER21neu overexpressing human breast cancer xenografts.” Cancer Res., 58:2825-2831, (1998).;;Batra, et al., “Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.” Proc. Natl. Acad. Sci. USA, 89:5867-5871 (1992).;;Blythman, et al. “Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells.” Nature, 290:145-146 (1981).;;Caron, et al., “Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia,” Clin. Cancer Res., 4: 1421-1428 (Jun. 1998).;;Carter, et al., “Humanization of an anti-p185 antibody for human cancer therapy.” Proc. Natl. Acad. Sci., USA, 89:4285-4289 (1992).;;Chari, “Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.” Adv. Drug Del. Rev., 31: 89-104 (1998).;;Chari, et al., “Immunoconjugates containing novel maytansinoids: promising anticancer drugs.” Cancer Res., 52:127-131 (1992).;;Curriculum vitae of Michael G. Rosenblum, Ph.D, last updated Mar. 12, 2014.;;Declaration by Barbara Klencke, M.D., filed on Jul. 6, 2010, in U.S. Appl. No. 11/949,351.;;Declaration by Mark X. Sliwokoswki, Ph.D., filed on Jul. 6, 2010, in U.S. Appl. No. 11/949,351.;;Declaration of Michael G. Rosenblum, Ph.D. dated Apr. 21, 2014.;;Declaration of Michael G. Rosenblum, Ph.D. dated May 29, 2014.;;Declaration of Walter Blättler and Ravi Chari filed on Sep. 11, 2012, in U.S. Appl. No. 11/949,351.;;Drewinko, et al., “Differential killing efficacy of twenty antitumor drugs on proliferating and non-proliferating human tumor cells.” Cancer Res. 41 :2328-2333 (1981).;;HERCEPTIN® Label, Sep. 1998.;;Hooijberg, et al., “Eradication of Large Human B Cell Tumors in Nude Mice with Unconjugated CD20 Monoclonal Antibodies and Jun. 15, Interleukin 2,” Cancer Res., 55: 2627-2634 (Jun. 15, 1995).;;Hudziak, et al., “p 185 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.” Mol. Cell. Biol., 9: 1165-1172 (1989).;;Knox, et al., “Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma,” Clin. Cancer Res., 2: 457-470 (Mar. 1996).;;Lewis et al. “Differential responses of human tumor cell lines to anti-p185 HER2 monoclonal antibodies,” Cancer Immunnol. Immunother. 37:255-263 (1993).;;Liu, et al. “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.” Proc. Natl. Acad. Sci., USA, 93:8618-8623 (1996).;;Liu, et al., “The development of antibody delivery systems to target cancer with highly potent maytansinoids.” Exp. Opin. Invest. Drugs, 6: 169-172 (1997).;;Louis Weiner “Monoclonal antibody therapy of cancer,” Semin. Oncol. 26, Suppl. 14:43-51 (1999).;;Maier, et al., “Requirements for the internalization of a murine monoclonal antibody directed against the HER-21neu gene product c-erbB-2,” Cancer Res., 51: 5361-53˜9 (1991).;;McKenzie, et al., “Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p 185.” Oncogene, 4:543-548 (1989).;;Morgan, et al., “Immunotoxins of Pseudomonas exotoxin A (PE): effect of linkage on conjugate yield, potency, selectivity and toxicity.” Mol. Immunol. 27:273-282 (1990).;;Office Action of Dec. 28, 2007, in U.S. Appl. No. 11/488,545.;;Office Action of Jan. 26, 2009 in U.S. Appl. No. 11/488,545. et al.",ACTIVE
242,HK,A1,HK 1201861 A1,048-060-794-633-877,2015-09-11,2015,HK 15102456 A,2015-03-10,US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,,AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL;;KING CHADWICK T T;;KLAKAMP SCOTT L L;;SU QIAOJUAN JANE,,https://lens.org/048-060-794-633-877,Patent Application,no,0,0,84,87,0,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K/;;A61K39/395;;A61K47/48;;A61P/;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,PENDING
243,US,A1,US 2013/0034705 A1,197-233-288-534-265,2013-02-07,2013,US 201113197750 A,2011-08-03,US 201113197750 A,2011-08-03,Molybdenum Composite Hybrid Laminates and Methods,"In an embodiment of the disclosure, there is provided a molybdenum composite hybrid laminate. The laminate has a plurality of composite material layers. The laminate further has a plurality of surface treated molybdenum foil layers interweaved between the composite material layers. The laminate further has a plurality of adhesive layers disposed between and bonding adjacent layers of the composite material layers and the molybdenum foil layers.",BOEING CO;;MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,THE BOEING COMPANY (2011-07-28),https://lens.org/197-233-288-534-265,Patent Application,yes,1,15,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B23P25/00;;B32B15/08;;B32B7/12;;B32B37/02;;B32B37/10;;B32B37/12;;B32B37/14;;B32B38/00;;B32B38/16;;C23F1/00;;H01R43/20,428/189;;428/457;;29/876;;29/458;;156/60;;156/64;;156/153;;156/272.8;;156/281;;216/35,0,0,,,,ACTIVE
244,US,B2,US 9085624 B2,192-353-646-896-827,2015-07-21,2015,US 26835208 A,2008-11-10,US 26835208 A;;US 87777404 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/192-353-646-896-827,Granted Patent,yes,108,2,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K39/00;;A61K47/48;;B82Y5/00;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,104,44,042-601-433-468-58X;;086-617-534-349-291;;077-950-844-586-930;;077-406-419-134-117;;067-782-603-238-967;;013-447-454-196-187;;014-234-489-298-615;;103-963-954-821-085;;008-822-347-989-692;;033-509-048-623-004;;165-322-209-862-791;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;003-420-832-784-996;;040-622-347-677-457;;030-080-528-694-129;;115-935-599-414-721;;016-435-611-136-112;;037-531-283-684-284;;025-279-035-199-960;;021-799-621-392-61X;;124-275-393-571-41X;;136-926-314-202-897;;112-409-472-179-059;;016-219-576-017-946;;022-890-862-570-978;;064-075-380-054-48X;;017-985-977-936-133;;045-904-151-504-498;;111-679-382-231-89X;;004-517-823-944-609;;119-625-566-432-941;;033-261-430-402-230;;027-477-313-726-928;;027-214-641-693-526;;008-019-042-176-997;;017-903-200-905-934;;077-406-419-134-117;;042-601-433-468-58X;;077-950-844-586-930,15520207;;10.1158/0008-5472.can-04-1722;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;10.1016/j.molimm.2004.11.003;;15829301;;10.1016/j.jim.2004.01.024;;15099763;;8845302;;3262420;;10.1182/blood-2003-01-0039;;12714494;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;3258189;;10.1021/jm00378a013;;6209394;;2005389;;10.4049/jimmunol.146.6.2017;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11352579;;10.1006/jmbi.2001.4628;;10.1038/313144a0;;2981413;;3017977;;10.1016/s0021-9258(18)67114-5;;11801540;;9816055;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;10.1002/ijc.11007;;12640678;;11454674;;12810643;;8947577;;10.1006/jmbi.1996.0617;;2103507;;10.1038/ng0297-146;;9020839;;9607595;;2430705;;10.1007/bf00199811;;10.1023/a:1011177318162;;11484948;;10.1016/s0969-8051(98)00120-6;;10382844;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;10.1016/0167-5699(93)90041-i;;8397766;;9584952;;10.3109/13550289809114515;;1560463;;10.1016/0022-2836(92)91010-m;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1093/oxfordjournals.jbchem.a003254;;12359067;;15185369;;10.1002/cbic.200300806;;10.1073/pnas.93.25.14815;;8962138;;pmc26219;;10.1016/j.jim.2004.01.024;;15099763;;15520207;;10.1158/0008-5472.can-04-1722;;10.1016/j.molimm.2004.11.003;;15829301,"Roitt et al, p. 5.8 and 5.9, in Immunology second edition, Gower Medical Publishing New York 1989.;;Henry et al, Cancer Res. 64: 7995-8001, Nov. 1, 2004.;;Stancoviski et al, Proceedings of the National Academy of Science USA 88: 8691-8695, 1991.;;Riemer et al. Mol. Immunol. 42: 1121-1124, 2005.;;Cochran et al, J. Immunol. Meth. 287: 147-158, 2004.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 07/531,410, filed Jun. 6, 1990, Vogelstein.;;U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati et al.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/430,938, filed Apr. 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovitz et al.;;U.S. Appl. No. 12/396,286, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 12/396,313, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 12/268,363, filed Nov. 10, 2008, Weber et al.;;Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvlll gene. Cell Growth Differ. 6(10):1251-9 (1995).;;Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.;;Francisco et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).;;Humphrey et al., (1988). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.;;Janeway et al. Immunobiology, 1994, p. 3:1-3:3.;;Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996).;;Kato et al. J. Med. Chem. 27:1602-1607 (1984).;;Kobrin et al. ""A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding"" J Immunol 146(6): 2017-2020, Mar. 1991.;;Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.;;Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 8(2):83-96 (2001).;;Kuan et al. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 17(2):71-78 (2000).;;Kuan et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. 88(6):962-969 (2000).;;Kuby et al. Immunology, Second Edition, 1994, p. 86-96.;;Lambert et al. in Immunotoxins 175-209 (A. Frankel, ed. 1988).;;Lambert et al. J. Biol. Chem. 260:12035-12041 (1985).;;Landry et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. Journal of Molecular. Biology 308(5):883-893 (2001).;;Libermann et al. (1985). Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 313:144-147.;;Livneh et al. ""Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells"" J Biol Chem., vol. 261, Issue 27, 12490-12497, 09, 1986.;;Lonardo et al. ""Evidence for the Epidermal Growth Factor Receptor As a Target for Lung Cancer Prevention"" Clin Cancer Res, 2002; 8(1): 54-60.;;Lorimer et al. ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."" Clinical Cancer Research, Aug. 1995, 1(8): 859-864.;;Liu et al. Proc. Natl. Acad. Sci. USA, Aug. 1996, 93: 8618-8623.;;Luo et al. Int. J. Cancer. 104(6):716-21 (2003).;;Luwor et al. ""Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR"" Cancer Research 61: 5355-5361, 2001.;;Mamot et al. Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells. Cancer Research 63:3154-3161 (2003).;;Martin, et al. J Mol Biol. Nov. 15, 1996;263(5):800-15.;;Mendelsohn, The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies, Semin Cancer Biol, Oct. 1990; 1(5):339-44.;;Mendez et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet.15(2):146-56 (1997).;;Mohammad et al. Clin Cancer Res, May 1998, 4(5): 1337-1343.;;Ohkawa et al. Cancer Immumol. Immunother. 23:81-86 (1986).;;Pederson et al. ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."" Annals of Oncology / ESMO Jun. 2001, 12(6): 745-760.;;Reist et al. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nuclear Medicine and Biology. 26(4):405-411 (1999).;;Tsukuda et al. Br. J. Cancer 52:111-116 (1985).;;Vitetta et al. Immunotoxins: magic bullets or misguided missiles? Immunol Today 14:252 (1993).;;Wikstrand et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J.Neurovirol. 4(2):148-158 (1998).;;U.S. Appl. No. 12/649,179, filed Dec. 29, 2009, Weber et al.;;Office Action dated Jan. 22, 2013 received in Japanese Patent Application 2010-262796 (with English translation).;;Office Action dated Sep. 6, 2013 in U.S. Appl. No. 12/649,179.;;Office Action issued Nov. 24, 2011 by the European Patent Office, received in European Patent Application No. 04 777 034.2.;;Office Action issued Nov. 24, 2011 by the European Patent Office, received in European Patent Application No. 04 777 147.2.;;Office Action dated Feb. 6, 2013 received in Australian Patent Application No. 2011265359.;;Office Action and English translation received in Chinese Application No. 200480018185.3, dated Nov. 5, 2012.;;Foote et al., ""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops."" Journal of Molecular Biology 224.2 (1992):487-499.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Appl. No. 6074/DELNP/2005.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Appl. No. 6073/DELNP/2005.;;Office Action dated Feb. 15, 2011, received in Japanese Patent Appl. No. 2006-517620.;;Office Action dated Feb. 8, 2011, received in Japanese Patent Appl. No. 2006-517700.;;Ghiotto et al., GenBank Acc. # AAK94829, Dec. 31, 2001.;;Office Action dated Mar. 16, 2011 and English summary, received in Mexican Patent Appl. No. PA/a/2005/014152.;;Office Action dated Mar. 24, 2011, received in Canadian Patent Appl. No. 2,530,285.;;Office Action dated Mar. 25, 2011, received in Canadian Patent Appl. No. 2,530,172.;;Rudikoff et al., ""Single Amino Acid Substitution Altering Antigen Binding Specificity"", Proc. Natl. Acad. Sci., 1982, Issue 79, pp. 1979-1983.;;Office Action dated Mar. 8, 2013 received in Mexican Patent Application MX/a/2012/001444 (with English translation).;;Office Action dated Mar. 8, 2013 received in Mexican Patent Application MX/a/2012/001445 (with English translation).;;Kala et al., J. Biochem 132: 535-514, 2002.;;Office Action dated May 24, 2012 in U.S. Appl. No. 12/649,179, filed Dec. 29, 2009.;;Piatesi et al, ChemBio Chem 5: 460-466, 2004.;;Lorimer et al. ""Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display."" Proc. Natl. Acad. Sci USA, Dec. 1996, vol. 93, pp. 14815-14820.;;Office Action dated Aug. 19, 2013, received in Korean Application No. 10-2013-7014050 with English translation.;;Office Action dated Sep. 12, 2013, received in U.S. Appl. No. 12/396,313.;;Cochran et al. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J lmmunol Meth 2004, 287: 147-158.;;Examiner Communication dated Oct. 20, 2009, received in European Appl. No. 04 777 147.2.;;Henry et al. A Prostate-Specific Membrange Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer. Cancer Res. Nov. 1, 2004. 64: 7995-8001.;;Issue Notification dated May 26, 2010, received in U.S. Appl. No. 10/877,774, Issue Date Jun. 15, 2010.;;Notice of Acceptance dated Jun. 10, 2010, received in Australian Application No. 2004260936.;;Notice of Allowance dated Dec. 8, 2008, received in U.S. Appl. No. 10/877,773.;;Notice of Allowance dated Jul. 15, 2010, received in U.S. Appl. No. 12/268,363.;;Notice of Allowance dated Jul. 28, 2010, received in Mexican Application No. PA/a/2005/014155.;;Notice of Allowance dated Oct. 17, 2008 received in U.S. Appl. No. 10/877,774.;;Office Action dated Jul. 12, 2010, received in U.S. Appl. No. 12/396,286.;;Office Action dated Jul. 12, 2010, received in U.S. Appl. No. 12/396,313.;;Office Action dated Jun. 25, 2010, received in Mexican Application No. PA/a/2005/014152.;;Office Action dated Mar. 17, 2010, received in Mexican Patent Appl. No. 2005/014155.;;Office Action dated Mar. 25, 2010, received in Australian Application No. 2004259398.;;Office Action dated May 11, 2010, received in Japanese Patent Appl. No. 2006/517620.;;Office Action dated May 25, 2010, received in Japanese Patent Appl. No. 2006-517700.;;Office Action dated Nov. 16, 2007, received in U.S. Appl. No. 10/877,774.;;Office Action dated Oct. 12, 2009, received in Australian patent application No. 2004260936.;;Office Action dated Sep. 23, 2009, received in European Patent Appl. No. 04 777 147.2.;;Patent Withdrawal Notice dated Apr. 24, 2009, for U.S. Appl. No. 10/877,774.;;Reimer et al. Matching of trastuzumab (Herceptin�) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol Innmunol. 2005, 42: 1121-1124.",ACTIVE
245,ES,T3,ES 2724527 T3,187-334-521-623-441,2019-09-11,2019,ES 12735384 T,2012-06-27,US 201113197750 A;;US 2012/0044459 W,2011-08-03,Laminados híbridos de material compuesto de molibdeno y métodos,"Un laminado (100) híbrido de material compuesto de molibdeno que comprende: una pluralidad de capas (106) de material compuesto; una pluralidad de capas (122) de hoja de molibdeno tratadas en la superficie entrelazadas entre las capas de material compuesto, en donde la capa de hoja de molibdeno se trata en la superficie a través de uno o más tratamientos de superficie seleccionados del grupo que comprende el tratamiento de la superficie sol gel, pintura sol gel a base de agua, granallado, lijado, arenado, limpieza con solvente, abrasión, limpieza química, ablación por láser y grabado químico; y una pluralidad de capas (134) adhesivas dispuestas entre y uniendo capas adyacentes de las capas de material compuesto y las capas de hoja de molibdeno; y en donde dos o más de las capas (106) de material compuesto tienen cada una una porción (144) recortada de hoja (123) de molibdeno tratada en la superficie, y las porciones (144) recortadas tienen bordes (148) interiores que están escalonados para evitar un recubrimiento de dos o más bordes (148) interiores.",BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,,https://lens.org/187-334-521-623-441,Granted Patent,no,0,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B3/06;;B29C73/10;;B32B7/12;;B32B15/00;;B32B15/08;;B32B19/02;;B32B37/14,,0,0,,,,ACTIVE
246,US,B2,US 9096672 B2,001-095-986-924-083,2015-08-04,2015,US 39631309 A,2009-03-02,US 39631309 A;;US 87777304 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/001-095-986-924-083,Granted Patent,yes,108,14,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/48;;B82Y5/00;;C07K16/22;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,103,48,004-272-966-072-139;;022-890-862-570-978;;037-531-283-684-284;;033-261-430-402-230;;077-406-419-134-117;;042-601-433-468-58X;;077-950-844-586-930;;086-617-534-349-291;;088-581-950-418-154;;006-553-734-546-212;;027-214-641-693-526;;008-019-042-176-997;;038-495-237-294-69X;;087-448-981-335-707;;055-904-468-981-551;;067-782-603-238-967;;064-678-224-734-734;;024-995-475-936-443;;050-646-523-937-465;;125-735-714-799-644;;013-447-454-196-187;;004-272-966-072-139;;045-751-499-875-041;;112-312-727-891-46X;;145-103-363-875-640;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;033-688-911-017-272;;008-822-347-989-692;;128-683-050-479-273;;041-969-682-554-154;;085-084-648-067-30X;;053-206-529-796-448;;033-509-048-623-004;;165-322-209-862-791;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;003-420-832-784-996;;040-622-347-677-457,10.1038/nbt832;;12778055;;9607595;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;1560463;;10.1016/0022-2836(92)91010-m;;10.1016/j.jim.2004.01.024;;15099763;;15520207;;10.1158/0008-5472.can-04-1722;;10.1016/j.molimm.2004.11.003;;15829301;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;10.4049/jimmunol.164.3.1432;;10640759;;8424945;;10.1021/bi00055a024;;10.1093/oxfordjournals.jbchem.a003254;;12359067;;15185369;;10.1002/cbic.200300806;;10.1093/jnci/75.1.151;;3859688;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/jmr.679;;15227640;;8845302;;3367154;;10.1097/00005072-198805000-00001;;10.1038/342877a0;;2687698;;10.1016/s0167-5699(97)01007-4;;9078685;;2428468;;3262420;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;9873732;;10.1016/s0960-894x(98)00610-6;;3802092;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;3258189;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1002/ijc.10189;;11920591;;12648464;;10.1016/s0014-4827(02)00098-8;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1021/jm00378a013;;6209394;;2005389;;10.4049/jimmunol.146.6.2017;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11352579;;10.1006/jmbi.2001.4628;;10.1038/313144a0;;2981413,"Doronnina et al, Nature Biotechnology 21(7): 778-941, Jul. 2003.;;Mohammad et al, Clin Cancer Res 4(5): 1337-43, May 1998.;;Toki et al, Abstracts of Papers of the American Chemical Society 223(2): A113, Apr. 7-11, 2002.;;Liu et al, Proc. Natl. Acad. Sci. U.S.A 93: 8618-8623, Aug. 1996.;;Office Action dated Jan. 15, 2013 received in Japanese Patent Application 2010-252825 (with English translation).;;Office Action dated Jan. 22, 2013 received in Japanese Patent Application 2010-262796 (with English translation).;;Office Action dated Feb. 6, 2013 received in Australian Patent Application No. 2011265359.;;Foote et al., ""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops."" Journal of Molecular Biology 224.2 (1992) : 487-499.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Appl. No. 6074/DELNP/2005.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Appl. No. 6073/DELNP/2005.;;Office Action dated Feb. 15, 2011, received in Japanese Patent Appl. No. 2006-517620.;;Office Action dated Feb. 8, 2011, received in Japanese Patent Appl. No. 2006-517700.;;Cochran et al. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Meth 2004, 287: 147-158.;;Green et al. Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates. Proc Amer Assoc Cancer Res, vol. 45, 2004. Abstract #5347. Presented at the American Association for Cancer Research Annual Meeting, Mar. 2004.;;Henry et al. A Prostate-Specific Membrange Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer. Cancer Res. Nov. 1, 2004. 64: 7995-8001.;;Office Action dated Aug. 7, 2009, received in U.S. Appl. No. 12/268,363.;;Office Action dated Jan. 25, 2010, received in U.S. Appl. No. 12/396,286.;;Office Action dated Jan. 7, 2010, received in U.S. Appl. No. 12/268,352.;;Office Action dated Jul. 15, 2009, received in Chinese Patent Appl. No. 200480018185.3.;;Office Action dated Mar. 12, 2010, received in Chinese Appl. No. 200480018260.6.;;Office Action dated Mar. 19, 2010, received in U.S. Appl. No. 12/268,363.;;Office Action dated Nov. 11, 2009, received in EP Appl. No. 04777034.2.;;Office Action dated Nov. 11, 2009, received in EP Appl. No. 04777147.2.;;Reimer et al. Matching of trastuzumab (Herceptin�) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol Immunol. 2005, 42: 1121-1124.;;Roitt et al. p. 5.8 and 5.9, in Immunology second edition, Gower Medical Publishing, New York, 1989.;;Stancovski et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA, 1991, 88: 8691-8695.;;Office Action dated Mar. 8, 2013 received in Mexican Patent Application MX/a/2012/001444 (with English translation).;;Office Action dated Mar. 8, 2013 received in Mexican Patent Application MX/a/2012/001445 (with English translation).;;Office Action dated May 1, 2013 in Canadian Application No. 2,530,172.;;Tamura, et al., Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only, Journal of Immunology, 2000, vol. 164, pp. 1432-1441.;;Brummell, et al., Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues, Biochemistry, 1993, vol. 32, pp. 1180-1187.;;Kala et al., J. Biochem 132: 535-514, 2002.;;Office Action dated May 24, 2012 in U.S. Appl. No. 12/649,179, filed Dec. 29, 2009.;;Piatesi et al,ChemBio Chem 5: 460-466, 2004.;;Office Action dated Jun. 11, 2012 in Canadian Patent Application No. 2,530,285.;;Office Action received in Korean Patent Application No. 10-2005-7024871, dated Jun. 29, 2012.;;Thorpe et al., ""An Immunotoxin Composed of Monoclonal Anti-Thy 1.1 Antibody and a Ribosome-Inactivating Protein from Saponaria officinalis: Potent Antitumor Effects in Vitro and in Vivo"", J. Natl. Cancer Inst., 75 pages, 151-159, Jul. 1985.;;Office action dated Jun. 28, 2013 received in Canadian Patent Application 2,530,285.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati et al.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovitz et al.;;U.S. Appl. No. 12/396,286, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 12/268,363, filed Nov. 10, 2008, Weber et al.;;U.S. Appl. No. 12/268,352, filed Nov. 10, 2008, Weber et al.;;Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):7843-8 (1996).;;Barrios et al. ""Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor"" J Mol Recognition 17: 332-338 (2004).;;Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6(10):1251-9 (1995).;;Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.;;Bumol et al, in Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).;;Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).;;Deo et al. Immunology Today (1997) 18:127.;;Diener et al, in Antibody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).;;Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.;;Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.;;Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.;;Doronnina et al. Nature Biotechnology, Jul. 2003, 21(7): 784, 941.;;Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence. Nature (1984) 307:521-527.;;Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. (1998) 8(23):3347-52.;;Endo et al. Cancer Res. (1980) 47:1076-1080.;;Examiner's First Report on Australian Patent Application No. 2004260936, dated Aug. 25, 2008, in 2 pages.;;Francisco et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.;;Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).;;Garcia De Palazzo, IE. et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 53(14):3217-20 (1993).;;Garnett et al. Cancer Res. 46:2407-2412 (1986).;;Ge H. et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98(3):357-61 (2002).;;Ghose et al, in Targeted Drugs 1-22 (E. Goldberg, ed. 1983).;;Gilmore et al., (1985). Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro. Cell 40:609-618.;;Green and Jakobovits J. Exp. Med. 188:483-495 (1998).;;Green et al. ""Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates"" American Association for Cancer Research Annual Meeting, Mar. 2004.;;Humphrey et al., (1988). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.;;Humphrey et al. ""Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma"" Proceedings of the National Academy of Sciences USA, Jun. 1990, 87 (11): 4207-4211.;;Hurwitz et al. Appl. Biochem. 2:25-35 (1980).;;International Search Report dated Aug. 1, 2005, from International Application No. PCT/US2004/020295.;;International Search Report dated Aug. 14, 2006, from International Application No. PCT/US2004/20564.;;Janeway et al. Immunobiology, 1994, p. 3:1-3:3.;;Johns et al. ""Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene"" Int J Cancer 98: 398-408 (2002).;;Jorissen et al. ""Epidermal growth factor receptor: mechanisms of activation and signaling"" Experimental Cell Research 284 (2003) 31-53.;;Jungbluth et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 100(2):639-644 (2003).;;Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996).;;Kato et al. J. Med. Chem. 27:1602-1607 (1984).;;Kobrin et al. ""A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding"" J Immunol 146(6): 2017-2020, Mar. 1991.;;Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.;;Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 8(2):83-96 (2001).;;Kuan et al. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 17(2):71-78 (2000).;;Kuan et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. 88(6):962-969 (2000).;;Kuby et al. Immunology, Second Edition, 1994, p. 86-96.;;Lambert et al. in Immunotoxins 175-209 (A. Frankel, ed. 1988).;;Lambert et al. J. Biol. Chem. 260:12035-12041 (1985).;;Landry et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. Journal of Molecular Biology. 308(5):883-893 (2001).;;Libermann et al. (1985). Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 313:144-147.",ACTIVE
247,US,B2,US 7628986 B2,021-466-464-885-924,2009-12-08,2009,US 87777304 A,2004-06-25,US 87777304 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/021-466-464-885-924,Granted Patent,yes,59,96,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/00;;A61K39/395;;A61K47/48;;C07K16/00;;C07K16/18;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;C12P21/08;;G01N33/53,424/130.1;;424/141.1;;424/143.1;;424/178.1;;424/179.1;;435/810;;530/387.1;;530/388.1;;530/388.15;;530/388.22;;530/391.1,107,79,004-272-966-072-139;;022-890-862-570-978;;037-531-283-684-284;;165-322-209-862-791;;055-904-468-981-551;;044-355-372-029-744;;103-755-269-224-85X;;112-409-472-179-059;;077-163-323-456-652;;053-206-529-796-448;;045-082-353-678-357;;085-084-648-067-30X;;021-799-621-392-61X;;041-969-682-554-154;;087-448-981-335-707;;067-782-603-238-967;;064-678-224-734-734;;024-995-475-936-443;;050-646-523-937-465;;013-447-454-196-187;;125-735-714-799-644;;004-272-966-072-139;;045-751-499-875-041;;112-312-727-891-46X;;145-103-363-875-640;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;033-688-911-017-272;;008-822-347-989-692;;053-206-529-796-448;;033-509-048-623-004;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;003-420-832-784-996;;040-622-347-677-457;;025-279-035-199-960;;002-538-287-083-621;;124-275-393-571-41X;;087-103-148-426-023;;136-926-314-202-897;;112-409-472-179-059;;016-219-576-017-946;;067-857-455-571-760;;043-637-817-489-241;;028-036-828-526-370;;064-075-380-054-48X;;150-632-545-202-265;;154-572-677-438-265;;045-904-151-504-498;;072-377-861-372-36X;;004-986-447-228-415;;029-269-446-589-556;;111-679-382-231-89X;;087-806-501-008-318;;093-272-820-060-870;;054-354-046-619-106;;004-517-823-944-609;;090-683-249-679-734;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;049-182-911-054-623;;027-389-935-773-753;;032-441-846-127-844;;006-301-071-808-697;;044-355-372-029-744;;073-659-966-706-479;;030-080-528-694-129;;115-935-599-414-721;;062-976-245-058-504,10.1038/nbt832;;12778055;;9607595;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;2005389;;10.4049/jimmunol.146.6.2017;;10.1002/jmr.679;;15227640;;11255078;;10.1016/s1040-8428(00)00134-7;;2285602;;10.1016/0960-0760(90)90438-q;;2103507;;10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#;;9506533;;12515857;;10.1073/pnas.232686499;;pmc141049;;pmc16575;;10.1073/pnas.130166597;;10852962;;12648464;;10.1016/s0014-4827(02)00098-8;;11454674;;10.1002/ijc.10189;;11920591;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;8845302;;3367154;;10.1097/00005072-198805000-00001;;10.1038/342877a0;;2687698;;10.1016/s0167-5699(97)01007-4;;9078685;;3262420;;2428468;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;9873732;;10.1016/s0960-894x(98)00610-6;;3802092;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;3258189;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1021/jm00378a013;;6209394;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11352579;;10.1006/jmbi.2001.4628;;10.1038/313144a0;;2981413;;10.1002/ijc.11007;;12640678;;2834047;;12810643;;10.1016/0006-2952(85)90140-6;;2578281;;8947577;;10.1006/jmbi.1996.0617;;2103507;;10.1038/ng0297-146;;9020839;;21566922;;10.3892/ijo.4.2.277;;7585629;;10.1016/s0092-8674(85)80052-0;;2988784;;2430705;;10.1007/bf00199811;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;6206272;;10.1093/jnci/73.3.721;;10.1038/309418a0;;6328312;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10.1016/0092-8674(83)90153-8;;6309409;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;3261803;;10.1093/jnci/80.14.1154;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;3017977;;10.1016/s0021-9258(18)67114-5;;11801540;;2855491;;10.1101/sqb.1988.053.01.059,"Doronnina et al, Nature Biotechnology 21(7): 778-784,941, Jul. 2003.;;Mohammad et al, Clin Cancer Res 4(5): 1337-43, May 1998.;;Liu et al, Proc. Natl. Acad. Sci. U.S.A 93: 8618-8623, Aug. 1996.;;Toki et al, Abstracts of Papers of the American Chemical Society 223(2): A113, Apr. 7-11, 2002.;;Kuby et al, Immunology, Second edition, pp. 86-96, 1994.;;Kobrin et al, J Immunology 146:2017-2020, 1991.;;Barrios et al, J Molecular Recognition 17: 332-338, 2004.;;Yang et al, Crit. Rev Oncol Hematol 38: 17-23, 2001.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;Mendelsohn, Cancer Cells 7:359 (1989).;;Mendelsohn, ""Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents"", J Steroid Biochem Mol Biol, Dec 20, 1990: 37 (6): 889-92.;;Mendelsohn, The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies, Semin Cancer Biol, Oct. 1990; 1(5):339-44.;;Schmidt et al., Expression of an Oncogenic Mutant EGF Receptor Markedly Increases The Sensitivity of Cells to an EGF-Receptor-Specific Antibody-Toxin, Int. J. Cancer, 75, 878-884 (Mar. 16, 1998).;;Janeway et al. ""The Structure of typical Antibody Molecule,"" Immunobiology, 1994, 3:1-3:3.;;Green et al. ""Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates"" American Association for Cancer Research Annual Meeting, Mar. 2004.;;Jungbluth et al. ""A monoclonal antibody recognizing human cancers with amplification / overexpression of the human epidermal growth factor receptor"" Proc Nat Acad Sci 100(2): 639-644, Jan. 2003.;;Sampson et al. ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors"" Proc Nat Acad Sci 97(13): 7503-7508, Jun. 2000.;;Jorissen et al. ""Epidermal growth factor receptor: mechanisms of activation and signaling"" Experimental Cell Research 284 (2003) 31-53.;;Luwor et al. Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR.;;Office Action dated Nov. 16, 2007, received in U.S. Appl. No. 10/877,774.;;Johns et al. ""Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene"" Int J Cancer 98: 398-408 (2002).;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990.;;U.S. Appl. No. 07/610,515, Nov. 8, 1990.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995.;;U.S. Appl. No. 08/464, 584, filed Jun. 5, 1995.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996.;;Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):7843-8 (1996).;;Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occuring human mutant EGFRvIII gene. Cell Growth Differ. 8(10):125-9 (1995).;;Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.;;Bumol et al, In Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).;;Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).;;Deo et al. Immunology Today (1997) 18:127.;;Diener et al, In Antobody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).;;Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.;;Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.;;Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.;;Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence. Nature (1984) 307:521-527.;;Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel: (Taxol), mitomycin C and doxorubicin Bloorg Med Chem Lett. (1998) 8(23):3347-52.;;Endo et al. Cancer Res. (1980) 47:1076-1080.;;Francisco et al. cAC10-vcMMAE, and anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basic for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.;;Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).;;Garcia de Palazzo, IE. et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 53(14):3217-20 (1993).;;Garnett et al. Cancer Res. 46:2407-2412 (1986).;;Ge H. et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98(3):357-61 (2002).;;Ghose et al, in Targeted Drugs 1-22 (E. Goldberg, ed. 1983).;;Gilmore et al., (1985). Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro. Cell 40:609-618.;;Green and Jakobovits J. Exp. Med. 188:483-495 (1998).;;Humphrey et al., (1988). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.;;Hurwitz et al. Appl. Biochem. 2:25-35 (1980).;;Jungbluth et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 100(2):639-44 (2003).;;Junghans et al. In Cancer Chemotherapy and Biotherapy 655-688 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996).;;Kato et al. J. Med. Chem. 27:1602-1607 (1984).;;Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.;;Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 8(2):83-96 (2001).;;Kuan et al. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 17(2):71-78 (2000).;;Kuan et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer 88(6):962-969 (2000).;;Lambert et al. In Immunotoxins 175-209 (A Frankel, ed. 1988);;Lambert et al. J. Biol. Chem. 260:12035-12041 (1985).;;Landry et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. Journal of Molecular Biology. 308(5):883-893 (2001).;;Libermann et al. (1985). Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 313:144-147.;;Luo et al. Int. J. Cancer. 104(6):716-21 (2003).;;Malden et al., (1988). Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme. Cancer Research 4:2711-2714.;;Mamot et al. Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells. Cancer Research 63:3154-3161 (2003).;;Manabe et al. Biochem. Pharmacol. 34 : 289-291 (1985).;;Martin, et al. J Mol Biol. Nov. 15, 1996;263(5):800-15.;;Mendelsohn J., The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol Oct. 1990;1(5):339-344.;;Mendez et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 15(2):146-56 (1997).;;Modjtahedi and Dean Int'l J. Oncology 4:277-296 (1994).;;Moscatello, G. et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55(23):5536-9 (1995).;;Nilsen et al., (1985). c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor. Cell 41:719-726.;;Ohkawa et al. Cancer Immumol. Immunother. 23:81-86 (1986).;;Olapade-Olaopa, EO. et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82(1):186-94 (2000).;;Pelley et al., (1988). Proviral-Activated c-erbB is i Leukemogenic but not Sacromagenic: Characterization of a Replication-Competent Retrovirus Containing the Activated c-erbB. Journal of Virology 62:1840-1844.;;Pietersz et al, in Antibody Mediated Delivery Systems 25-53 (J. Rodwell, ed. 1988).;;Relst et al. Astatine-211 labeling of internalizing anti EGFRvIII monoclonal antibody using N succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nuclear Medicine and Biology. 26(4):405-411 (1999).;;Relst et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nuclear Medicine and Biology. 24(7):639-647 (1997).;;Sela et al. in Immunoconjugates 189-216 (C. Vogel, ed. 1987).;;Shouval et al. Proc. Natl. Acad. Sci. 85: 8276-8280 (1988).;;Trouet et al. Proc. Natl. Acad. Sci. 79: 626-629 (1982).;;Tsukada et al. Br. J. Cancer 52:111-116 (1985).;;Tsukada et al. J. Natl. Canc. Inst. 73:721-729 (1984).;;Ullrich et al. (1984). Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells. Nature 309:418-425.;;Valerius et al. Blood 90:4485-4492 (1997).;;Vitetta et al. Immunotoxins: magic bullets or misguided missiles? Immunol Today 14:252 (1993).;;Wells et al., (1988). Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB. Proc. Natl. Acad. Sci. USA 85:7597-7601.;;Wikstrand et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunology, Immunotherapy. 50(12):639-652 (2002).;;Wikstrand et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carinomas malignant gliomas. Cancer Research. 55(14):3140-3148 (1995).;;Wikstrand et al. The class IIl variant of the epidermal growth factor receptor (EGFRvlll): characterization and utilization as an immunotherapeutic target. J.Neurovirol. 4(2):148-158 (1998).;;Wong et al. (1987). Increased Expression of the Epidermal Growth Factor Receptor Gene in Malignant Gliomas is invariably Associated with Gene Amplification. Proc. Natl. Acad. Sci. USA 84:6899-6903.;;Yamamoto et al., (1983). A New Avain Erythroblastosis Virus , AEV-H Carries erbB Gene Responsible for the Induction of Both Erythroblastosis and Sarcoma. Cell 34:225-232.;;Yamazaki et al. (1988). Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors Molecular and Cellular Biology 8:1816-1820.;;Yang and Reisfeld. J. Natl. Canc. Inst. 80:1154-1159 (1988).;;Yang X et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hemato 38(1):17-23 (2001).;;Yang X-D et al. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. Cancer Research 59(6):1236-1243 (1999).;;Livneh et al. ""Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells"" J Biol Chem., vol. 261, Issue 27, 12490-12497, 09, 1986.;;Lonardo et al. ""Evidence for the Epidermal Growth Factor Receptor As a Target for Lung Cancer Prevention"" Clin Cancer Res, 2002; 8(1): 54-60.;;Schlessinger et al. ""Signal Transduction by Epidermal Growth Factor Receptor"", Cold Spring Harb Symp Quant Biol, Jan. 1, 1988; 53: 515-519.",ACTIVE
248,EP,A1,EP 2739466 A1,199-291-159-193-108,2014-06-11,2014,EP 12735384 A,2012-06-27,US 201113197750 A;;US 2012/0044459 W,2011-08-03,MOLYBDENUM COMPOSITE HYBRID LAMINATES AND METHODS,,BOEING CO,MATSEN MARC R;;NEGLEY MARK A;;PIEHL MARC J;;BLOHOWIAK KAY Y;;LANDMANN ALAN E;;BOSSI RICHARD H;;CARLSEN ROBERT L;;FOLTZ GREGORY ALAN;;BUTLER GEOFFREY A;;PINGREE LIAM S CAVANAUGH;;MOORE STEPHEN G;;GARDNER JOHN MARK;;ANDERSON ROBERT A,,https://lens.org/199-291-159-193-108,Patent Application,yes,0,0,16,16,0,B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B29C73/10;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B32B7/12;;Y02T50/40;;Y10T29/49885;;Y10T156/10;;Y10T428/24752;;Y10T29/49208;;Y10T428/31678;;B29C73/10;;B32B15/08;;B32B3/06;;B32B2250/42;;B32B2260/021;;B32B2405/00;;B32B2605/18;;B32B7/12;;B32B15/00;;B32B19/02;;B32B27/00;;B32B37/144;;B32B2305/08;;B32B2307/202;;B32B2307/204;;B32B2307/54;;B32B2307/558;;B32B2311/00;;B32B2398/00,B32B7/12;;B32B3/06;;B32B15/00;;B32B15/08;;B32B19/02;;B32B27/00,,0,0,,,,ACTIVE
249,US,B2,US 9073998 B2,162-782-484-882-672,2015-07-07,2015,US 39628609 A,2009-03-02,US 39628609 A;;US 87777304 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE;;AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/162-782-484-882-672,Granted Patent,yes,108,3,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K47/48;;A61K39/00;;A61K39/395;;B82Y5/00;;C07K14/71;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,100,69,087-448-981-335-707;;055-904-468-981-551;;067-782-603-238-967;;064-678-224-734-734;;024-995-475-936-443;;050-646-523-937-465;;125-735-714-799-644;;013-447-454-196-187;;004-272-966-072-139;;045-751-499-875-041;;112-312-727-891-46X;;145-103-363-875-640;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;033-688-911-017-272;;008-822-347-989-692;;128-683-050-479-273;;041-969-682-554-154;;085-084-648-067-30X;;053-206-529-796-448;;033-509-048-623-004;;165-322-209-862-791;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;003-420-832-784-996;;040-622-347-677-457;;030-080-528-694-129;;115-935-599-414-721;;016-435-611-136-112;;037-531-283-684-284;;025-279-035-199-960;;021-799-621-392-61X;;002-538-287-083-621;;124-275-393-571-41X;;087-103-148-426-023;;136-926-314-202-897;;112-409-472-179-059;;103-755-269-224-85X;;112-409-472-179-059;;016-219-576-017-946;;067-857-455-571-760;;022-890-862-570-978;;043-637-817-489-241;;028-036-828-526-370;;064-075-380-054-48X;;150-632-545-202-265;;017-985-977-936-133;;154-572-677-438-265;;045-904-151-504-498;;072-377-861-372-36X;;045-082-353-678-357;;062-976-245-058-504;;077-163-323-456-652;;004-986-447-228-415;;029-269-446-589-556;;111-679-382-231-89X;;087-806-501-008-318;;093-272-820-060-870;;054-354-046-619-106;;004-517-823-944-609,8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/jmr.679;;15227640;;8845302;;3367154;;10.1097/00005072-198805000-00001;;10.1038/342877a0;;2687698;;10.1016/s0167-5699(97)01007-4;;9078685;;2428468;;3262420;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;9873732;;10.1016/s0960-894x(98)00610-6;;3802092;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;3258189;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1002/ijc.10189;;11920591;;12648464;;10.1016/s0014-4827(02)00098-8;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1021/jm00378a013;;6209394;;2005389;;10.4049/jimmunol.146.6.2017;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11352579;;10.1006/jmbi.2001.4628;;10.1038/313144a0;;2981413;;3017977;;10.1016/s0021-9258(18)67114-5;;11801540;;9816055;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;10.1002/ijc.11007;;12640678;;11454674;;2834047;;12810643;;10.1016/0006-2952(85)90140-6;;2578281;;8947577;;10.1006/jmbi.1996.0617;;2103507;;2285602;;10.1016/0960-0760(90)90438-q;;2103507;;10.1038/ng0297-146;;9020839;;21566922;;10.3892/ijo.4.2.277;;9607595;;7585629;;10.1016/s0092-8674(85)80052-0;;2988784;;2430705;;10.1007/bf00199811;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;10.1023/a:1011177318162;;11484948;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;pmc16575;;10.1073/pnas.130166597;;10852962;;2855491;;10.1101/sqb.1988.053.01.059;;10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#;;9506533;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;pmc1977178;;2410001;;10.1038/bjc.1985.157;;6206272;;10.1093/jnci/73.3.721;;10.1038/309418a0;;6328312;;10.1182/blood.v90.11.4485.4485_4485_4492;;9373259;;10.1182/blood.v90.11.4485;;10.1016/0167-5699(93)90041-i;;8397766,"Roitt et al, p. 5.8 and 5.9, in Immunology second edition, Gower Medical Publishing New York 1989.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;U.S. Appl. No. 07/601,515, filed Nov. 8, 1990, Kucherlapati et al.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovitz et al.;;U.S. Appl. No. 12/396,313, filed Mar. 2, 2009, Weber et al.;;U.S. Appl. No. 12/268,363, filed Nov. 10, 2008, Weber et al.;;Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):784308 (1996).;;Barrios et al. ""Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor"" J Mol Recognition 17: 332-338 (2004).;;Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6(10):1251-9 (1995).;;Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.;;Bumol et al, in Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).;;Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).;;Deo et al. Immunology Today (1997) 18:127.;;Diener et al, in Antibody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).;;Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.;;Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.;;Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.;;Doronnina et al. Nature Biotechnology, Jul. 2003, 21(7): 784, 941.;;Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence. Nature (1984) 307:521-527.;;Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. (1998) 8(23):3347-52.;;Endo et al. Cancer Res. (1980) 47:1076-1080.;;Francisco et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.;;Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).;;Garcia De Palazzo, IE. et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 53(14):3217-20 (1993).;;Garnett et al. Cancer Res. 46:2407-2412 (1986).;;Ge H. et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98(3):357-61 (2002).;;Ghose et al, in Targeted Drugs 1-22 (E. Goldberg, ed. 1983).;;Gilmore et al., (1985). Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro. Cell 40:609-618.;;Green and Jakobovits J. Exp. Med. 188:483-495 (1998).;;Green et al. ""Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates"" American Association for Cancer Research Annual Meeting, Mar. 2004.;;Humphrey et al., (1988). Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts. Cancer Research 48:2231-2238.;;Humphrey et al. ""Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma"" Proceedings of the National Academy of Sciences USA, Jun. 1990, 87 (11): 4207-4211.;;Hurwitz et al. Appl. Biochem. 2:25-35 (1980).;;Janeway et al. Immunobiology, 1994, p. 3:1-3:3.;;Johns et al. ""Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene"" Int J Cancer 98: 398-408 (2002).;;Jorissen et al. ""Epidermal growth factor receptor: mechanisms of activation and signaling"" Experimental Cell Research 284 (2003) 31-53.;;Jungbluth et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 100(2):639-644 (2003).;;Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippinott Raven (1996).;;Kato et al. J. Med. Chem. 27:1602-1607 (1984).;;Kobrin et al. ""A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding"" J Immunol 146(6): 2017-2020, Mar. 1991.;;Kris et al., (1985). Antibodies Against a Synthetic Peptide as a Probe for the Kinase Activity of the Avian EGF Receptor and v-erB Protein. Cell 40:619-625.;;Kuan et al. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 8(2):83-96 (2001).;;Kuan et al. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. 17(2):71-78 (2000).;;Kuan et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. 88(6):962-969 (2000).;;Kuby et al. Immunology, Second Edition, 1994, p. 86-96.;;Lambert et al. in Immunotoxins 175-209 (A. Frankel, ed. 1988).;;Lambert et al. J. Biol. Chem. 260:12035-12041 (1985).;;Landry et al. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. Journal of Molecular Biology. 308(5):883-893 (2001).;;Libermann et al. (1985). Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin. Nature 313:144-147.;;Livneh et al. ""Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells"" J Biol Chem., vol. 261, Issue 27, 12490-12497, 09, 1986.;;Lonardo et al. ""Evidence for the Epidermal Growth Factor Receptor as a Target for Lung Cancer Prevention"" Clin Cancer Res, 2002; 8(1): 54-60.;;Lorimer et al. ""Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors."" Clinical Cancer Research, Aug. 1995, 1(8): 859-864.;;Liu et al. Proc. Natl. Acad. Sci. USA, Aug. 1996, 93: 8618-8623.;;Luo et al. Int. J. Cancer. 104(6):716-21 (2003).;;Luwor et al. ""Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR"" Cancer Research 61: 5355-5361, 2001.;;Malden et al., (1988). Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme. Cancer Research 4:2711-2714.;;Mamot et al. Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells. Cancer Research 63:3154-3161 (2003).;;Manabe et al. Biochem. Pharmacol. 34 : 289-291 (1985).;;Martin, et al. J Mol Biol. Nov. 15, 1996;263(5):800-15.;;Mendelsohn J., The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol Oct. 1990;1(5):339-344.;;Mendelsohn, ""Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents"", J Steroid Biochem Mol Biol, Dec. 20, 1990; 37 (6):889-92.;;Mendelsohn, The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies, Semin Cancer Biol, Oct. 1990; 1(5):339-44.;;Mendelsohn, Cancer Cells 7:359 (1989).;;Mendez et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet.15(2):146-56 (1997).;;Modjtahedi and Dean Int'l J. Oncology 4:277-296 (1994).;;Mohammad et al. Clin Cancer Res, May 1998, 4(5): 1337-1343.;;Moscatello, G. et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55(23):5536-9 (1995).;;Nilsen et al., (1985). c-erbB Activation in ALV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor. Cell 41:719-726.;;Ohkawa et al. Cancer Immumol. Immunother. 23:81-86 (1986).;;Olapade-Olaopa, EO. et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 82(1):186-94 (2000).;;Pederson et al. ""The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy."" Annals of Oncology / ESMO Jun. 2001, 12(6): 745-760.;;Pelley et al., (1988). Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication-Competent Retrovirus Containing the Activated c-erbB. Journal of Virology 62: 1840-1844.;;Pietersz et al, in Antibody Mediated Delivery Systems 25-53 (J. Rodwell, ed. 1988).;;Reist et al. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nuclear Medicine and Biology. 26(4):405-411 (1999).;;Reist et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nuclear Medicine and Biology. 24(7):639-647 (1997).;;Sampson et al. ""Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors"" Proc Nat Acad Sci 97(13): 7503-7508, Jun. 2000.;;Schlessinger et al. ""Signal Transduction by Epidermal Growth Factor Receptor"", Cold Spring Harb Symp Quant Biol, Jan. 1, 1988; 53: 515-519.;;Schmidt et al., Expression of an Oncogenic Mutant EGF Receptor Markedly Increases the Sensitivity of Cells to an EGF-Receptor-Specific Antibody-Toxin, Int. J. Cancer, 75, 878-884 (Mar. 16, 1998).;;Sela et al. in Immunoconjugates 189-216 (C. Vogel, ed. 1987).;;Shouval et al. Proc. Natl. Acad. Sci. 85: 8276-8280 (1988).;;Toki et al. Abstracts of Papers of the American Chemical Society, Apr. 2002, 223(2):A1113, 7-11.;;Trouet et al. Proc. Natl. Acad. Sci. 79: 626-629 (1982).;;Tsukada et al. Br. J. Cancer 52:111-116 (1985).;;Tsukada et al. J. Natl. Canc. Inst. 73:721-729 (1984).;;Ullrich et al. (1984). Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells. Nature 309:418-425.;;Valerius et al. Blood 90:4485-4492 (1997).;;Vitetta et al. Immunotoxins: magic bullets or misguided missiles? Immunol Today 14:252 (1993).",ACTIVE
250,US,A1,US 2009/0175887 A1,196-303-153-902-942,2009-07-09,2009,US 39628609 A,2009-03-02,US 39628609 A;;US 87777304 A;;US 48314503 P;;US 52557003 P;;US 56245304 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD;;FENG XIAO;;FOORD ORIT;;GREEN LARRY;;GUDAS JEAN M;;KEYT BRUCE;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL S;;KING CHADWICK T;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/196-303-153-902-942,Patent Application,yes,70,29,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,424/178.1;;435/375,0,0,,,,ACTIVE
251,US,A1,US 2020/0062860 A1,151-252-376-467-95X,2020-02-27,2020,US 201916673234 A,2019-11-04,US 201916673234 A;;US 201514743886 A;;US 26835208 A;;US 87777404 A;;US 56245304 P;;US 52557003 P;;US 48314503 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD F;;FENG XIAO;;FOORD ORIT;;GREEN LARRY L;;GUDAS JEAN M;;KEYT BRUCE A;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE R F;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL SINGH;;KING CHADWICK TERENCE;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/151-252-376-467-95X,Patent Application,yes,0,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/30;;A61K39/395;;A61K47/48;;A61K47/68;;B82Y5/00;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,0,0,,,,ACTIVE
252,US,B2,US 10508153 B2,034-361-749-982-542,2019-12-17,2019,US 201514743886 A,2015-06-18,US 201514743886 A;;US 26835208 A;;US 87777404 A;;US 56245304 P;;US 52557003 P;;US 48314503 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD F;;FENG XIAO;;FOORD ORIT;;GREEN LARRY L;;GUDAS JEAN M;;KEYT BRUCE A;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE R F;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL SINGH;;KING CHADWICK TERENCE;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/034-361-749-982-542,Granted Patent,yes,123,1,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/28;;A61K39/00;;A61K39/395;;A61K47/48;;A61K47/68;;B82Y5/00;;C07K16/22;;C07K16/30;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,434,167,032-214-592-514-94X;;042-741-242-328-693;;026-589-266-128-73X;;033-870-601-973-366;;080-633-663-618-912;;027-477-313-726-928;;013-142-717-038-23X;;054-707-943-234-995;;068-033-680-421-173;;012-434-436-039-701;;087-448-981-335-707;;055-904-468-981-551;;067-782-603-238-967;;064-678-224-734-734;;006-553-734-546-212;;045-942-104-775-903;;017-386-037-070-267;;001-779-867-387-972;;035-554-935-107-802;;024-995-475-936-443;;029-611-134-469-353;;077-406-419-134-117;;124-416-510-861-245;;014-113-432-888-031;;125-735-714-799-644;;013-447-454-196-187;;004-272-966-072-139;;045-751-499-875-041;;112-312-727-891-46X;;012-104-543-895-325;;145-103-363-875-640;;001-711-151-176-765;;033-261-430-402-230;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;021-182-185-908-148;;033-688-911-017-272;;042-601-433-468-58X;;008-822-347-989-692;;128-683-050-479-273;;041-969-682-554-154;;085-084-648-067-30X;;053-206-529-796-448;;027-214-641-693-526;;033-509-048-623-004;;049-928-993-608-092;;165-322-209-862-791;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;044-866-756-228-616;;069-165-512-595-028;;058-648-791-423-620;;003-420-832-784-996;;020-367-308-901-689;;103-729-004-244-688;;040-622-347-677-457;;037-531-283-684-284;;030-080-528-694-129;;115-935-599-414-721;;010-953-281-569-514;;016-435-611-136-112;;017-903-200-905-934;;025-279-035-199-960;;021-799-621-392-61X;;095-334-545-560-259;;002-538-287-083-621;;124-275-393-571-41X;;087-103-148-426-023;;136-926-314-202-897;;025-692-172-883-979;;103-755-269-224-85X;;112-409-472-179-059;;016-219-576-017-946;;067-857-455-571-760;;022-890-862-570-978;;043-637-817-489-241;;103-932-348-507-545;;028-036-828-526-370;;053-158-286-316-214;;150-632-545-202-265;;045-872-081-200-101;;145-254-035-276-41X;;017-985-977-936-133;;154-572-677-438-265;;008-019-042-176-997;;008-019-042-176-997;;135-943-065-643-592;;033-769-003-424-862;;077-950-844-586-930;;045-904-151-504-498;;072-377-861-372-36X;;157-729-192-316-421;;027-477-313-726-928;;045-082-353-678-357;;062-976-245-058-504;;077-163-323-456-652;;004-986-447-228-415;;086-617-534-349-291;;015-399-941-370-866;;088-581-950-418-154;;038-495-237-294-69X;;057-971-690-843-179;;029-269-446-589-556;;093-272-820-060-870;;051-707-000-800-833;;004-705-560-504-051;;004-517-823-944-609;;016-265-697-674-181;;090-683-249-679-734;;072-729-813-791-160;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;049-182-911-054-623;;013-142-717-038-23X;;027-389-935-773-753;;032-441-846-127-844;;006-301-071-808-697;;044-355-372-029-744;;073-659-966-706-479;;100-394-462-349-099;;186-732-989-640-404;;063-634-487-523-604;;165-749-823-188-437;;075-889-605-642-840;;031-970-152-284-72X;;009-483-512-107-343;;094-424-423-768-724;;065-684-269-783-203;;112-811-296-657-597;;128-037-910-947-545;;030-309-956-160-927;;064-021-604-555-029;;031-886-516-535-883;;037-531-283-684-284;;100-216-688-182-170;;086-378-024-269-624;;067-653-203-289-895;;001-075-703-287-400;;065-271-121-674-291;;048-110-926-130-802;;004-402-270-959-674;;057-205-729-571-877;;069-970-853-729-540;;005-038-448-235-576;;152-475-651-861-295;;047-010-764-744-638;;175-134-379-959-97X;;115-916-545-155-724;;092-117-309-419-982;;133-939-910-996-391;;022-400-834-786-515;;005-461-375-871-624;;059-212-558-154-670;;034-626-837-626-258;;034-526-119-277-42X;;002-666-993-527-919;;032-214-592-514-94X;;005-461-375-871-624;;142-206-526-949-177,8258342;;8258341;;10.1002/eji.1830231231;;10.1038/347090a0;;2118596;;10.1182/blood-2002-01-0008;;12200383;;10527689;;10.1006/clim.1999.4781;;14568943;;10.4049/jimmunol.171.9.4680;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10556035;;10.1006/jmbi.1999.3141;;pmc2034020;;10.1038/bjc.1995.435;;7547242;;12189730;;10.1007/978-1-4615-0549-5_2;;11560969;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/jmr.679;;15227640;;8845302;;3367154;;10.1097/00005072-198805000-00001;;8424945;;10.1021/bi00055a024;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1016/0167-7799(96)80921-8;;8746117;;10.1006/jmbi.1999.3192;;10543973;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10.1038/342877a0;;2687698;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1016/j.jim.2004.01.024;;15099763;;10.1002/ijc.1572;;11774237;;12218124;;10.4049/jimmunol.169.6.3076;;2428468;;3262420;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;9873732;;10.1016/s0960-894x(98)00610-6;;7608568;;10.4049/jimmunol.155.2.925;;3802092;;9530559;;10.1016/s1380-2933(97)10003-3;;10.2210/pdb1aqk/pdb;;1560463;;10.1016/0022-2836(92)91010-m;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;10.2210/pdb1hez/pdb;;10.1016/s0969-2126(01)00630-x;;11587642;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;15520207;;10.1158/0008-5472.can-04-1722;;3258189;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1002/ijc.10189;;11920591;;12648464;;10.1016/s0014-4827(02)00098-8;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1093/oxfordjournals.jbchem.a003254;;12359067;;10.1021/jm00378a013;;6209394;;10656818;;10.1006/jmbi.1999.3444;;2005389;;10.4049/jimmunol.146.6.2017;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;2908625;;10.1007/978-1-4613-1083-9_12;;4044586;;10.1016/s0021-9258(17)38981-0;;11416113;;10.1093/jnci/93.12.921;;11352579;;10.1006/jmbi.2001.4628;;1961196;;10.1016/0161-5890(91)90003-3;;10.1006/jmbi.1997.0950;;9150407;;10.1038/313144a0;;2981413;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;3017977;;10.1016/s0021-9258(18)67114-5;;11801540;;10.1038/nbt1135;;16151405;;9816055;;10.1073/pnas.93.25.14815;;8962138;;pmc26219;;10.1002/ijc.11007;;12640678;;11454674;;10.1006/jmbi.1996.0548;;8876650;;2834047;;12810643;;10.1016/0006-2952(85)90140-6;;2578281;;8947577;;10.1006/jmbi.1996.0617;;10.1074/jbc.m808802200;;19224862;;pmc2667743;;2285602;;10.1016/0960-0760(90)90438-q;;2103507;;10.1038/ng0297-146;;9020839;;21566922;;10.3892/ijo.4.2.277;;9607595;;7585629;;10.1007/978-1-4684-6831-1_14;;10.1016/s0092-8674(85)80052-0;;2988784;;10.1007/s002620050622;;10550550;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;pmc297746;;10.1073/pnas.86.15.5938;;2762305;;10.2210/pdb3hfm/pdb;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1023/a:1011177318162;;11484948;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;15185369;;10.1002/cbic.200300806;;15185369;;10.1002/cbic.200300806;;10.1111/j.1600-065x.1992.tb01419.x;;1464422;;11000403;;10.1016/s0161-5890(00)00049-3;;10.1016/j.molimm.2004.11.003;;15829301;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;7671250;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;pmc16575;;10.1073/pnas.130166597;;10852962;;2855491;;10.1101/sqb.1988.053.01.059;;10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#;;9506533;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;10.2210/pdb6fab/pdb;;10.1021/bi00229a022;;2015229;;10.4049/jimmunol.164.3.1432;;10640759;;10.1093/jnci/75.1.151;;3859688;;10.1007/s00262-002-0352-9;;12700948;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;10.1038/309418a0;;6328312;;12079396;;10.1016/s0022-2836(02)00264-4;;8812702;;10.1006/meth.1996.0054;;10.1016/0167-5699(93)90041-i;;8397766;;10.1021/bi00489a001;;2271534;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1093/protein/8.8.749;;8637844;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10556035;;10.1006/jmbi.1999.3141;;10.1016/0092-8674(83)90153-8;;6309409;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;3261803;;10.1093/jnci/80.14.1154;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;9417940;;10.1006/jmbi.1997.1407;;10482197;;10.1158/0008-5472.can-16-2269;;27635041;;10.1073/pnas.89.13.5867;;pmc49398;;1352878;;7207595;;10.1038/290145a0;;9626458;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;10837619;;10.1016/s0169-409x(97)00095-1;;1727373;;7237431;;7540106;;10.1128/mcb.9.3.1165-1172.1989;;2566907;;pmc362707;;10.1128/mcb.9.3.1165;;9816191;;8102322;;10.1007/bf01518520;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;15989600;;10.1517/13543784.6.2.169;;10561017;;1680547;;2566965;;2342490;;10.1016/0161-5890(90)90140-u;;9717827;;1967301;;10.1200/jco.1990.8.1.103;;10.1038/sj.onc.1202526;;10327070;;19010901;;10.1158/0008-5472.can-08-1776;;10.1200/jco.1997.15.8.2894;;9256133;;1715033;;10.1016/0161-5890(91)90056-p;;10213223;;10565792;;2470152;;10.1126/science.2470152;;8845823;;10.1248/bpb.18.1279;;7923157;;8253530;;10.1002/ijc.2910550610;;10.1128/mcb.10.11.6064;;10.1128/mcb.10.11.6064-6068.1990;;pmc361407;;1700279;;10.1016/j.tibtech.2004.03.006;;10.1016/s0167-7799(04)00080-0;;15109810;;8703804;;10.1046/j.1365-2141.1996.d01-1730.x;;pmc2034088;;8519647;;10.1038/bjc.1995.517;;10.1385/1-59259-114-0:87;;11217378;;8258342;;8258341;;10.1002/eji.1830231231;;10.1128/mcb.10.11.6064;;10.1128/mcb.10.11.6064-6068.1990;;pmc361407;;1700279;;12525512;;10.1200/jco.2003.05.137,"Klein et al., Eur. J. Immunol. 23 (12), 3248-3262, 1993.;;Weichhold et al., Nature 347: 90-92, 1990.;;Claudio et al., Blood 100 (6): 2175-2186, 2002.;;Wang et al., Clin. Immunol. 93 (2): 132-142, 1999.;;Weitkamp et al., J. Immunol. 171 (9): 4680-4688. 2003.;;Rudikoff et al., Proc Natl Acad Sci USA vol. 79 pp. 1979-1983 (Year: 1982).;;Wu et al., Journal of Molecular Biology, vol. 294, pp. 151-162 (Year: 1999).;;European Search Report dated May 17, 2016 in European Patent Application No. 15193917.0.;;Negri et al., In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab′)2 bispecific monoclonal antibody. British Journal of Cancer 72: 928-933, 1995.;;Board Decision dated Feb. 27, 2017 in U.S. Appl. No. 12/649,179.;;Extended European Search Report dated Mar. 4, 2016, for Application No. 15193910.5, in 10 pages.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati et al.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovitz et al.;;Advisory Action dated Jan. 9, 2013 in U.S. Appl. No. 12/649,179.;;Akers et al., “Formulation Development of Protein Dosage Forms,” Pharmaceutical Biotechnology, Kluwer, Dordrecht, NL, vol. 14, Jan. 1, 2002, pp. 47-127.;;Arteaga et al., “The Epidermanl Growth Factor Receptor: From Mutant Oncogene in Nonhuman Cancers to Therapeutic Target in Human Neoplasia,” Journal of Clinical Oncology, 2001 (Sep. 15 Supplement), vol. 19, No. 18s: pp. 32s-40s.;;Babcook et al., “A Novel Strategy for Generating Monoclonal Antibodies From Single, Isolated Lymphocytes Producing Antibodies of Defined Specificities,” Proc. Nat'l Acad. Sci. U.S.A. 93(15):7843-8, 1993.;;Barrios et al., “Length of the Antibody Heavy Chain Complementarity Determining Region 3 as a Specificity-Determining Factor,” J. Mol. Recognition 17:332-338, 2004.;;Batra et al., “Epidermal Growth Factor Ligand-Independent, Unregulated, Cell-Transforming Potential of a Naturally Occurring Human Mutant EGFRvIII Gene,” Cell Growth Differ. 6(10):1251-9, 1995.;;Bigner et al., “Gene Amplification in Malignant Human Gliomas: Clinical and Histopathologic Aspects,” J. Neuropathol. Exp. Neural, 47:191-205, 1988.;;Brummell et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry, 1993, vol. 32, pp. 1180-1187.;;Bumol et al., in Antibody Mediated Delivery Systems, J. Rodwell, Ed., 1988, pp. 55-79.;;Campbell, Chapter 1, Monoclonal Antibody Technology, 1984 pp. 1-32, Elsevier Science Publishers B.V., The Netherlands.;;Casset et al. “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,” Biochemical and Biophysical Research Communications, 2003, vol. 307, pp. 198 205.;;Chamow et al., “Immunoadhesins: Principles and Application,” Tibtech, Feb. 1996, pp. 52-60, vol. 14.;;Chen et al., “Selection and Analysis of an Optimized Antl-VEGF Antibody: Crystal Structure of an Affinity Matured Fab in Complex with Antigen,” J. Mol. Biol., 1999, vol. 293, pp. 865 881.;;Chen et al., “Influence of Histidine on the Stability and Physical Properties of a Fully Human Antibody in Aqueous and Solid Forms,” Pharmaceutical Research, Dec. 2003, pp. 1952-1960, vol. 20(12).;;Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature 342(6252):877-883, Dec. 21-28, 1989.;;Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Res. Immunol., Jan. 1994, pp. 33-36, vol. 145(1).;;Cochran et al., “Domain-Level Antibody Epitope Mapping Through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments,” J. Immunol. Meth. 287:147-158, 2004.;;Damstrup et al., “Epidermal Growth Factor Receptor Mutation Type III Transfected into a Small Lung Cancer Cell Line is Predominantly Localized at the Cell Surface and Enhances the Malignant Phenotype,” Int. J. Cancer, 2002, 97: pp. 7-14.;;Deo et al., “Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies,” Immunology Today 18:127-135, 1997.;;De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity Determining Regions Containing Specificity Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” J. Immunol, 2002, vol. 169, pp. 3076-3084.;;Diener et al., in Antibody Mediated Delivery Systems, J. Rodwell, Ed., 1988, pp. 1-23.;;Dillman, et al, “Preclinical Trials With Combinations and Conjugates of T101 Monoclonal Antibody and Doxorubicin,” Cancer Res. 46:4886-4891, 1986.;;Dillman et al., “Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug,” Cancer Res. 48:6097-3102, 1988.;;Doronina et al., “Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy,” Nature Biotechnology 21:778-784, 2003.;;Downward et al., “Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence,” Nature 307:521-527, 1984.;;Dubowchik et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Paclitaxel (Taxol), Mitomycin C and Doxorubicin,” Bioorg. Med. Chem, Letters 8(23):3347-3352, 1998.;;Ellis et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma,” The Journal of Immunology, 1995, pp. 925-937, Vo. 155.;;Endo et al., “In Vitro Cytotoxicity of a Human Serum Albumin-mediated Conjugate of Methotrexate with Antl-MM46 Monoclonal Antibody ,” Cancer Res, 47:1076-1080,1987.;;EPO Notification—Invitation pursuant to Article 94(3) and Rule 71(1) EPC dated Mar. 11, 2014 in European Application No. 04 777 034.2.;;EPO Notification—Invitation pursuant to Article 94(3) and Rule 71(1) EPC dated Mar. 11, 2014 in European Application No. 04 777 147.2.;;European Patent Office Result of Consultation dated Apr. 26, 2012, for Application No. 04777147.2, in 3 pages.;;Examiner Communication dated Oct. 20, 2009, received in European Patent Application. No. 04777147.2.;;Examiner's First Report on Australian Patent Application No. 2004260936, dated Aug. 25, 2008, in 2 pages.;;Extended European Search Report dated May 4, 2012, for Application No. 11188665.1, in 10 pages.;;Extended European Search Report dated May 4, 2012, for Application No. 11188666.9, in 11 pages.;;Faber et al., “Three-dimensional Structure of a Human Fab with High Affinity for Tetanus Toxoid,” Immunotechnology 3:253-270, 1998.;;File History, U.S. Appl. No. 10/877,773, filed Jun. 25, 2004.;;File History, U.S. Appl. No. 10/877,774, filed Jun. 25, 2004.;;File History, U.S. Appl. No. 12/268,352, filed Nov. 10, 2008.;;File History, U.S. Appl. No. 12/268,363, filed Nov. 10, 2008.;;File History, U.S. Appl. No. 12/396,286, filed Mar. 2, 2009.;;File History, U.S. Appl. No. 12/396,313, filed Mar. 2, 2009.;;First Examination Report dated Mar. 31, 2009, received in Indian Patent Application No. 6074/DELNP.2005.;;Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J. Mol. Biol. 224(2):487-499, 1992.;;Francisco et al., “cAC10-vcMMAE, an Anti-CD30-Monomethyl Auristatin E Conjugate With Potent and Selective Antitumor Activity,” Blood, Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Fung et al., “Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Viris,” Cell 33:357-368, 1984.;;Gammett et al., “Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate With Differences in the Disease Potential of Viral erbB Genes,” Proc. Nat'l Acad. Sci. USA 83:6053-6057, 1986.;;Garcia De Palazzo, I.E. et al., “Expression of Mutated Eipdermal Growth Factor Receptor by Non-Small Cell Lung Carcinomas,” Cancer Res. 53(14):3217-3220, 1993.;;Garnett et al., “An Improved Synthesis of a Methotrexate-Albumin-791T/36 Monoclonal Antibody Conjugate Cytotoxic to Human Osteogenic Sarcoma Cell Lines,” Cancer Res. 46:2407-2412, 1986.;;Ge, H. et al., “Evidence of High Incidence of EGFRvIII Expression and Coexpression with EGFR in Human Invasive Breast Cancer by Laser Capture Microdissection and Immunohistochemical Analysis,” Int. J. Cancer 98(3):357-361, 2002.;;Ghiotto et al., GenBank Acc. # AAK94829, Dec. 31, 2001.;;Ghose et al., in Targeted Drugs, E. Goldberg., Ed., 1983, pp. 1-22.;;Gilmore et al., “Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro,” Cell 40:609-618, 1985.;;Graille et al., “Complex Between Peptostreptococcus Magnus Protein L and a Human Antibody Reveals Structural Convergence in the Interaction Modes of Fab Binding Proteins,” Structure 9:679-687, Aug. 2001.;;Green et al, “Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes,” J. Exp. Med. 188:483-495, 1998.;;Green et al., “Generation and Characterization of Fully Human EGFRvIII Antibodies Suitable for Immunoconjugates,” American Association for Cancer Research Annual Meeting, Mar. 2004.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Application No. 6073/DELNP/2005.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Application No. 6074/DELNP/2005.;;Henry et al,, “A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer,” Cancer Res. 64:7995-8001, 2004.;;Houghten et al., “Relative Importance of Position and Individual Amino Acid Residues in Peptide Antigen-Antibody Interactions: Implications in the Mechanism of Antigenic Drift and Antigenic Shift,” New Approaches to Immunization, Vaccines 86, Cold Spring Harbor Laboratory, p. 21-25, 1986.;;Humphrey et al., “Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts,” Cancer Research 48:2231-2238.;;Humphrey et al., “Anti-Synthetic Peptide Antibody Reacting at the Fusion Junction of Deletion-Mutant Epidermal Growth Factor Receptors in Human Glioblastoma,” Proceedings of the National Academy of Sciences USA 87(11):4207-4211, Jun. 1990.;;Hurwitz et al., Appl. Biochem. 2:25-35, 1980.;;International Search Report dated Aug. 1, 2005, from International Patent Application No. PCT/US2004/020295.;;International Search Report dated Aug. 14, 2006, from International Patent Application No. PCT/US2004/020564.;;Issue Notification dated May 26, 2010, received in U.S. Appl. No. 10/877,774, Issue Date Jun. 15, 2010.;;Issue Notification dated Jun. 3, 2015 in U.S. Appl. No. 12/268,363.;;Issue Notification dated Jun. 17, 2015, received in U.S. Appl. No. 12/396,286.;;Issue Notification dated Jun. 30, 2015, received in U.S. Appl. No. 12/268,352.;;Issue Notification dated Jul. 15, 2015, received in U.S. Appl. No. 12/396,313.;;Janeway et al., “The structure of a typical antibody”, Immunobiology, 1994, pp. 3:1-3:3.;;Johns et al., “Novel Monoclonal Antibody Specific for the de2-7 Epidermal Growth Factor Receptor (EGFR) That Also Recognizes the EGFR Expressed in Cells Containing Amplification of the EGFR Gene,” Int. J. Cancer 98:398-408, 2002.;;Jorissen et al., “Epidermal Growth Factor Receptor: Mechanisms of Activation and Signaling,” Expreimental Cell Research 284:31-53, 2003.;;Jungbluth et al., “A Monoclonal Antibody Recognizing Human Cancers With Amplification/Overexpression of the Human Epidermal Growth Factor Receptor,” Proc. Nat'l Acad. Sci. USA 100(2):639-644, 2003.;;Junghans et al., in Cancer Chemotherapy and Biotherapy, Chafner and Longo, Eds., Lippincott Raven, 1996, pp. 655-686.;;Kala et al., “Phage Displayed Antibodies to Heat Stable Alkaline Phosphatase: Framework Region as a Determinant of Specificity,” J. Biochem 132:535-541, 2002.;;Kato et al., “A novel method of conjugation of daunomycin with antibody with a poly(L-glutamic acid) derivative as intermediate drug carrier. An anti-.alpha.-fetoprotein antibody-daunomycin conjugate,” J. Med. Chem. 27:1602-1607, 1984.;;Knappik et al., “Fully Synthetic Hyuman Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,” J. Mol. Biol. 2000, pp. 57-86, vol. 296.;;Kobrin et al., “A V Region Mutation in a Phosphocholine-Binding Monoclonal Antibody Results in Loss of Antigen Binding,” J. Immunol, 146(6):2017-2020, Mar. 1991.;;Kris et al., “Antibodies Against a Synthetic peptide as a Probe for the Kinase Activity of the Avian EGF Recptor and v-erB Protein,” Cell 40:619-625, 1985.;;Kuan et al., “EGF Mutant Receptor vIII as a Molecular Target in Cancer Therapy,” Endocrine Related Cancer 8(2):83-96, 2001.;;Kuan et al., “EGFRvIII as a Promising Target for Antibody-Based Brain Tumor Therapy,” Brain Tumor Pathology 17(2):71-78, 2000.;;Kuan et al., “Increased Binding Affinity Enhances Targeting of Glioma Xenografts by EGFRvIII-Specific scFv,” International Journal of Cancer 88(6):962-969, 2000.;;Kuby et al., Immunology, 2nd Ed., 1994, pp. 86-96.;;Lambert et al., in Immunotoxins, A. Frankel, Ed., 1988, pp. 175-209.;;Lambert et al., “Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins,” J. Biol. Chem. 260:12035-12041, 1985.;;Lammering et al., “Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization. Journal of the National Cancer Institute,” Jun. 20, 2001, vol. 93, No. 12.;;Lamminmaki et al., “Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol,” The Journal of Biological Chemistry, vol. 276 (39), Sep. 28, 2001, pp. 36687 36694.;;Landry et al., “Antibody Recognition of a Conformational Epitope in a Peptide Antigen: Fv-Peptide Complex of an Antibody Fragment Specific for the Mutant EGF Receptor, EGFRvIII,” Journal of Molecular Biology 308(5):883-893, 2001.;;Lederman et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,” Molecular Immunology, 1991, pp. 1171 1181, vol. 28 (11).;;Lescar et al., “Three-Dimensional Structure of a Fab-Peptide Complex: Structural Basis of HIV-1 protease Inhibition by a Monoclonal Antibody,” J. Mo. Biol 297:1207-1222, 1997.;;Li et al., “β Endorphin Omission Analogs: Dissociation of Immunoreactivity from other Biological Activities,” Proc. Natl. Acad. Sci. USA, Jun. 1980, pp. 3211 3214, vol. 77 (6).;;Libermann et al., “Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin,” Nature 313:144-147, 1985.;;Liu et al., “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids,” Proc. Nat'l Acad. Sci USA, 93:8618-8623, Aug. 1996.;;Livneh et al., “Reconstitution of Human Epidermal Growth Factor Receptors and Its Deletion Mutants in Cultured Hamster Cells,” J. Biol. Chem., 261(27):12490-12797, Sep. 1986.;;Lonardo et al., “Evidence for the Epidermal Growth Factor Receptor As a Target for Lung Cancer Prevention,” Clin. Cancer Res. 8(1):54-60, 2002.;;Lonberg, “Human antibodies from transgenic animals,” Nature Biotechnology 23: 1117-1125, 2005.;;Lorimer et al., “Immunotoxins That Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors,” Clinical Cancer Research 1(8):859-864, Aug. 1995.;;Lorimer et al., Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display, Proc. Natl. Acad. Sci, USA 93: 14815-14820, Dec. 1996.;;Luo et al., “Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme,” Int. J. Cancer 104(6):716-721, 2003.;;Luwor et al., “Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Eitehr the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR,” Cancer Research 61:5355-5361, 2001.;;Maccallum et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 1996, pp. 732-745, vol. 262.;;Malden et al., “Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme,” Cancer Research 4:2711-2714, 1988.;;Mamot et al., “Epidermal Growth Factor Receptor (EGFR)-Targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-Overexpressing Tumor Cells,” Cancer Research 63:3154-3161, 2003.;;Manabe et al., “Production of a monoclonal antibody-mitomycin C conjugate, utilizing dextran T-40, and its biological activity,” Biochem. Pharmacol. 34:289-291, 1985.;;Martin et al., “Structural Families in Loops of Homologous Proteins: Automatic Classification, Modelling and Application to Antibodies,” J. Mol. Biol. 263(5):800-815, Nov. 15, 1996.;;McNutt et al., “Antagonism of Secreted PCSK9 Increases Low Denisty Lipoprotein Receptor Expression in HepG2 Cells,” The Journal of Biological Chemistry, Apr. 17, 2009, pp. 10561-10570, vol. 284(16).;;Mendelsohn, “Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies as Potential Anti-Cancer Agents,” J. Steroid Biochem. Mol. Biol. 37(6):889-892, Dec. 20, 1990.;;Mendelsohn, “Potential Clinical Applications of Anti-EGF Receptor Monoclonal Antibodies” Cancer Cells 7:359, 1989.;;Mendelsohn, J., “The Epidermal Growth Factor Receptor as a Target for Therapy With Antireceptor Monoclonal Antibodies,” Semin. Cancer Biol. 1(5):339-344, Oct. 1990.;;Mendez et al., Functional Transplant of Megabase Human Immunoglobulin Ioci Recapitulates Human Antibody Response in Mice, Nat. Genet. 15(2):146-156, 1997.;;Modjtahedi and Dean, “The Receptor for EGF and Its Ligands—Expression, Prognostic Value and Target for Therapy in Cancer ,” Int'l J. Oncology 4:277-296, 1994.;;Mohammad et al., “Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1,” Clin. Cancer Res. 4(5);1337-1343, May 1998.;;Moscatello, G. et al., “Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors,” Cancer Res. 55(23):5536-5539, 1995.;;Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Teritiary Structure Prediction, 1994, pp. 491-495.;;Nilsen et al., “c-erbB activation in AIV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor,” Cell 41:719-726, 1985.;;Notice of Acceptance dated Jun. 10, 2010, received in Australian Patent Application No. 2004260936.;;Notice of Acceptance dated May 27, 2010, received in Australian Patent Application No. 2004260936. Note: NoA dated May 27, 2010 indicated that it would be published on Jun. 20, 2010.;;Notice of Allowance dated Apr. 23, 2014, received in U.S. Appl. No. 12/396,286.;;Notice of Allowance dated Dec. 8, 2008, received in U.S. Appl. No. 10/877,773.;;Notice of Allowance dated Feb. 5, 2014 in U.S. Appl. No. 12/268,352.;;Notice of Allowance dated Feb. 17, 2015, received in U.S. Appl. No. 12/268,363.;;Notice of Allowance dated Jan. 17, 2014 received in U.S. Appl. No. 12/268,363.;;Notice of Allowance dated Jul. 13, 2009, received in U.S. Appl. No. 10/877,773.;;Notice of Allowance dated Jul. 15, 2010, received in U.S. Appl. No. 12/268,363.;;Notice of Allowance dated Jul. 13, 2010, received in U.S. Appl. No. 12/268,352.;;Notice of Allowance dated Jul. 28, 2010, received in Mexican Patent Application No. PA/a/2005/014155.;;Notice of Allowance dated Jul. 1, 2014 in U.S. Appl. No. 12/268,363.;;Notice of Allowance dated Jun. 24, 2009, received in U.S. Appl. No. 10/877,774.;;Notice of Allowance dated Mar. 2, 2015, received in U.S. Appl. No. 12/396,286.;;Notice of Allowance dated Mar. 16, 2015, received in U.S. Appl. No. 12/268,352.;;Notice of Allowance dated Mar. 26, 2015, received in U.S. Appl. No. 12/396,313.;;Notice of Allowance dated Oct. 4, 2013, received in U.S. Appl. No. 12/268,352.;;Notice of Allowance dated Oct. 17, 2008, received in U.S. Appl. No. 10/877,774.;;Notice of Allowance dated Sep. 17, 2013, received in U.S. Appl. No. 12/268,363.;;Notice of Allowance dated Oct. 1, 2014 in U.S. Appl. No. 12/268,352.;;Notice of Allowance dated Oct. 1, 2014 in U.S. Appl. No. 12/396,313.;;Notice of Allowance dated Sep. 26, 2014, received in U.S. Appl. No. 12/396,286.;;Office Action dated Apr. 8, 2011, received in Australian Patent Application No. 2010202054.;;Office Action dated Apr. 8, 2011, received in Australian Patent Application No. 2010219363.;;Office Action dated Apr. 10, 2012, received in Korean Application No. 10-2011-7031662.;;Office Action dated Apr. 13, 2015, received in Japanese Patent App. No. 2013-272029 (with English Translation).;;Office Action dated Apr. 13, 2015, received in Japanese Patent App. No. 2013-272028 (with English Translation).;;Office Action dated Apr. 23, 2014 in Korean Application No. 10-2014-7004191 with English Translation.;;Office Action dated Apr. 23, 2014 in Korean Application No. 10-2014-7000817 with English Translation.;;Office Action dated Apr. 27, 2007, received in Chinese Patent Application No. 200480018260.6.;;Office Action dated Apr. 27, 2011, received in Chinese Patent Application No. 200480018260.6 (with English Translation).;;Office Action dated Apr. 30, 2014 in Chinese Application No. 200480018185.3 with English Translation.;;Office Action dated Aug. 23, 2013 in Chinese Application No. 200480018185.3 (with English translation).;;Office Action dated Aug. 27, 2013, received in Japanese Patent Application No. 2010-252825 (with English translation).;;Office Action dated Aug. 27, 2013, received in Japanese Patent Application No. 2010-262796 (with English translation).;;Office Action dated Aug. 7, 2009, received in U.S. Appl. No. 12/268,363.;;Office Action dated Aug. 19, 2013, received in Korean Patent App. No. 10-2013-7014050 (with English translation).;;Office Action dated Aug. 26, 2011, received in Chinese Patent Application No. 200480018185.3.;;Office Action dated Aug. 22, 2014, received in Chinese Application No. 201110460536.8 with English Translation.;;Office Action dated Feb. 6, 2013 received in Australian Patent Application No. 2011265359.;;Office Action dated Dec. 2, 2012, received in Korean Patent Application 10-2012-7026173.;;Office Action dated Dec. 3, 2014 in Chinese Application No. 200480018185.3 with English Translation.;;Office Action dated Dec. 4, 2007, received in U.S. Appl. No. 10/877,773.;;Office Action dated Dec. 18, 2014 in Korean Application No. 10-2005-7024871 with English Translation.;;Office Action dated Dec. 26, 2008, received in Indian Patent Application No. 6073/DELNP/2005.;;Office Action dated Feb. 8, 2011, received in Japanese Patent Application 2006-517470.;;Office Action dated Feb. 15, 2011, received in Japanese Patent Application No. 2006-517620.;;Office Action dated Feb. 17, 2014 in Korean Application No. 10-2005-7024883 with English Translation.;;Office Action dated Jan. 7, 2010, received in U.S. Appl. No. 12/268,352.;;Office Action dated Jan. 10, 2013, received in U.S. Appl. No. 12/474,176.;;Office Action dated Jan. 11, 2010, received in U.S. Appl. No. 12/396,313.;;Office Action dated Jan. 13, 2015, received in Chinese Patent Application No. 201110233784.9.;;Office Action dated Jan. 15, 2013 received in Japanese Patent Application 2010-252825 (with English translation).;;Office Action dated Jan. 15, 2015, received in Korean Patent Application No. 10-2014-7029678 (with English Translation).;;Office Action dated Jan. 22, 2013 received in Japanese Patent Application 2010-262796 (with English translation).;;Office Action dated Jan. 25, 2010, received in U.S. Appl. No. 12/396,286.;;Office Action dated Jan. 28, 2014 in Chinese Application No. 201110460536.8 with English Translation.;;Office Action dated Jan. 29, 2014, received in U.S. Appl. No. 12/649,179.;;Office Action dated Jan. 31, 2014 in U.S. Appl. No. 12/396,286.;;Office Action dated Jul. 1, 2011, received in Korean Patent Application No. 10-2005-7024871.;;Office Action dated Jul. 11, 2008, received in Chinese Patent Application No. 200480018260.6.;;Office Action dated Jul. 11, 2013, received in Korean Application No. 10-2013-7011483 with English Translation.;;Office Action dated Jul. 11, 2014 in Canadian Patent App. No. 2,530,172.;;Office Action dated Jul. 12, 2010, received in U.S. Appl. No. 12/396,286.;;Office Action dated Jul. 12, 2010, received in U.S. Appl. No. 12/396,313.;;Office Action dated Jul. 15, 2009, received in Chinese Patent Application No. 200480018185.3.;;Office Action dated Jul. 28, 2015, received in Korean Patent Application No. 10-2014-7029678 (with English Translation).;;Office Action dated Jul. 29, 2013 , received in Chinese Patent Application No. 201110233784.9 (with English Translation).;;Office Action dated Jun. 9, 2013, received in Chinese Application No. 2011104605368 with English Translation.;;Office Action dated Jun. 11, 2012 in Canadian Patent Application No. 2,530,285.;;Office Action dated Jun. 12, 2014 in Canadian Application No. 2530285.;;Office Action dated Jun. 13, 2008, received in U.S. Appl. No. 10/877,773.;;Office Action dated Jun. 13, 2014 in Chinese Application No. 201110233784.9 with English Translation.;;Office Action dated Jun. 25, 2010, received in Mexican Patent Application No. PA/a/2005/014152.;;Office action dated Jun. 28, 2013 received in Canadian Patent Application 2,530,285.;;Office Action dated Mar. 3, 2014 received in Japanese Patent Application No. 2010-262796 with English Translation.;;Office Action dated Mar. 10, 2014 received in Japanese Patent Application No. 2010-252825 with English Translation.;;Office Action dated Mar. 8, 2013 received in Mexican Patent Application MX/a/2012/001444 (with English translation).;;Office Action dated Mar. 8, 2013 received in Mexican Patent Application MX/a/2012/001445 (with English translation).;;Office Action dated Mar. 12, 2010, received in Chinese Patent Application No. 200480018260.6.;;Office Action dated Mar. 16, 2011, and English summary, received in Mexican Patent Application No. PA/a/2005/014152 A59.;;Office Action dated Mar. 17, 2010, received in Mexican Patent Application No. 2005/014155.;;Office Action dated Mar. 19, 2010, received in U.S. Appl. No. 12/268,363.;;Office Action dated Mar. 20, 2014, received in Korean Patent Application No. 10-2005-7024871 (with English Translation).;;Office Action dated Mar. 12, 2015, received in U.S. Appl. No. 12/649,179.;;Office Action dated Mar. 24, 2011, received in Canadian Patent Application No. 2,530,285.;;Office Action dated Mar. 24, 2012, received in Korean Patent Application No. 10-2005-7024883 (with English Translation).;;Office Action dated Mar. 25, 2010, received in Australian Patent Application No. 2004259398.;;Office Action dated Mar. 25, 2011, received in Canadian Patent Application No. 2,530,172.;;Office Action dated May 1, 2013 in Canadian Application No. 2,530,172.;;Office Action dated May 2, 2011, received in Korean Patent Application No. 10-2005-7024883 (with English Translation).;;Office Action dated May 3, 2011, received in U.S. Appl. No. 12/649,179.;;Office Action dated May 11, 2010, received in Japanese Patent Application No. 2006-517620.;;Office Action dated May 14, 2012, received in Canadian Patent Application No. 2,530,172.;;Office Action dated May 24, 2012, received in U.S. Appl. No. 12/649,179, filed Dec. 29, 2009.;;Office Action dated May 25, 2010, received in Japanese Patent Application No. 2006-5117700.;;Office Action dated May 28, 2015 received in Chinese Patent Application No. 201110460536.8 (with English translation).;;Office Action dated Nov. 3, 2009, received in Mexican Patent Application No. PA/a/2005/014152.;;Office Action dated Nov. 3, 2009, received in Mexican Patent Application No. PA/a/2005/014152 (English Translation only).;;Office Action dated Nov. 11, 2009, received in European Patent Application No. 04777034.2.;;Office Action dated Nov. 11, 2009, received in European Patent Application No. 04777147.2.;;Office Action dated Nov. 16, 2007, received in U.S. Appl. No. 10/877,774.;;Office Action dated Nov. 19, 2013, received in Mexican Patent Application No. MX/a/2012/001444 with English Translation.;;Office Action dated Nov. 24, 2011, received in European Patent Application No. 04777034.2.;;Office Action dated Nov. 24, 2011, received in European Patent Application No. 04777147.2.;;Office Action dated Nov. 28, 2014, received in Korean Patent Application No. 10-2014-7000817 with English translation.;;Office Action dated Oct. 7, 2013, received in U.S. Appl. No. 12/396,286.;;Office Action dated Oct. 11, 2013, received in European Pat. App No. 11188665.1.;;Office Action dated Oct. 11, 2013, received in European Pat. App No. 11188666.9.;;Oral Proceedings Summons dated Oct. 25, 2013, received in European Pat. App. No. 04777034.2.;;Oral Proceedings Summons dated Oct. 25, 2013, received in European Pat. App. No. 04777147.2.;;Office Action dated Oct. 12, 2009, received in Australian Patent Application No. 2004260936, in 2 pages.;;Office Action dated Oct. 13, 2014 in Australian Application No. 2012268864.;;Office Action dated Oct. 29, 2010, received in U.S. Appl. No. 12/649,179.;;Office Action dated Sep. 6, 2013, received in U.S. Appl. No. 12/649,179.;;Office Action dated Sep. 12, 2013, received in U.S. Appl. No. 12/396,313.;;Office Action dated Sep. 23, 2009, received in European Patent Application No. 04 777 147.2, in 6 pages.;;Office Action dated Sep. 30, 2014 in U.S. Appl. No. 12,649,179.;;Office Action dated Sep. 30, 2014 in Indian Patent App. No. 8485/DELNP/2009.;;Office Action received in Korean Patent Application No. 10-2005-7024871, dated Jun. 29, 2012.;;Office action dated Oct. 8, 2012 in Mexican Patent Application MX/a/2012/001445.;;Office action date Oct. 16, 2012 in Mexican Patent Application MX/a/2012/001444.;;Office Action dated Oct. 16, 2015 in Canadian Patent Application No. 2,530,285.;;Office Action dated Nov. 7, 2012, received in Korean Patent Application No. 10-2012-7019601.;;Office Action and English translation receieved in Chinese Application No. 200480018185.3, dated Nov. 5, 2012.;;Ohkawa et al., “Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human α-fetoprotein conjugated with mitomycin C via human serum albumin,” Cancer Immunol. Immunother. 23:81-86, 1986.;;Ohmi et al,, “Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3×anti-c-ErbB-2 bispecific antibody”, Cancer Imunol. Immunother., vol. 48, pp. 456-462, Oct. 1999.;;Olapade-Olaopa, E.O. et al., “Evidence for the Differential Expression of a Variant EGF Receptor Protein in Human Prostate Cancer,” Br. J. Cancer 82(1):186-194, 2000.;;Padlan et al., “Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL 10 Fab Lysozyme Complex,” Proc. Natl. Acad. Sci., vol. 86, Aug. 1989, pp. 5938 5942.;;Patent Withdrawal Notice dated Apr. 24, 2009, for U.S. Appl. No. 10/877,774.;;Paul, “Fundamental Immunology,” Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 1993, pp. 290-295.;;Payne, G. “Progress in immunoconjugate cancer therapeutics,” Cancer Cell, vol. 3, pp. 207-212, 2012. et al.",ACTIVE
253,US,B2,US 11492411 B2,178-637-730-526-308,2022-11-08,2022,US 201916673234 A,2019-11-04,US 201916673234 A;;US 201514743886 A;;US 26835208 A;;US 87777404 A;;US 56245304 P;;US 52557003 P;;US 48314503 P,2003-06-27,Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD F;;FENG XIAO;;FOORD ORIT;;GREEN LARRY L;;GUDAS JEAN M;;KEYT BRUCE A;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE R F;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL SINGH;;KING CHADWICK TERENCE;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/178-637-730-526-308,Granted Patent,yes,124,0,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/30;;A61K39/00;;A61K39/395;;A61K47/48;;A61K47/68;;B82Y5/00;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,438,163,068-033-680-421-173;;012-434-436-039-701;;087-448-981-335-707;;055-904-468-981-551;;186-732-989-640-404;;063-634-487-523-604;;165-749-823-188-437;;067-782-603-238-967;;034-626-837-626-258;;064-678-224-734-734;;075-889-605-642-840;;006-553-734-546-212;;031-970-152-284-72X;;009-483-512-107-343;;045-942-104-775-903;;017-386-037-070-267;;094-424-423-768-724;;065-684-269-783-203;;035-554-935-107-802;;001-779-867-387-972;;024-995-475-936-443;;026-589-266-128-73X;;077-406-419-134-117;;029-611-134-469-353;;124-416-510-861-245;;014-113-432-888-031;;013-447-454-196-187;;125-735-714-799-644;;004-272-966-072-139;;045-751-499-875-041;;112-811-296-657-597;;112-312-727-891-46X;;012-104-543-895-325;;145-103-363-875-640;;001-711-151-176-765;;022-400-834-786-515;;002-666-993-527-919;;034-526-119-277-42X;;033-261-430-402-230;;014-234-489-298-615;;019-845-050-845-357;;103-963-954-821-085;;011-171-559-635-599;;087-098-327-694-214;;046-385-127-360-775;;004-905-691-936-256;;021-182-185-908-148;;033-688-911-017-272;;042-601-433-468-58X;;128-037-910-947-545;;030-309-956-160-927;;008-822-347-989-692;;128-683-050-479-273;;041-969-682-554-154;;085-084-648-067-30X;;053-206-529-796-448;;027-214-641-693-526;;033-509-048-623-004;;049-928-993-608-092;;064-021-604-555-029;;165-322-209-862-791;;005-419-140-766-345;;009-417-133-046-629;;084-140-179-723-657;;117-357-237-248-341;;059-212-558-154-670;;069-165-512-595-028;;044-866-756-228-616;;058-648-791-423-620;;003-420-832-784-996;;020-367-308-901-689;;103-729-004-244-688;;005-461-375-871-624;;031-886-516-535-883;;040-622-347-677-457;;037-531-283-684-284;;037-531-283-684-284;;100-216-688-182-170;;030-080-528-694-129;;115-935-599-414-721;;010-953-281-569-514;;016-435-611-136-112;;017-903-200-905-934;;025-279-035-199-960;;021-799-621-392-61X;;095-334-545-560-259;;067-653-203-289-895;;002-538-287-083-621;;124-275-393-571-41X;;087-103-148-426-023;;136-926-314-202-897;;001-075-703-287-400;;025-692-172-883-979;;103-755-269-224-85X;;112-409-472-179-059;;016-219-576-017-946;;067-857-455-571-760;;022-890-862-570-978;;065-271-121-674-291;;043-637-817-489-241;;054-707-943-234-995;;103-932-348-507-545;;028-036-828-526-370;;053-158-286-316-214;;150-632-545-202-265;;045-872-081-200-101;;048-110-926-130-802;;004-402-270-959-674;;145-254-035-276-41X;;017-985-977-936-133;;057-205-729-571-877;;154-572-677-438-265;;069-970-853-729-540;;008-019-042-176-997;;008-019-042-176-997;;135-943-065-643-592;;005-038-448-235-576;;033-769-003-424-862;;077-950-844-586-930;;045-904-151-504-498;;072-377-861-372-36X;;157-729-192-316-421;;152-475-651-861-295;;047-010-764-744-638;;027-477-313-726-928;;045-082-353-678-357;;062-976-245-058-504;;077-163-323-456-652;;175-134-379-959-97X;;004-986-447-228-415;;005-461-375-871-624;;115-916-545-155-724;;086-617-534-349-291;;015-399-941-370-866;;092-117-309-419-982;;088-581-950-418-154;;038-495-237-294-69X;;142-206-526-949-177;;057-971-690-843-179;;029-269-446-589-556;;093-272-820-060-870;;051-707-000-800-833;;004-705-560-504-051;;133-939-910-996-391;;004-517-823-944-609;;033-870-601-973-366;;042-741-242-328-693;;086-378-024-269-624;;080-633-663-618-912;;090-683-249-679-734;;016-265-697-674-181;;072-729-813-791-160;;000-945-104-174-949;;001-201-806-511-780;;119-625-566-432-941;;049-182-911-054-623;;013-142-717-038-23X;;027-389-935-773-753;;032-441-846-127-844;;006-301-071-808-697;;044-355-372-029-744;;073-659-966-706-479;;100-394-462-349-099,12189730;;10.1007/978-1-4615-0549-5_2;;11560969;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/jmr.679;;15227640;;10482197;;10.1158/0008-5472.can-16-2269;;27635041;;10.1073/pnas.89.13.5867;;pmc49398;;1352878;;8845302;;8703804;;10.1046/j.1365-2141.1996.d01-1730.x;;3367154;;10.1097/00005072-198805000-00001;;7207595;;10.1038/290145a0;;8424945;;10.1021/bi00055a024;;9626458;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1016/0167-7799(96)80921-8;;8746117;;10837619;;10.1016/s0169-409x(97)00095-1;;1727373;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10.1006/jmbi.1999.3192;;10543973;;10.1038/342877a0;;2687698;;10.1182/blood-2002-01-0008;;12200383;;10.1016/j.jim.2004.01.024;;15099763;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1002/ijc.1572;;11774237;;12218124;;10.4049/jimmunol.169.6.3076;;3262420;;2428468;;10.1038/nbt832;;12778055;;10.1038/307521a0;;6320011;;7237431;;9873732;;10.1016/s0960-894x(98)00610-6;;7608568;;10.4049/jimmunol.155.2.925;;3802092;;9530559;;10.1016/s1380-2933(97)10003-3;;10.2210/pdb1aqk/pdb;;8253530;;10.1002/ijc.2910550610;;10.1385/1-59259-114-0:87;;11217378;;pmc2034088;;8519647;;10.1038/bjc.1995.517;;1560463;;10.1016/0022-2836(92)91010-m;;10.1182/blood-2003-01-0039;;12714494;;6305505;;10.1016/0092-8674(83)90417-8;;pmc386436;;10.1073/pnas.83.16.6053;;3016739;;8391918;;3457627;;10.1002/ijc.10224;;11920586;;10.1016/0092-8674(85)90209-0;;2982500;;10.2210/pdb1hez/pdb;;10.1016/s0969-2126(01)00630-x;;11587642;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;15520207;;10.1158/0008-5472.can-04-1722;;7540106;;10.1128/mcb.9.3.1165-1172.1989;;2566907;;pmc362707;;10.1128/mcb.9.3.1165;;3258189;;10.1073/pnas.87.11.4207;;1693434;;pmc54077;;10.1002/ijc.10189;;11920591;;12648464;;10.1016/s0014-4827(02)00098-8;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1093/oxfordjournals.jbchem.a003254;;12359067;;10.1021/jm00378a013;;6209394;;10656818;;10.1006/jmbi.1999.3444;;9816191;;2005389;;10.4049/jimmunol.146.6.2017;;10.1016/0092-8674(85)90210-7;;2982501;;10.1677/erc.0.0080083;;11397666;;10.1007/bf02482738;;11210174;;11093822;;10.1002/1097-0215(20001215)88:6<962::aid-ijc20>3.0.co;2-u;;10.1016/j.tibtech.2004.03.006;;10.1016/s0167-7799(04)00080-0;;15109810;;4044586;;10.1016/s0021-9258(17)38981-0;;2908625;;10.1007/978-1-4613-1083-9_12;;11416113;;10.1093/jnci/93.12.921;;11352579;;10.1006/jmbi.2001.4628;;1961196;;10.1016/0161-5890(91)90003-3;;10.1006/jmbi.1997.0950;;9150407;;10.1128/mcb.10.11.6064;;10.1128/mcb.10.11.6064-6068.1990;;pmc361407;;1700279;;8102322;;10.1007/bf01518520;;10.1038/313144a0;;2981413;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;15989600;;10.1517/13543784.6.2.169;;3017977;;10.1016/s0021-9258(18)67114-5;;11801540;;10.1038/nbt1135;;16151405;;9816055;;10.1073/pnas.93.25.14815;;8962138;;pmc26219;;10.1002/ijc.11007;;12640678;;11454674;;10.1006/jmbi.1996.0548;;8876650;;1680547;;2834047;;12810643;;10.1016/0006-2952(85)90140-6;;2578281;;8947577;;10.1006/jmbi.1996.0617;;2566965;;10.1074/jbc.m808802200;;19224862;;pmc2667743;;2285602;;10.1016/0960-0760(90)90438-q;;2103507;;10.1038/ng0297-146;;9020839;;21566922;;10.3892/ijo.4.2.277;;9607595;;2342490;;10.1016/0161-5890(90)90140-u;;7585629;;pmc2034020;;10.1038/bjc.1995.435;;7547242;;10.1007/978-1-4684-6831-1_14;;10.1016/s0092-8674(85)80052-0;;2988784;;10.1007/s002620050622;;10550550;;10638988;;pmc2363203;;10.1054/bjoc.1999.0898;;pmc297746;;10.1073/pnas.86.15.5938;;2762305;;10.2210/pdb3hfm/pdb;;9717827;;1967301;;10.1200/jco.1990.8.1.103;;12676579;;10.1016/s1535-6108(03)00057-6;;10.1023/a:1011177318162;;11484948;;10.1038/sj.onc.1202526;;10327070;;10.1128/jvi.62.5.1840-1844.1988;;2833627;;pmc253246;;19010901;;10.1158/0008-5472.can-08-1776;;15185369;;10.1002/cbic.200300806;;15185369;;10.1002/cbic.200300806;;10.1111/j.1600-065x.1992.tb01419.x;;1464422;;10.1200/jco.1997.15.8.2894;;9256133;;11000403;;10.1016/s0161-5890(00)00049-3;;10.1016/j.molimm.2004.11.003;;15829301;;10.1016/s0969-8051(98)00120-6;;10382844;;10.1016/s0969-8051(97)00080-2;;9352535;;7671250;;1715033;;10.1016/0161-5890(91)90056-p;;10213223;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;pmc16575;;10.1073/pnas.130166597;;10852962;;2855491;;10.1101/sqb.1988.053.01.059;;10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#;;9506533;;10565792;;pmc282412;;2460865;;10.1073/pnas.85.21.8276;;10.1128/mcb.10.11.6064;;10.1128/mcb.10.11.6064-6068.1990;;pmc361407;;1700279;;2470152;;10.1126/science.2470152;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;10.2210/pdb6fab/pdb;;10.1021/bi00229a022;;2015229;;8845823;;10.1248/bpb.18.1279;;10.4049/jimmunol.164.3.1432;;10640759;;10.1093/jnci/75.1.151;;3859688;;12525512;;10.1200/jco.2003.05.137;;10.1007/s00262-002-0352-9;;12700948;;pmc345799;;6952214;;10.1073/pnas.79.2.626;;10.1038/309418a0;;6328312;;12079396;;10.1016/s0022-2836(02)00264-4;;8812702;;10.1006/meth.1996.0054;;7923157;;10.1016/0167-5699(93)90041-i;;8397766;;10527689;;10.1006/clim.1999.4781;;10.1038/347090a0;;2118596;;10561017;;14568943;;10.4049/jimmunol.171.9.4680;;pmc282239;;2902633;;10.1073/pnas.85.20.7597;;10.1021/bi00489a001;;2271534;;10.1093/protein/8.8.749;;8637844;;10.1007/s00262-001-0243-5;;11862416;;7606735;;9584952;;10.3109/13550289809114515;;pmc299192;;10.1073/pnas.84.19.6899;;3477813;;10556035;;10.1006/jmbi.1999.3141;;10.1016/0092-8674(83)90153-8;;6309409;;10.1128/mcb.8.4.1816-1820.1988;;pmc363345;;10.1128/mcb.8.4.1816;;3380099;;3261803;;10.1093/jnci/80.14.1154;;11255078;;10.1016/s1040-8428(00)00134-7;;10096554;;9417940;;10.1006/jmbi.1997.1407,"Extended European Search Report dated Jun. 17, 2020 in Application No. 20155925.9.;;Office Action dated Jun. 1, 2020 in Japanese Application No. 2019-107945 with English Translation.;;Office Action with English Translation dated Aug. 17, 2020 received in Japanese Patent Application No. 2017-163089 in 24 pages.;;Office Action with English Translation dated Aug. 17, 2020 received in Japanese Patent Application No. 2017-175574 in 29 pages.;;Office Action with English Translation dated Jan. 12, 2021 received in Japanese Patent Application No. 2019-107945 in 9 pages.;;U.S. Appl. No. 07/919,297, filed Jul. 30, 1992, Kucherlapati et al.;;U.S. Appl. No. 08/759,620, filed Dec. 3, 1996, Jakobovitz et al.;;U.S. Appl. No. 07/610,515, filed Nov. 8, 1990, Kucherlapati et al.;;U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.;;U.S. Appl. No. 07/466,008, filed Jan. 12, 1990, Kucherlapati.;;U.S. Appl. No. 08/486,859, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/486,853, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/464,584, filed Jun. 5, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/463,191, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/462,837, filed Jun. 5, 1995, Kucherlapati et al.;;U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.;;U.S. Appl. No. 08/430,938, filed Apr. 27, 1995, Kucherlapati et al.;;U.S. Appl. No. 08/376,279, filed Jan. 20, 1995, Jakobovitz et al.;;U.S. Appl. No. 08/234,145, filed Apr. 28, 1994, Kucherlapati et al.;;U.S. Appl. No. 08/112,848, filed Aug. 27, 1993, Kucherlapati et al.;;“Anti-c-ErbB2/c-Neu (Ab-5), clone TA-1,” http://www.millipore.com/catalogue/item/mabe320, accessed May 28, 2014.;;“Mertansine,” Wikipedia, http://en.wikipedia.org/w/index/php?title=Metansine&oldid=45829581, accessed May 28, 2014.;;“Trastuzumab,” Wikipedia, http://en.wikipeida.org/wiki/Trastuzumab, accessed May 28, 2014.;;Akers et al., “Formulation Development of Protein Dosage Forms,” Pharmaceutical Biotechnology, Kluwer, Dordrecht, NL, vol. 14, Jan. 1, 2002, pp. 47-127.;;Arteaga et al., “The Epidermanl Growth Factor Receptor: From Mutant Oncogene in Nonhuman Cancers to Therapeutic Target in Human Neoplasia,” Journal of Clinical Oncology, 2001 (Sep. 15 Supplement), vol. 19, No. 18s: pp. 32s-40s.;;Babcook et al., “A Novel Strategy for Generating Monoclonal Antibodies From Single, Isolated Lymphocytes Producing Antibodies of Defined Specificities,” Proc. Nat'l Acad. Sci. U.S.A. 93(15):7843-8, 1993.;;Barrios et al., “Length of the Antibody Heavy Chain Complementarity Determining Region 3 as a Specificity-Determining Factor,” J. Mol. Recognition 17:332-338, 2004.;;Baselga et al., “Phase II Study of Weekly Intravenous Trastuzumab (Herceptin®) in Patients With HER2/neu—Overexpresing Metastatic Breast Cancer,” Semin. Oncol. 26, SuppI12:78-83 (1999).;;Baselga et al., “Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER21neu overexpressing human breast cancer xenografts.” Cancer Res., 58:2825˜2831, (1998).;;Batra et al., “Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.” Proc. Natl. Acad. Sci. USA, 89:5867-5871 (1992).;;Batra et al., “Epidermal Growth Factor Ligand-Independent, Unregulated, Cell-Transforming Potential of a Naturally Occurring Human Mutant EGFRvIII Gene,” Cell Growth Differ. 6(10):1251-9, 1995.;;Bergamasch et al., Saporin, an ribosome-inactivating protein used to prepare immunotoxins, induced cell death via apoptosis, British Journal of Haematology vol. 93, Issue 4, pp. 789-794 Jun. 1996.;;Bigner et al., “Gene Amplification in Malignant Human Gliomas: Clinical and Histopathologic Aspects,” J. Neuropathol. Exp. Neurol. 47:191-205, 1988.;;Blythman et al. “Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells.” Nature, 290:145-146 (1981).;;Brummell et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,” Biochemistry, 1993, vol. 32, pp. 1180-1187.;;Bumol et al., in Antibody Mediated Delivery Systems, J. Rodwell, Ed., 1988, pp. 55-79.;;Campbell, Chapter 1, Monoclonal Antibody Technology, 1984 pp. 1-32, Elsevier Science Publishers B.V., The Netherlands.;;Caron et al., “Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia,” Clin. Cancer Res., 4: 1421-1428 (Jun. 1998).;;Carter et al., “Humanization of an anti-p185 antibody for human cancer therapy.” Proc. Natl. Acad. Sci., USA, 89:4285-4289 (1992).;;Casset et al. “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,” Biochemical and Biophysical Research Communications, 2003, vol. 307, pp. 198 205.;;Chamow et al., “Immunoadhesins: Principles and Application,” Tibtech, Feb. 1996, pp. 52-60, vol. 14.;;Chari “Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy.” Adv. Drug Del. Rev., 31: 89-104 (1998).;;Chari et al., “Immunoconjugates containing novel maytansinoids: promising anticancer drugs.” Cancer Res., 52:127-131 (1992).;;Chen et al., “Influence of Histidine on the Stability and Physical Properties of a Fully Human Antibody in Aqueous and Solid Forms,” Pharmaceutical Research, Dec. 2003, pp. 1952-1960, vol. 20(12).;;Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity Matured Fab in Complex with Antigen,” J. Mol. Biol., 1999, vol. 293, pp. 865 881.;;Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature 342(6252):877-883, Dec. 21-28, 1989.;;Claudio et al., “A molecular compendium of genes expressed in multiple myeloma,” Blood (Sep. 15, 2002) 100 (6):2175-2186.;;Cochran et al., “Domain-Level Antibody Epitope Mapping Through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments,” J. Immunol. Meth. 287:147-158, 2004.;;Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Res. Immunol., Jan. 1994, pp. 33-36, vol. 145(1).;;Damstrup et al., “Epidermal Growth Factor Receptor Mutation Type III Transfected into a Small Lung Cancer Cell Line is Predominantly Localized at the Cell Surface and Enhances the Malignant Phenotype,” Int. J. Cancer, 2002, 97: pp. 7-14.;;De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity Determining Regions Containing Specificity Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” J. Immunol, 2002, vol. 169, pp. 3076-3084.;;Deo et al., “Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies,” Immunology Today 18:127-135, 1997.;;Diener et al., in Antibody Mediated Delivery Systems, J. Rodwell, Ed., 1988, pp. 1-23.;;Dillman et al., “Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug,” Cancer Res. 48:6097-3102, 1988.;;Dillman, et al., “Preclinical Trials With Combinations and Conjugates of T101 Monoclonal Antibody and Doxorubicin,” Cancer Res. 46:4886-4891, 1986.;;Doronina et al., “Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy,” Nature Biotechnology 21:778-784, 2003.;;Downward et al., “Close Similarity of Epidermal Growth Factor Receptor and v-erb B Oncogene Protein Sequence,” Nature 307:521-527, 1984.;;Drewinko et al., “Differential killing efficacy of twenty antitumor drugs on proliferating and non-proliferating human tumor cells.” Cancer Res. 41 :2328-2333 (1981).;;Dubowchik et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Paclitaxel (Taxol), Mitomycin C and Doxorubicin,” Bioorg. Med. Chem. Letters 8(23):3347-3352, 1998.;;Ellis et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma,” The Journal of Immunology, 1995, pp. 925-937, Vo. 155.;;Endo et al., “In Vitro Cytotoxicity of a Human Serum Albumin-mediated Conjugate of Methotrexate with Anti-MM46 Monoclonal Antibody,” Cancer Res. 47:1076-1080,1987.;;Faber et al., “Three-dimensional Structure of a Human Fab with High Affinity for Tetanus Toxoid,” Immunotechnology 3:253-270, 1998.;;Ferrini et al., Targeting of T Lymphocytes Against EGF-Receptor+ Tumor Cells by Bispecific Monoclonal Antibodies:Requirement of CD3 Molecule Cross-Linking for T Cell Activation, Int. J. Cancer 55: 931-937, 1993.;;Flavell et al., Comparison of Immunotoxins Bearing a Single Saporin Molecule with Multiple Toxin Conjgates. Immunotoxin, Methods and Protocols vol. 166 of the series Methods in Molecular Biology™ pp. 87-100.;;Flavell et al., Preclinical Studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN fo rthe treatment of human-B-cell tumours. Br. J. Cancer Dec. 1995; 72(6): 1373-1379.;;Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J. Mol. Biol. 224(2):487-499, 1992.;;Francisco et al., “cAC10-vcMMAE, an Anti-CD30-Monomethyl Auristatin E Conjugate With Potent and Selective Antitumor Activity,” Blood, Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.;;Fung et al., “Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Viris,” Cell 33:357-368, 1984.;;Gammett et al., “Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate With Differences in the Disease Potential of Viral erbB Genes,” Proc. Nat'l Acad. Sci. USA 83:6053-6057, 1986.;;Garcia De Palazzo, I.E. et al., “Expression of Mutated Eipdermal Growth Factor Receptor by Non-Small Cell Lung Carcinomas,” Cancer Res. 53(14):3217-3220, 1993.;;Garnett et al., “An Improved Synthesis of a Methotrexate-Albumin-791T/36 Monoclonal Antibody Conjugate Cytotoxic to Human Osteogenic Sarcoma Cell Lines,” Cancer Res. 46:2407-2412, 1986.;;Ge, H. et al., “Evidence of High Incidence of EGFRvIII Expression and Coexpression with EGFR in Human Invasive Breast Cancer by Laser Capture Microdissection and Immunohistochemical Analysis,” Int. J. Cancer 98(3):357-361, 2002.;;Ghiotto et al., GenBank Acc. # AAK94829, Dec. 31, 2001.;;Ghose et al., in Targeted Drugs, E. Goldberg., Ed., 1983, pp. 1-22.;;Gilmore et al., “Protein Phosphorlytion at Tyrosine is Induced by the v-erb B Gene Product in Vivo and In Vitro,” Cell 40:609-618, 1985.;;Graille et al., “Complex Between Peptostreptococcus Magnus Protein L and a Human Antibody Reveals Structural Convergence in the Interaction Modes of Fab Binding Proteins,” Structure 9:679-687, Aug. 2001.;;Green et al., “Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes,” J. Exp. Med. 188:483-495, 1998.;;Green et al., “Generation and Characterization of Fully Human EGFRvIII Antibodies Suitable for Immunoconjugates,” American Association for Cancer Research Annual Meeting, Mar. 2004.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Application No. 6073/DELNP/2005.;;Hearing Notification dated Mar. 18, 2011, received in Indian Patent Application No. 6074/DELNP/2005.;;Henry et al., “A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer,” Cancer Res. 64:7995-8001, 2004.;;HERCEPTIN® Label, Sep. 1998.;;Hooijberg et al., “Eradication of Large Human B Cell Tumors in Nude Mice with Unconjugated CD20 Monoclonal Antibodies and Jun. 15, Interleukin 2,” Cancer Res., 55:2627-2634 (Jun. 15, 1995).;;Houghten et al., “Relative Importance of Position and Individual Amino Acid Residues in Peptide Antigen-Antibody Interactions: Implications in the Mechanism of Antigenic Drift and Antigenic Shift,” New Approaches to Immunization, Vaccines 86, Cold Spring Harbor Laboratory, p. 21-25, 1986.;;Hudziak et al., “p 185 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.” Mol. Cell. Biol., 9: 1165-1172 (1989).;;Humphrey et al., “Amplification and Expression of the Epidermal Growth Factor Receptor Gene in Human Glioma Xenografts,” Cancer Research 48:2231-2238.;;Humphrey et al., “Anti-Synthetic Peptide Antibody Reacting at the Fusion Junction of Deletion-Mutant Epidermal Growth Factor Receptors in Human Glioblastoma,” Proceedings of the National Academy of Sciences USA 87(11):4207-4211, Jun. 1990.;;Hurwitz et al., Appl. Biochem. 2:25-35, 1980.;;Janeway et al., “The structure of a typical antibody”, Immunobiology, 1994, pp. 3:1-3:3.;;Johns et al., “Novel Monoclonal Antibody Specific for the de2-7 Epidermal Growth Factor Receptor (EGFR) That Also Recognizes the EGFR Expressed in Cells Containing Amplification of the EGFR Gene,” Int. J. Cancer 98:398-408, 2002.;;Jorissen et al., “Epidermal Growth Factor Receptor: Mechanisms of Activation and Signaling,” Expreimental Cell Research 284:31-53, 2003.;;Jungbluth et al., “A Monoclonal Antibody Recognizing Human Cancers With Amplification/Overexpression of the Human Epidermal Growth Factor Receptor,” Proc. Nat'l Acad. Sci. USA 100(2):639-644, 2003.;;Junghans et al., in Cancer Chemotherapy and Biotherapy, Chafner and Longo, Eds., Lippincott Raven, 1996, pp. 655-686.;;Kala et al., “Phage Displayed Antibodies to Heat Stable Alkaline Phosphatase: Framework Region as a Determinant of Specificity,” J. Biochem 132:535-541, 2002.;;Kato et al., “A novel method of conjugation of daunomycin with antibody with a poly(L-glutamic acid) derivative as intermediate drug carrier. An anti-.alpha.-fetoprotein antibody-daunomycin conjugate,” J. Med. Chem. 27:1602-1607, 1984.;;Klein et al., “Expressed human immunoglobulin ϰ genes and their hypermutation,” Eur. J. Immunol. (Dec. 1993) vol. 23, Issue 12, pp. 3248-3271.;;Knappik et al., “Fully Synthetic Hyuman Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,” J. Mol. Biol. 2000, pp. 57-86, vol. 296.;;Knox et al., “Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma,” Clin. Cancer Res., 2: 457-470 (Mar. 1996).;;Kobrin et al., “A V Region Mutation in a Phosphocholine-Binding Monoclonal Antibody Results in Loss of Antigen Binding,” J. Immunol. 146(6):2017-2020, Mar. 1991.;;Kris et al., “Antibodies Against a Synthetic peptide as a Probe for the Kinase Activity of the Avian EGF Recptor and v-erB Protein,” Cell 40:619-625, 1985.;;Kuan et al., “EGF Mutant Receptor vIII as a Molecular Target in Cancer Therapy,” Endocrine Related Cancer 8(2):83-96, 2001.;;Kuan et al., “EGFRvIII as a Promising Target for Antibody-Based Brain Tumor Therapy,” Brain Tumor Pathology 17(2):71-78, 2000.;;Kuan et al., “Increased Binding Affinity Enhances Targeting of Glioma Xenografts by EGFRvIII-Specific scFv,” International Journal of Cancer 88(6):962-969, 2000.;;Kuby et al., Immunology, 2nd Ed., 1994, pp. 86-96.;;Kufer et al. A Revival of Bispecific Antibodies, Trends in Biotechnology, vol. 22, No. 5, pp. 238-244, (2004).;;Lambert et al., “Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins,” J. Biol. Chem. 260:12035-12041, 1985.;;Lambert et al., in Immunotoxins, A. Frankel, Ed., 1988, pp. 175-209.;;Lammering et al., “Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization. Journal of the National Cancer Institute,” Jun. 20, 2001, vol. 93, No. 12.;;Lamminmaki et al., “Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol,” The Journal of Biological Chemistry, vol. 276 (39), Sep. 28, 2001, pp. 36687 36694.;;Landry et al., “Antibody Recognition of a Conformational Epitope in a Peptide Antigen: Fv-Peptide Complex of an Antibody Fragment Specific for the Mutant EGF Receptor, EGFRvIII,” Journal of Molecular Biology 308(5):883-893, 2001.;;Lederman et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,” Molecular Immunology, 1991, pp. 1171 1181, vol. 28 (11).;;Lescar et al., “Three-Dimensional Structure of a Fab-Peptide Complex: Structural Basis of HIV-1 protease Inhibition by a Monoclonal Antibody,” J. Mo. Biol 297:1207-1222, 1997.;;Lev, Sima et al., “Receptor Functions and Ligand-Dependnet Transforming Potential of a Chimeric kit Proto-Oncogene” Molecular and Cellular Biology Nov. 1990, pp. 6064-6068.;;Lewis et al., “Differential responses of human tumor cell lines to anti-p185 HER2 monoclonal antibodies,” Cancer Immunnol. Immunother. 37:255-263 (1993).;;Li et al., “β Endorphin Omission Analogs: Dissociation of Immunoreactivity from other Biological Activities,” Proc. Natl. Acad. Sci. USA, Jun. 1980, pp. 3211 3214, vol. 77 (6).;;Libermann et al., “Amplification, Enhanced Expression and Possible Rearrangement of EGF Receptor Gene in Primary Human Brain Tumours of Glial Origin,” Nature 313:144-147, 1985.;;Liu et al., “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids,” Proc. Nat'l Acad. Sci USA, 93:8618-8623, Aug. 1996.;;Liu et al., “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.” Proc. Natl. Acad. Sci., USA, 93:8618-8623 (1996).;;Liu et al., “The development of antibody delivery systems to target cancer with highly potent maytansinoids.” Exp. Opin. Invest. Drugs, 6: 169-172 (1997).;;Livneh et al., “Reconstitution of Human Epidermal Growth Factor Receptors and Its Deletion Mutants in Cultured Hamster Cells,” J. Biol. Chem., 261(27):12490-12797, Sep. 1986.;;Lonardo et al., “Evidence for the Epidermal Growth Factor Receptor as a Target for Lung Cancer Prevention,” Clin. Cancer Res. 8(1):54-60, 2002.;;Lonberg, “Human antibodies from transgenic animals,” Nature Biotechnology 23: 1117-1125, 2005.;;Lorimer et al., “Immunotoxins That Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors,” Clinical Cancer Research 1(8):859-864, Aug. 1995.;;Lorimer et al., Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display, Proc. Natl. Acad. Sci. USA 93: 14815-14820, Dec. 1996.;;Luo et al., “Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme,” Int. J. Cancer 104(6):716-721, 2003.;;Luwor et al., “Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Eitehr the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR,” Cancer Research 61:5355-5361, 2001.;;MacCallum et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 1996, pp. 732-745, vol. 262.;;Maier et al., “Requirements for the internalization of a murine monoclonal antibody directed against the HER-21neu gene product c-erbB-2,” Cancer Res., 51: 5361-53˜9 (1991).;;Malden et al., “Selective Amplification of the Cytoplasmic Domain of the Epidermal Growth Factor Receptor Gene in Glioblastoma Multiforme,” Cancer Research 4:2711-2714, 1988.;;Mamot et al., “Epidermal Growth Factor Receptor (EGFR)-Targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-Overexpressing Tumor Cells,” Cancer Research 63:3154-3161, 2003.;;Manabe et al., “Production of a monoclonal antibody-mitomycin C conjugate, utilizing dextran T-40, and its biological activity,” Biochem. Pharmacol. 34:289-291, 1985.;;Martin et al., “Structural Families in Loops of Homologous Proteins: Automatic Classification, Modelling and Application to Antibodies,” J. Mol. Biol. 263(5):800-815, Nov. 15, 1996.;;McKenzie et al., “Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p 185.” Oncogene, 4:543-548 (1989).;;McNutt et al., “Antagonism of Secreted PCSK9 Increases Low Denisty Lipoprotein Receptor Expression in HepG2 Cells,” The Journal of Biological Chemistry, Apr. 17, 2009, pp. 10561-10570, vol. 284(16).;;Mendelsohn, “Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies as Potential Anti-Cancer Agents,” J. Steroid Biochem. Mol. Biol. 37(6):889-892, Dec. 20, 1990.;;Mendelsohn, “Potential Clinical Applications of Anti-EGF Receptor Monoclonal Antibodies” Cancer Cells 7:359, 1989.;;Mendelsohn, J., “The Epidermal Growth Factor Receptor as a Target for Therapy With Antireceptor Monoclonal Antibodies,” Semin. Cancer Biol. 1(5):339-344, Oct. 1990.;;Mendez et al., Functional Transplant of Megabase Human Immunoglobulin Ioci Recapitulates Human Antibody Response in Mice, Nat. Genet. 15(2):146-156, 1997.;;Modjtahedi and Dean, “The Receptor for EGF and Its Ligands—Expression, Prognostic Value and Target for Therapy in Cancer,” Int'l J. Oncology 4:277-296, 1994.;;Mohammad et al., “Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1,” Clin. Cancer Res. 4(5);1337-1343, May 1998.;;Morgan et al., “Immunotoxins of Pseudomonas exotoxin A (PE): effect of linkage on conjugate yield, potency, selectivity and toxicity.” Mol. Immunol. 27:273-282 (1990).;;Moscatello, G. et al., “Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors,” Cancer Res. 55(23):5536-5539, 1995.;;Negri et al., In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab′)2 bispecific monoclonal antibody. British Journal of Cancer 72: 928-933, 1995.;;Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Teritiary Structure Prediction, 1994, pp. 491-495.;;Nilsen et al., “c-erbB activation in AlV-Induced Erythroblastosis: Novel RNA Processing and Promoter Insertion Results in Expression of an Amino-Truncated EGF Receptor,” Cell 41:719-726, 1985.;;Ohkawa et al., “Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human α-fetoprotein conjugated with mitomycin C via human serum albumin,” Cancer Immunol. Immunother. 23:81-86, 1986.;;Ohmi et al., “Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 × anti-c-ErbB-2 bispecific antibody”, Cancer Imunol. Immunother., vol. 48, pp. 456-462, Oct. 1999.;;Olapade-Olaopa, E.O. et al., “Evidence for the Differential Expression of a Variant EGF Receptor Protein in Human Prostate Cancer,” Br. J. Cancer 82(1):186-194, 2000.;;Padlan et al., “Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL 10 Fab Lysozyme Complex,” Proc. Natl. Acad. Sci., vol. 86, Aug. 1989, pp. 5938 5942.;;Pagliaro et al., “Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity,” Clin. Cancer Res., 4:1971-1976 (Aug. 1998).;;Paik et al., “Pathologic Findings From the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer,” Journal of Clin. Onc., 8 (1): 103-112 (Jan. 1990).;;Paul, “Fundamental Immunology,” Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 1993, pp. 290-295.;;Payne, G. “Progress in immunoconjugate cancer therapeutics,” Cancer Cell, vol. 3, pp. 207-212, 2012.;;Pederson et al., “The Type III Epidermal Growth Factor Receptor Mutation, Biological Significance and Potential Target for Anti-Cancer Therapy,” Annals of Oncology/ESMO 12(6):745-760, Jun. 2001.;;Pegram et al., “Inhibitory effects of combinations of HER-2/neu if antibody and chemotherapeutic agents used for treatment of human breast cancers.” Oncogene, 18:2241-2251 (1999).;;Pelley et al., “Proviral-Activated c-erbB is Leukemogenic but not Sarcomagenic: Characterization of a Replication-Competent Retrovirus Containing the Activated c-erbB,” Jornal of Virology 62:1840-1844, 1988.;;Phillips et al., “Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.” Cancer Res. 68: 9280-9290 (2008).;;Piatesi et al., “Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diels-Alder Activity,” ChemBio Chern 5:460-466, 2004.;;Piatesi et al., “Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diels-Alder Activity,” ChemBioChem, 2004, pp. 460-466, vol. 5.;;Pietersz et al., “Antibody Conjugates for the Treatment of Cancer,” Immunological Reviews, vol. 129, pp. 57-80, 1992.;;Pietersz et al., in Antibody Mediated Delivery Systems, J. Rodwell, Ed., 1988, pp. 25-53.;;Press et al., “HER-2Ineu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.” J. Clin. Oncol. 15:2894-2904 (1997).;;Ramsland et al., “An Unusual Human IgM Antibody with a Protruding HCDR3 and High Avidity for its Peptide Ligands,” Molecular Immunology 37:295-310, 2000.;;Reimer et al., “Matching of Trastuzumab (Herceptin®) Epitope Mimics Onto the Surface of Her-2/neu—A New Method of Epitope Definition,” Mol. Immunol. 42:1121-1124, 2005.;;Reist et al., “Astatine-211 labeling of Internalizing Anti-EGFRvIII Monoclonal Antibody Using N-Succinimidyl 5-[211At]astato-3-pyridinecarboxylate,” Nuclear Medicine and Biology 26(4):405-411, 1999.;;Reist et al., “In Vitro and In Vivo Behavior of Radiolabeled Chimeric Anti-EGFRvIII Monoclonal Antibody: Comparison With Its Murine Parent,” Nuclear Medicine and Biology 24(7):639-647, 1997.;;Reist et al., “Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts,” Cancer Res. Oct. 1, 1995; 55(19): 4375-82.;;Ring et al., “Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2.” Mol. Immunol., 28: 915-917 (1991).;;Roitt et al., Immunology, 2nd Ed., Gower Medical Publishing, New York, 1989, pp. 5.8-5.9.;;Rosenblum et al., “Recombinant immunotoxins directed against the c-erbB-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.” Clin. Cancer Res., 5:865-874 (1999).;;Rudikoff et al., “Single Amino Acid Substitution Altering Antigen Binding Specificity,” Proc. Nat'l. Acad. Sci.1982, 79:1979-1983. vol. 79.;;Sampson et al., “Unarmed, Tumor-Specific Monoclonal Antibody Effectively Treats Brain Tumors,” Proc. Nat. Acad. Sci. 97(13):7503-7508, Jun. 2000.;;Schlessinger et al., “Signal Transduction by Epidermal Growth Factor Receptor,” Cold Spring Harbor Symposium Quantum Biology 53:515-519, Jan. 1, 1988.;;Schmidt et al., “Expression of an Oncogenic Mutant EGF Receptor Markedly Increases the Sensitivity of Cells to an EGF-Receptor-Specific Antibody-Toxin,” Int. J. Cancer 75:878-884, Mar. 16, 1998.;;Sela et al., in Immunoconjugates, C. Vogel, Ed., 1987, pp. 189-216.;;Sgouros et al., “Pharmacokinetics and Dosimetry of an a-Particle Emitter Labeled Antibody: Bi-HuM195 (Anti-CD33) in Patients with Leukemia,” 1. Nucl. Med., 40: 1935-1946 (1999).;;Shouval et al., “Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens,” Proc. Natl Acad. Sci. 85:8276-8280, 1988.;;Sima, et al., “Receptor Functions and Ligand-Dependent Transforming Potential of a Chimeric kit Proto-Oncogene” Molecular and Cellular Biology Nov. 1990, pp. 6064-6068.;;Slamon et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.” Science 244:707-712 (1989).;;Stancovski et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth,” Proc. Natl Acad. Sci. USA 88:8691-8695, 1991.;;Strong et al., “Three-Dimensional Structure of Murine Anti-p-azophenylarsonate Fab 36-71. 1. X-ray Chrystallography, Site-Directed Mutagenesis, and Modeling of the Complex with Hapten,” Biochemistry, 30:3739-3748, 1991.;;Supplementary European Search Report dated May 4, 2009, received in European Patent Application No. 04777034.2.;;Suzuki et al., “Immunoselective cell growth inhibition by antibody-Adriamycin conjugates targeting c-erbB2 product on human cancer cells.” Biol. Pharm. Bull. 18: 1279-1282 (1995).;;Tamura et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs ) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,” Journal of Immunology, 2000, vol. 164, pp. 1432-1441.;;Thorpe et al., “An Immunotoxin Composed of Monoclonal Anti-Thy 1.1 Antibody and a Ribosome-Inactivating Protein from Saponaria Officinalis: Potent Antitumor Effects in Vitro and in Vivo,” J. Natl. Cancer Inst., 75 pages, 151-159, Jul. 1985.;;Toki et al., Abstracts of Papers of the American Chemical Society 223(2):A1113, Apr. 7-11, 2002.;;Tolcher AW et al., “Cantuzumab mertansine, a maytansinoid imminoconjugate directed to the CanAg antigen: a phase I, pharmokinetic, and biologic correlative study.” J. Clin. Oncol. Jan. 15, 2003; 21(2):211-22.;;Trail et al., “Monoclonal Antibody Drug Immunoconjugates for Targeted Treatment of Cancer.” Cancer Immunol. Immunother 52:328-337, 2003.;;Trouet et al., “A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies,” Proc. Nat'l Acad. Sci. 79:626-629, 1982.;;Tsukada et al., “Suppression of human α-foetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti α-foetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier,” Br. J. Cancer 52:111-116, 1985.;;Ullrich et al., “Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells,” Nature 309:418-425, 1984.;;Vajdos et al., “Comprehensive Functional Maps of the Antigen Binding Site of an Anti ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol., 2002, vol. 320, pp. 415 428.;;Valerius et al., “FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy,” Blood 90(11):4485-4492, 1997.;;Van Regenmortel, “Mapping Epitope Structure and Activity: From One-Dimensional Prediction to Four-Dimensionial Description of Antigenic Specificity,” A Comapnion to Methods in Enzymology 9, 1996, pp. 465-472, Article No. 0054.;;Vitetta et al., “Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.” Cancer Res., 54:5301.5309 (1994).;;Vitetta et al., “Immunotoxins: Magic Bullets or Misguided Missiles?” Immunology Today 14:252, 1993.;;Wang et al., “Immunoglobulin VH Gene Expression in Human Aging,” Clinical Immunology (Nov. 1999) vol. 93, Issue 2, pp. 132-142.;;Weichhold et al., “Megabase inversions in the human genome as physiological events,” Nature (1990) 347: 90-92.;;Weiner, Louis. “Monoclonal antibody therapy of cancer,” Semin. Oncol. 26, Suppl. 14:43-51 (1999).;;Weitkamp et al., “Infant and Adult Human B Cell Responses to Rotavirus Share Common Immunodominant Variable Gene Repertoires,” J. Immunol. (Nov. 1, 2003) 171 (9):4680-4688.;;Wells et al., “Genetic Determinants of Neoplastic Transformation by the Retroviral Oncogene v-erbB,” Proc. Nat'l Acad. Sci. USA 85:7597-7601, 1988.;;Wells, “Additivity of Mutational Effects in Proteins,” The American Chemical Society, Sep. 18, 1990 pp. 8509-8571, vol. 29 (37).;;Whitlow et al., “1.85 a Structure of Anti-Fluorescein Apr. 4, 2020 Fab,” Protein Engineering 8(8):749-761, 1995.;;Wikstrand et al., “Generation of Anti-Idotypic Reagents in the EGFRvIII Tumor-Associated Antigen System,” Cancer Immunology, Immunotherapy 50(12):639-652, 2002.;;Wikstrand et al., “Monoclonal Antibodies Against EGFRvIII Are Tumor Specific and React With Breast and Lung Carcinomas Malignant Gliomas,” Cancer Research 55(14):3140-3148, 1995. et al.",ACTIVE
254,US,A1,US 2015/0315288 A1,147-132-252-435-39X,2015-11-05,2015,US 201514743886 A,2015-06-18,US 201514743886 A;;US 26835208 A;;US 87777404 A;;US 56245304 P;;US 52557003 P;;US 48314503 P,2003-06-27,ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF,"The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.",AMGEN FREMONT INC,WEBER RICHARD F;;FENG XIAO;;FOORD ORIT;;GREEN LARRY L;;GUDAS JEAN M;;KEYT BRUCE A;;LIU YING;;RATHANASWAMI PALANISWAMI;;RAYA ROBERT;;YANG XIAO DONG;;CORVALAN JOSE R F;;FOLTZ IAN;;JIA XIAO-CHI;;KANG JASPAL SINGH;;KING CHADWICK TERENCE;;KLAKAMP SCOTT L;;SU QIAOJUAN JANE,AMGEN FREMONT INC (2004-10-26),https://lens.org/147-132-252-435-39X,Patent Application,yes,9,2,84,87,144,A61K2039/505;;B82Y5/00;;C07K2317/92;;Y10S435/81;;C07K2317/34;;A61K47/6803;;A61K47/6849;;A61K47/6897;;C07K16/2863;;A61P1/00;;A61P11/00;;A61P13/08;;A61P13/12;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28;;G01N33/532;;G01N33/574;;C07K16/30;;C07K2317/21;;C07K2317/77;;A61K2039/505;;B82Y5/00;;C07K2317/92;;A61K47/6803;;A61K47/6849;;A61K47/6897;;Y10S435/81;;C07K2317/34;;C07K16/2863,C07K16/30;;A61K39/395;;A61K47/48;;C07K16/22;;C07K16/28;;C07K17/00;;C12N/;;C12N5/06;;G01N33/53,,7,7,013-142-717-038-23X;;027-477-313-726-928;;032-214-592-514-94X;;042-741-242-328-693;;026-589-266-128-73X;;033-870-601-973-366;;080-633-663-618-912,10556035;;10.1006/jmbi.1999.3141;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;8258342;;8258341;;10.1002/eji.1830231231;;10.1038/347090a0;;2118596;;10.1182/blood-2002-01-0008;;12200383;;10527689;;10.1006/clim.1999.4781;;14568943;;10.4049/jimmunol.171.9.4680,"Wu et al., Journal of Molecular Biology, Vol. 294, pp. 151-162 (Year: 1999);;Rudikoff et al., Proc Natl Acad Sci USA Vol 79 pp 1979-1983 (Year: 1982);;Klein et al., Eur. J. Immunol. 23 (12), 3248-3262, 1993.;;Weichhold et al., Nature 347: 90-92, 1990.;;Claudio et al., Blood 100 (6): 2175-2186, 2002.;;Wang et al., Clin. Immunol. 93 (2): 132-142, 1999.;;Weitkamp et al., J. Immunol. 171 (9): 4680-4688. 2003.",ACTIVE
